<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16815329</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>28</EndPage><MedlinePgn>21-8</MedlinePgn></Pagination><Abstract><AbstractText>Imbalances in neurotrophins or their high-affinity Trk receptors have long been reported in neurodegenerative diseases. However, a molecular link between these gene products and neuronal cell death has not been established. In the trisomy 16 (Ts16) mouse there is increased apoptosis in the cortex, and hippocampal neurons undergo accelerated cell death that cannot be rescued by administration of brain-derived neurotrophic factor (BDNF). Ts16 neurons have normal levels of the TrkB tyrosine kinase receptor but an upregulation of the TrkB.T1 truncated receptor isoform. Here we show that restoration of the physiological level of the TrkB.T1 receptor by gene targeting rescues Ts16 cortical cell and hippocampal neuronal death. Moreover, it corrects resting Ca2+ levels and restores BDNF-induced intracellular signaling mediated by full-length TrkB in Ts16 hippocampal neurons. These data provide a direct link between neuronal cell death and abnormalities in Trk neurotrophin receptor levels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dorsey</LastName><ForeName>Susan G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Neural Development Group, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, USA. sdorsey@son.umaryland.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renn</LastName><ForeName>Cynthia L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Carim-Todd</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Barrick</LastName><ForeName>Colleen A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Bambrick</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Krueger</LastName><ForeName>Bruce K</ForeName><Initials>BK</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Christopher W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Tessarollo</LastName><ForeName>Lino</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01-AR02177</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K22NR00174</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS40492</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020813">Receptor, trkB</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2006 Jul 6;51(1):1-3. doi: 10.1016/j.neuron.2006.06.019.</RefSource><PMID Version="1">16815323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018390" MajorTopicYN="N">Gene Targeting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008818" MajorTopicYN="N">Mice, Neurologic Mutants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020813" MajorTopicYN="N">Receptor, trkB</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014314" MajorTopicYN="N">Trisomy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16815329</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.06.009</ArticleId><ArticleId IdType="pii">S0896-6273(06)00462-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16825573</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>313</Volume><Issue>5783</Issue><PubDate><Year>2006</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response.</ArticleTitle><Pagination><StartPage>104</StartPage><EndPage>107</EndPage><MedlinePgn>104-7</MedlinePgn></Pagination><Abstract><AbstractText>The unfolded protein response (UPR) allows the endoplasmic reticulum (ER) to recover from the accumulation of misfolded proteins, in part by increasing its folding capacity. Inositol-requiring enzyme-1 (IRE1) promotes this remodeling by detecting misfolded ER proteins and activating a transcription factor, X-box-binding protein 1, through endonucleolytic cleavage of its messenger RNA (mRNA). Here, we report that IRE1 independently mediates the rapid degradation of a specific subset of mRNAs, based both on their localization to the ER membrane and on the amino acid sequence they encode. This response is well suited to complement other UPR mechanisms because it could selectively halt production of proteins that challenge the ER and clear the translocation and folding machinery for the subsequent remodeling process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollien</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Pharmacology, University of California San Francisco, Howard Hughes Medical Institute, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissman</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021382">Protein Sorting Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071701">Regulatory Factor X Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D004722">Endoribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D005095">Exoribonucleases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C511918">inositol requiring enzyme-1, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="C487208">pcm protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>T8ID5YZU6Y</RegistryNumber><NameOfSubstance UI="D004229">Dithiothreitol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2006 Jul 7;313(5783):52-3. doi: 10.1126/science.1130469.</RefSource><PMID Version="1">16825557</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004229" MajorTopicYN="N">Dithiothreitol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004722" MajorTopicYN="N">Endoribonucleases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005095" MajorTopicYN="N">Exoribonucleases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017344" MajorTopicYN="N">Genes, Insect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021382" MajorTopicYN="N">Protein Sorting Signals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="Y">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071701" MajorTopicYN="N">Regulatory Factor X Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16825573</ArticleId><ArticleId IdType="doi">10.1126/science.1129631</ArticleId><ArticleId IdType="pii">313/5783/104</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16837572</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>30</Issue><PubDate><Year>2006</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease beta-amyloid peptides are released in association with exosomes.</ArticleTitle><Pagination><StartPage>11172</StartPage><EndPage>11177</EndPage><MedlinePgn>11172-7</MedlinePgn></Pagination><Abstract><AbstractText>Although the exact etiology of Alzheimer's disease (AD) is a topic of debate, the consensus is that the accumulation of beta-amyloid (Abeta) peptides in the senile plaques is one of the hallmarks of the progression of the disease. The Abeta peptide is formed by the amyloidogenic cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases. The endocytic system has been implicated in the cleavages leading to the formation of Abeta. However, the identity of the intracellular compartment where the amyloidogenic secretases cleave and the mechanism by which the intracellularly generated Abeta is released into the extracellular milieu are not clear. Here, we show that beta-cleavage occurs in early endosomes followed by routing of Abeta to multivesicular bodies (MVBs) in HeLa and N2a cells. Subsequently, a minute fraction of Abeta peptides can be secreted from the cells in association with exosomes, intraluminal vesicles of MVBs that are released into the extracellular space as a result of fusion of MVBs with the plasma membrane. Exosomal proteins were found to accumulate in the plaques of AD patient brains, suggesting a role in the pathogenesis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honsho</LastName><ForeName>Masanori</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zahn</LastName><ForeName>Tobias R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Geiger</LastName><ForeName>Kathrin D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Verkade</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D005095">Exoribonucleases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005095" MajorTopicYN="N">Exoribonucleases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16837572</ArticleId><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="doi">10.1073/pnas.0603838103</ArticleId><ArticleId IdType="pii">0603838103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ross C. A., Poirier M. A. Nat. Med. 2004;10:S10&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A., Steiner H., Willem M., Kaiser H., Meyer C., Walter J., Lammich S., Multhaup G., Haass C. J. Biol. Chem. 2000;275:30849&#x2013;30854.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801872</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D., Winkler E., Regula J. T., Pesold B., Steiner H., Haass C. Nat. Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T., Bieger S. C., Bruhl B., Tienari P. J., Ida N., Allsop D., Roberts G. W., Masters C. L., Dotti C. G., Unsicker K., Beyreuther K. Nat. Med. 1997;3:1016&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A., Beher D., Prokop S., Steiner H., Kaether C., Shearman M. S., Haass C. J. Biol. Chem. 2005;280:6471&#x2013;6478.</Citation><ArticleIdList><ArticleId IdType="pubmed">15591316</ArticleId></ArticleIdList></Reference><Reference><Citation>Runz H., Rietdorf J., Tomic I., de Bernard M., Beyreuther K., Pepperkok R., Hartmann T. J. Neurosci. 2002;22:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pubmed">11880497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechards M., Xia W., Oorschot V. M., Selkoe D. J., Klumperman J. Traffic. 2003;4:553&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">12839498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Proc. Natl. Acad. Sci. USA. 2001;98:5815&#x2013;5820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33296</ArticleId><ArticleId IdType="pubmed">11309494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R., Keller P., Haass C., Thiele C., Simons K. J. Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Koo E. H., Mellon A., Hung A. Y., Selkoe D. J. Nature. 1992;357:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Lemere C. A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L., Selkoe D. J. Nat. Med. 1995;1:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K., Vaz W. L. Annu. Rev. Biophys. Biomol. Struct. 2004;33:269&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15139814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L., Simons K. J. Cell Sci. 2005;118:1099&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764592</ArticleId></ArticleIdList></Reference><Reference><Citation>Abad-Rodriguez J., Ledesma M. D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., Dotti C. G. J. Cell Biol. 2004;167:953&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172459</ArticleId><ArticleId IdType="pubmed">15583033</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel K. S., Cheng H., Lin W., Sakurai T., Li T., Nukina N., Wong P. C., Xu H., Thinakaran G. J. Biol. Chem. 2004;279:44945&#x2013;44954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Yamazaki T., Citron M., Podlisny M. B., Koo E. H., Teplow D. B., Haass C. Ann. N.Y. Acad. Sci. 1996;777:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Grbovic O. M., Mathews P. M., Jiang Y., Schmidt S. D., Dinakar R., Summers-Terio N. B., Ceresa B. P., Nixon R. A., Cataldo A. M. J. Biol. Chem. 2003;278:31261&#x2013;31268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761223</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo L. M., Sambamurti K., Efthimiopoulos S., Pappolla M. A., Robakis N. K. J. Neurosci. Res. 1995;40:694&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">7602619</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevrier B., Raposo G. Curr. Opin. Cell Biol. 2004;16:415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rink J., Ghigo E., Kalaidzidis Y., Zerial M. Cell. 2005;122:735&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A., Fukumoto H., Shah T., Whelan C. M., Irizarry M. C., Hyman B. T. J. Cell Sci. 2003;116:3339&#x2013;3346.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829747</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G., Teplow D. B., Siman R., Greenberg B., Sisodia S. S. J. Biol. Chem. 1996;271:9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>de Renzis S., Sonnichsen B., Zerial M. Nat. Cell Biol. 2002;4:124&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788822</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., et al. Nature. 1992;359:325&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., et al. Nature. 1992;359:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., De Strooper B. Science. 1999;286:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T. Trends Neurosci. 2001;24:S45&#x2013;S48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11881745</ArticleId></ArticleIdList></Reference><Reference><Citation>Langui D., Girardot N., El Hachimi K. H., Allinquant B., Blanchard V., Pradier L., Duyckaerts C. Am. J. Pathol. 2004;165:1465&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618656</ArticleId><ArticleId IdType="pubmed">15509518</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R. H., Milner T. A., Li F., Nam E. E., Edgar M. A., Yamaguchi H., Beal M. F., Xu H., Greengard P., Gouras G. K. Am. J. Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelchen-Matthews A., Raposo G., Marsh M. Trends Microbiol. 2004;12:310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">15223058</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G., Nijman H. W., Stoorvogel W., Liejendekker R., Harding C. V., Melief C. J., Geuze H. J. J. Exp. Med. 1996;183:1161&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192324</ArticleId><ArticleId IdType="pubmed">8642258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., Amigorena S. Nat. Med. 1998;4:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">9585234</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C., Boussac M., Veron P., Ricciardi-Castagnoli P., Raposo G., Garin J., Amigorena S. J. Immunol. 2001;166:7309&#x2013;7318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11390481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevrier B., Vilette D., Archer F., Loew D., Faigle W., Vidal M., Laude H., Raposo G. Proc. Natl. Acad. Sci. USA. 2004;101:9683&#x2013;9688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470735</ArticleId><ArticleId IdType="pubmed">15210972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokubo H., Saido T. C., Iwata N., Helms J. B., Shinohara R., Yamaguchi H. Neurobiol. Aging. 2005;26:409&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokubo H., Lemere C. A., Yamaguchi H. Neurosci. Lett. 2000;290:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C., Schmitt S., Willem M., Haass C. Traffic. 2006;7:408&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">16536739</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W. H., Cuervo A. M., Kumar A., Peterhoff C. M., Schmidt S. D., Lee J. H., Mohan P. S., Mercken M., Farmery M. R., Tjernberg L. O., et al. J. Cell Biol. 2005;171:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., Simons K. J. Biol. Chem. 2005;280:36815&#x2013;36823.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., Michikawa M., Yoshikawa Y., Terao K., et al. J. Neurosci. 2004;24:4894&#x2013;4902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729458</ArticleId><ArticleId IdType="pubmed">15152051</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gassart A., Geminard C., Hoekstra D., Vidal M. Traffic. 2004;5:896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479454</ArticleId></ArticleIdList></Reference><Reference><Citation>Theos A. C., Truschel S. T., Raposo G., Marks M. S. Pigment Cell Res. 2005;18:322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788625</ArticleId><ArticleId IdType="pubmed">16162173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., et al. Nat. Med. 2001;7:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231627</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A. E., Larregina A. T., Shufesky W. J., Sullivan M. L., Stolz D. B., Papworth G. D., Zahorchak A. F., Logar A. J., Wang Z., Watkins S. C., et al. Blood. 2004;104:3257&#x2013;3266.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284116</ArticleId></ArticleIdList></Reference><Reference><Citation>von Schwedler U. K., Stuchell M., Muller B., Ward D. M., Chung H. Y., Morita E., Wang H. E., Davis T., He G. P., Cimbora D. M., et al. Cell. 2003;114:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505570</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A., Meyn L., Fluhrer R., Teplow D. B., Walter J., Haass C. J. Biol. Chem. 2002;277:5637&#x2013;5643.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Okayama H. Mol. Cell. Biol. 1987;7:2745&#x2013;2752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC367891</ArticleId><ArticleId IdType="pubmed">3670292</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiffele P., Verkade P., Fra A. M., Virta H., Simons K., Ikonen E. J. Cell Biol. 1998;140:795&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141752</ArticleId><ArticleId IdType="pubmed">9472032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F. Acta Morphol. Acad. Sci. Hung. 1971;19:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik N. J., Daymon M. E. J. Clin. Pathol. 1982;35:1092&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC497889</ArticleId><ArticleId IdType="pubmed">6752207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16844381</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0969-9961</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity.</ArticleTitle><Pagination><StartPage>669</StartPage><EndPage>678</EndPage><MedlinePgn>669-78</MedlinePgn></Pagination><Abstract><AbstractText>Prion (PrP) and amyloid-beta (Abeta) peptides are involved in the neuronal loss that occurs in Prion disorders (PrD) and Alzheimer's disease (AD), respectively, partially due to Ca(2+) dysregulation. Besides, the endoplasmic reticulum (ER) stress has an active role in the neurotoxic mechanisms that lead to these pathologies. Here, we analyzed whether the ER-mediated apoptotic pathway is involved in the toxic effect of synthetic PrP and Abeta peptides. In PrP106-126- and Abeta1-40-treated cortical neurons, the release of Ca(2+) through ER ryanodine (RyR) and inositol 1,4,5-trisphosphate (IP(3)R) receptors induces ER stress and leads to increased cytosolic Ca(2+) and reactive oxygen species (ROS) levels and subsequently to apoptotic death involving mitochondrial cytochrome c release and caspases activation. These results demonstrate that the early PrP- and Abeta-induced perturbation of ER Ca(2+) homeostasis is a death message that leads to neuronal loss, suggesting that the regulation of ER Ca(2+) levels may be a potential therapeutical target for PrD and AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreiro</LastName><ForeName>Elisabete</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology of Coimbra, Institute of Biochemistry, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Catarina R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Cl&#xe1;udia M F</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053496">Inositol 1,4,5-Trisphosphate Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.9.3.1</RegistryNumber><NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053496" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16844381</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2006.05.011</ArticleId><ArticleId IdType="pii">S0969-9961(06)00133-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16849325</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>39</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP.</ArticleTitle><Pagination><StartPage>29096</StartPage><EndPage>29104</EndPage><MedlinePgn>29096-104</MedlinePgn></Pagination><Abstract><AbstractText>Recently we have identified the novel mitochondrial peptidase responsible for degrading presequences and other short unstructured peptides in mitochondria, the presequence peptidase, which we named PreP peptidasome. In the present study we have identified and characterized the human PreP homologue, hPreP, in brain mitochondria, and we show its capacity to degrade the amyloid beta-protein (Abeta). PreP belongs to the pitrilysin oligopeptidase family M16C containing an inverted zinc-binding motif. We show that hPreP is localized to the mitochondrial matrix. In situ immuno-inactivation studies in human brain mitochondria using anti-hPreP antibodies showed complete inhibition of proteolytic activity against Abeta. We have cloned, overexpressed, and purified recombinant hPreP and its mutant with catalytic base Glu(78) in the inverted zinc-binding motif replaced by Gln. In vitro studies using recombinant hPreP and liquid chromatography nanospray tandem mass spectrometry revealed novel cleavage specificities against Abeta-(1-42), Abeta-(1-40), and Abeta Arctic, a protein that causes increased protofibril formation an early onset familial variant of Alzheimer disease. In contrast to insulin degrading enzyme, which is a functional analogue of hPreP, hPreP does not degrade insulin but does degrade insulin B-chain. Molecular modeling of hPreP based on the crystal structure at 2.1 A resolution of AtPreP allowed us to identify Cys(90) and Cys(527) that form disulfide bridges under oxidized conditions and might be involved in redox regulation of the enzyme. Degradation of the mitochondrial Abeta by hPreP may potentially be of importance in the pathology of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falkevall</LastName><ForeName>Annelie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Stockholm University SE-106 91 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alikhani</LastName><ForeName>Nyosha</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bhushan</LastName><ForeName>Shashi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Pavel F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kenneth A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Eneqvist</LastName><ForeName>Therese</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tjernberg</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ankarcrona</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Glaser</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.21.25</RegistryNumber><NameOfSubstance UI="C514899">PREP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013367" MajorTopicYN="N">Submitochondrial Particles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16849325</ArticleId><ArticleId IdType="doi">10.1074/jbc.M602532200</ArticleId><ArticleId IdType="pii">S0021-9258(19)34002-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16862115</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>442</Volume><Issue>7105</Issue><PubDate><Year>2006</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.</ArticleTitle><Pagination><StartPage>920</StartPage><EndPage>924</EndPage><MedlinePgn>920-4</MedlinePgn></Pagination><Abstract><AbstractText>Frontotemporal dementia (FTD) with ubiquitin-immunoreactive neuronal inclusions (both cytoplasmic and nuclear) of unknown nature has been linked to a chromosome 17q21 region (FTDU-17) containing MAPT (microtubule-associated protein tau). FTDU-17 patients have consistently been shown to lack a tau-immunoreactive pathology, a feature characteristic of FTD with parkinsonism linked to mutations in MAPT (FTDP-17). Furthermore, in FTDU-17 patients, mutations in MAPT and genomic rearrangements in the MAPT region have been excluded by both genomic sequencing and fluorescence in situ hybridization on mechanically stretched chromosomes. Here we demonstrate that FTDU-17 is caused by mutations in the gene coding for progranulin (PGRN), a growth factor involved in multiple physiological and pathological processes including tumorigenesis. Besides the production of truncated PGRN proteins due to premature stop codons, we identified a mutation within the splice donor site of intron 0 (IVS0 + 5G &gt; C), indicating loss of the mutant transcript by nuclear degradation. The finding was made within an extensively documented Belgian FTDU-17 founder family. Transcript and protein analyses confirmed the absence of the mutant allele and a reduction in the expression of PGRN. We also identified a mutation (c.3G &gt; A) in the Met1 translation initiation codon, indicating loss of PGRN due to lack of translation of the mutant allele. Our data provide evidence that PGRN haploinsufficiency leads to neurodegeneration because of reduced PGRN-mediated neuronal survival. Furthermore, in a Belgian series of familial FTD patients, PGRN mutations were 3.5 times more frequent than mutations in MAPT, underscoring a principal involvement of PGRN in FTD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Universiteitsplein 1, BE-2610 Antwerpen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gijselinck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>van der Zee</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wils</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Pirici</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dermaut</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sciot</LastName><ForeName>Raf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Santens</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>De Pooter</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mattheijssens</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Van den Broeck</LastName><ForeName>Marleen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cuijt</LastName><ForeName>Ivy</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Vennekens</LastName><ForeName>Krist'l</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Kumar-Singh</LastName><ForeName>Samir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022821">RNA Splice Sites</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020161" MajorTopicYN="N">Physical Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022821" MajorTopicYN="N">RNA Splice Sites</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId><ArticleId IdType="doi">10.1038/nature05017</ArticleId><ArticleId IdType="pii">nature05017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16862116</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>442</Volume><Issue>7105</Issue><PubDate><Year>2006</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.</ArticleTitle><Pagination><StartPage>916</StartPage><EndPage>919</EndPage><MedlinePgn>916-9</MedlinePgn></Pagination><Abstract><AbstractText>Frontotemporal dementia (FTD) is the second most common cause of dementia in people under the age of 65 years. A large proportion of FTD patients (35-50%) have a family history of dementia, consistent with a strong genetic component to the disease. In 1998, mutations in the gene encoding the microtubule-associated protein tau (MAPT) were shown to cause familial FTD with parkinsonism linked to chromosome 17q21 (FTDP-17). The neuropathology of patients with defined MAPT mutations is characterized by cytoplasmic neurofibrillary inclusions composed of hyperphosphorylated tau. However, in multiple FTD families with significant evidence for linkage to the same region on chromosome 17q21 (D17S1787-D17S806), mutations in MAPT have not been found and the patients consistently lack tau-immunoreactive inclusion pathology. In contrast, these patients have ubiquitin (ub)-immunoreactive neuronal cytoplasmic inclusions and characteristic lentiform ub-immunoreactive neuronal intranuclear inclusions. Here we demonstrate that in these families, FTD is caused by mutations in progranulin (PGRN) that are likely to create null alleles. PGRN is located 1.7 Mb centromeric of MAPT on chromosome 17q21.31 and encodes a 68.5-kDa secreted growth factor involved in the regulation of multiple processes including development, wound repair and inflammation. PGRN has also been strongly linked to tumorigenesis. Moreover, PGRN expression is increased in activated microglia in many neurodegenerative diseases including Creutzfeldt-Jakob disease, motor neuron disease and Alzheimer's disease. Our results identify mutations in PGRN as a cause of neurodegenerative disease and indicate the importance of PGRN function for neuronal survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Matt</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Gass</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Snowden</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Adamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sadovnick</LastName><ForeName>A Dessa</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Rollinson</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cannon</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dwosh</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Neary</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Melquist</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Zdenek</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Eriksen</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zehr</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McGowan</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400356</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018388">Codon, Terminator</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018388" MajorTopicYN="N">Codon, Terminator</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020161" MajorTopicYN="N">Physical Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId><ArticleId IdType="doi">10.1038/nature05016</ArticleId><ArticleId IdType="pii">nature05016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16908860</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>34</Issue><PubDate><Year>2006</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>12867</StartPage><EndPage>12872</EndPage><MedlinePgn>12867-72</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is characterized by two primary pathological features: amyloid plaques and neurofibrillary tangles. The interconnection between amyloid and tau aggregates is of intense interest, but mouse models have yet to reveal a direct interrelationship. We now show that NO may be a key factor that connects amyloid and tau pathologies. Genetic removal of NO synthase 2 in mice expressing mutated amyloid precursor protein results in pathological hyperphosphorylation of mouse tau, its redistribution to the somatodendritic compartment in cortical and hippocampal neurons, and aggregate formation. Lack of NO synthase 2 in the amyloid precursor protein Swedish mutant mouse increased insoluble beta-amyloid peptide levels, neuronal degeneration, caspase-3 activation, and tau cleavage, suggesting that NO acts at a junction point between beta-amyloid peptides, caspase activation, and tau aggregation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colton</LastName><ForeName>C A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Division of Neurology, and Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA. glia01@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitek</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Wink</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Cantillana</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Previti</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496317">Nos2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15273</RefSource><Note>Weinberg, B [corrected to Weinberg, JB]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="Y">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: No conflicts declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16908860</ArticleId><ArticleId IdType="pmc">PMC1550768</ArticleId><ArticleId IdType="doi">10.1073/pnas.0601075103</ArticleId><ArticleId IdType="pii">0601075103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A., Shoji M., Harigaya Y., Kawarabayashi T., Ikeda M., Naito M., Matsubara E., Abe K., Nakazato Y. Virchows Arch. 2002;441:358&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">12404061</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomidokoro Y., Ishiguro K., Harigaya Y., Matsubara E., Ikeda M. Neurosci. Lett. 2001;299:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11165762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P., et al. Proc. Natl. Acad. Sci. USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwaab C., Hosokawa M., McGeer P. Exp. Neurol. 2004;188:52&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15191802</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Shepherd J., Murphy P., Golde T., Kayed R., Metherate R., Mattson M., Akbari Y., LaFerla F. M. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., Dickson D., Lin W., Chisholm L., Corral A., Jones G., Yen S., Sahara N., Skipper L., Yager D., et al. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K., Alonso Adel C., Chen S., Chohan M., El-Akkad E., Gong C., Khatoon S., Li B., Liu F., Rahman A., et al. Biochim. Biophys. Acta. 2005;1739:198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Capsoni S., Ugolini G., Comparini A., Ruberti F., Berardi N., Cattaneo A. Proc. Natl. Acad. Sci. USA. 2000;97:6826&#x2013;6831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18754</ArticleId><ArticleId IdType="pubmed">10841577</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigo J., Fernandez-Vizarra P., Castro-Blanco S., Bentura M., Nieto M., Gomez-Isla T., Martinez-Murillo R., MartInez A., Serrano J., Fernandez A. Neuroscience. 2004;128:73&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450355</ArticleId></ArticleIdList></Reference><Reference><Citation>Luth H., Munch G., Arendt T. Brain Res. 2002;953:135&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Zhao M., Hirano A., Dickson D. J. Neuropathol. Exp. Neurol. 1999;58:1163&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560659</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M., Richey Harris P., Sayre L., Beckman J., Perry G. J. Neurosci. 1997;17:2653&#x2013;2657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573097</ArticleId><ArticleId IdType="pubmed">9092586</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver C., Espinoza M., Kress Y., Davies P. Neurobiol. Aging. 2000;21:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K., Knight H., Refolo L., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., et al. Neurobiol. Dis. 2000;7:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., Vanmechelen E. Neurosci. Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul-Murphy P., Baker M., Yu X., et al. Nat. Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S., Nordhoff E., Lurz R., Schugardt N., Rautenberg S., et al. Proc. Natl. Acad. Sci. USA. 2002;99:16400&#x2013;16406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139900</ArticleId><ArticleId IdType="pubmed">12200548</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J., Vitek M., Xu F., Previti M., Davis J., Van Nostrand W. J. Neurosci. 2005;25:6271&#x2013;6627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725284</ArticleId><ArticleId IdType="pubmed">16000616</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S., Nixon R., Matthews P. Methods Mol. Biol. 2005;299:279&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued L., Stowers C., Scallet A., Xu L. Brain Res. 2005;1035:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713273</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlander R. N. Engl. J. Med. 2003;348:1365&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin T., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A., Lu M., Fu Y., Garcia-Sierra F., LaPointe N., et al. Proc. Natl. Acad. Sci. USA. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C., Calingasan N., Nezexon J., Ding A., Lucia S., Perle K., Fuortes M., Lin M., Ehert S., Kwon N., et al. J. Exp. Med. 2005;202:1163&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213235</ArticleId><ArticleId IdType="pubmed">16260491</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y., Tsukamoto E., Niikura T., Yamagishi Y., Ishizaka M., Aiso S., Takashima A., Nishimoto I. J. Neurosci. Res. 2004;75:417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">14743455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Chan S., Mattson M. Neuromol. Med. 2002;2:29&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230303</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P., Rosemuller J. M., Van Muiswinkel F. Exp. Neurol. 1998;154:89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875271</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson B., Ischiropoulous H., Lee V., Trojanowski J. Free Radical Biol. Med. 2002;32:1264&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage Rubsamen M., Apelt J., Schliebs R. Neurosci. Lett. 2001;302:73&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11290390</ArticleId></ArticleIdList></Reference><Reference><Citation>Guix F., Uribesalgo I., Coma M., Munoz F. Prog. Neurobiol. 2005;76:126&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinz E., Kochanek P., Dixon C., Clark R., Carcillo J., Schiding J., Chen M., Wieniewski S., Carlos T., Williams C., et al. J. Clin. Invest. 1999;104:647&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408535</ArticleId><ArticleId IdType="pubmed">10487779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Rowan M., Anwyl R. J. Neurosci. 2004;24:6049&#x2013;6056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729673</ArticleId><ArticleId IdType="pubmed">15240796</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D., Espey M., Ridnour L., Hofseth L., Manardi D., Harris C., Wink D. Proc. Natl. Acad. Sci. USA. 2004;101:8894&#x2013;8899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC428443</ArticleId><ArticleId IdType="pubmed">15178764</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg J., Ridnour L., Perruccio E., Espey M., Wink D., Roberts D. Proc. Natl. Acad. Sci. USA. 2005;102:13141&#x2013;13146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201579</ArticleId><ArticleId IdType="pubmed">16150726</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D., Vitolo O., Trinchese F., Jacob J., Palmeri A., Arancio O. J. Neurosci. 2005;25:6887&#x2013;6897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>Keynes R. G., Garthwaite J. Curr. Mol. Med. 2004;4:179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15032712</ArticleId></ArticleIdList></Reference><Reference><Citation>Brune B. Antiox. Redox. Signal. 2005;7:497&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">15706097</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannick J., Schonhoff C., Papeta N., Gharfourifar P., Szibor M., Fang K., Gaston B. J. Cell Biol. 2001;154:1111&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150810</ArticleId><ArticleId IdType="pubmed">11551979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Talanian R., Billiar T. J. Biol. Chem. 1997;272:31138&#x2013;31148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9388267</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Vizarra P., Fernandez A., Castro-Blanco S., Encinas J., Serrano J., Bentura M., Munoz P., Martinez-Murioll R., Rodrigo R. Neurobiol. Dis. 2004;15:287&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006699</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte S., Lu B., Sohn Y., Etienne D., Kraft J., Ganju N., Wands J. Neurobiol. Aging. 2000;21:309&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayre L., Perry G., Harris P., Liu Y., Schubert K., Smith M. J. Neurochem. 2000;74:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617129</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D., Espey M. G., Vitek M. P., Miranda K., Wink D. Proc. Natl. Acad. Sci. USA. 2002;99:12691&#x2013;12696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130522</ArticleId><ArticleId IdType="pubmed">12226478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek M., Snell J., Chernyshev O., Colton C. Biophys. Biochem. Res. Commun. 1997;240:391&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">9388488</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L., Cassatella M., Szendrel G., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Nature. 1995;374:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Duport S., Garthwaite J. Neuroscience. 2005;135:1155&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16165295</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannan C., Roberts M. Glia. 2004;48:120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378654</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman R., Poon W., Blurton-Jones M., Torp R., Vitek M., LaFerla F., Rohn T., Cotman C. J. Clin. Invest. 2004;114:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc A. Prog. Neurol. Psychopharmacol. Biol. Psychiatry. 2003;27:215&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12657361</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder L., Guillozet-Bongaarts A., Garcia-Sierra F., Berry R. Biochem. Biophys. Acta. 2005;1739:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615640</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds M., Berry R., Binder L. Biochemistry. 2005;44:1690&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">15683253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush A. Trends Neurosci. 2003;26:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689772</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton C., Chernyshev O., Gilbert D., Vitek M. Ann. N.Y. Acad. Sci. 2000;899:292&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">10863548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., David D., Ferrari A., Gotz J. Curr. Drug Topics. 2004;5:503&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">15270197</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D., Schenk D. Annu. Rev. Pharmacol. Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubach V., Shesely E., Smithies O., Sherman P. Proc. Natl. Acad. Sci. USA. 1995;92:10688&#x2013;10692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40677</ArticleId><ArticleId IdType="pubmed">7479866</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg B., Misukonis M., Shami P., Mason S., Sauls D., Dittman W., Wood E., Smith G., McDonald B., Bachus K. Blood. 1995;86:1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542498</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S., Park E., Zhou P., Frys K., Ross M., Iadecola C. J. Cereb. Blood Flow Metab. 2005;25:493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">15689953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Qian L., Iadecola C. J. Cereb. Blood Flow Metab. 2005;25:348&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">15660100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1691865</PMID><DateCompleted><Year>1990</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>248</Volume><Issue>4954</Issue><PubDate><Year>1990</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing.</ArticleTitle><Pagination><StartPage>492</StartPage><EndPage>495</EndPage><MedlinePgn>492-5</MedlinePgn></Pagination><Abstract><AbstractText>The beta-amyloid protein (beta/A4), derived from a larger amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. APP is an integral membrane glycoprotein and is secreted as a carboxyl-terminal truncated molecule. APP cleavage, which is a membrane-associated event, occurred at a site located within the beta/A4 region. This suggests that an intact amyloidogenic beta/A4 fragment is not generated during normal APP catabolism. Therefore, an early event in amyloid formation may involve altered APP processing that results in the release and subsequent deposition of intact beta/A4.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>S S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2181.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Unterbeck</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG 03359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 07914</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004274">DNA, Recombinant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>33507-63-0</RegistryNumber><NameOfSubstance UI="D013373">Substance P</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004274" MajorTopicYN="N">DNA, Recombinant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013373" MajorTopicYN="N">Substance P</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>4</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>4</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1691865</ArticleId><ArticleId IdType="doi">10.1126/science.1691865</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16921174</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>Pt 11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy.</ArticleTitle><Pagination><StartPage>2977</StartPage><EndPage>2983</EndPage><MedlinePgn>2977-83</MedlinePgn></Pagination><Abstract><AbstractText>We assessed the impact of amyloid precursor protein (APP) gene locus duplications in early onset Alzheimer's disease in a Dutch population-based sample. Using real-time PCR and an in-house-developed multiplex amplicon quantification assay, we identified a genomic APP duplication in 1 out of 10 multigenerational families segregating early onset Alzheimer's disease. In this family, cerebral amyloid angiopathy (CAA) coincided with this disease. The duplicated genomic region included no other genes than APP and extended maximally over 0.7 Mb. In a sample of 65 familial early onset patients, we observed the same APP genomic duplication in one patient (1.7%), while in 36 isolated patients duplications in the APP locus were absent. This indicated that APP locus duplications explained &lt;2% of familial, non-autosomal dominant Alzheimer's disease and are an infrequent cause of de novo mutation. Our findings corroborated a recent French study, and indicated that investigating genomic duplications in the APP locus in families segregating Alzheimer's disease and CAA should be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwers</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gijselinck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Theuns</LastName><ForeName>Jessie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goossens</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wauters</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Del-Favero</LastName><ForeName>Jurgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="Y">Gene Duplication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId><ArticleId IdType="doi">10.1093/brain/awl203</ArticleId><ArticleId IdType="pii">awl203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16930778</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation.</ArticleTitle><Pagination><StartPage>1637</StartPage><EndPage>1643</EndPage><MedlinePgn>1637-43</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A number of studies associate Alzheimer's disease with APOE polymorphism and alleles which favor the increased expression of immunological mediators such as cytokines or acute phase proteins. We integrated this information to better define risk and determine the relative importance of APOE and immunological mediators.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated functional gene variants for APOE, IL-10 (3 loci), ACT (2 loci), HMGCR, IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma, and IL-6 found for 260 AD patients and 190 controls enrolled in Northern Italy. A fuzzy latent classification approach, namely grade-of-membership analysis (GoM), was taken to identify extreme pure type risk sets, or profiles. This approach automatically relates individuals to each profile via graded membership scores.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Four extreme pure type risk sets were identified. Set I defined low intrinsic risk and had a low probability of carrying pro-inflammatory alleles or APOE epsilon4. Three sufficient risk sets were identified: early onset AD (set II) was characterized by a high density of pro-inflammatory alleles, a rapid cognitive decline and independent of APOE epsilon4. Late onset AD had a lower density (ages 65-74, set III), or a subset homozygous (ages 75+, set IV), for these alleles and a high probability of one or two APOE epsilon4 alleles. A total of 97% of the subjects who were cases strongly resembled, i.e. had at least 50% membership in, the sufficient risk sets, as did 25% of middle aged control subjects. IL-10, HMGCR, ACT, and IL-1beta gene variants were each more informative in identifying the risk sets than was APOE.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">AD likely has many determinants including APOE polymorphism and gene variants that modulate innate immunity. Identification of these factors, risk prediction for individuals, and successful prevention and treatment trials require integration of relevant information.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Licastro</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental Pathology, School of Medicine, University of Bologna, Via S. Giacomo 14, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porcellini</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Calogero</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lio</LastName><ForeName>Domenico</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Corder</LastName><ForeName>Elizabeth H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16930778</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.07.007</ArticleId><ArticleId IdType="pii">S0197-4580(06)00259-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16936277</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>169</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.</ArticleTitle><Pagination><StartPage>1048</StartPage><EndPage>1063</EndPage><MedlinePgn>1048-63</MedlinePgn></Pagination><Abstract><AbstractText>Experiments with amyloid-beta (Abeta)-42-immunized transgenic mouse models of Alzheimer's disease have revealed amyloid plaque disruption and apparent cognitive function recovery. Neuropathological examination of patients vaccinated against purified Abeta-42 (AN-1792) has demonstrated that senile plaque disruption occurred in immunized humans as well. Here, we examined tissue histology and quantified and biochemically characterized the remnant amyloid peptides in the gray and white matter and leptomeningeal/cortical vessels of two AN-1792-vaccinated patients, one of whom developed meningoencephalitis. Compact core and diffuse amyloid deposits in both vaccinated individuals were focally absent in some regions. Although parenchymal amyloid was focally disaggregated, vascular deposits were relatively preserved or even increased. Immunoassay revealed that total soluble amyloid levels were sharply elevated in vaccinated patient gray and white matter compared with Alzheimer's disease cases. Our experiments suggest that although immunization disrupted amyloid deposits, vascular capture prevented large-scale egress of Abeta peptides. Trapped, solubilized amyloid peptides may ultimately have cascading toxic effects on cerebrovascular, gray and white matter tissues. Anti-amyloid immunization may be most effective not as therapeutic or mitigating measures but as a prophylactic measure when Abeta deposition is still minimal. This may allow Abeta mobilization under conditions in which drainage and degradation of these toxic peptides is efficient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patton</LastName><ForeName>R Lyle</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>The Longtine Center for Molecular Biology and Genetics, W.H. Civin Laboratory for Neuropathology, M.D. Sun Health Research Institute, 10515 W. Santa Fe Dr., Sun City, AZ 85351, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalback</LastName><ForeName>Walter M</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Esh</LastName><ForeName>Chera L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Kokjohn</LastName><ForeName>Tyler A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Van Vickle</LastName><ForeName>Gregory D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Luehrs</LastName><ForeName>Dean C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Yu-Min</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brune</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Isidro</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Newel</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Casta&#xf1;o</LastName><ForeName>Eduardo M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Roher</LastName><ForeName>Alex E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG-18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG-19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG-19795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023582">Alzheimer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Pathol. 2006 Sep;169(3):738-9. doi: 10.2353/ajpath.2006.060633.</RefSource><PMID Version="1">16936250</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023582" MajorTopicYN="Y">Alzheimer Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="N">Meningoencephalitis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16936277</ArticleId><ArticleId IdType="pmc">PMC1698828</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2006.060269</ArticleId><ArticleId IdType="pii">S0002-9440(10)62779-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004;16:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342006</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B. Alzheimer&#x2019;s disease and immunotherapy. Curr Alzheimer Res. 2004;1:149&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelinas DS, Dasilva K, Fenili D, George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14657&#x2013;14662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521991</ArticleId><ArticleId IdType="pubmed">15297619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. Alzheimer&#x2019;s disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618542</ArticleId><ArticleId IdType="pubmed">15215183</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, deq Uervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer&#x2019;s disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Weksler ME, Gouras G, Relkin NR, Szabo P. The immune system, amyloid-beta peptide, and Alzheimer&#x2019;s disease. Immunol Rev. 2005;205:244&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882358</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2004;75:1472&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738770</ArticleId><ArticleId IdType="pubmed">15377700</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer&#x2019;s disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid &#x3b2;-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR. Morphology and toxicity of Abeta-(1&#x2013;42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer&#x2019;s disease. J Biol Chem. 1996;271:20631&#x2013;20635.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702810</ArticleId></ArticleIdList></Reference><Reference><Citation>Esh C, Patton L, Kalback W, Kokjohn TA, Lopez J, Brune D, Newell AJ, Beach T, Schenk D, Games D, Paul S, Bales K, Ghetti B, Castano EM, Roher AE. Altered APP processing in PDAPP (Val717&#x2192;Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry. 2005;44:13807&#x2013;13819.</Citation><ArticleIdList><ArticleId IdType="pubmed">16229470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, Ball MJ. Chemical characterization of A beta 17&#x2013;42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem. 1994;269:10987&#x2013;10990.</Citation><ArticleIdList><ArticleId IdType="pubmed">8157623</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. Beta-amyloid-(1&#x2013;42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:10836&#x2013;10840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47873</ArticleId><ArticleId IdType="pubmed">8248178</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer&#x2019;s disease. J Biol Chem. 1993;268:3072&#x2013;3083.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE. Isolation, chemical characterization, and quantitation of A&#x3b2; 3-pyroglutamyl peptides from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun. 1997;237:188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9266855</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, Barton E, Neal J, Ferrer I, Wilkinson D, Bayer A, Holmes C, Weller RO, Nicoll JAR. Effects of Abeta immunotherapy on cerebral amyloid angiopathy in human Alzheimer&#x2019;s disease. Abstracts of the 107th meeting of the British Neuropathological Society. Neuropathol Appl Neurobiol. 2006;32(Suppl 1):3&#x2013;4.</Citation></Reference><Reference><Citation>Roher AE, Palmer KC, Chau V, Ball MJ. Isolation and chemical characterization of Alzheimer&#x2019;s disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein. J Cell Biol. 1988;107:2703&#x2013;2716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115630</ArticleId><ArticleId IdType="pubmed">3060472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenson JD, Clarke S, Roher AE. Chemical modification of deposited amyloid-&#x3b2; peptides. Methods Enzymol. 1999;309:89&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507019</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T. Isoaspartate formation and neurodegeneration in Alzheimer&#x2019;s disease. Arch Biochem Biophys. 2000;381:225&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032409</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES, Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer&#x2019;s disease. Neurol Res. 2005;27:869&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">16354549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci. 2004;1019:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246983</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazil MI, Chung H, Maxfield FR. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer&#x2019;s disease amyloid fibrils by microglia. J Biol Chem. 2000;275:16941&#x2013;16947.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747968</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer&#x2019;s amyloid &#x3b2;-peptide by microglial cells. J Biol Chem. 1999;274:32301&#x2013;32308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542270</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, Roher AE. The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer&#x2019;s disease. J Biol Chem. 1998;273:29719&#x2013;29726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9792685</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo LM, Roher AE. Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci. 1996;16:6021&#x2013;6037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579176</ArticleId><ArticleId IdType="pubmed">8815885</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer&#x2019;s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer&#x2019;s disease. Biochim Biophys Acta. 1998;1406:291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630681</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer&#x2019;s disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer&#x2019;s disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer&#x2019;s disease mouse model immunized with amyloid-beta derivatives. J Neurosci. 2004;24:6277&#x2013;6282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729550</ArticleId><ArticleId IdType="pubmed">15254082</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380:168&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600393</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford F, Suo Z, Fang C, Sawar A, Su G, Arendash G, Mullan M. The vasoactivity of A&#x3b2; peptides. Ann NY Acad Sci. 1997;826:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329679</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti S, Mullan M. Inhibition of angiogenesis by A&#x3b2; peptides. Angiogenesis. 2004;7:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302999</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Town T, Parker T, Humphrey J, Mullan M. A&#x3b2; vasoactivity: an inflammatory reaction. Ann NY Acad Sci. 2000;903:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818494</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Cerebrovascular effects of amyloid-&#x3b2; peptides: mechanisms and implications for Alzheimer&#x2019;s dementia. Cell Mol Neurobiol. 2003;23:681&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11530195</ArticleId><ArticleId IdType="pubmed">14514024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-A&#x3b2; immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid-&#x3b2; accumulates in putative interstitial fluid drainage pathways in Alzheimer&#x2019;s disease. Am J Pathol. 1998;153:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer&#x2019;s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol. 2003;29:106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12662319</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer&#x2019;s disease. Mol Med. 2003;9:112&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1430731</ArticleId><ArticleId IdType="pubmed">12865947</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Cohen NR, Nicoll JA. Cerebrovascular disease and the pathophysiology of Alzheimer&#x2019;s disease: implications for therapy. Panminerva Med. 2004;46:239&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">15876980</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med. 2001;7:609&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950067</ArticleId><ArticleId IdType="pubmed">11778650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE. Elevated A&#x3b2; and apolipoprotein E in A&#x3b2;PP transgenic mice and its relationship to amyloid accumulation in Alzheimer&#x2019;s disease. Mol Med. 2000;6:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949958</ArticleId><ArticleId IdType="pubmed">10952022</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins LS, Murphy GM, Jr, Forno LS, Catalano R, Cordell B. P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer&#x2019;s disease brain. Am J Pathol. 1996;149:585&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865300</ArticleId><ArticleId IdType="pubmed">8701997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Norton DD, Wang X, Kusiak JW. Abeta 17&#x2013;42 in Alzheimer&#x2019;s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain. 2002;125:2036&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pubmed">12183349</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS. Specific spatial learning deficits become severe with age in &#x3b2;-amyloid precursor protein transgenic mice that harbor diffuse &#x3b2;-amyloid deposits but do not form plaques. Proc Nat Acad Sci USA. 2001;98:14675&#x2013;14680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64740</ArticleId><ArticleId IdType="pubmed">11724968</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillot T, Goethals M, Vanloo B, Talussot C, Brasseur R, Vandekerckhove J, Rosseneu M, Lins L. Fusogenic properties of the C-terminal domain of the Alzheimer &#x3b2;-amyloid peptide. J Biol Chem. 1996;271:28757&#x2013;28765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910517</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides: implications for neurotoxicity. J Biol Chem. 1996;271:26482&#x2013;26489.</Citation><ArticleIdList><ArticleId IdType="pubmed">8900116</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchesi VT. An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2005;102:9093&#x2013;9098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166615</ArticleId><ArticleId IdType="pubmed">15967987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P. Abeta42 immunization in Alzheimer&#x2019;s disease generates Abeta N-terminal antibodies. Ann Neurol. 2005;58:430&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16130106</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D. Intracranial administration of deglycosylated modified C-terminal-specific anti-A antibody efficiently clears amyloid plaques without activating microglia in amyloid depositing transgenic mice. J Neuroinflammation. 2006;3:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479322</ArticleId><ArticleId IdType="pubmed">16686956</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Weiss N, Kokjohn TA, Kuo Y: M, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T. Increased A&#x3b2; peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer&#x2019;s disease. Biochemistry. 2002;41:11080&#x2013;11090.</Citation><ArticleIdList><ArticleId IdType="pubmed">12220172</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY. Amyloid-&#x3b2; peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol. 2004;164:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171973</ArticleId><ArticleId IdType="pubmed">14709545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG. Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport. 2003;14:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960758</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer&#x2019;s disease: pro-CAA position statement. Neurobiol Aging. 2004;25:589&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172734</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-Abeta(42)- and anti-Abeta(40)-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006;116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of A&#x3b2; 1&#x2013;42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001;22:721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, Cribbs DH, Glabe CG, Tenner AJ. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer&#x2019;s disease. J Neuroinflammation. 2005;2:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326209</ArticleId><ArticleId IdType="pubmed">16332263</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaney MO, Webster SD, Kuo YM, Roher AE. Molecular modeling of the A&#x3b2;-42 peptide from Alzheimer&#x2019;s disease. Protein Eng. 1998;11:761&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796824</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16943563</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>35</Issue><PubDate><Year>2006</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>9047</StartPage><EndPage>9056</EndPage><MedlinePgn>9047-56</MedlinePgn></Pagination><Abstract><AbstractText>Various environmental and genetic factors influence the onset and progression of Alzheimer's disease (AD). Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which controls circulating levels of glucocorticoid hormones, occurs early in AD, resulting in increased cortisol levels. Disturbances of the HPA axis have been associated with memory impairments and may contribute to the cognitive decline that occurs in AD, although it is unknown whether such effects involve modulation of the amyloid beta-peptide (Abeta) and tau. Using in vitro and in vivo experiments, we report that stress-level glucocorticoid administration increases Abeta formation by increasing steady-state levels of amyloid precursor protein (APP) and beta-APP cleaving enzyme. Additionally, glucocorticoids augment tau accumulation, indicating that this hormone also accelerates the development of neurofibrillary tangles. These findings suggest that high levels of glucocorticoids, found in AD, are not merely a consequence of the disease process but rather play a central role in the development and progression of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, and Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, California 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billings</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Roozendaal</LastName><ForeName>Benno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>McGaugh</LastName><ForeName>James L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH012526</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 MH012526</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG0212982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-12526</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>W980KJ009P</RegistryNumber><NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003345" MajorTopicYN="N">Corticosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16943563</ArticleId><ArticleId IdType="pmc">PMC6675335</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2797-06.2006</ArticleId><ArticleId IdType="pii">26/35/9047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abraham I, Harkany T, Horvath KM, Veenema AH, Penke B, Nyakas C, Luiten PG. Chronic corticosterone administration dose-dependently modulates Abeta(1&#x2013;42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J Neuroendocrinol. 2000;12:486&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">10844576</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Disease Cooperative Study. Neurology. 2000;54:588&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680787</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM. Intraneuronal Abeta causes the onset of early Alzheimer&#x2019;s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:S85&#x2013;S88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Budas G, Coughlan CM, Seckl JR, Breen KC. The effect of corticosteroids on amyloid beta precursor protein/amyloid precursor-like protein expression and processing in vivo. Neurosci Lett. 1999;276:61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">10586975</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallman MF. Fast glucocorticoid actions on brain: back to the future. Front Neuroendocrinol. 2005;26:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242180</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, Johns CA, Horvath TB. Cortisol and Alzheimer&#x2019;s disease. I. Basal studies. Am J Psychiatry. 1986;143:300&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">3953862</ArticleId></ArticleIdList></Reference><Reference><Citation>de Quervain DJ, Poirier R, Wollmer MA, Grimaldi LM, Tsolaki M, Streffer JR, Hock C, Nitsch RM, Mohajeri MH, Papassotiropoulos A. Glucocorticoid-related genetic susceptibility for Alzheimer&#x2019;s disease. Hum Mol Genet. 2004;13:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">14583441</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM. Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo. J Neurochem. 1993;61:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">8515288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge YW, Maloney B, Sambamurti K, Lahiri DK. Functional characterization of the 5&#x2032; flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB J. 2004;18:1037&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059977</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer&#x2019;s amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999;97:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem. 1996;66:1836&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">8780008</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald BS, Mathe AA, Mohs RC, Levy MI, Johns CA, Davis KL. Cortisol and Alzheimer&#x2019;s disease. II. Dexamethasone suppression, dementia severity, and affective symptoms. Am J Psychiatry. 1986;143:442&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">3953887</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris-White ME, Chu T, Miller SA, Simmons M, Teter B, Nash D, Cole GM, Frautschy SA. Estrogen (E2) and glucocorticoid (Gc) effects on microglia and A beta clearance in vitro and in vivo. Neurochem Int. 2001;39:435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578779</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:5217&#x2013;5224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440804</ArticleId><ArticleId IdType="pubmed">15917461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:8843&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER, Wilkinson CW, Farris W, Mehta PD, Craft S. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J Neuropathol Exp Neurol. 2005;64:139&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK. Functional characterization of amyloid &#x3b2; precursor protein regulatory elements: rationale for the identification of genetic polymorphism. Ann NY Acad Sci. 2004;1030:282&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Masugi F, Ogihara T, Sakaguchi K, Otsuka A, Tsuchiya Y, Morimoto S, Kumahara Y, Saeki S, Nishide M. High plasma levels of cortisol in patients with senile dementia of the Alzheimer&#x2019;s type. Methods Find Exp Clin Pharmacol. 1989;11:707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">2560104</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Molchan SE, Hill JL, Mellow AM, Lawlor BA, Martinez R, Sunderland T. The dexamethasone suppression test in Alzheimer&#x2019;s disease and major depression: relationship to dementia severity, depression, and CSF monoamines. Int Psychogeriatr. 1990;2:99&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">1713799</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasman B, Olsson T, Viitanen M, Carlstrom K. A subtle disturbance in the feedback regulation of the hypothalamic-pituitary-adrenal axis in the early phase of Alzheimer&#x2019;s disease. Psychoneuroendocrinology. 1995;20:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">7899539</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology. 2001;56:1094&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">11320185</ArticleId></ArticleIdList></Reference><Reference><Citation>Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology. 1985;117:2505&#x2013;2511.</Citation><ArticleIdList><ArticleId IdType="pubmed">2998738</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozendaal B. 1999 Curt P. Richter Award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology. 2000;25:213&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737694</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozendaal B, Phillips RG, Power AE, Brooke SM, Sapolsky RM, McGaugh JL. Memory retrieval impairment induced by hippocampal CA3 lesions is blocked by adrenocortical suppression. Nat Neurosci. 2001;4:1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">11713467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 2004;18:1034&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059975</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R. Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci. 1994;14:5373&#x2013;5380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577078</ArticleId><ArticleId IdType="pubmed">8083742</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, Lawlor BA. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer&#x2019;s disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry. 1998;155:286&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">9464214</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzic N, Vujcic M, Ristic-Fira A, Krstic-Demonacos M, Milanovic D, Kanazir DT, Ruzdijic S. Effects of age and dexamethasone treatment on glucocorticoid response element and activating protein-1 binding activity in rat brain. J Gerontol A Biol Sci Med Sci. 2003;58:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663692</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis J. New piece in Alzheimer&#x2019;s puzzle. Science. 1993;261:828&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346434</ArticleId></ArticleIdList></Reference><Reference><Citation>Umegaki H, Ikari H, Nakahata H, Endo H, Suzuki Y, Ogawa O, Nakamura A, Yamamoto T, Iguchi A. Plasma cortisol levels in elderly female subjects with Alzheimer&#x2019;s disease: a cross-sectional and longitudinal study. Brain Res. 2000;881:241&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11036168</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol. 2001;166:7496&#x2013;7503.</Citation><ArticleIdList><ArticleId IdType="pubmed">11390503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Bennett DA, Li Y, Bienias JL, Mendes de Leon CF, Evans DA. Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology. 2005;64:380&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AP, Zilliacus J, McEwan IJ, Dahlman-Wright K, Almlof T, Carlstedt-Duke J, Gustafsson JA. Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol. 1993;47:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">8274424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Su J, Head E, Cotman CW. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer&#x2019;s disease. Neurobiol Dis. 2003;14:391&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16966547</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI.</ArticleTitle><Pagination><StartPage>834</StartPage><EndPage>842</EndPage><MedlinePgn>834-42</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the neural basis of cognitive complaints in healthy older adults in the absence of memory impairment and to determine whether there are medial temporal lobe (MTL) gray matter (GM) changes as reported in Alzheimer disease (AD) and amnestic mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were 40 euthymic individuals with cognitive complaints (CCs) who had normal neuropsychological test performance. The authors compared their structural brain MRI scans to those of 40 patients with amnestic MCI and 40 healthy controls (HCs) using voxel-based morphometry and hippocampal volume analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CC and MCI groups showed similar patterns of decreased GM relative to the HC group on whole brain analysis, with differences evident in the MTL, frontotemporal, and other neocortical regions. The degree of GM loss was associated with extent of both memory complaints and performance deficits. Manually segmented hippocampal volumes, adjusted for age and intracranial volume, were significantly reduced only in the MCI group, with the CC group showing an intermediate level.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cognitive complaints in older adults may indicate underlying neurodegenerative changes even when unaccompanied by deficits on formal testing. The cognitive complaint group may represent a pre-mild cognitive impairment stage and may provide an earlier therapeutic opportunity than mild cognitive impairment. MRI analysis approaches incorporating signal intensity may have greater sensitivity in early preclinical stages than volumetric methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Brain Imaging Laboratory, Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA. andrew.saykin@dartmouth.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wishart</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Rabin</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Santulli</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Flashman</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>T L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Mamourian</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB005149</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG19771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16966547</ArticleId><ArticleId IdType="mid">NIHMS414646</ArticleId><ArticleId IdType="pmc">PMC3488276</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000234032.77541.a2</ArticleId><ArticleId IdType="pii">67/5/834</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment&#x2014;a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand. 2002;106:403&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392483</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry. 2000;15:983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113976</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JL, Miller TP, Tinklenberg JR. Correlates of memory decline: a 4-year longitudinal study of older adults with memory complaints. Psychol Aging. 1992;7:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">1610506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Christensen H, Korten AE, Jacomb PA, Henderson AS. Memory complaints as a precursor of memory impairment in older people: a longitudinal analysis over 7&#x2013; 8 years. Psychol Med. 2001;31:441&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305852</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Jonker C, Hooijer C, Lindeboom J. Subjective memory complaints may announce dementia. Neurology. 1996;46:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559359</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Jonker C, Geerlings MI, Lindeboom J. Subjective memory complaints in the elderly: depressive symptoms and future dementia. Br J Psychiatry. 1997;171:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">9373429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobiansky R, Blizard R, Livingston G, Mann A. The Gospel Oak Study stage IV: the clinical relevance of subjective memory impairment in older people. Psychol Med. 1995;25:779&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">7480455</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm A, Masaki K, Davis D, et al. Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology. 2004;63:1960&#x2013;1961.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557525</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc. 1993;41:1029&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">8409146</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF. Alzheimer&#x2019;s disease: risk and protection. Med J Aust. 1997;167:443&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">9364167</ArticleId></ArticleIdList></Reference><Reference><Citation>Derouesne C, Lacomblez L, Thibault S, LePoncin M. Memory complaints in young and elderly subjects. Int J Geriatr Psychiatry. 1999;14:291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">10340191</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, Petersen RC, Ivnik RJ, Malec JF, Tangalos EG. Subjective memory complaints, psychological distress, and longitudinal change in objective memory performance. Psychol Aging. 1996;11:272&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">8795055</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology. 2001;57:2149. Correspondence.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739854</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Russ C, Richards M, Brayne C, Lovestone S, Mann A. Depression, APoE genotype and subjective memory impairment: a cross-sectional study in an African-Caribbean population. Psychol Med. 2001;31:431&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305851</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Wishart HA. Mild cognitive impairment: conceptual issues and structural and functional brain correlates. Semin Clin Neuropsychiatry. 2003;8:12&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006163</ArticleId><ArticleId IdType="pubmed">12567329</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter LC, Caselli RJ, Johnson SC, Reiman EM, Osborne D. Apolipoprotein e e4 affects new learning in cognitively normal individuals at risk for Alzheimer&#x2019;s disease. Neurobiol Aging. 2003;24:947&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928055</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Butterworth P, Anstey KJ, et al. Memory complaints in a community sample aged 60 &#x2013; 64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, ApoE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med. 2004;34:1495&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pubmed">15724880</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Gunning FM, Head D, et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the pre-frontal gray matter. Cereb Cortex. 1997;7:268&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143446</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni G, Testa C, Zorzan A, et al. Detection of grey matter loss in mild Alzheimer&#x2019;s disease with voxel based morphometry. J Neurol Neurosurg Psychiatry. 2003;73:657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757361</ArticleId><ArticleId IdType="pubmed">12438466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakzanis KK. Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer&#x2019;s type. J Clin Exp Neuropsychol. 1998;20:259&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Jack CR., Jr Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003;13:197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">13677801</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Maller JJ. The role of volumetric MRI in understanding mild cognitive impairment and similar classifications. Aging Ment Health. 2003;7:238&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage. 2001;14:1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11707080</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisserand DJ, van Boxtel MP, Pruessner JC, Hofman P, Evans AC, Jolles J. A voxel-based morphometric study to determine individual differences in gray matter density associated with age and cognitive change over time. Cereb Cortex. 2004;14:966&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115735</ArticleId></ArticleIdList></Reference><Reference><Citation>Taki Y, Goto R, Evans A, et al. Voxel-based morphometry of human brain with age and cerebrovascular risk factors. Neurobiol Aging. 2004;25:455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013566</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron J-C. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport. 2002;13:1939&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">12395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen C, Testa C, Laakso MP, et al. A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2005;76:11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739300</ArticleId><ArticleId IdType="pubmed">15607988</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron JC, Chetelat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer&#x2019;s disease. Neuroimage. 2001;14:298&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Scahill RI, Fox NC, et al. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage. 2002;17:29&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482066</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Burton EJ, Rombouts SA, et al. A comprehensive study of gray matter loss in patients with Alzheimer&#x2019;s disease using optimized voxel-based morphometry. Neuroimage. 2003;18:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725765</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, McMillan C, Moore P, et al. What&#x2019;s in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer&#x2019;s disease, frontotemporal dementia and corticobasal degeneration. Brain. 2004;127:628&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">14761903</ArticleId></ArticleIdList></Reference><Reference><Citation>Busatto GF, Garrido GE, Almeida OP, et al. A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer&#x2019;s disease. Neurobiol Aging. 2003;24:221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498956</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin LA, Saykin AJ, Wishart HA, Copenhaver BR, Flashman LA, Santulli RB. Telephone-based screening for MCI and cognitive complaints: preliminary validation by comprehensive assessment. Presented at the 2004 International Neuropsychological Society Meeting; 2004.</Citation></Reference><Reference><Citation>Rabin LA, Saykin AJ, Wishart HA, Wang PJ, Nutter-Upham KE, Flashman LA. Telephone-based screening for MCI and cognitive complaints: preliminary validation of alternate test forms. Presented at the 24th Annual Conference of the National Academy of Neuropsychology; November 17&#x2013;20, 2004; Seattle, WA.</Citation></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment&#x2013;beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurica P, Leitten C, Mattis S. Dementia Rating Scale-2. Lutz, FL: Psychological Assessment Resources, Inc; 2001.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: adult version research edition manual. San Antonio, TX: The Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test-second edition: adult version manual. San Antonio, TX: The Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Goodglass H, Kaplan E, Barresi B. Boston Diagnostic Aphasia Examination. 3. Philadelphia: Lippincott Williams &amp; Wilkins; 2001.</Citation></Reference><Reference><Citation>Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System. San Antonio, TX: The Psychological Corporation; 2001.</Citation></Reference><Reference><Citation>Reitan R, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: theory and clinical interpretation. Tucson, AZ: Neuropsychology Press; 1985.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale. San Antonio, TX: Harcourt, Brace; 1997.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale-third edition WMS-III administration and scoring manual. San Antonio, TX: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G. Wisconsin Card Sorting Test manual revised and expanded. Odessa, FL: Psychological Assessment Resources; 1993.</Citation></Reference><Reference><Citation>Axelrod BN, Goldman RS, Heaton RK, et al. Discriminability of the Wisconsin Card Sorting Test using the standardization sample. J Clin Exp Neuropsychol. 1996;18:338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">8877618</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Sliwinski M. Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J Clin Exp Neuropsychol. 1991:933&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">1779032</ArticleId></ArticleIdList></Reference><Reference><Citation>Barona A, Reynolds C, Chastain R. A demographically based index of pre-morbid intelligence for the WAIS-R. J Consult Clin Psychol. 1984;52:885&#x2013;887.</Citation></Reference><Reference><Citation>Squire LR, Wetzel CD, Slater PC. Memory complaint after electroconvulsive therapy: assessment with a new self-rating instrument. Biol Psychiatry. 1979;14:791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">497304</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Janssen R, Sprehn G, Spira T, Kaplan J, O&#x2019;Connor B. Longitudinal evaluation of neuropsychological function in homosexual men with hiv-1 infection; 18 month follow-up. J Neuropsychiatry Clin Neurosci. 1991;3:286&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821245</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ. Neurobehavioral function and activities of daily living rating scale (NBFADL-63 item version) Hanover: Dartmouth Medical School; 1992.</Citation></Reference><Reference><Citation>Jorm AF, Jacomb PA. An informant questionnaire on cognitive decline in the elderly (IQCODE): Socio-demographic correlates reliability, validity and some norms. Psychol Med. 1989;19:1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">2594878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Lose TL, et al. Development and validation of Geriatric Depression Rating Scale: a preliminary report. J Psychiatr Res. 1982;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Santulli R, Saykin A, Rabin L, et al. Differential sensitivity of cognitive complaints associated with amnestic MCI: analysis of patient and informant reports. Presented at the Alzheimer&#x2019;s Association International Conference on the Prevention of Dementia; Washington, DC. June 18 &#x2013;21, 2005.</Citation></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">1164215</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW. Revised ischemic score for diagnosing multi-infarct dementia. J Clin Psychiatry. 1985;46:514&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">4066617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazekas F, Barkhof F, Wahlund LO, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis. 2002;13:31&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11901240</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387493</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Cohen G, Harris G, et al. Image processing for the study of brain structure and function: problems and programs. J Neuropsychiatry Clin Neurosci. 1992;4:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">1627972</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Rajarethinam R, Cizadlo T, et al. Automatic atlas-based volume estimation of human brain regions from MR images. J Comput Assist Tomogr. 1996;20:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">8576490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KF. Voxel-based morphometry&#x2014;the methods. Neuroimage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR., Jr MRI-based hippocampal volume measurements in epilepsy. Epilepsia. 1994;35:S21&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pubmed">8206012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasboun D, Chantome M, Zouaoui A, et al. MR determination of hippocampal volume: comparison of three methods. AJNR Am J Neuroradiol. 1996;17:1091&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8338626</ArticleId><ArticleId IdType="pubmed">8791921</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh TL, Saykin AJ, Wishart HA, et al. Hippocampal volume and shape analysis in an older adult population. Clin Neuropsychol. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482482</ArticleId><ArticleId IdType="pubmed">17366281</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvernoy H. The human hippocampus. New York: J.F. Bergmann Verlag Munchen; 1988.</Citation></Reference><Reference><Citation>Watson C, Andermann F, Gloor P, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology. 1992;42:1743&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">1513464</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol. 2006;63:15&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401731</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc. 2001;7:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L. Clinical Dementia Rating (CDR) Psychopharmacol Bull. 1988;24:637&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Okonek A, Mandelkern MA, et al. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. Int Psychogeriatr. 1994;6:23&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054492</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Markesbery WR. Linguistic ability in early life and the neuropathology of Alzheimer&#x2019;s disease and cerebrovascular disease: findings from the nun study. Ann NY Acad Sci. 2000;903:34&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818486</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Jacqmin-Gadda H, Orgogozo J-M, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005;128:1093&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15774508</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman L, Jones S, Berger A-K, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer&#x2019;s disease: a meta-analysis. Neuropsychology. 2005;19:520&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16060827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisk JD, Rockwood K. Outcomes of incident mild cognitive impairment in relation to case definition. J Neurol Neurosurg Psychiatry. 2005;76:1175&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739767</ArticleId><ArticleId IdType="pubmed">16024904</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot JC, de Leeuw F-E, Oudkerk M, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology. 2001;56:1539&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402112</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Chen ST, Komo S, et al. Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2001;16:1071&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746653</ArticleId></ArticleIdList></Reference><Reference><Citation>Jungwirth S, Fischer P, Weissgram S, Kirchmeyr W, Bauer P, Tragl K. Subjective memory complaints and objective memory impairment in the Vienna-Transdanube aging community. J Am Geriatr Soc. 2004;52:263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">14728638</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8:448&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Huh TJ, Faust RR, et al. Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. Neuropsychology. 2004;18:38&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744186</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Ashburner J, Frackowiak RS. Computational neuroanatomy: new perspectives for neuroradiology. Rev Neurol (Paris) 2001;157:797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11677400</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisserand DJ, Pruessner JC, Sanz Arigita EJ, et al. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. Neuroimage. 2002;17:657&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol. 2003;2:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16987729</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>10</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.</ArticleTitle><Pagination><StartPage>828</StartPage><EndPage>834</EndPage><MedlinePgn>828-34</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Serial MRI scanning of autosomal dominant mutation carriers for Alzheimer's disease provides an opportunity to track changes that could predate symptoms or clinical diagnosis of the disease. We used hierarchical modelling to assess how hippocampal and whole-brain volumes change as familial Alzheimer's disease progresses from the presymptomatic stage through to diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nine mutation carriers had serial clinical assessments and volumetric MRI scans (41 scans: range 3-8 per patient) at different clinical stages (presymptomatic, mild cognitive impairment, or clinical Alzheimer's disease). 25 healthy controls had serial scanning (54 scans: range 2-4 per patient) for comparison. We measured whole brain and total hippocampal volumes using semi-automated techniques, and adjusted for total intracranial volume. Hierarchical models were developed to estimate differences in volume and atrophy rate between mutation carriers and controls in relation to when the disease was clinically diagnosed.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Mutation carriers had significantly increased hippocampal and whole-brain atrophy rates compared with controls and these differences increased with time. Differences in hippocampal and whole-brain atrophy rates between controls and mutation carriers were evident 5.5 and 3.5 years, respectively, before diagnosis of Alzheimer's disease. At a cross-sectional level, differences in mean hippocampal volume between mutation carriers and controls became significant 3 years before clinical diagnosis, whereas differences in mean brain volumes became significant only 1 year before diagnosis.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Structural changes can be seen on MRI scans that predate the clinical onset of familial Alzheimer's disease. Longitudinal measures of atrophy rates can identify differences between mutation carriers and controls 2-3 years earlier than cross-sectional volumetric measures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ridha</LastName><ForeName>Basil H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, Institute of Neurology, London, UK. bridha@dementia.ion.ucl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Godbolt</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pepple</LastName><ForeName>Tracey</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G116/143</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2006 Oct;5(10):805-6. doi: 10.1016/S1474-4422(06)70556-7.</RefSource><PMID Version="1">16987723</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(06)70550-6</ArticleId><ArticleId IdType="pii">S1474-4422(06)70550-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16990547</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>313</Volume><Issue>5794</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.</ArticleTitle><Pagination><StartPage>1781</StartPage><EndPage>1784</EndPage><MedlinePgn>1781-4</MedlinePgn></Pagination><Abstract><AbstractText>Protein aggregation is an established pathogenic mechanism in Alzheimer's disease, but little is known about the initiation of this process in vivo. Intracerebral injection of dilute, amyloid-beta (Abeta)-containing brain extracts from humans with Alzheimer's disease or beta-amyloid precursor protein (APP) transgenic mice induced cerebral beta-amyloidosis and associated pathology in APP transgenic mice in a time- and concentration-dependent manner. The seeding activity of brain extracts was reduced or abolished by Abeta immunodepletion, protein denaturation, or by Abeta immunization of the host. The phenotype of the exogenously induced amyloidosis depended on both the host and the source of the agent, suggesting the existence of polymorphic Abeta strains with varying biological activities reminiscent of prion strains.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coomaraswamy</LastName><ForeName>Janaky</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>Tristan</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kilger</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Neuenschwander</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Abramowski</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jaton</LastName><ForeName>Anneliese L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Vigouret</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Paganetti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Ghiso</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS45357</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-00165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014020">Tissue Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011489" MajorTopicYN="N">Protein Denaturation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014020" MajorTopicYN="N">Tissue Extracts</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId><ArticleId IdType="doi">10.1126/science.1131864</ArticleId><ArticleId IdType="pii">313/5794/1781</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17012232</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>281</Volume><Issue>47</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice.</ArticleTitle><Pagination><StartPage>36180</StartPage><EndPage>36186</EndPage><MedlinePgn>36180-6</MedlinePgn></Pagination><Abstract><AbstractText>The low density lipoprotein receptor-related protein (LRP) is highly expressed in the brain and has been shown to alter the metabolism of amyloid precursor protein and amyloid-beta peptide (Abeta) in vitro. Previously we developed mice that overexpress a functional LRP minireceptor (mLRP2) in their brains and crossed them to the PDAPP mouse model of Alzheimer disease. Overexpression of mLRP2 in 22-month-old PDAPP mice with amyloid plaques increased a pool of carbonate-soluble Abeta in the brain and worsened memory-related behavior. In the current study, we examined the effects of mLRP2 overexpression on 3-month-old PDAPP mice that had not yet developed amyloid plaques. We found significantly higher levels of membrane-associated Abeta42 in the hippocampus of mice that overexpressed mLRP2. Using immunohistochemical methods, we observed significant intraneuronal Abeta42 in the hippocampus and frontal cortex of PDAPP mice, which frequently co-localized with the lysosomal marker LAMP-1. Interestingly, PDAPP mice lacking apolipoprotein E (apoE) had much less intraneuronal Abeta42. We also found that PC12 cells overexpressing mLRP2 cleared Abeta42 and Abeta40 more rapidly from media than PC12 cells transfected with the vector only. Preincubation of apoE3 or apoE4 with Abeta42 increased the rate of Abeta clearance, and this effect was partially blocked by receptor-associated protein. Our results support the hypothesis that LRP binds and endocytoses Abeta42 both directly and via apoE but that endocytosed Abeta42 is not completely degraded and accumulates in intraneuronal lysosomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zerbinatti</LastName><ForeName>Celina V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahrle</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyungjin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cam</LastName><ForeName>Judy A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32-NS41872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17012232</ArticleId><ArticleId IdType="doi">10.1074/jbc.M604436200</ArticleId><ArticleId IdType="pii">S0021-9258(20)68171-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17018285</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>127</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>197</EndPage><MedlinePgn>185-97</MedlinePgn></Pagination><Abstract><AbstractText>Embryonic multipotent neural precursors are exposed to extracellular signals instructing them to adopt different fates, neuronal or glial. However, the mechanisms by which precursors integrate these signals to make timely fate choices remained undefined. Here we show that direct nuclear signaling by a receptor tyrosine kinase inhibits the responses of precursors to astrocyte differentiation factors while maintaining their neurogenic potential. Upon neuregulin-induced activation and presenilin-dependent cleavage of ErbB4, the receptor's intracellular domain forms a complex with TAB2 and the corepressor N-CoR. This complex undergoes nuclear translocation and binds promoters of astrocytic genes, repressing their expression. Consistent with this observation, astrogenesis occurs precociously in ErbB4 knockout mice. Our studies define how presenilin-dependent nuclear signaling by a receptor tyrosine kinase directly regulates gene transcription and cell fate. This pathway could be of importance for neural stem cell biology and for understanding the pathogenesis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sardi</LastName><ForeName>S Pablo</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Neurobiology Program and Department of Neurology, Children's Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtie</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Koirala</LastName><ForeName>Samir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Patten</LastName><ForeName>Brooke A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Corfas</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS035884</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-HD 18655</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS35884</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007484-06</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539127">NCOR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539128">Ncor1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539129">Ncor1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056971">Nuclear Receptor Co-Repressor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410585">TAB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C587689">ERBB4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C587690">Erbb4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C587691">Erbb4 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066247">Receptor, ErbB-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2006 Oct 6;127(1):45-8. doi: 10.1016/j.cell.2006.09.013.</RefSource><PMID Version="1">17018275</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056971" MajorTopicYN="N">Nuclear Receptor Co-Repressor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066247" MajorTopicYN="N">Receptor, ErbB-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020798" MajorTopicYN="N">Two-Hybrid System Techniques</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17018285</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.07.037</ArticleId><ArticleId IdType="pii">S0092-8674(06)01207-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17021177</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>40</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis.</ArticleTitle><Pagination><StartPage>10222</StartPage><EndPage>10231</EndPage><MedlinePgn>10222-31</MedlinePgn></Pagination><Abstract><AbstractText>Memory function is likely subserved by multiple distributed neural networks, which are disrupted by the pathophysiological process of Alzheimer's disease (AD). In this study, we used multivariate analytic techniques to investigate memory-related functional magnetic resonance imaging (fMRI) activity in 52 individuals across the continuum of normal aging, mild cognitive impairment (MCI), and mild AD. Independent component analyses revealed specific memory-related networks that activated or deactivated during an associative memory paradigm. Across all subjects, hippocampal activation and parietal deactivation demonstrated a strong reciprocal relationship. Furthermore, we found evidence of a nonlinear trajectory of fMRI activation across the continuum of impairment. Less impaired MCI subjects showed paradoxical hyperactivation in the hippocampus compared with controls, whereas more impaired MCI subjects demonstrated significant hypoactivation, similar to the levels observed in the mild AD subjects. We found a remarkably parallel curve in the pattern of memory-related deactivation in medial and lateral parietal regions with greater deactivation in less-impaired MCI and loss of deactivation in more impaired MCI and mild AD subjects. Interestingly, the failure of deactivation in these regions was also associated with increased positive activity in a neocortical attentional network in MCI and AD. Our findings suggest that loss of functional integrity of the hippocampal-based memory systems is directly related to alterations of neural activity in parietal regions seen over the course of MCI and AD. These data may also provide functional evidence of the interaction between neocortical and medial temporal lobe pathology in early AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Celone</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calhoun</LastName><ForeName>Vince D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Atri</LastName><ForeName>Alireza</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Elizabeth F</ForeName><Initials>EF</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Saul L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>DePeau</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Doreen M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS002189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG004953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR014075</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-NS02189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41-RR14075</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17021177</ArticleId><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2250-06.2006</ArticleId><ArticleId IdType="pii">26/40/10222</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc. 2001;7:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Yousem DM, Cristinzio C, Kusevic I, Yassa MA, Caffo BS, Zeger SL. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain. 2006;129:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744898</ArticleId><ArticleId IdType="pubmed">16627465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell AJ, Sejnowski TJ. An information-maximization approach to blind separation and blind deconvolution. Neural Comput. 1995;7:1129&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">7584893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005;64:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett M, Johnsrude IS, Owen AM. The problem of functional localization in the human brain. Nat Rev Neurosci. 2002;3:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994756</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun VD, Adali T, Pearlson GD, Pekar JJ. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp. 2001;14:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871952</ArticleId><ArticleId IdType="pubmed">11559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua EF, Schacter DL, Rand-Giovannetti E, Sperling RA. Understanding metamemory: neural correlates of the cognitive process and subjective level of confidence in recognition memory. NeuroImage. 2006;29:1150&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303318</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa N, Adali T, Li Y, Calhoun V. Comparison of blind source separation algorithms for fMRI using a new matlab toolbox: GIFT. Proc IEEE Int Conf Acoustics, Speech, Signal Processing; 2005. pp. 401&#x2013;404.</Citation></Reference><Reference><Citation>Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, Morris JC. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord. 2004;18:190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592129</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815133</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Prince SE, Cabeza R. When less means more: deactivations during encoding that predict subsequent memory. NeuroImage. 2004;23:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528092</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, Sperling RA. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrieli JD. Memory systems analyses of mnemonic disorders in aging and age-related diseases. Proc Natl Acad Sci USA. 1996;93:13534&#x2013;13540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33642</ArticleId><ArticleId IdType="pubmed">8942968</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia. 2004;42:980&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">14998712</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, Hansen KW, Gleason CE, Carlsson CM, Ries ML, Asthana S, Chen K, Reiman EM, Alexander GE. Activation of brain regions vulnerable to Alzheimer's disease: The effect of mild cognitive impairment. Neurobiol Aging. 2006 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci USA. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, Petersen RC, Boeve BF, Knopman D, Tang-Wai DF, Ivnik RJ, Smith GE, Tangalos EG, Jack CR., Jr Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003;61:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744465</ArticleId><ArticleId IdType="pubmed">12939424</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini JL, Ripley BD. A new statistical approach to detecting significant activation in functional MRI. NeuroImage. 2000;12:366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">10988031</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Alford M, Adame A, Rockenstein E, Galasko D, Salmon D, Hansen LA, Thal LJ. Abeta1&#x2013;42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology. 2003;61:206&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874400</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, LeMestric C, Landeau B, Desgranges B, Eustache F, Baron JC. Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study. J Neurol Neurosurg Psychiatry. 2001;71:315&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737577</ArticleId><ArticleId IdType="pubmed">11511703</ArticleId></ArticleIdList></Reference><Reference><Citation>Milham MP, Erickson KI, Banich MT, Kramer AF, Webb A, Wszalek T, Cohen NJ. Attentional control in the aging brain: insights from an fMRI study of the stroop task. Brain Cogn. 2002;49:277&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139955</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EK. The prefrontal cortex and cognitive control. Nat Rev Neurosci. 2000;1:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252769</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz CH, Rogers BP, Meyerand ME. Power spectrum ranked independent component analysis of a periodic fMRI complex motor paradigm. Hum Brain Mapp. 2003;18:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871872</ArticleId><ArticleId IdType="pubmed">12518291</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis. 2005;7:235&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006667</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's disease cooperative study experience. Neurology. 1997;48:1508&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191756</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997;9:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447429</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Goekoop R, Stam CJ, Barkhof F, Scheltens P. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. NeuroImage. 2005a;26:1078&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961047</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005b;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmithorst VJ, Holland SK. Comparison of three methods for generating group statistical inferences from independent component analysis of functional magnetic resonance imaging data. J Magn Reson Imaging. 2004;19:365&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265794</ArticleId><ArticleId IdType="pubmed">14994306</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol. 1999;45:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder LX, Avison MJ. Women at risk for AD show increased parietal activation during a fluency task. Neurology. 2002;58:1197&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Bates J, Chua E, Cocchiarella A, Schacter DL, Rosen B, Albert M. fMRI studies of associative encoding in young and elderly controls and mild AD patients. J Neurol Neurosurg Psychiatry. 2003a;74:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738201</ArticleId><ArticleId IdType="pubmed">12486265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Chua E, Cocchiarella A, Rand-Giovannetti E, Poldrack R, Schacter DL, Albert M. Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation. NeuroImage. 2003b;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230827</ArticleId><ArticleId IdType="pubmed">14568509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Bates J, Cocchiarella A, Schacter D, Rosen B, Albert M. Encoding novel face-name associations: a functional MRI study. Hum Brain Mapp. 2001;14:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871827</ArticleId><ArticleId IdType="pubmed">11559958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Greve D, Dale A, Killiany R, Rosen B, Holmes J, Rosas HD, Cocchiarella A, Firth P, Lake S, Lange N, Routledge C, Albert M. fMRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci USA. 2002;99:455&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117581</ArticleId><ArticleId IdType="pubmed">11756667</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-&#x3b2; plaques. J Neurosci. 2004;24:4535&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17030655</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>10</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.</ArticleTitle><Pagination><StartPage>1402</StartPage><EndPage>1408</EndPage><MedlinePgn>1402-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Epidemiologic and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, for example, docosahexaenoic acid and eicosapentaenoic acid, may prevent Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine effects of dietary omega-3 fatty acid supplementation on cognitive functions in patients with mild to moderate AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized, double-blind, placebo-controlled clinical trial.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Two hundred four patients with AD (age range [mean +/- SD], 74 +/- 9 years) whose conditions were stable while receiving acetylcholine esterase inhibitor treatment and who had a Mini-Mental State Examination (MMSE) score of 15 points or more were randomized to daily intake of 1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid (omega-3 fatty acid-treated group) or placebo for 6 months, after which all received omega-3 fatty acid supplementation for 6 months more.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was cognition measured with the MMSE and the cognitive portion of the Alzheimer Disease Assessment Scale. The secondary outcome was global function as assessed with the Clinical Dementia Rating Scale; safety and tolerability of omega-3 fatty acid supplementation; and blood pressure determinations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred seventy-four patients fulfilled the trial. At baseline, mean values for the Clinical Dementia Rating Scale, MMSE, and cognitive portion of the Alzheimer Disease Assessment Scale in the 2 randomized groups were similar. At 6 months, the decline in cognitive functions as assessed by the latter 2 scales did not differ between the groups. However, in a subgroup (n = 32) with very mild cognitive dysfunction (MMSE &gt;27 points), a significant (P&lt;.05) reduction in MMSE decline rate was observed in the omega-3 fatty acid-treated group compared with the placebo group. A similar arrest in decline rate was observed between 6 and 12 months in this placebo subgroup when receiving omega-3 fatty acid supplementation. The omega-3 fatty acid treatment was safe and well tolerated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Administration of omega-3 fatty acid in patients with mild to moderate AD did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale. However, positive effects were observed in a small group of patients with very mild AD (MMSE &gt;27 points).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freund-Levi</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Caring Sciences and Society, Section of Clinical Geriatrics, Karolinska University Hospital Huddinge, Stockholm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksdotter-J&#xf6;nhagen</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cederholm</LastName><ForeName>Tommy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Basun</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fax&#xe9;n-Irving</LastName><ForeName>Gerd</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Garlind</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vedin</LastName><ForeName>Inger</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Vessby</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wahlund</LastName><ForeName>Lars-Olof</ForeName><Initials>LO</Initials></Author><Author ValidYN="Y"><LastName>Palmblad</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00211159</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015990" MajorTopicYN="N">Placebo Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17030655</ArticleId><ArticleId IdType="doi">10.1001/archneur.63.10.1402</ArticleId><ArticleId IdType="pii">63/10/1402</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17035647</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>355</Volume><Issue>15</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1525</StartPage><EndPage>1538</EndPage><MedlinePgn>1525-38</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzheimer's disease and psychosis, aggression, or agitation were randomly assigned to receive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose, 1.0 mg per day), or placebo. Doses were adjusted as needed, and patients were followed for up to 36 weeks. The main outcomes were the time from initial treatment to the discontinuation of treatment for any reason and the number of patients with at least minimal improvement on the Clinical Global Impression of Change (CGIC) scale at 12 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences among treatments with regard to the time to the discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median, 8.0 weeks) (P=0.52). The median time to the discontinuation of treatment due to a lack of efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P=0.002). The time to the discontinuation of treatment due to adverse events or intolerability favored placebo. Overall, 24% of patients who received olanzapine, 16% of patients who received quetiapine, 18% of patients who received risperidone, and 5% of patients who received placebo discontinued their assigned treatment owing to intolerability (P=0.009). No significant differences were noted among the groups with regard to improvement on the CGIC scale. Improvement was observed in 32% of patients assigned to olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, and 21% of patients assigned to placebo (P=0.22).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease. (ClinicalTrials.gov number, NCT00015548 [ClinicalTrials.gov].).</AbstractText><CopyrightInformation>Copyright 2006 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>Barry D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>T Scott</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><CollectiveName>CATIE-AD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00015548</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2006 Oct 12;355(15):1604-6. doi: 10.1056/NEJMe068163.</RefSource><PMID Version="1">17035654</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2007 Jan 25;356(4):416; author reply 417-8. doi: 10.1056/NEJMc063094.</RefSource><PMID Version="1">17251541</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2007 Jan 25;356(4):416-7; author reply 417-8.</RefSource><PMID Version="1">17256186</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>ACP J Club. 2007 Mar-Apr;146(2):35.</RefSource><PMID Version="1">17335158</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Clin Pract Neurol. 2007 May;3(5):248-9. doi: 10.1038/ncpneuro0472.</RefSource><PMID Version="1">17389878</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2007 May;10(2):58. doi: 10.1136/ebmh.10.2.58.</RefSource><PMID Version="1">17459989</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Fam Pract. 2007 Jan;56(1):14.</RefSource><PMID Version="1">17607819</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Curr Neurol Neurosci Rep. 2007 Sep;7(5):363-5. doi: 10.1007/s11910-007-0056-9.</RefSource><PMID Version="1">17764624</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa061240</ArticleId><ArticleId IdType="pii">355/15/1525</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17052657</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data.</ArticleTitle><Pagination><StartPage>911</StartPage><EndPage>916</EndPage><MedlinePgn>911-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several genes underlying rare monogenic forms of Parkinson's disease have been identified over the past decade. Despite evidence for a role for genetics in sporadic Parkinson's disease, few common genetic variants have been unequivocally linked to this disorder. We sought to identify any common genetic variability exerting a large effect in risk for Parkinson's disease in a population cohort and to produce publicly available genome-wide genotype data that can be openly mined by interested researchers and readily augmented by genotyping of additional repository subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We did genome-wide, single-nucleotide-polymorphism (SNP) genotyping of publicly available samples from a cohort of Parkinson's disease patients (n=267) and neurologically normal controls (n=270). More than 408,000 unique SNPs were used from the Illumina Infinium I and HumanHap300 assays.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We have produced around 220 million genotypes in 537 participants. This raw genotype data has been and as such is the first publicly accessible high-density SNP data outside of the International HapMap Project. We also provide here the results of genotype and allele association tests.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We generated publicly available genotype data for Parkinson's disease patients and controls so that these data can be mined and augmented by other researchers to identify common genetic variability that results in minor and moderate risk for disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fung</LastName><ForeName>Hon-Chung</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Matarin</LastName><ForeName>Mar</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sim&#xf3;n-S&#xe1;nchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Britton</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Langefeld</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stiegert</LastName><ForeName>Matt L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Schymick</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Okun</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Mandel</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Foote</LastName><ForeName>Kelly D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Ram&#xf3;n L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Peckham</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>De Vrieze</LastName><ForeName>Fabienne Wavrant</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Gwinn-Hardy</LastName><ForeName>Katrina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2006 Nov;5(11):896-7. doi: 10.1016/S1474-4422(06)70580-4.</RefSource><PMID Version="1">17052652</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17052657</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(06)70578-6</ArticleId><ArticleId IdType="pii">S1474-4422(06)70578-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17053149</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>314</Volume><Issue>5798</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Common Kibra alleles are associated with human memory performance.</ArticleTitle><Pagination><StartPage>475</StartPage><EndPage>478</EndPage><MedlinePgn>475-8</MedlinePgn></Pagination><Abstract><AbstractText>Human memory is a polygenic trait. We performed a genome-wide screen to identify memory-related gene variants. A genomic locus encoding the brain protein KIBRA was significantly associated with memory performance in three independent, cognitively normal cohorts from Switzerland and the United States. Gene expression studies showed that KIBRA was expressed in memory-related brain structures. Functional magnetic resonance imaging detected KIBRA allele-dependent differences in hippocampal activations during memory retrieval. Evidence from these experiments suggests a role for KIBRA in human memory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papassotiropoulos</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Psychiatry Research, University of Zurich, Zurich 8057, Switzerland. papas@bli.unizh.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hoerndli</LastName><ForeName>Frederic J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>John V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Kim-Dung</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Corneveaux</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Osborne</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wollmer</LastName><ForeName>M Axel</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Aerni</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Coluccia</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>H&#xe4;nggi</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mondadori</LastName><ForeName>Christian R A</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Buchmann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>de Quervain</LastName><ForeName>Dominique J-F</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH057899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HL086528-01</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24NS051872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C472551">CLSTN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513637">WWC1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013557" MajorTopicYN="N" Type="Geographic">Switzerland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17053149</ArticleId><ArticleId IdType="doi">10.1126/science.1129837</ArticleId><ArticleId IdType="pii">314/5798/475</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17055784</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1550-4131</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Cell metabolism</Title><ISOAbbreviation>Cell Metab</ISOAbbreviation></Journal><ArticleTitle>Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.</ArticleTitle><Pagination><StartPage>349</StartPage><EndPage>362</EndPage><MedlinePgn>349-62</MedlinePgn></Pagination><Abstract><AbstractText>Huntington's disease (HD) is a fatal, dominantly inherited disorder caused by polyglutamine repeat expansion in the huntingtin (htt) gene. Here, we observe that HD mice develop hypothermia associated with impaired activation of brown adipose tissue (BAT). Although sympathetic stimulation of PPARgamma coactivator 1alpha (PGC-1alpha) was intact in BAT of HD mice, uncoupling protein 1 (UCP-1) induction was blunted. In cultured cells, expression of mutant htt suppressed UCP-1 promoter activity; this was reversed by PGC-1alpha expression. HD mice showed reduced food intake and increased energy expenditure, with dysfunctional BAT mitochondria. PGC-1alpha is a known regulator of mitochondrial function; here, we document reduced expression of PGC-1alpha target genes in HD patient and mouse striatum. Mitochondria of HD mouse brain show reduced oxygen consumption rates. Finally, HD striatal neurons expressing exogenous PGC-1alpha were resistant to 3-nitropropionic acid treatment. Altered PGC-1alpha function may thus link transcription dysregulation and mitochondrial dysfunction in HD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda</LastName><ForeName>Victor V</ForeName><Initials>VV</Initials></Author><Author ValidYN="Y"><LastName>Torrence</LastName><ForeName>Anne E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Libby</LastName><ForeName>Randell T</ForeName><Initials>RT</Initials></Author><Author ValidYN="Y"><LastName>Satterfield</LastName><ForeName>Terrence F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Lazarowski</LastName><ForeName>Eduardo R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Merle L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Morton</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Bammler</LastName><ForeName>Theodor K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Strand</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Libin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Easley</LastName><ForeName>Courtney N</ForeName><Initials>CN</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Annette C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Krainc</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Luquet</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>La Spada</LastName><ForeName>Albert R</ForeName><Initials>AR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00057</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK063986</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK17047</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS050352</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Metab</MedlineTA><NlmUniqueID>101233170</NlmUniqueID><ISSNLinking>1550-4131</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486497">PPARGC1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002001" MajorTopicYN="N">Adipose Tissue, Brown</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="N">Body Temperature</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001833" MajorTopicYN="N">Body Temperature Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071248" MajorTopicYN="N">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17055784</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2006.10.004</ArticleId><ArticleId IdType="pii">S1550-4131(06)00332-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17065436</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>43</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism.</ArticleTitle><Pagination><StartPage>10939</StartPage><EndPage>10948</EndPage><MedlinePgn>10939-48</MedlinePgn></Pagination><Abstract><AbstractText>It has been postulated that the development of amyloid plaques in Alzheimer's disease (AD) may result from an imbalance between the generation and clearance of the amyloid-beta peptide (Abeta). Although familial AD appears to be caused by Abeta overproduction, sporadic AD (the most prevalent form) may result from impairment in clearance. Recent evidence suggests that several proteases may contribute to the degradation of Abeta. Furthermore, astrocytes have recently been implicated as a potential cellular mediator of Abeta degradation. In this study, we examined the possibility that matrix metalloproteinases (MMPs), proteases known to be expressed and secreted by astrocytes, could play a role in extracellular Abeta degradation. We found that astrocytes surrounding amyloid plaques showed enhanced expression of MMP-2 and MMP-9 in aged amyloid precursor protein (APP)/presenilin 1 mice. Moreover, astrocyte-conditioned medium (ACM) degraded Abeta, lowering levels and producing several fragments after incubation with synthetic human Abeta(1-40) and Abeta(1-42). This activity was attenuated with specific inhibitors of MMP-2 and -9, as well as in ACM derived from mmp-2 or -9 knock-out (KO) mice. In vivo, significant increases in the steady-state levels of Abeta were found in the brains of mmp-2 and -9 KO mice compared with wild-type controls. Furthermore, pharmacological inhibition of the MMPs with N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide (GM 6001) increased brain interstitial fluid Abeta levels and elimination of half-life in APPsw mice. These results suggest that MMP-2 and -9 may contribute to extracellular brain Abeta clearance by promoting Abeta catabolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Ke-Jie</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Qingli</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Xiaoou</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Haowei</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Fong-Fu</ForeName><Initials>FF</Initials></Author><Author ValidYN="Y"><LastName>Turk</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chung Y</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Jason C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Moo</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS048283</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS48283</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40525</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040525</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60-DK20579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41-RR00954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-DK56341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17065436</ArticleId><ArticleId IdType="pmc">PMC6674654</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2085-06.2006</ArticleId><ArticleId IdType="pii">26/43/10939</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke. 2002;33:2711&#x2013;2717.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411666</ArticleId></ArticleIdList></Reference><Reference><Citation>Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-&#x3b2; peptide (1&#x2013;40) J Neurosci. 1996;16:7910&#x2013;7919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579235</ArticleId><ArticleId IdType="pubmed">8987819</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes K, Turner AJ, Kenny AJ. Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry. J Neurochem. 1992;58:2088&#x2013;2096.</Citation><ArticleIdList><ArticleId IdType="pubmed">1315375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000;275:36621&#x2013;36625.</Citation><ArticleIdList><ArticleId IdType="pubmed">10973971</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbach GJ, Dehn D, Nagel B, Del Turco D, Deller T. Laser microdissection of immunolabeled astrocytes allows quantification of astrocytic gene expression. J Neurosci Methods. 2004a;138:141&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325122</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbach GJ, Dehn D, Del Turco D, Staufenbiel M, Deller T. Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition. Glia. 2004b;48:76&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326617</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004;10:302&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294177</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem. 2002;81:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12067222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb S, Gottschall PE. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem. 1996;66:1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627321</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb S, Wenjun Zhang J, Gottschall PE. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res. 2003;970:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">12706262</ArticleId></ArticleIdList></Reference><Reference><Citation>Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19:608&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">9793760</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem. 2001;276:24540&#x2013;24548.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337485</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem. 2003;278:2081&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464614</ArticleId></ArticleIdList></Reference><Reference><Citation>Emonard H, Marcq V, Mirand C, Hornebeck W. Inhibition of gelatinase A by oleic acid. Ann NY Acad Sci. 1999;878:647&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415797</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003;100:4162&#x2013;4167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Schaefer ME, Stack R, Sullivan M, Summers B. Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci. 1994;732:315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">7978801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschall PE, Yu X, Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res. 1995;42:335&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">8583501</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J. LRP: a bright beacon at the blood-brain barrier. J Clin Invest. 2003;112:1483&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259136</ArticleId><ArticleId IdType="pubmed">14617749</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001;276:47863&#x2013;47868.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604391</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem. 1997;272:22389&#x2013;22392.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278386</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurochkin IV. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci. 2001;26:421&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Yin KJ, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol. 2003;54:379&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953271</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res. 2002;69:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111810</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003;23:1992&#x2013;1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742010</ArticleId><ArticleId IdType="pubmed">12657655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills JC, Andersson N, Hong CV, Stappenbeck TS, Gordon JI. Molecular characterization of mouse gastric epithelial progenitor cells. Proc Natl Acad Sci USA. 2002;99:14819&#x2013;14824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137502</ArticleId><ArticleId IdType="pubmed">12409607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills JC, Andersson N, Stappenbeck TS, Chen CC, Gordon JI. Molecular characterization of mouse gastric zymogenic cells. J Biol Chem. 2003;278:46138&#x2013;46145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12963718</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res. 2002;100:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12008026</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. APMIS. 1999;107:38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase H, Meng Q, Malinovskii V, Huang W, Chung L, Bode W, Maskos K, Brew K. Engineering of selective TIMPs. Ann NY Acad Sci. 1999;878:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima G, Suzuki R, Asai J, Fujimoto T. Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg. 2002;104:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932042</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis. 2001;8:834&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pype S, Moechars D, Dillen L, Mercken M. Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem. 2003;84:602&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558980</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem. 1997;272:6641&#x2013;6646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045694</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730&#x2013;32738.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Kasunic TC, Woods AS, Cotter RJ, Ball MJ, Fridman R. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun. 1994;205:1755&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7811262</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging. 1998;19:S69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562472</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Takaki Y, Iwata N, Trojanowski J, Saido TC. Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. Sci Aging Knowledge Environ. 2003;2003:PE1.</Citation><ArticleIdList><ArticleId IdType="pubmed">12844556</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JP, Wilson DJ. Preparation and characterization of type 1 astrocytes cultured from adult rat cortex, cerebellum, and striatum. Glia. 1992;5:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1531812</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Loffler BM. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J. 1997;328:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218999</ArticleId><ArticleId IdType="pubmed">9396733</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 1993;16:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504355</ArticleId></ArticleIdList></Reference><Reference><Citation>Seta KA, Roth RA. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem Biophys Res Commun. 1997;231:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">9070242</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1&#x2013;40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003;2:506&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878439</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem. 1998;41:640&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484512</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis. 1996;3:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S. The plasmin system is induced by and degrades amyloid-&#x3b2; aggregates. J Neurosci. 2000;20:3937&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772619</ArticleId><ArticleId IdType="pubmed">10818128</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) Crit Rev Biochem Mol Biol. 2002;37:375&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12540195</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry. 1999;38:11570&#x2013;11576.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471309</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Uden E, Mallory M, Veinbergs I, Alford M, Rockenstein E, Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci. 2002;22:9298&#x2013;9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758061</ArticleId><ArticleId IdType="pubmed">12417655</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2003;24:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498966</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20:1657&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772918</ArticleId><ArticleId IdType="pubmed">10684867</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61:1965&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229004</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93:411&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839071</ArticleId><ArticleId IdType="pubmed">9590175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Sweeney D, Gandy SE, Sisodia SS. The profile of soluble amyloid beta protein in cultured cell media: detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem. 1996;271:31894&#x2013;31902.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wang KC, Tarnawski M, Lach B. Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol (Berl) 2000;100:356&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GM, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM, Clements JM. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard. Glia. 1996;18:332&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8972801</ArticleId></ArticleIdList></Reference><Reference><Citation>Woessner JF., Jr Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann NY Acad Sci. 1999;878:388&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease: a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin KJ, Lee JM, Chen SD, Xu J, Hsu CY. Amyloid-&#x3b2; induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J Neurosci. 2002;22:9764&#x2013;9770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757851</ArticleId><ArticleId IdType="pubmed">12427831</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin KJ, Hsu CY, Hu XY, Chen H, Chen SW, Xu J, Lee JM. Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-&#x3b2; peptide-induced cerebrovascular endothelial cell death. J Neurosci. 2006;26:2290&#x2013;2299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674809</ArticleId><ArticleId IdType="pubmed">16495456</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998;21:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498303</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Asahina M, Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol (Berl) 2000;99:91&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JW, Gottschall PE. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J Neurosci Methods. 1997;76:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem. 2004;89:807&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140180</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ, Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ, Snyder RO. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods. 2002;28:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413414</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17071923</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>Pt 11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Proteome-based plasma biomarkers for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3042</StartPage><EndPage>3050</EndPage><MedlinePgn>3042-50</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression. Biomarkers have been sought in CSF but no previous study has used two-dimensional gel electrophoresis coupled with mass spectrometry to seek biomarkers in peripheral tissue. We performed a case-control study of plasma using this proteomics approach to identify proteins that differ in the disease state relative to aged controls. For discovery-phase proteomics analysis, 50 people with Alzheimer's dementia were recruited through secondary services and 50 normal elderly controls through primary care. For validation purposes a total of 511 subjects with Alzheimer's disease and other neurodegenerative diseases and normal elderly controls were examined. Image analysis of the protein distribution of the gels alone identifies disease cases with 56% sensitivity and 80% specificity. Mass spectrometric analysis of the changes observed in two-dimensional electrophoresis identified a number of proteins previously implicated in the disease pathology, including complement factor H (CFH) precursor and alpha-2-macroglobulin (alpha-2M). Using semi-quantitative immunoblotting, the elevation of CFH and alpha-2M was shown to be specific for Alzheimer's disease and to correlate with disease severity although alternative assays would be necessary to improve sensitivity and specificity. These findings suggest that blood may be a rich source for biomarkers of Alzheimer's disease and that CFH, together with other proteins such as alpha-2M may be a specific markers of this illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hye</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College London, MRC Centre for Neurodegeneration Research London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynham</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Thambisetty</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Causevic</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Byers</LastName><ForeName>H L</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rijsdijk</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tabrizi</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Banner</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Poppe</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Sham</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493495">CFH protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000511">alpha-Macroglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-65-4</RegistryNumber><NameOfSubstance UI="D017242">Complement Factor H</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017242" MajorTopicYN="N">Complement Factor H</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015180" MajorTopicYN="N">Electrophoresis, Gel, Two-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="Y">Proteome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000511" MajorTopicYN="N">alpha-Macroglobulins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17071923</ArticleId><ArticleId IdType="doi">10.1093/brain/awl279</ArticleId><ArticleId IdType="pii">129/11/3042</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17081980</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>127</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>The C terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>606</EndPage><MedlinePgn>591-606</MedlinePgn></Pagination><Abstract><AbstractText>Voltage-gated calcium channels play a central role in regulating the electrical and biochemical properties of neurons and muscle cells. One of the ways in which calcium channels regulate long-lasting neuronal properties is by activating signaling pathways that control gene expression, but the mechanisms that link calcium channels to the nucleus are not well understood. We report that a C-terminal fragment of Ca(V)1.2, an L-type voltage-gated calcium channel (LTC), translocates to the nucleus and regulates transcription. We show that this calcium channel associated transcription regulator (CCAT) binds to a nuclear protein, associates with an endogenous promoter, and regulates the expression of a wide variety of endogenous genes important for neuronal signaling and excitability. The nuclear localization of CCAT is regulated both developmentally and by changes in intracellular calcium. These findings provide evidence that voltage-gated calcium channels can directly activate transcription and suggest a mechanism linking voltage-gated channels to the function and differentiation of excitable cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gomez-Ospina</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuruta</LastName><ForeName>Fuminori</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Barreto-Chang</LastName><ForeName>Odmara</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dolmetsch</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS048564</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036681" MajorTopicYN="N">Fluorescence Recovery After Photobleaching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015640" MajorTopicYN="N">Ion Channel Gating</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17081980</ArticleId><ArticleId IdType="mid">NIHMS14679</ArticleId><ArticleId IdType="pmc">PMC1750862</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.10.017</ArticleId><ArticleId IdType="pii">S0092-8674(06)01343-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adler MW, Rogers TJ. Are chemokines the third major system in the brain? J. Leukoc. Biol. 2005;78:1204&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204637</ArticleId></ArticleIdList></Reference><Reference><Citation>An WF, Bowlby MR, Betty M, Cao J, Ling HP, Mendoza G, Hinson JW, Mattsson KI, Strassle BW, Trimmer JS, Rhodes KJ. Modulation of A-type potassium channels by a family of calcium sensors. Nature. 2000;403:553&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">10676964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bading H, Ginty DD, Greenberg ME. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. Science. 1993;260:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097060</ArticleId></ArticleIdList></Reference><Reference><Citation>Barallobre MJ, Pascual M, Del Rio JA, Soriano E. The Netrin family of guidance factors: emphasis on Netrin-1 signalling. Brain Res. Brain Res. Rev. 2005;49:22&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15960985</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrion AM, Link WA, Ledo F, Mellstrom B, Naranjo JR. DREAM is a Ca2+-regulated transcriptional repressor. Nature. 1999;398:80&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078534</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 2005;57:411&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382099</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">9346240</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies TC, Barr KJ, Jones DH, Zhu D, Kidder GM. Multiple members of the connexin gene family participate in preim-plantation development of the mouse. Dev. Genet. 1996;18:234&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">8631157</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jongh KS, Colvin AA, Wang KK, Catterall WA. Differential proteolysis of the full-length form of the L-type calcium channel alpha 1 subunit by calpain. J. Neurochem. 1994;63:1558&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">7931310</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, Heist EK, Tsien RW. Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippo-campal neurons. Nature. 1998;392:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9515967</ArticleId></ArticleIdList></Reference><Reference><Citation>Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC325809</ArticleId><ArticleId IdType="pubmed">6828386</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolmetsch RE, Pajvani U, Fife K, Spotts JM, Greenberg ME. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science. 2001;294:333&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">11598293</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005851</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T, Cuadra AE, Ma H, Bunemann M, Gerhardstein BL, Cheng T, Eick RT, Hosey MM. C-terminal fragments of the alpha 1C (CaV1.2) subunit associate with and regulate L-type calcium channels containing C-terminal-truncated alpha 1C subunits. J. Biol. Chem. 2001;276:21089&#x2013;21097.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274161</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhardstein BL, Gao T, Bunemann M, Puri TS, Adair A, Ma H, Hosey MM. Proteolytic processing of the C terminus of the alpha(1C) subunit of L-type calcium channels and the role of a proline-rich domain in membrane tethering of proteolytic fragments. J. Biol. Chem. 2000;275:8556&#x2013;8563.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722694</ArticleId></ArticleIdList></Reference><Reference><Citation>Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature. 1999;401:703&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537109</ArticleId></ArticleIdList></Reference><Reference><Citation>Guldenagel M, Sohl G, Plum A, Traub O, Teubner B, Weiler R, Willecke K. Expression patterns of connexin genes in mouse retina. J. Comp. Neurol. 2000;425:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">10954839</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase H, Pfitzmaier B, Morano I. Expression of Ca2+ channel subunits during cardiac ontogeny in mice and rats: identification of fetal alpha 1C and beta subunit isoforms. J. Cell. Biochem. 2000;76:695&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Arnold FJ, Bading H. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat. Neurosci. 2001;4:261&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224542</ArticleId></ArticleIdList></Reference><Reference><Citation>Helguera G, Olcese R, Song M, Toro L, Stefani E. Tissue-specific regulation of Ca(2+) channel protein expression by sex hormones. Biochim. Biophys. Acta. 2002;1569:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11853958</ArticleId></ArticleIdList></Reference><Reference><Citation>Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, Gilbert MM, Snutch TP, Catterall WA. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel alpha 1 subunits. J. Cell Biol. 1993;123:949&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200142</ArticleId><ArticleId IdType="pubmed">8227151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hell JW, Westenbroek RE, Breeze LJ, Wang KK, Chavkin C, Catterall WA. N-methyl-D-aspartate receptor-induced proteolytic conversion of postsynaptic class C L-type calcium channels in hippocampal neurons. Proc. Natl. Acad. Sci. USA. 1996;93:3362&#x2013;3367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39613</ArticleId><ArticleId IdType="pubmed">8622942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme JT, Konoki K, Lin TW, Gritsenko MA, Camp DG, II, Bigelow DJ, Catterall WA. Sites of proteolytic processing and noncovalent association of the distal C-terminal domain of CaV1.1 channels in skeletal muscle. Proc. Natl. Acad. Sci. USA. 2005;102:5274&#x2013;5279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC555994</ArticleId><ArticleId IdType="pubmed">15793008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme JT, Yarov-Yarovoy V, Lin TW, Scheuer T, Catterall WA. Autoinhibitory control of the CaV1.2 channel by its proteolytically processed distal C-terminal domain. J. Physiol. 2006;576:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995633</ArticleId><ArticleId IdType="pubmed">16809371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, Thompson RM, Clark HB, Gomez CM. C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Hum. Mol. Genet. 2006;15:1587&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubodera T, Yokota T, Ohwada K, Ishikawa K, Miura H, Matsuoka T, Mizusawa H. Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. Neurosci. Lett. 2003;341:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">12676347</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995;23:1686&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC306922</ArticleId><ArticleId IdType="pubmed">7784172</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science. 1999;286:785&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531066</ArticleId></ArticleIdList></Reference><Reference><Citation>Marg A, Shan Y, Meyer T, Meissner T, Brandenburg M, Vinkemeier U. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J. Cell Biol. 2004;165:823&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172394</ArticleId><ArticleId IdType="pubmed">15210729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur M, Tucker PW, Samuels HH. PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Mol. Cell. Biol. 2001;21:2298&#x2013;2311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86864</ArticleId><ArticleId IdType="pubmed">11259580</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan JI, Curran T. Role of ion flux in the control of c-fos expression. Nature. 1986;322:552&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">2426600</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy TH, Worley PF, Baraban JM. L-type voltage-sensitive calcium channels mediate synaptic activation of immediate early genes. Neuron. 1991;7:625&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">1657056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, McFadden G, Greenberg ME. Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron. 1990;4:571&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">2157471</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996;68:850&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">8779443</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibasaki F, Price ER, Milan D, McKeon F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature. 1996;382:370&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">8684469</ArticleId></ArticleIdList></Reference><Reference><Citation>Venance L, Glowinski J, Giaume C. Electrical and chemical transmission between striatal GABAergic output neurones in rat brain slices. J. Physiol. 2004;559:215&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665072</ArticleId><ArticleId IdType="pubmed">15235091</ArticleId></ArticleIdList></Reference><Reference><Citation>Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Yoo Y, Okuhama NN, Tucker PW, Liu G, Guan JL. Regulation of RNA-polymerase-II-dependent transcription by N-WASP and its nuclear-binding partners. Nat. Cell Biol. 2006;8:756&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767080</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z, Dudek H, Miranti CK, Greenberg ME. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J. Neurosci. 1996;16:5425&#x2013;5436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578897</ArticleId><ArticleId IdType="pubmed">8757255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J. 1990;9:3545&#x2013;3550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552104</ArticleId><ArticleId IdType="pubmed">2170117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17088210</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories.</ArticleTitle><Pagination><StartPage>437</StartPage><EndPage>444</EndPage><MedlinePgn>437-44</MedlinePgn></Pagination><Abstract><AbstractText>Arc/Arg3.1 is robustly induced by plasticity-producing stimulation and specifically targeted to stimulated synaptic areas. To investigate the role of Arc/Arg3.1 in synaptic plasticity and learning and memory, we generated Arc/Arg3.1 knockout mice. These animals fail to form long-lasting memories for implicit and explicit learning tasks, despite intact short-term memory. Moreover, they exhibit a biphasic alteration of hippocampal long-term potentiation in the dentate gyrus and area CA1 with an enhanced early and absent late phase. In addition, long-term depression is significantly impaired. Together, these results demonstrate a critical role for Arc/Arg3.1 in the consolidation of enduring synaptic plasticity and memory storage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plath</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology, Department of Biology-Chemistry-Pharmacy, Freie Universit&#xe4;t Berlin, 14195 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohana</LastName><ForeName>Ora</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Dammermann</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Errington</LastName><ForeName>Mick L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xiaosong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Engelsberg</LastName><ForeName>Arne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mahlke</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Welzl</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kobalz</LastName><ForeName>Ursula</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Stawrakakis</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Esperanza</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Waltereit</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bick-Sander</LastName><ForeName>Anika</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Therstappen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>Sam F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Blanquet</LastName><ForeName>Veronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Salmen</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>B&#xf6;sl</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Lipp</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Seth G N</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Bliss</LastName><ForeName>Tim V P</ForeName><Initials>TV</Initials></Author><Author ValidYN="Y"><LastName>Wolfer</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Kuhl</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U117512674</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092069">activity regulated cytoskeletal-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIV03811UC</RegistryNumber><NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015139" MajorTopicYN="N">Blotting, Southern</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003214" MajorTopicYN="N">Conditioning, Classical</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004307" MajorTopicYN="N">Dose-Response Relationship, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007608" MajorTopicYN="N">Kainic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17088210</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.08.024</ArticleId><ArticleId IdType="pii">S0896-6273(06)00646-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1709023</PMID><DateCompleted><Year>1991</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>1991</Year><Month>May</Month></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Structural stability of paired helical filaments requires microtubule-binding domains of tau: a model for self-association.</ArticleTitle><Pagination><StartPage>717</StartPage><EndPage>728</EndPage><MedlinePgn>717-28</MedlinePgn></Pagination><Abstract><AbstractText>Highly purified and SDS-soluble paired helical filaments (PHFs) were immunogold labeled and immunoblotted with antibodies to tau: Tau 14 (N-terminal half), AH-1 (microtubule-binding domain), and Tau 46 (C-terminal end). The main component of PHFs was modified tau of 68, 64, and 60 kd, also called A68 or PHF-tau. Trypsin digestion reduced the maximum width of PHFs by 10%-20%, increased aggregation of filaments, and abolished the binding of Tau 14, but had no effect on the binding of AH-1. The smallest tau-reactive tryptic fragments were 13 and 7-8 kd, positive with AH-1, and negative with Tau 46. Our results and the model of Crowther and Wischik suggest that by self-association and anti-parallel arrangement of the microtubule-binding domains, PHF-tau forms the backbone of PHFs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ksiezak-Reding</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Albert Einstein College of Medicine, Bronx, New York 10461.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG06803</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG1136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG4145</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.1</RegistryNumber><NameOfSubstance UI="D002918">Chymotrypsin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.4</RegistryNumber><NameOfSubstance UI="D014357">Trypsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002918" MajorTopicYN="N">Chymotrypsin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014357" MajorTopicYN="N">Trypsin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1709023</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(91)90169-z</ArticleId><ArticleId IdType="pii">0896-6273(91)90169-Z</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17110330</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>127</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice.</ArticleTitle><Pagination><StartPage>697</StartPage><EndPage>708</EndPage><MedlinePgn>697-708</MedlinePgn></Pagination><Abstract><AbstractText>Spinocerebellar ataxia type 1 (SCA1) is one of nine inherited, typically adult onset, polyglutamine neurodegenerative diseases. To examine whether development impacts SCA1, we used a conditional transgenic mouse model of SCA1 to delay the postnatal expression of mutant ATXN1 until after completion of cerebellar development. Delayed postnatal expression of mutant ATXN1 led to a substantial reduction in severity of disease in adults in comparison with early postnatal gene expression. This was linked to a destabilization of RORalpha, a transcription factor critical for cerebellar development. In SCA1 mice, there was a depletion of RORalpha and a reduction in expression of genes controlled by RORalpha. Partial loss of RORalpha enhanced mutant ATXN1 pathogenicity. Additionally, evidence points to the existence of a complex containing ATXN1, RORalpha, and the RORalpha coactivator Tip60. These studies indicate RORalpha and Tip60 have a role in SCA1 and suggest a mechanism by which compromising cerebellar development contributes to severity of neurodegeneration in an adult.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>Heliane G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duvick</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zu</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Kerri</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jorgensen</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lysholm</LastName><ForeName>Alana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burright</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zoghbi</LastName><ForeName>Huda Y</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>H Brent</ForeName><Initials>HB</Initials></Author><Author ValidYN="Y"><LastName>Andresen</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Harry T</ForeName><Initials>HT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS22920</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS27699</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS45667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593749">ATXN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067696">Ataxin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067528">Ataxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593750">Atxn1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057094">Nuclear Receptor Subfamily 1, Group F, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539738">RORA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D051548">Histone Acetyltransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2006 Nov 17;127(4):669-71. doi: 10.1016/j.cell.2006.11.010.</RefSource><PMID Version="1">17110325</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067696" MajorTopicYN="N">Ataxin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067528" MajorTopicYN="N">Ataxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051548" MajorTopicYN="N">Histone Acetyltransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008818" MajorTopicYN="N">Mice, Neurologic Mutants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057094" MajorTopicYN="N">Nuclear Receptor Subfamily 1, Group F, Member 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17110330</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.09.036</ArticleId><ArticleId IdType="pii">S0092-8674(06)01296-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17116874</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>49</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>18787</StartPage><EndPage>18792</EndPage><MedlinePgn>18787-92</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid-beta (Abeta) cascade hypothesis of Alzheimer's disease (AD) maintains that accumulation of Abeta peptide constitutes a critical event in the early disease pathogenesis. The direct binding between Abeta and apolipoprotein E (apoE) is an important factor implicated in both Abeta clearance and its deposition in the brain's parenchyma and the walls of meningoencephalic vessels as cerebral amyloid angiopathy. With the aim of testing the effect of blocking the apoE/Abeta interaction in vivo as a potential novel therapeutic target for AD pharmacotherapy, we have developed Abeta12-28P, which is a blood-brain-barrier-permeable nontoxic, and nonfibrillogenic synthetic peptide homologous to the apoE binding site on the full-length Abeta. Abeta12-28P binds with high affinity to apoE, preventing its binding to Abeta, but has no direct effect on Abeta aggregation. Abeta12-28P shows a strong pharmacological effect in vivo. Its systemic administration resulted in a significant reduction of Abeta plaques and cerebral amyloid angiopathy burden and a reduction of the total brain level of Abeta in two AD transgenic mice models. The treatment did not affect the levels of soluble Abeta fraction or Abeta oligomers, indicating that inhibition of the apoE/Abeta interaction in vivo has a net effect of increasing Abeta clearance over deposition and at the same time does not create conditions favoring formation of toxic oligomers. Furthermore, behavioral studies demonstrated that treatment with Abeta12-28P prevents a memory deficit in transgenic animals. These findings provide evidence of another therapeutic approach for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadowski</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. sadowm01@med.nyu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pankiewicz</LastName><ForeName>Joanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Scholtzova</LastName><ForeName>Henrieta</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Pankaj D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Prelli</LastName><ForeName>Frances</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Quartermain</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020245</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG020747</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015408</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 20747</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 15408</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092395">amyloid beta-protein (12-28)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17116874</ArticleId><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="doi">10.1073/pnas.0604011103</ArticleId><ArticleId IdType="pii">0604011103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H. Ann Neurol. 1993;34:752&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239575</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Proc Natl Acad Sci USA. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. J Neurochem. 2004;89:807&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140180</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J. J Clin Invest. 2003;112:1483&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC259136</ArticleId><ArticleId IdType="pubmed">14617749</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C. Neuron. 1995;15:219&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">7619525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J. J Neuropath Exp Neurol. 1998;57:674&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">9690671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Nature. 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Casta&#xf1;o EM, Golabek AA, Vogel T, Frangione B. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li YS, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, et al. Am J Pathol. 2004;165:937&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618605</ArticleId><ArticleId IdType="pubmed">15331417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, et al. Proc Natl Acad Sci USA. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM. J Neurosci. 2003;23:7889&#x2013;7896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740607</ArticleId><ArticleId IdType="pubmed">12944519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Brewer BH, Potter H, Brewer HB., Jr Neurobiol Aging. 1996;17:773&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892351</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Jiang Y, Nixon RA, Mathews PM. Methods Mol Biol. 2005;299:267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980611</ArticleId></ArticleIdList></Reference><Reference><Citation>Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA. Proc Natl Acad Sci USA. 2006;103:3781&#x2013;3786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450154</ArticleId><ArticleId IdType="pubmed">16537455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T. J Neurosci. 2004;24:6277&#x2013;6282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729550</ArticleId><ArticleId IdType="pubmed">15254082</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. J Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe D. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu FM, Lin MT, Milner TA, Gouras GK. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong YS, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, Yamada S, Kumar S, Calero M, Bading J, Frangione B, Holtzman D, Miller CA, Strickland DK, Ghiso J, et al. J Clin Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu ZH, Sagare A, Davis J, Yan SD, Hamm K, Xu F, Parisi M, Larue B, Hu HW, et al. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Neurol. 2003;61:1185&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17121991</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>49</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression.</ArticleTitle><Pagination><StartPage>18727</StartPage><EndPage>18732</EndPage><MedlinePgn>18727-32</MedlinePgn></Pagination><Abstract><AbstractText>The molecular mechanism underlying the pathogenesis of the majority of cases of sporadic Alzheimer's disease (AD) is unknown. A history of stroke was found to be associated with development of some AD cases, especially in the presence of vascular risk factors. Reduced cerebral perfusion is a common vascular component among AD risk factors, and hypoxia is a direct consequence of hypoperfusion. Previously we showed that expression of the beta-site beta-amyloid precursor protein (APP) cleavage enzyme 1 (BACE1) gene BACE1 is tightly controlled at both the transcriptional and translational levels and that increased BACE1 maturation contributes to the AD pathogenesis in Down's syndrome. Here we have identified a functional hypoxia-responsive element in the BACE1 gene promoter. Hypoxia up-regulated beta-secretase cleavage of APP and amyloid-beta protein (Abeta) production by increasing BACE1 gene transcription and expression both in vitro and in vivo. Hypoxia treatment markedly increased Abeta deposition and neuritic plaque formation and potentiated the memory deficit in Swedish mutant APP transgenic mice. Taken together, our results clearly demonstrate that hypoxia can facilitate AD pathogenesis, and they provide a molecular mechanism linking vascular factors to AD. Our study suggests that interventions to improve cerebral perfusion may benefit AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiulian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Brain Research Center, and Graduate Program in Neuroscience, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Guiqiong</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Qing</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Weihui</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Dobie</LastName><ForeName>Frederick</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>L Eric</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Weihong</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17121991</ArticleId><ArticleId IdType="pmc">PMC1693730</ArticleId><ArticleId IdType="doi">10.1073/pnas.0606298103</ArticleId><ArticleId IdType="pii">0606298103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattson MP. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR. Ann NY Acad Sci. 2002;977:9&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480729</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. J Am Med Assoc. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Altieri M, Di Piero V, Pasquini M, Gasparini M, Vanacore N, Vicenzini E, Lenzi GL. Neurology. 2004;62:2193&#x2013;2197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15210881</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Wilson RS, Cochran EJ, Bienias JL, Arnold SE, Evans DA, Bennett DA. Neurology. 2003;60:1082&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682310</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. N Engl J Med. 2003;348:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Kukull W, Mayeux R. Neurology. 2005;64:494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699381</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF. Neurology. 1998;51:159&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674796</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF. J Biol Chem. 1999;274:9038&#x2013;9044.</Citation><ArticleIdList><ArticleId IdType="pubmed">10085152</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LE, Bunn HF. J Biol Chem. 2003;278:19575&#x2013;19578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639949</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh CW, Ratcliffe PJ. Nat Med. 2003;9:677&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778166</ArticleId></ArticleIdList></Reference><Reference><Citation>Halterman MW, Miller CC, Federoff HJ. J Neurosci. 1999;19:6818&#x2013;6824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782875</ArticleId><ArticleId IdType="pubmed">10436039</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulsinelli WA, Brierley JB, Plum F. Ann Neurol. 1982;11:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">7103425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Nagayama T, Jin K, Stetler RA, Zhu RL, Graham SH, Simon RP. J Neurosci. 1998;18:4914&#x2013;4928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792571</ArticleId><ArticleId IdType="pubmed">9634557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp FR, Bernaudin M. Nat Rev Neurosci. 2004;5:437&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, Tong Y, Xiao C, Huang Y, Zhang S, et al. FASEB J. 2005;19:739&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, He G, Song W. FASEB J. 2006;20:1369&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816112</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CAF, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, et al. J Biol Chem. 2005;280:17777&#x2013;17785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749709</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Sudhof TC. J Biol Chem. 2004;279:10542&#x2013;10550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, Paganetti P, Mathews PM, Harroch S, Buxbaum JD. Mol Cell Neurosci. 2004;25:642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">15080893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y. Proc Natl Acad Sci USA. 2001;98:13554&#x2013;13559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B. J Biol Chem. 2003;278:48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R. Nat Med. 2004;10:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge YW, Maloney B, Sambamurti K, Lahiri DK. FASEB J. 2004;18:1037&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Song W. Mol Cell Biol. 2006;26:3353&#x2013;3364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1447409</ArticleId><ArticleId IdType="pubmed">16611980</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Mol Cell Biol. 2004;24:865&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC343820</ArticleId><ArticleId IdType="pubmed">14701757</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Am J Pathol. 2004;164:719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602259</ArticleId><ArticleId IdType="pubmed">14742275</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, Ghetti B, Gambetti P, Tabaton M, Teller JK. Nature. 2000;405:531&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850703</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Ann Neurol. 2002;51:783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112088</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, et al. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Tong Y, Qing H, Chen CH, Song W. FASEB J. 2006;20:1361&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816111</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan A, Curtin PT. Proc Natl Acad Sci USA. 1993;90:3928&#x2013;3932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46419</ArticleId><ArticleId IdType="pubmed">8387202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, et al. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, et al. Proc Natl Acad Sci USA. 2004;101:3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhou W, Tong Y, He G, Song W. FASEB J. 2006;20:285&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449801</ArticleId></ArticleIdList></Reference><Reference><Citation>Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. Neuron. 2003;39:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848931</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerbach ID, Vinters HV. J Neuropathol Exp Neurol. 2006;65:610&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783171</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster NJ, Green KN, Peers C, Vaughan PF. J Neurochem. 2002;83:1262&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472881</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster NJ, Green KN, Settle VJ, Peers C, Vaughan PF. Brain Res Mol Brain Res. 2004;130:161&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM. J Alzheimers Dis. 2003;5:209&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">12897406</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin J, Schneider L, Novit A, Luczak S. Cochrane Database Syst Rev. 2001 CD000359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17122850</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>444</Volume><Issue>7118</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Global variation in copy number in the human genome.</ArticleTitle><Pagination><StartPage>444</StartPage><EndPage>454</EndPage><MedlinePgn>444-54</MedlinePgn></Pagination><Abstract><AbstractText>Copy number variation (CNV) of DNA sequences is functionally significant but has yet to be fully ascertained. We have constructed a first-generation CNV map of the human genome through the study of 270 individuals from four populations with ancestry in Europe, Africa or Asia (the HapMap collection). DNA from these individuals was screened for CNV using two complementary technologies: single-nucleotide polymorphism (SNP) genotyping arrays, and clone-based comparative genomic hybridization. A total of 1,447 copy number variable regions (CNVRs), which can encompass overlapping or adjacent gains or losses, covering 360 megabases (12% of the genome) were identified in these populations. These CNVRs contained hundreds of genes, disease loci, functional elements and segmental duplications. Notably, the CNVRs encompassed more nucleotide content per genome than SNPs, underscoring the importance of CNV in genetic diversity and evolution. The data obtained delineate linkage disequilibrium patterns for many CNVs, and reveal marked variation in copy number among populations. We also demonstrate the utility of this resource for genetic disease studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Redon</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Shumpei</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fitch</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Feuk</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>George H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>T Daniel</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Fiegler</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Shapero</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wenwei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Eun Kyung</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Dallaire</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Juan R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Gratac&#xf2;s</LastName><ForeName>M&#xf2;nica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kalaitzopoulos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Komura</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Lyndal</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Kohji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Somerville</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Tchinda</LastName><ForeName>Joelle</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Valsesia</LastName><ForeName>Armand</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Woodwark</LastName><ForeName>Cara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fengtang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Junjun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zerjal</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Armengol</LastName><ForeName>Lluis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Estivill</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Tyler-Smith</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Nigel P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Aburatani</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Keith W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Stephen W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Hurles</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>077008</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>077009</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>077014</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2006 Nov 23;444(7118):428-9. doi: 10.1038/444428a.</RefSource><PMID Version="1">17122840</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005828" MajorTopicYN="N">Genetics, Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="Y">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">UKMS4526</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17122850</ArticleId><ArticleId IdType="mid">UKMS4526</ArticleId><ArticleId IdType="pmc">PMC2669898</ArticleId><ArticleId IdType="doi">10.1038/nature05329</ArticleId><ArticleId IdType="pii">nature05329</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iafrate AJ, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebat J, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305:525&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15273396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp AJ, et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet. 2005;77:78&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226196</ArticleId><ArticleId IdType="pubmed">15918152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuzun E, et al. Fine-scale structural variation of the human genome. Nat Genet. 2005;37:727&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895083</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet. 2006;38:75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16327808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA. Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet. 2006;38:82&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16327809</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarroll SA, et al. Common deletion polymorphisms in the human genome. Nat Genet. 2006;38:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16468122</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke DP, et al. Linkage Disequilibrium and Heritability of CNPs within Duplicated Regions of the Human Genome. Am J Hum Genet. 2006;79:275&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559496</ArticleId><ArticleId IdType="pubmed">16826518</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredman D, et al. Complex SNP-related sequence variation in segmental genome duplications. Nat Genet. 2004;36:861&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247918</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet. 2006;7:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16418744</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman JL, et al. Copy Number Variation: New Insights in Genome Diversity. Genome Research. 2006;16:949&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">16809666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges CB. The Bar &#x2018;gene&#x2019;: a duplication. Science. 1936;83:210&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">17796454</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckland PR. Polymorphically duplicated genes: their relevance to phenotypic variation in humans. Ann Med. 2003;35:308&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">12952017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen DQ, Webber C, Ponting CP. Bias of Selection on Human Copy-Number Variants. PLoS Genet. 2006;2:e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1366494</ArticleId><ArticleId IdType="pubmed">16482228</ArticleId></ArticleIdList></Reference><Reference><Citation>Repping S, et al. High mutation rates have driven extensive structural polymorphism among human Y chromosomes. Nat Genet. 2006;38:463&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16501575</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, Lupski JR. Molecular mechanisms for genomic disorders. Annu Rev Genomics Hum Genet. 2002;3:199&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupski JR, Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet. 2005;1:e49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352149</ArticleId><ArticleId IdType="pubmed">16444292</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw-Smith C, et al. Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet. 2004;41:241&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735726</ArticleId><ArticleId IdType="pubmed">15060094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez E, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15637236</ArticleId></ArticleIdList></Reference><Reference><Citation>Aitman TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature. 2006;439:851&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482158</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongmans MC, et al. CHARGE syndrome: the phenotypic spectrum of mutations in the CHD7 gene. J Med Genet. 2006;43:306&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563221</ArticleId><ArticleId IdType="pubmed">16155193</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet. 2006;15(Suppl 1):R57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651370</ArticleId></ArticleIdList></Reference><Reference><Citation>IHMC A haplotype map of the human genome. Nature. 2005;437:1299&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiegler H, et al. Accurate and reliable high-throughput detection of copy number variation in the human genome. Genome Res. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665640</ArticleId><ArticleId IdType="pubmed">17122085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff RH, Meijer GA. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH) Nucleic Acids Res. 2006;34:445&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356528</ArticleId><ArticleId IdType="pubmed">16439806</ArticleId></ArticleIdList></Reference><Reference><Citation>Komura D, et al. Genome-Wide Detection of Human Copy Number Variants using High Density DNA Oligonucleotide Arrays. Genome Res. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665641</ArticleId><ArticleId IdType="pubmed">17122084</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries BB, et al. Diagnostic genome profiling in mental retardation. Am J Hum Genet. 2005;77:606&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275609</ArticleId><ArticleId IdType="pubmed">16175506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirtenberger M, Hemminki K, Chen B, Burwinkel B. SNP microarray analysis for genome-wide detection of crossover regions. Hum Genet. 2005;117:389&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15933847</ArticleId></ArticleIdList></Reference><Reference><Citation>Marth GT, Czabarka E, Murvai J, Sherry ST. The allele frequency spectrum in genome-wide human variation data reveals signals of differential demographic history in three large world populations. Genetics. 2004;166:351&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1470693</ArticleId><ArticleId IdType="pubmed">15020430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurles M. How homologous recombination generates a mutable genome. Hum Genomics. 2005;2:179&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525126</ArticleId><ArticleId IdType="pubmed">16197735</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankiewicz P, Lupski JR. Genome architecture, rearrangements and genomic disorders. Trends Genet. 2002;18:74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11818139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey JA, et al. Recent segmental duplications in the human genome. Science. 2002;297:1003&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung J, et al. Genome-wide detection of segmental duplications and potential assembly errors in the human genome sequence. Genome Biol. 2003;4:R25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC154576</ArticleId><ArticleId IdType="pubmed">12702206</ArticleId></ArticleIdList></Reference><Reference><Citation>Aradhya S, et al. Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes. Hum Mol Genet. 2001;10:2557&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709543</ArticleId></ArticleIdList></Reference><Reference><Citation>Neitz M, Neitz J. Numbers and ratios of visual pigment genes for normal red-green color vision. Science. 1995;267:1013&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7863325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chance PF, et al. 2 Autosomal-Dominant Neuropathies Result from Reciprocal DNA Duplication/Deletion of a Region on Chromosome-17. Hum Mol Genet. 1994;3:223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">8004087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupski JR, Stankiewicz P, editors. Genomic Disorders: the genomic basis of disease. Humana Press; Totawa, New Jersey: 2006.</Citation><ArticleIdList><ArticleId IdType="pubmed">18724050</ArticleId></ArticleIdList></Reference><Reference><Citation>Deininger PL, Batzer MA. Alu repeats and human disease. Mol Genet Metab. 1999;67:183&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz S, et al. REPuter: the manifold applications of repeat analysis on a genomic scale. Nucleic Acids Res. 2001;29:4633&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC92531</ArticleId><ArticleId IdType="pubmed">11713313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurles M. Gene duplication: the genomic trade in spare parts. PLoS Biol. 2004;2:E206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449868</ArticleId><ArticleId IdType="pubmed">15252449</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake JA, et al. Conserved noncoding sequences are selectively constrained and not mutation cold spots. Nat Genet. 2006;38:223&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejerano G, et al. Ultraconserved elements in the human genome. Science. 2004;304:1321&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15131266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer C, Holloway S, Zawalnyski P, Schinzel A, FitzPatrick D. A chromosomal duplication map of malformations: regions of suspected haplo- and triplolethality&#x2013;and tolerance of segmental aneuploidy&#x2013;in humans. Am J Hum Genet. 1999;64:1702&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377914</ArticleId><ArticleId IdType="pubmed">10330358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal RR, Rohlf JF. Biometry. W.H. Freeman and Co; 1994.</Citation></Reference><Reference><Citation>Futreal PA, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665285</ArticleId><ArticleId IdType="pubmed">14993899</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JK, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki K, Sasaki H, Jonasson F, Kojima M, Cheng HM. Racial differences of lens transparency properties with aging and prevalence of age-related cataract applying a WHO classification system. Ophthalmic Res. 2004;36:332&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15627834</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentonyte R, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37:357&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15735647</ArticleId></ArticleIdList></Reference><Reference><Citation>Orru S, Giuressi E, Carcassi C, Casula M, Contu L. Mapping of the major psoriasis-susceptibility locus (PSORS1) in a 70-Kb interval around the corneodesmosin gene (CDSN) Am J Hum Genet. 2005;76:164&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1196420</ArticleId><ArticleId IdType="pubmed">15529278</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiansen J, et al. Chromosome 1q21.1 contiguous gene deletion is associated with congenital heart disease. Circ Res. 2004;94:1429&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15117819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupski JR, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66:219&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">1677316</ArticleId></ArticleIdList></Reference><Reference><Citation>Chance PF, et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell. 1993;72:143&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8422677</ArticleId></ArticleIdList></Reference><Reference><Citation>Matise TC, et al. Detection of tandem duplications and implications for linkage analysis. Am J Hum Genet. 1994;54:1110&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1918201</ArticleId><ArticleId IdType="pubmed">8198134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005;6:95&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716906</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Z, Royle NJ, Jeffreys AJ. A novel human DNA polymorphism resulting from transfer of DNA from chromosome 6 to chromosome 16. Genomics. 1990;7:222&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">1971807</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward KJ, et al. Heterogeneous duplications in patients with Pelizaeus-Merzbacher disease suggest a mechanism of coupled homologous and nonhomologous recombination. Am J Hum Genet. 2005;77:966&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1285180</ArticleId><ArticleId IdType="pubmed">16380909</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg NA, et al. Genetic structure of human populations. Science. 2002;298:2381&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamshad MJ, et al. Human population genetic structure and inference of group membership. Am J Hum Genet. 2003;72:578&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180234</ArticleId><ArticleId IdType="pubmed">12557124</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461096</ArticleId><ArticleId IdType="pubmed">10835412</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir BS, Cockerham CC. Estimating F-statistics for the analysis of population structure. Evolution. 1984;38:1358&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">28563791</ArticleId></ArticleIdList></Reference><Reference><Citation>Turgeon D, Carrier JS, Chouinard S, Belanger A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos. 2003;31:670&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12695357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson W, 3rd, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics. 2004;84:707&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475248</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y, et al. Spread of an inactive form of caspase-12 in humans is due to recent positive selection. Am J Hum Genet. 2006;78:659&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1424700</ArticleId><ArticleId IdType="pubmed">16532395</ArticleId></ArticleIdList></Reference><Reference><Citation>Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human genome. PLoS Biol. 2006;4:e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382018</ArticleId><ArticleId IdType="pubmed">16494531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat. 2004;24:277&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15365985</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, et al. A common inversion under selection in Europeans. Nat Genet. 2005;37:129&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabeti PC, et al. Detecting recent positive selection in the human genome from haplotype structure. Nature. 2002;419:832&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397357</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaja R, et al. Genome assembly comparison to identify structural variants in the human genome. Nat Genet. submitted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674632</ArticleId><ArticleId IdType="pubmed">17115057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett EA, Coleman LE, Tsui C, Pittard WS, Devine SE. Natural genetic variation caused by transposable elements in humans. Genetics. 2004;168:933&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1448813</ArticleId><ArticleId IdType="pubmed">15514065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman L, Rousseeuw PJ. Finding groups in data: an introduction to cluster analysis. Wiley; New York: 1990.</Citation></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EC, et al. Searching for signals of evolutionary selection in 168 genes related to immune function. Hum Genet. 2006;119:92&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362345</ArticleId></ArticleIdList></Reference><Reference><Citation>Petes TD. Meiotic recombination hot spots and cold spots. Nat Rev Genet. 2001;2:360&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11331902</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers S, Bottolo L, Freeman C, McVean G, Donnelly P. A fine-scale map of recombination rates and hotspots across the human genome. Science. 2005;310:321&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermitzakis ET, et al. Comparison of human chromosome 21 conserved nongenic sequences (CNGs) with the mouse and dog genomes shows that their selective constraint is independent of their genic environment. Genome Res. 2004;14:852&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC479112</ArticleId><ArticleId IdType="pubmed">15078857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17145504</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss.</ArticleTitle><Pagination><StartPage>831</StartPage><EndPage>843</EndPage><MedlinePgn>831-43</MedlinePgn></Pagination><Abstract><AbstractText>Beta amyloid (Abeta), a peptide generated from the amyloid precursor protein (APP) by neurons, is widely believed to underlie the pathophysiology of Alzheimer's disease. Recent studies indicate that this peptide can drive loss of surface AMPA and NMDA type glutamate receptors. We now show that Abeta employs signaling pathways of long-term depression (LTD) to drive endocytosis of synaptic AMPA receptors. Synaptic removal of AMPA receptors is necessary and sufficient to produce loss of dendritic spines and synaptic NMDA responses. Our studies indicate the central role played by AMPA receptor trafficking in Abeta-induced modification of synaptic structure and function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehm</LastName><ForeName>Jannic</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Malinow</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH049159</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS032827</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH049159</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008444</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018354" MajorTopicYN="N">Alphavirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012845" MajorTopicYN="N">Sindbis Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17145504</ArticleId><ArticleId IdType="mid">NIHMS14785</ArticleId><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.10.035</ArticleId><ArticleId IdType="pii">S0896-6273(06)00872-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashby MC, De La Rue SA, Ralph GS, Uney J, Collingridge GL, Henley JM. Removal of AMPA receptors (AMPARs) from synapses is preceded by transient endocytosis of extrasynaptic AMPARs. J Neurosci. 2004;24:5172&#x2013;5176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309030</ArticleId><ArticleId IdType="pubmed">15175386</ArticleId></ArticleIdList></Reference><Reference><Citation>Baude A, Nusser Z, Roberts JD, Mulvihill E, McIlhinney RA, Somogyi P. The metabotropic glutamate receptor (mGluR1 alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron. 1993;11:771&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">8104433</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M, Malenka RC. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci. 2000;3:1291&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100150</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM. Intraneuronal Abeta causes the onset of early Alzheimer&#x2019;s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350458</ArticleId><ArticleId IdType="pubmed">4727084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolshakov VY, Carboni L, Cobb MH, Siegelbaum SA, Belardetti F. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. Nat Neurosci. 2000;3:1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11036267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolshakov VY, Siegelbaum SA. Postsynaptic induction and presynaptic expression of hippocampal long-term depression. Science. 1994;264:1148&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909958</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgdorff AJ, Choquet D. Regulation of AMPA receptor lateral movements. Nature. 2002;417:649&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12050666</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer GJ. Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res. 1995;42:674&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600300</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TC, Tran IC, Backos DS, Esteban JA. NMDA receptor-dependent activation of the small GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD. Neuron. 2005;45:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabelli RJ, Shelton DL, Segal RA, Shatz CJ. Blockade of endogenous ligands of trkB inhibits formation of ocular dominance columns. Neuron. 1997;19:63&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9247264</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RC, Lissin DV, von Zastrow M, Nicoll RA, Malenka RC. Rapid redistribution of glutamate receptors contributes to long-term depression in hippocampal cultures. Nat Neurosci. 1999;2:454&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321250</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter TL, Rissman RA, Mishizen-Eberz AJ, Wolfe BB, Hamilton RL, Gandy S, Armstrong DM. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer&#x2019;s disease patients according to Braak stage. Exp Neurol. 2004;187:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">15144856</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT. AMPA receptor downscaling at the onset of Alzheimer&#x2019;s disease pathology in double knockin mice. Proc Natl Acad Sci U S A. 2006;103:3410&#x2013;3415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413872</ArticleId><ArticleId IdType="pubmed">16492745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung HJ, Xia J, Scannevin RH, Zhang X, Huganir RL. Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. J Neurosci. 2000;20:7258&#x2013;7267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772789</ArticleId><ArticleId IdType="pubmed">11007883</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A. 1994;91:11993&#x2013;11997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45362</ArticleId><ArticleId IdType="pubmed">7991571</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport. 1997;8:3213&#x2013;3217.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek SM, Bear MF. Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade. Proc Natl Acad Sci U S A. 1992;89:4363&#x2013;4367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49082</ArticleId><ArticleId IdType="pubmed">1350090</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein G, Buranosky R, Crain BJ. Dendritic pathology of granule cells in Alzheimer&#x2019;s disease is unrelated to neuritic plaques. J Neurosci. 1994;14:5077&#x2013;5088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577187</ArticleId><ArticleId IdType="pubmed">8046469</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, Holscher C, Herron CE. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol. 2001;85:708&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160505</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacchino J, Criado JR, Games D, Henriksen S. In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice. Brain Res. 2000;876:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10973607</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Jensen FE, Tsao B. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci. 1992;12:2685&#x2013;2705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575840</ArticleId><ArticleId IdType="pubmed">1613552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science. 2000;287:2262&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731148</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat AJ, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, Knott GW, Svoboda K. Transient and persistent dendritic spines in the neocortex in vivo. Neuron. 2005;45:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka R, Ricoll R, Mucke L. Plaque-independent Disruption of Neuroal Circuits in Alzheimer&#x2019;s Disease Mouse Models. Proc Natl Acad Sci. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, You JL, Wu MY, Hsu KS. Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycene-induced long term depression. J Biol Chem. 2004;279:12286&#x2013;12292.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709549</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Roder JC, Bear MF. Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. J Neurophysiol. 2001;86:321&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431513</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaac J, Nicoll R, Malenka R. Evidence for silent synapses: implication for the expression of LTP. Neuron. 1995;15:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauer JA, Malenka R, Nicoll R. A persistent postsynaptic modification mediates long-term potentiation in the hippocampus. Neuron. 1988;1:911&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CH, Chung HJ, Lee HK, Huganir RL. Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc Natl Acad Sci U S A. 2001a;98:11725&#x2013;11730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58797</ArticleId><ArticleId IdType="pubmed">11573007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Anwyl R, Suh YH, Djamgoz MBA, Rowan MJ. Use-Dependent Effects of Amyloidogenic Fragments of beta-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo. Journal of Neuroscience. 2001b;21:1327&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762223</ArticleId><ArticleId IdType="pubmed">11160403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer&#x2019;s disease. Genes Brain Behav. 2005;4:173&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopec CD, Li B, Wei W, Boehm J, Malinow R. Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J Neurosci. 2006;26:2000&#x2013;2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674938</ArticleId><ArticleId IdType="pubmed">16481433</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003;13:246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901839</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999;840:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10517949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Liu L, Wang YT, Sheng M. Clathrin adaptor AP2 and NSF interact with overlapping sites of GluR2 and play distinct roles in AMPA receptor trafficking and hippocampal LTD. Neuron. 2002;36:661&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">12441055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Simonetta A, Sheng M. Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons. Neuron. 2004;43:221&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260958</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Hessler N, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slices. Nature. 1995;375:400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760933</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JW, Ju W, Foster K, Lee SH, Ahmadian G, Wyszynski M, Wang YT, Sheng M. Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization. Nat Neurosci. 2000;3:1282&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Luscher C, Xia H, Beattie EC, Carroll RC, von Zastrow M, Malenka RC, Nicoll RA. Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron. 1999;24:649&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595516</ArticleId></ArticleIdList></Reference><Reference><Citation>Luthi A, Chittajallu R, Duprat F, Palmer MJ, Benke TA, Kidd FL, Henley JM, Isaac JT, Collingridge GL. Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction. Neuron. 1999;24:389&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571232</ArticleId></ArticleIdList></Reference><Reference><Citation>Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science. 1999;283:1923&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082466</ArticleId></ArticleIdList></Reference><Reference><Citation>Man HY, Lin JW, Ju WH, Ahmadian G, Liu L, Becker LE, Sheng M, Wang YT. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron. 2000;25:649&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774732</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology. 2001;56:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Miesenbock G, De Angelis DA, Rothman JE. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature. 1998;394:192&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9671304</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, et al. Early phenotypic changes in transgenic mice that over-express different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Malenka RC. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron. 1992;9:967&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">1419003</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron. 2004;44:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimchinsky EA, Sabatini BL, Svoboda K. Structure and function of dendritic spines. Annu Rev Physiol. 2002;64:313&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11826272</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusser Z, Lujan R, Laube G, Roberts JD, Molnar E, Somogyi P. Cell type and pathway dependence of synaptic AMPA receptor number and variability in the hippocampus. Neuron. 1998;21:545&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768841</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliet SH, Malenka RC, Nicoll RA. Bidirectional control of quantal size by synaptic activity in the hippocampus. Science. 1996;271:1294&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">8638114</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer MJ, Irving AJ, Seabrook GR, Jane DE, Collingridge GL. The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology. 1997;36:1517&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pubmed">9517422</ArticleId></ArticleIdList></Reference><Reference><Citation>Passafaro M, Nakagawa T, Sala C, Sheng M. Induction of dendritic spines by an extracellular domain of AMPA receptor subunit GluR2. Nature. 2003;424:677&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904794</ArticleId></ArticleIdList></Reference><Reference><Citation>Passafaro M, Piech V, Sheng M. Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. Nat Neurosci. 2001;4:917&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues SM, Schafe GE, LeDoux JE. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron. 2004;44:75&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450161</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25:11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumpel S, LeDoux J, Zador A, Malinow R. Postsynaptic receptor trafficking underlying a form of associative learning. Science. 2005;308:83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush AM, Wu J, Rowan MJ, Anwyl R. Group I metabotropic glutamate receptor (mGluR)-dependent long-term depression mediated via p38 mitogen-activated protein kinase is inhibited by previous high-frequency stimulation and activation of mGluRs and protein kinase C in the rat dentate gyrus in vitro. J Neurosci. 2002;22:6121&#x2013;6128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757950</ArticleId><ArticleId IdType="pubmed">12122073</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell E, Sizemore M, Karimzadegan S, Chen L, Bredt DS, Nicoll RA. Direct interactions between PSD-95 and stargazin control synaptic AMPA receptor number. Proc Natl Acad Sci U S A. 2002;99:13902&#x2013;13907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129795</ArticleId><ArticleId IdType="pubmed">12359873</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidenman KJ, Steinberg JP, Huganir R, Malinow R. Glutamate receptor subunit 2 Serine 880 phosphorylation modulates synaptic transmission and mediates plasticity in CA1 pyramidal cells. J Neurosci. 2003;23:9220&#x2013;9228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740838</ArticleId><ArticleId IdType="pubmed">14534256</ArticleId></ArticleIdList></Reference><Reference><Citation>Selig DK, Hjelmstad GO, Herron C, Nicoll RA, Malenka RC. Independent mechanisms for long-term depression of AMPA and NMDA responses. Neuron. 1995;15:417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">7544143</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D. Alzheimer&#x2019;s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, Kim MJ. Postsynaptic signaling and plasticity mechanisms. Science. 2002;298:776&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399578</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Hayashi Y, Esteban JA, Malinow R. Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell. 2001;105:331&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11348590</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, Mok SS, Bornstein JC. Alzheimer&#x2019;s disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001;2:595&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484003</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR, Bear MF. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat Neurosci. 2001;4:1079&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">11687813</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci. 2004;24:4535&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Takumi Y, Ramirez-Leon V, Laake P, Rinvik E, Ottersen OP. Different modes of expression of AMPA and NMDA receptors in hippocampal synapses. Nat Neurosci. 1999;2:618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">10409387</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorns V, Mallory M, Hansen L, Masliah E. Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer&#x2019;s disease and Lewy body variant. Acta Neuropathol (Berl) 1997;94:539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9444355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Maruyama K, Saido TC, Kume H, Shinozake K, Tokuhiro S, Capell A, Walter J, Grunberg J, Hass C, Iwatsubo T. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci. 1997;94:2025&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20036</ArticleId><ArticleId IdType="pubmed">9050898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyszkiewicz JP, Yan Z. beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J Neurophysiol. 2005;93:3102&#x2013;3111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659527</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W, Gurubhagavatula S, Paradis M, Romano D, Sisodia S, Human B, Neve R, Tanze R. Isolation and Characterization of APLP2 encoding a homologue of the Alzheimer&#x2019;s Associated Amyloid Beta Protein Precursor. Nature Genetics. 1993;5:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220435</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol. 1997;17:2360&#x2013;2371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC232085</ArticleId><ArticleId IdType="pubmed">9111305</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Chung HJ, Wihler C, Huganir RL, Linden DJ. Cerebellar long-term depression requires PKC-regulated interactions between GluR2/3 and PDZ domain-containing proteins [In Process Citation] Neuron. 2000;28:499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144359</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao MY, Zhou Q, Nicoll RA. Metabotropic glutamate receptor activation causes a rapid redistribution of AMPA receptors. Neuropharmacology. 2001;41:664&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11640920</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste R, Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu Rev Neurosci. 2001;24:1071&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanillo D, Sprengel R, Hvalby O, Jensen V, Burnashev N, Rozov A, Kaiser KM, Koster HJ, Borchardt T, Worley P, et al. Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science. 1999;284:1805&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron. 2004;44:749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell. 2002;110:443&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Lin A, Chang P, Gan WB. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron. 2005;46:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15848798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17158800</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>51</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism.</ArticleTitle><Pagination><StartPage>19524</StartPage><EndPage>19529</EndPage><MedlinePgn>19524-9</MedlinePgn></Pagination><Abstract><AbstractText>Phosphatidylinositol 4,5-bisphosphate (PIP2) is an important cellular effector whose functions include the regulation of ion channels and membrane trafficking. Aberrant PIP2 metabolism has also been implicated in a variety of human disease states, e.g., cancer and diabetes. Here we report that familial Alzheimer's disease (FAD)-associated presenilin mutations cause an imbalance in PIP2 metabolism. We find that the transient receptor potential melastatin 7 (TRPM7)-associated Mg2+ -inhibited cation (MIC) channel underlies ion channel dysfunction in presenilin FAD mutant cells, and the observed channel deficits are restored by the addition of PIP2, a known regulator of the MIC/TRPM7 channel. Lipid analyses show that PIP2 turnover is selectively affected in FAD mutant presenilin cells. We also find that modulation of cellular PIP2 closely correlates with 42-residue amyloid beta-peptide (Abeta42) levels. Our data suggest that PIP2 imbalance may contribute to Alzheimer's disease pathogenesis by affecting multiple cellular pathways, such as the generation of toxic Abeta42 as well as the activity of the MIC/TRPM7 channel, which has been linked to other neurodegenerative conditions. Thus, our study suggests that brain-specific modulation of PIP2 may offer a therapeutic approach in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Landman</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Doctoral Program in Neurobiology and Behavior, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Soon Youn</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Sun Young</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Voronov</LastName><ForeName>Sergey V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Serban</LastName><ForeName>Geo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Min Suk</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Myung Kyu</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Sungkwon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Wan</ForeName><Initials>TW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS43467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS51186</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS051186</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD047733</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD047733</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050053">TRPM Cation Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C068961">phosphatidylinositol 4,5-biphosphate kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C486583">TRPM7 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050053" MajorTopicYN="N">TRPM Cation Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: T.-W.K. is a shareholder and consultant of SMART Biosciences, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17158800</ArticleId><ArticleId IdType="pmc">PMC1748258</ArticleId><ArticleId IdType="doi">10.1073/pnas.0604954103</ArticleId><ArticleId IdType="pii">0604954103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Bertram L. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S. J Clin Invest. 2005;115:1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087184</ArticleId><ArticleId IdType="pubmed">15864339</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Landman N, Kim TW. Cytokine Growth Factor Rev. 2004;15:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450250</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Kisslinger JA, Kopan R. Nature. 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Gu Y, Hasegawa H, Ruan X, Arawaka S, Fraser P, Westaway D, Mount H, St George-Hyslop P. J Biol Chem. 2002;277:36521&#x2013;36526.</Citation><ArticleIdList><ArticleId IdType="pubmed">12119298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H, Koo EH. Cell. 2002;110:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297048</ArticleId></ArticleIdList></Reference><Reference><Citation>Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK. EMBO J. 2004;23:2586&#x2013;2596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449766</ArticleId><ArticleId IdType="pubmed">15192701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH. J Biol Chem. 2005;280:31537&#x2013;31547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014629</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse S, Thinakaran G, Luo JJ, Kusiak JW, Tomita T, Iwatsubo T, Qian X, Ginty DD, Price DL, Borchelt DR, et al. Neuron. 1998;21:1213&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856475</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, et al. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. J Cell Biol. 2000;149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulos A, Marambaud P, Efthimiopoulos S, Shioi J, Cui W, Li HC, Schutte M, Gordon R, Holstein GR, Martinelli G, et al. Mol Cell. 1999;4:893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">10635315</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, et al. J Cell Biol. 2004;166:1041&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, Lopes KO, Kim SH, Zheng H, Greengard P, et al. J Biol Chem. 2003;278:3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem JY, Saura CA, Pietrzik C, Christianson J, Wanamaker C, King LT, Veselits ML, Tomita T, Gasparini L, Iwatsubo T, et al. Neurobiol Dis. 2002;11:64&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460547</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Doran M. J Neurol. 2006;253:139&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267640</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rademakers R, Saerens J, Pickut BA, Peeters K, van den Broeck M, Vennekens K, et al. Ann Neurol. 2004;55:617&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122701</ArticleId></ArticleIdList></Reference><Reference><Citation>Parekh AB, Putney JW., Jr Physiol Rev. 2005;85:757&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15788710</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, Kurosaki T, Fleig A, Scharenberg AM. Cell. 2003;114:191&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887921</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh BC, Hille B. Curr Opin Neurobiol. 2005;15:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922587</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, Tymianski M. Cell. 2003;115:863&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermosura MC, Nayakanti H, Dorovkov MV, Calderon FR, Ryazanov AG, Haymer DS, Garruto RM. Proc Natl Acad Sci USA. 2005;102:11510&#x2013;11515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183597</ArticleId><ArticleId IdType="pubmed">16051700</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Nat Cell Biol. 2000;2:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozak JA, Kerschbaum HH, Cahalan MD. J Gen Physiol. 2002;120:221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234455</ArticleId><ArticleId IdType="pubmed">12149283</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakriya M, Lewis RS. J Gen Physiol. 2002;119:487&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2233817</ArticleId><ArticleId IdType="pubmed">11981025</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, et al. J Biol Chem. 2000;275:34086&#x2013;34091.</Citation><ArticleIdList><ArticleId IdType="pubmed">10915801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, et al. Nature. 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Runnels LW, Yue L, Clapham DE. Nat Cell Biol. 2002;4:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941371</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz LF, Hirdes W, Suh BC, Hilgemann DW, Mackie K, Hille B. J Gen Physiol. 2005;126:243&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2266577</ArticleId><ArticleId IdType="pubmed">16129772</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, Moskowitz HS, Gipson K, Wenk MR, Voronov S, Obayashi M, Flavell R, Fitzsimonds RM, Ryan TA, De Camilli P. Nature. 2004;431:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">15386003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrigley JD, Schurov I, Nunn EJ, Martin AC, Clarke EE, Ellis S, Bonnert TP, Shearman MS, Beher D. J Biol Chem. 2005;280:12523&#x2013;12535.</Citation><ArticleIdList><ArticleId IdType="pubmed">15613471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, van Dorsselaer A, Wang R, Selkoe DJ, Wolfe MS. Biochemistry. 2004;43:9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae YS, Lee TG, Park JC, Hur JH, Kim Y, Heo K, Kwak JY, Suh PG, Ryu SH. Mol Pharmacol. 2003;63:1043&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">12695532</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson PS, Garcia EP, Slepnev VI, David C, Zhang X, Grabs D, Sossin WS, Bauerfeind R, Nemoto Y, De Camilli P. Nature. 1996;379:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">8552192</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Muller U, Saftig P, De Strooper B, et al. Proc Natl Acad Sci USA. 2002;99:4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123710</ArticleId><ArticleId IdType="pubmed">11917117</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Schneider I, Dewachter I, Caluwaerts N, Kretzschmar H, Van Leuven F. J Biol Chem. 2003;278:2484&#x2013;2489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12431992</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G. J Biol Chem. 2004;279:44945&#x2013;44954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzman AL, Singh N, Tsiper M, Gregori L, Dranovsky A, Vitek MP, Glabe CG, St George-Hyslop PH, Goldgaber D. Proc Natl Acad Sci USA. 1999;96:7932&#x2013;7937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22165</ArticleId><ArticleId IdType="pubmed">10393925</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, Netzer WJ, Zhong M, Lin Y, Du G, Frohman M, Foster DA, Sisodia SS, Xu H, Gorelick FS, Greengard P. Proc Natl Acad Sci USA. 2006;103:1941&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413665</ArticleId><ArticleId IdType="pubmed">16449386</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, et al. Nat Cell Biol. 2005;7:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumori A, Okochi M, Tagami S, Jiang J, Itoh N, Nakayama T, Yanagida K, Ishizuka-Katsura Y, Morihara T, Kamino K, et al. Biochemistry. 2006;45:4907&#x2013;4914.</Citation><ArticleIdList><ArticleId IdType="pubmed">16605258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SY, Shin SY, Kim HS, Bae CD, Uhm DY, Park MK, Chung S. Biochem Biophys Res Commun. 2006;339:810&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">16325775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17160900</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>80</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>139</EndPage><MedlinePgn>126-39</MedlinePgn></Pagination><Abstract><AbstractText>We report the development and validation of experimental methods, study designs, and analysis software for pooling-based genomewide association (GWA) studies that use high-throughput single-nucleotide-polymorphism (SNP) genotyping microarrays. We first describe a theoretical framework for establishing the effectiveness of pooling genomic DNA as a low-cost alternative to individually genotyping thousands of samples on high-density SNP microarrays. Next, we describe software called "GenePool," which directly analyzes SNP microarray probe intensity data and ranks SNPs by increased likelihood of being genetically associated with a trait or disorder. Finally, we apply these methods to experimental case-control data and demonstrate successful identification of published genetic susceptibility loci for a rare monogenic disease (sudden infant death with dysgenesis of the testes syndrome), a rare complex disease (progressive supranuclear palsy), and a common complex disease (Alzheimer disease) across multiple SNP genotyping platforms. On the basis of these theoretical calculations and their experimental validation, our results suggest that pooling-based GWA studies are a logical first step for determining whether major genetic associations exist in diseases with high heritability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>John V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Translational Genomics Research Institute, Phoenix, AZ, 85004, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Halperin</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Tembe</LastName><ForeName>Waibhav D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Melquist</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Homer</LastName><ForeName>Nils</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Brun</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Szelinger</LastName><ForeName>Szabolcs</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Coon</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Zismann</LastName><ForeName>Victoria L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Aasly</LastName><ForeName>Jan O</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Heun</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kolsch</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magdalini</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Daniilidou</LastName><ForeName>Makrina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Papassotiropoulos</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL086528</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH057899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HL086528-01</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U24NS043571</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS043571</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="Y">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006059" MajorTopicYN="N">Gonadal Dysgenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="Y">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17160900</ArticleId><ArticleId IdType="pmc">PMC1785308</ArticleId><ArticleId IdType="doi">10.1086/510686</ArticleId><ArticleId IdType="pii">S0002-9297(07)60927-6</ArticleId></ArticleIdList><ReferenceList><Title>Web Resources</Title><Reference><Citation>Affymetrix, http://www.affymetrix.com/</Citation></Reference><Reference><Citation>GenePool, http://genepool.tgen.org/</Citation></Reference><Reference><Citation>Illumina, http://www.illumina.com/</Citation></Reference><Reference><Citation>Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for AD, PSP, and SIDDT)</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, Rice J, Foroud T, Uhl GR (2006) Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet 141:844&#x2013;853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922200</ArticleId><ArticleId IdType="pubmed">16894614</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu QR, Drgon T, Walther D, Johnson C, Poleskaya O, Hess J, Uhl GR (2005) Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci USA 102:11864&#x2013;1186910.1073/pnas.0500329102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500329102</ArticleId><ArticleId IdType="pmc">PMC1183486</ArticleId><ArticleId IdType="pubmed">16091475</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig DW, Stephan DA (2005) Applications of whole-genome high-density SNP genotyping. Expert Rev Mol Diagn 5:159&#x2013;17010.1586/14737159.5.2.159</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.5.2.159</ArticleId><ArticleId IdType="pubmed">15833046</ArticleId></ArticleIdList></Reference><Reference><Citation>Butcher LM, Meaburn E, Dale PS, Sham P, Schalkwyk LC, Craig IW, Plomin R (2005) Association analysis of mild mental impairment using DNA pooling to screen 432 brain-expressed single-nucleotide polymorphisms. Mol Psychiatry 10:384&#x2013;39210.1038/sj.mp.4001589</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001589</ArticleId><ArticleId IdType="pubmed">15452586</ArticleId></ArticleIdList></Reference><Reference><Citation>Butcher LM, Meaburn E, Knight J, Sham PC, Schalkwyk LC, Craig IW, Plomin R (2005) SNPs, microarrays and pooled DNA: identification of four loci associated with mild mental impairment in a sample of 6000 children. Hum Mol Genet 14:1315&#x2013;132510.1093/hmg/ddi142</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi142</ArticleId><ArticleId IdType="pubmed">15800012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendoorn B, Norton N, Kirov G, Williams N, Hamshere ML, Spurlock G, Austin J, Stephens MK, Buckland PR, Owen MJ, et al (2000) Cheap, accurate and rapid allele frequency estimation of single nucleotide polymorphisms by primer extension and DHPLC in DNA pools. Hum Genet 107:488&#x2013;49310.1007/s004390000397</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004390000397</ArticleId><ArticleId IdType="pubmed">11140947</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Hellard S, Ballereau SJ, Visscher PM, Torrance HS, Pinson J, Morris SW, Thomson ML, Semple CA, Muir WJ, Blackwood DH, et al (2002) SNP genotyping on pooled DNAs: comparison of genotyping technologies and a semi automated method for data storage and analysis. Nucleic Acids Res 30:e7410.1093/nar/gnf070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gnf070</ArticleId><ArticleId IdType="pmc">PMC137092</ArticleId><ArticleId IdType="pubmed">12140336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinds DA, Seymour AB, Durham LK, Banerjee P, Ballinger DG, Milos PM, Cox DR, Thompson JF, Frazer KA (2004) Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels. Hum Genomics 1:421&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500196</ArticleId><ArticleId IdType="pubmed">15606997</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton N, Williams NM, O&#x2019;Donovan MC, Owen MJ (2004) DNA pooling as a tool for large-scale association studies in complex traits. Ann Med 36:146&#x2013;15210.1080/07853890310021724</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890310021724</ArticleId><ArticleId IdType="pubmed">15119834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sham P, Bader JS, Craig I, O&#x2019;Donovan M, Owen M (2002) DNA pooling: a tool for large-scale association studies. Nat Rev Genet 3:862&#x2013;87110.1038/nrg930</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg930</ArticleId><ArticleId IdType="pubmed">12415316</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt BJ, Payne F, Rance HE, Nutland S, Todd JA, Clayton DG (2002) Identification of the sources of error in allele frequency estimations from pooled DNA indicates an optimal experimental design. Ann Hum Genet 66:393&#x2013;40510.1046/j.1469-1809.2002.00125.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1469-1809.2002.00125.x</ArticleId><ArticleId IdType="pubmed">12485472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal A, van den Boom D, Kammerer S, Honisch C, Adam G, Cantor CR, Kleyn P, Braun A (2002) Association testing by DNA pooling: an effective initial screen. Proc Natl Acad Sci USA 99:16871&#x2013;1687410.1073/pnas.262671399</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.262671399</ArticleId><ArticleId IdType="pmc">PMC139236</ArticleId><ArticleId IdType="pubmed">12475937</ArticleId></ArticleIdList></Reference><Reference><Citation>Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, et al (2001) High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98:581&#x2013;58410.1073/pnas.021506298</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.021506298</ArticleId><ArticleId IdType="pmc">PMC14630</ArticleId><ArticleId IdType="pubmed">11136232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurinke C, van den Boom D, Cantor CR, Koster H (2001) Automated genotyping using the DNA MassArray technology. Methods Mol Biol 170:103&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">11357675</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurinke C, van den Boom D, Cantor CR, Koster H (2002) The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol 77:57&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">12227737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kammerer S, Burns-Hamuro LL, Ma Y, Hamon SC, Canaves JM, Shi MM, Nelson MR, Sing CF, Cantor CR, Taylor SS, et al (2003) Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci USA 100:4066&#x2013;407110.1073/pnas.2628028100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2628028100</ArticleId><ArticleId IdType="pmc">PMC153049</ArticleId><ArticleId IdType="pubmed">12646697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR, Marnellos G, Kammerer S, Hoyal CR, Shi MM, Cantor CR, Braun A (2004) Large-scale validation of single nucleotide polymorphisms in gene regions. Genome Res 14:1664&#x2013;166810.1101/gr.2421604</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.2421604</ArticleId><ArticleId IdType="pmc">PMC509276</ArticleId><ArticleId IdType="pubmed">15289484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K, Oeth P, Kammerer S, Denissenko MF, Ekblom J, Jurinke C, van den Boom D, Braun A, Cantor CR (2004) Mining disease susceptibility genes through SNP analyses and expression profiling using MALDI-TOF mass spectrometry. J Proteome Res 3:218&#x2013;22710.1021/pr034080s</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr034080s</ArticleId><ArticleId IdType="pubmed">15113097</ArticleId></ArticleIdList></Reference><Reference><Citation>Meaburn E, Butcher LM, Liu L, Fernandes C, Hansen V, Al-Chalabi A, Plomin R, Craig I, Schalkwyk LC (2005) Genotyping DNA pools on microarrays: tackling the QTL problem of large samples and large numbers of SNPs. BMC Genomics 6:5210.1186/1471-2164-6-52</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-6-52</ArticleId><ArticleId IdType="pmc">PMC1079828</ArticleId><ArticleId IdType="pubmed">15811185</ArticleId></ArticleIdList></Reference><Reference><Citation>Macgregor S, Visscher PM, Montgomery G (2006) Analysis of pooled DNA samples on high density arrays without prior knowledge of differential hybridization rates. Nucleic Acids Res 34:e5510.1093/nar/gkl136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl136</ArticleId><ArticleId IdType="pmc">PMC1440945</ArticleId><ArticleId IdType="pubmed">16627870</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Zou G, Zhao H (2006) Two-stage designs in case-control association analysis. Genetics 173:1747&#x2013;176010.1534/genetics.105.042648</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.105.042648</ArticleId><ArticleId IdType="pmc">PMC1526674</ArticleId><ArticleId IdType="pubmed">16624925</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbee N, Speed TP (2006) A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics 22:7&#x2013;1210.1093/bioinformatics/bti741</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bti741</ArticleId><ArticleId IdType="pubmed">16267090</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig DW, Huentelman MJ, Hu-Lince D, Zismann VL, Kruer MC, Lee AM, Puffenberger EG, Pearson JM, Stephan DA (2005) Identification of disease causing loci using an array-based genotyping approach on pooled DNA. BMC Genomics 6:13810.1186/1471-2164-6-138</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-6-138</ArticleId><ArticleId IdType="pmc">PMC1262713</ArticleId><ArticleId IdType="pubmed">16197552</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Melquist S, Cruts M, Theuns J, Del-Favero J, Poorkaj P, Baker M, Sleegers K, Crook R, De Pooter T, et al (2005) High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 14:3281&#x2013;329210.1093/hmg/ddi361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi361</ArticleId><ArticleId IdType="pubmed">16195395</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44:2015&#x2013;2019</Citation><ArticleIdList><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, et al (1996) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55:97&#x2013;105</Citation><ArticleIdList><ArticleId IdType="pubmed">8558176</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Osborne D, Reiman EM, Hentz JG, Barbieri CJ, Saunders AM, Hardy J, Graff-Radford NR, Hall GR, Alexander GE (2001) Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. J Neurol Sci 189:93&#x2013;9810.1016/S0022-510X(01)00577-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00577-9</ArticleId><ArticleId IdType="pubmed">11535238</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Hentz JG, Osborne D, Graff-Radford NR, Barbieri CJ, Alexander GE, Hall GR, Reiman EM, Hardy J, Saunders AM (2002) Apolipoprotein E and intellectual achievement. J Am Geriatr Soc 50:49&#x2013;5410.1046/j.1532-5415.2002.50007.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2002.50007.x</ArticleId><ArticleId IdType="pubmed">12028246</ArticleId></ArticleIdList></Reference><Reference><Citation>Toft M, Sando SB, Melquist S, Ross OA, White LR, Aasly JO, Farrer MJ (2005) LRRK2 mutations are not common in Alzheimer&#x2019;s disease. Mech Ageing Dev 126:1201&#x2013;120510.1016/j.mad.2005.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2005.06.010</ArticleId><ArticleId IdType="pubmed">16087219</ArticleId></ArticleIdList></Reference><Reference><Citation>Puffenberger EG, Hu-Lince D, Parod JM, Craig DW, Dobrin SE, Conway AR, Donarum EA, Strauss KA, Dunckley T, Cardenas JF, et al (2004) Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. Proc Natl Acad Sci USA 101:11689&#x2013;1169410.1073/pnas.0401194101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401194101</ArticleId><ArticleId IdType="pmc">PMC511011</ArticleId><ArticleId IdType="pubmed">15273283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovmar L, Ahlford A, Jonsson M, Syvanen AC (2005) Silhouette scores for assessment of SNP genotype clusters. BMC Genomics 6:3510.1186/1471-2164-6-35</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-6-35</ArticleId><ArticleId IdType="pmc">PMC555759</ArticleId><ArticleId IdType="pubmed">15760469</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisco A, Bolshakova N (2002) Clustering genomic expression data: design and evaluation principles. In: Berrar D, Dubitzky W, Granzow M (eds) A practical approach to microarray data analysis. Kwuwer Academic Publishers, Boston, Dordrecht, and London</Citation></Reference><Reference><Citation>Brohede J, Dunne R, McKay JD, Hannan GN (2005) PPC: an algorithm for accurate estimation of SNP allele frequencies in small equimolar pools of DNA using data from high density microarrays. Nucleic Acids Res 33:e14210.1093/nar/gni142</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gni142</ArticleId><ArticleId IdType="pmc">PMC1240117</ArticleId><ArticleId IdType="pubmed">16199750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HC, Pan CC, Lin CY, Fann CS (2006) PDA: pooled DNA analyzer. BMC Bioinformatics 7:23310.1186/1471-2105-7-233</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-233</ArticleId><ArticleId IdType="pmc">PMC1539032</ArticleId><ArticleId IdType="pubmed">16643673</ArticleId></ArticleIdList></Reference><Reference><Citation>Meaburn E, Butcher LM, Schalkwyk LC, Plomin R (2006) Genotyping pooled DNA using 100K SNP microarrays: a step towards genomewide association scans. Nucleic Acids Res 34:e2710.1093/nar/gnj027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gnj027</ArticleId><ArticleId IdType="pmc">PMC1368655</ArticleId><ArticleId IdType="pubmed">16478714</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskvina V, Norton N, Williams N, Holmans P, Owen M, O&#x2019;Donovan M (2005) Streamlined analysis of pooled genotype data in SNP-based association studies. Genet Epidemiol 28:273&#x2013;28210.1002/gepi.20062</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.20062</ArticleId><ArticleId IdType="pubmed">15700279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G, Zhao H (2004) The impacts of errors in individual genotyping and DNA pooling on association studies. Genet Epidemiol 26:1&#x2013;1010.1002/gepi.10277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.10277</ArticleId><ArticleId IdType="pubmed">14691952</ArticleId></ArticleIdList></Reference><Reference><Citation>Huentelman MJ, Craig DW, Shieh AD, Corneveaux JJ, Hu-Lince D, Pearson JV, Stephan DA (2005) SNiPer: improved SNP genotype calling for Affymetrix 10K GeneChip microarray data. BMC Genomics 6:14910.1186/1471-2164-6-149</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-6-149</ArticleId><ArticleId IdType="pmc">PMC1280925</ArticleId><ArticleId IdType="pubmed">16262895</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#x2019;er I, de Bakker PI, Maller J, Yelensky R, Altshuler D, Daly MJ (2006) Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet 38:663&#x2013;66710.1038/ng1816</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1816</ArticleId><ArticleId IdType="pubmed">16715096</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P (2005) A haplotype map of the human genome. Nature 437:1299&#x2013;132010.1038/nature04226</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04226</ArticleId><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>Millenaar FF, Okyere J, May ST, van Zanten M, Voesenek LA, Peeters AJ (2006) How to decide? Different methods of calculating gene expression from short oligonucleotide array data will give different results. BMC Bioinformatics 7:13710.1186/1471-2105-7-137</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-137</ArticleId><ArticleId IdType="pmc">PMC1431565</ArticleId><ArticleId IdType="pubmed">16539732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL (2003) Apolipoprotein E &#x3b5;4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology 60:246&#x2013;252</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L (2004) Risk and protective effects of the APOE gene towards Alzheimer&#x2019;s disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry 75:828&#x2013;83310.1136/jnnp.2003.021493</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.021493</ArticleId><ArticleId IdType="pmc">PMC1739059</ArticleId><ArticleId IdType="pubmed">15145993</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, Baker A, Jonasdottir A, Ingason A, Gudnadottir VG, et al (2005) A common inversion under selection in Europeans. Nat Genet 37:129&#x2013;13710.1038/ng1508</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1508</ArticleId><ArticleId IdType="pubmed">15654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38:209&#x2013;21310.1038/ng1706</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1706</ArticleId><ArticleId IdType="pubmed">16415888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauderman WJ, Morrison JM (2006) Quanto 1.1: a computer program for power and sample size calculations for genetic epidemiology studies (http://hydra.usc.edu/gxe)</Citation></Reference><Reference><Citation>Yang HC, Liang YJ, Huang MC, Li LH, Lin CH, Wu JY, Chen YT, Fann CS (2006) A genome-wide study of preferential amplification/hybridization in microarray-based pooled DNA experiments. Nucleic Acids Res 34:e10610.1093/nar/gkl446</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl446</ArticleId><ArticleId IdType="pmc">PMC1616968</ArticleId><ArticleId IdType="pubmed">16931491</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson CL, Knight J, Butcher LM, Hansen VK, Meaburn E, Schalkwyk LC, Craig IW, Powell JF, Sham PC, Al-Chalabi A (2005) A central resource for accurate allele frequency estimation from pooled DNA genotyped on DNA microarrays. Nucleic Acids Res 33:e2510.1093/nar/gni028</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gni028</ArticleId><ArticleId IdType="pmc">PMC549427</ArticleId><ArticleId IdType="pubmed">15701753</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, et al (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308:385&#x2013;38910.1126/science.1109557</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1109557</ArticleId><ArticleId IdType="pmc">PMC1512523</ArticleId><ArticleId IdType="pubmed">15761122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17167789</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>120</StartPage><EndPage>129</EndPage><MedlinePgn>120-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To find a panel of proteins in antemortem cerebrospinal fluid (CSF) that could be used to differentiate between samples from Alzheimer's disease (AD) patients and samples from healthy and neurological control subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For a test cohort, antemortem CSF proteins from 34 AD and 34 non-AD patients were separated using two-dimensional gel electrophoresis. The resulting protein patterns were analyzed using the random forest multivariate statistical method. Protein spots of interest were identified using tandem time-of-flight mass spectrometry. A validation cohort consisting of CSF from 18 AD patients and 10 non-AD subjects was analyzed in a similar way.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using the test cohort, a panel of 23 spots was identified that could be used to differentiate AD and non-AD gels with a sensitivity of 94%, a specificity of 94%, and a predicted classification error rate of only 5.9%. These proteins are related to the transport of beta-amyloid, the inflammatory response, proteolytic inhibition, and neuronal membrane proteins. The 23 spots separately classified the validation cohort with 90% sensitivity (probable AD subjects), 83% specificity, and a predicted classification error rate of 14% in a blinded analysis. The total observed sensitivity is 93%, the total observed specificity is 90%, and the predicted classification error rate is 8.3%.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">A panel of possible CSF biomarkers for AD has been identified using proteomic methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finehout</LastName><ForeName>Erin J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>School of Chemical and Biomolecular Engineering, Department of Nuerology and Neuroscience, Cornell University Medical College, Ithaca, NY 14853-5201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franck</LastName><ForeName>Zsofia</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Leila H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kelvin H</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01MH59926</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2007 May;61(5):497; author reply 497-8. doi: 10.1002/ana.21109.</RefSource><PMID Version="1">17358005</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015180" MajorTopicYN="N">Electrophoresis, Gel, Two-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17167789</ArticleId><ArticleId IdType="doi">10.1002/ana.21038</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17174898</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>127</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Postnatal deletion of Numb/Numblike reveals repair and remodeling capacity in the subventricular neurogenic niche.</ArticleTitle><Pagination><StartPage>1253</StartPage><EndPage>1264</EndPage><MedlinePgn>1253-64</MedlinePgn></Pagination><Abstract><AbstractText>Neural stem cells are retained in the postnatal subventricular zone (SVZ), a specialized neurogenic niche with unique cytoarchitecture and cell-cell contacts. Although the SVZ stem cells continuously regenerate, how they and the niche respond to local changes is unclear. Here we generated nestin-creER(tm) transgenic mice with inducible Cre recombinase in the SVZ and removed Numb/Numblike, key regulators of embryonic neurogenesis from postnatal SVZ progenitors and ependymal cells. This resulted in severe damage to brain lateral ventricle integrity and identified roles for Numb/Numblike in regulating ependymal wall integrity and SVZ neuroblast survival. Surprisingly, the ventricular damage was eventually repaired: SVZ reconstitution and ventricular wall remodeling were mediated by progenitors that escaped Numb deletion. Our results show a self-repair mechanism in the mammalian brain and may have implications for both niche plasticity in other areas of stem cell biology and the therapeutic use of neural stem cells in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Chay T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Departments of Physiology and Biochemistry, University of California, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzadeh</LastName><ForeName>Zaman</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Soriano-Navarro</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rasin</LastName><ForeName>Mladen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Denan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sestan</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Verdugo</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Alvarez-Buylla</LastName><ForeName>Arturo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jan</LastName><ForeName>Lily Y</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Jan</LastName><ForeName>Yuh-Nung</ForeName><Initials>YN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD045481</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS040929</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS28478</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH084234</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047200</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 R01 NS047200</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577485">Nes protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106293">Numb protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106292">Numbl protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C045073">Cre recombinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D019426">Integrases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004805" MajorTopicYN="N">Ependyma</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019426" MajorTopicYN="N">Integrases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020547" MajorTopicYN="N">Lateral Ventricles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17174898</ArticleId><ArticleId IdType="mid">NIHMS15156</ArticleId><ArticleId IdType="pmc">PMC1876765</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.10.041</ArticleId><ArticleId IdType="pii">S0092-8674(06)01469-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn S, Joyner AL. In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog. Nature. 2005;437:894&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">16208373</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004;41:683&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003168</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdnik D, Torok T, Gonzalez-Gaitan M, Knoblich JA. The endocytic protein alpha-Adaptin is required for numb-mediated asymmetric cell division in Drosophila. Dev Cell. 2002;3:221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand N, Castro DS, Guillemot F. Proneural genes and the specification of neural cell types. Nat Rev Neurosci. 2002;3:517&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094208</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell K. Cortical neuron specification: it has its time and place. Neuron. 2005;46:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882634</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael ST. Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol. 2006;59:735&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16634041</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers CB, Peng Y, Nguyen H, Gaiano N, Fishell G, Nye JS. Spatiotemporal selectivity of response to Notch1 signals in mammalian forebrain precursors. Development. 2001;128:689&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171394</ArticleId></ArticleIdList></Reference><Reference><Citation>Conover JC, Doetsch F, Garcia-Verdugo JM, Gale NW, Yancopoulos GD, Alvarez-Buylla A. Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone. Nat Neurosci. 2000;3:1091&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">11036265</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. Regeneration of a germinal layer in the adult mammalian brain. Proc Natl Acad Sci USA. 1999;96:11619&#x2013;11624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18083</ArticleId><ArticleId IdType="pubmed">10500226</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuccillo M, Joyner AL, Fishell G. Morphogen to mitogen: the multiple roles of hedgehog signalling in vertebrate neural development. Nat Rev Neurosci. 2006;7:772&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">16988653</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz M, Barde YA. Radial glial cells defined and major intermediates between embryonic stem cells and CNS neurons. Neuron. 2005;46:369&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002;244:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11944939</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera DG, Garcia-Verdugo JM, Alvarez-Buylla A. Adult-derived neural precursors transplanted into multiple regions in the adult brain. Ann Neurol. 1999;46:867&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi A, Miyata T, Sawamoto K, Takashita N, Murayama A, Akamatsu W, Ogawa M, Okabe M, Tano Y, Goldman SA, Okano H. Nestin-EGFP transgenic mice: visualization of the self-renewal and multipotency of CNS stem cells. Mol Cell Neurosci. 2001;17:259&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">11178865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegstein AR, Noctor SC. Patterns of neuronal migration in the embryonic cortex. Trends Neurosci. 2004;27:392&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219738</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HS, Wang D, Shen Q, Schonemann MD, Gorski JA, Jones KR, Temple S, Jan LY, Jan YN. Inactivation of Numb and Numblike in embryonic dorsal forebrain impairs neurogenesis and disrupts cortical morphogenesis. Neuron. 2003;40:1105&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim DA, Tramontin AD, Trevejo JM, Herrera DG, Garcia-Verdugo JM, Alvarez-Buylla A. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron. 2000;28:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindvall O, Kokaia Z. Recovery and rehabilitation in stroke: stem cells. Stroke. 2004;35:2691&#x2013;2694.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459434</ArticleId></ArticleIdList></Reference><Reference><Citation>Machold R, Hayashi S, Rutlin M, Muzumdar MD, Nery S, Corbin JG, Gritli-Linde A, Dellovade T, Porter JA, Rubin LL, et al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron. 2003;39:937&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971894</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle FT, Tramontin AD, Garcia-Verdugo JM, Alvarez-Buylla A. Radial glia give rise to adult neural stem cells in the subventricular zone. Proc Natl Acad Sci USA. 2004;101:17528&#x2013;17532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC536036</ArticleId><ArticleId IdType="pubmed">15574494</ArticleId></ArticleIdList></Reference><Reference><Citation>Morhenn VB, Murakami M, O'Grady T, Nordberg J, Gallo RL. Characterization of the expression and function of N-methyl-D-aspartate receptor in keratinocytes. Exp Dermatol. 2004;13:505&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura T, Yamaguchi T, Tokunaga A, Hara A, Hamaguchi T, Kato K, Iwamatsu A, Okano H, Kaibuchi K. Role of numb in dendritic spine development with a Cdc42 GEF intersectin and EphB2. Mol Biol Cell. 2006;17:1273&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382316</ArticleId><ArticleId IdType="pubmed">16394100</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen PH, Zou K, Hwang JK, Jan YN, Zhong W. Progenitor cell maintenance requires numb and numblike during mouse neurogenesis. Nature. 2002;419:929&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">12410312</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen PH, Zou K, Krauss S, Zhong W. Continuing role for mouse Numb and Numbl in maintaining progenitor cells during cortical neurogenesis. Nat Neurosci. 2004;7:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">15273690</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakic P. Developmental and evolutionary adaptations of cortical radial glia. Cereb Cortex. 2003;13:541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764027</ArticleId></ArticleIdList></Reference><Reference><Citation>Roegiers F, Jan YN. Asymmetric cell division. Curr Opin Cell Biol. 2004;16:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15196564</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncarati R, Sestan N, Scheinfeld MH, Berechid BE, Lopez PA, Meucci O, McGlade JC, Rakic P, D'Adamio L. The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. Proc Natl Acad Sci U S A. 2002;99:7102&#x2013;7107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124535</ArticleId><ArticleId IdType="pubmed">12011466</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawamoto K, Wichterle H, Gonzalez-Perez O, Cholfin JA, Yamada M, Spassky N, Murcia NS, Garcia-Verdugo JM, Marin O, Rubenstein JL, et al. New neurons follow the flow of cerebrospinal fluid in the adult brain. Science. 2006;311:629&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp CD, Fowler M, Jackson THt, Houghton J, Warren A, Nanda A, Chandler I, Cappell B, Long A, Minagar A, Alexander JS. Human neuroepithelial cells express NMDA receptors. BMC Neurosci. 2003;4:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC293342</ArticleId><ArticleId IdType="pubmed">14614784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Zhong W, Jan YN, Temple S. Asymmetric Numb distribution is critical for asymmetric cell division of mouse cerebral cortical stem cells and neuroblasts. Development. 2002;129:4843&#x2013;4853.</Citation><ArticleIdList><ArticleId IdType="pubmed">12361975</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916792</ArticleId></ArticleIdList></Reference><Reference><Citation>Spassky N, Merkle FT, Flames N, Tramontin AD, Garcia-Verdugo JM, Alvarez-Buylla A. Adult ependymal cells are postmitotic and are derived from radial glial cells during embryogenesis. J Neurosci. 2005;25:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725217</ArticleId><ArticleId IdType="pubmed">15634762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sur M, Rubenstein JL. Patterning and plasticity of the cerebral cortex. Science. 2005;310:805&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">16272112</ArticleId></ArticleIdList></Reference><Reference><Citation>Temple S. The development of neural stem cells. Nature. 2001;414:112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramontin AD, Garcia-Verdugo JM, Lim DA, Alvarez-Buylla A. Postnatal development of radial glia and the ventricular zone (VZ): a continuum of the neural stem cell compartment. Cereb Cortex. 2003;13:580&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764031</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropepe V, Craig CG, Morshead CM, van der Kooy D. Transforming growth factor-alpha null and senescent mice show decreased neural progenitor cell proliferation in the forebrain subependyma. J Neurosci. 1997;17:7850&#x2013;7859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793925</ArticleId><ArticleId IdType="pubmed">9315905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Gleeson JG. Nucleokinesis in neuronal migration. Neuron. 2005;46:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882636</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaezi A, Bauer C, Vasioukhin V, Fuchs E. Actin cable dynamics and Rho/Rock orchestrate a polarized cytoskeletal architecture in the early steps of assembling a stratified epithelium. Dev Cell. 2002;3:367&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">12361600</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Klein R, Tian X, Cheng HT, Kopan R, Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004;269:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W, Feder JN, Jiang MM, Jan LY, Jan YN. Asymmetric localization of a mammalian numb homolog during mouse cortical neurogenesis. Neuron. 1996;17:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755477</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17179457</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>296</Volume><Issue>23</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Long-term effects of cognitive training on everyday functional outcomes in older adults.</ArticleTitle><Pagination><StartPage>2805</StartPage><EndPage>2814</EndPage><MedlinePgn>2805-14</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Cognitive training has been shown to improve cognitive abilities in older adults but the effects of cognitive training on everyday function have not been demonstrated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the effects of cognitive training on daily function and durability of training on cognitive abilities.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Five-year follow-up of a randomized controlled single-blind trial with 4 treatment groups. A volunteer sample of 2832 persons (mean age, 73.6 years; 26% black), living independently in 6 US cities, was recruited from senior housing, community centers, and hospitals and clinics. The study was conducted between April 1998 and December 2004. Five-year follow-up was completed in 67% of the sample.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Ten-session training for memory (verbal episodic memory), reasoning (inductive reasoning), or speed of processing (visual search and identification); 4-session booster training at 11 and 35 months after training in a random sample of those who completed training.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Self-reported and performance-based measures of daily function and cognitive abilities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The reasoning group reported significantly less difficulty in the instrumental activities of daily living (IADL) than the control group (effect size, 0.29; 99% confidence interval [CI], 0.03-0.55). Neither speed of processing training (effect size, 0.26; 99% CI, -0.002 to 0.51) nor memory training (effect size, 0.20; 99% CI, -0.06 to 0.46) had a significant effect on IADL. The booster training for the speed of processing group, but not for the other 2 groups, showed a significant effect on the performance-based functional measure of everyday speed of processing (effect size, 0.30; 99% CI, 0.08-0.52). No booster effects were seen for any of the groups for everyday problem-solving or self-reported difficulty in IADL. Each intervention maintained effects on its specific targeted cognitive ability through 5 years (memory: effect size, 0.23 [99% CI, 0.11-0.35]; reasoning: effect size, 0.26 [99% CI, 0.17-0.35]; speed of processing: effect size, 0.76 [99% CI, 0.62-0.90]). Booster training produced additional improvement with the reasoning intervention for reasoning performance (effect size, 0.28; 99% CI, 0.12-0.43) and the speed of processing intervention for speed of processing performance (effect size, 0.85; 99% CI, 0.61-1.09).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reasoning training resulted in less functional decline in self-reported IADL. Compared with the control group, cognitive training resulted in improved cognitive abilities specific to the abilities trained that continued 5 years after the initiation of the intervention.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00298558.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Sherry L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Human Development and Family Studies, Pennsylvania State University, State College, PA 16801. slw@psu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tennstedt</LastName><ForeName>Sharon L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Marsiske</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Karlene</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Koepke</LastName><ForeName>Kathy Mann</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Rebok</LastName><ForeName>George W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Frederick W</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Stoddard</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><CollectiveName>ACTIVE Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00298558</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 NR004508</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG14276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG14260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG024102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG14289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NR004507</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NR04508</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG14263</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NR04507</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014263</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG14282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2006 Dec 20;296(23):2852-4. doi: 10.1001/jama.296.23.2852.</RefSource><PMID Version="1">17179463</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008606" MajorTopicYN="N">Mental Processes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17179457</ArticleId><ArticleId IdType="mid">NIHMS24850</ArticleId><ArticleId IdType="pmc">PMC2910591</ArticleId><ArticleId IdType="doi">10.1001/jama.296.23.2805</ArticleId><ArticleId IdType="pii">296/23/2805</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kelly-Hayes M, Jette AM, Wolf PA, D&#x2019;Agostino RB, Odell PM. Functional limitations and disability among elders in the Framingham Study. Am J Public Health. 1992;82:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1694176</ArticleId><ArticleId IdType="pubmed">1533995</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuck AE, Walthert JM, Nikolaus T, Bula CJ, Hohmann C, Beck JC. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med. 1999;48:445&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky FD, Callahan CM, Fitzgerald JF, Johnson RJ. Changes in functional status and the risks of subsequent nursing home placement and death. J Gerontol B Psychol Sci Soc Sci. 1993;48:S94&#x2013;S101.</Citation><ArticleIdList><ArticleId IdType="pubmed">8482831</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis S. Societal Mechanisms for Maintaining Competence in Old Age. Springer Publishing; New York, NY: 1997.</Citation></Reference><Reference><Citation>Royall DR, Palmer R, Chiodo LK, Polk MJ. Normal rates of cognitive change in successful aging: the freedom house study. J Int Neuropsychol Soc. 2005;11:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16519269</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RN, Massman PJ, Doody RS. Cognitive intervention in Alzheimer disease: a randomized placebocontrolled study. Alzheimer Dis Assoc Disord. 2001;15:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry KE, Simmons-D&#x2019;Gerolamo SS. Long-term effectiveness of spaced-retrieval memory training for older adults with probable Alzheimer&#x2019;s disease. Exp Aging Res. 2005;31:261&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebok GW, Balcerak U. Memory self-efficacy and performance differences in young and old adults: effects of mnemonic training. Dev Psychol. 1989;25:714&#x2013;721.</Citation></Reference><Reference><Citation>Willis SL. Cognitive training and everyday competence. Annu Rev Gerontol Geriatr. 1987;7:159&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3120748</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hara R, Brooks JO, III, Friedman L, Schroder CM, Morgan KS, Kraemer HC. Long-term effects of mnemonic training in community-dwelling older adults [published online ahead of print June 14, 2006] J Psychiatr Res. doi:1 0.1016/j.jpsychires.2006.04.01 O.</Citation><ArticleIdList><ArticleId IdType="pubmed">16780878</ArticleId></ArticleIdList></Reference><Reference><Citation>Derwinger A, Stigsdotter Neely A, MacDonald S, Backman L. Forgetting numbers in old age: strategy and learning speed matter. Gerontology. 2005;51:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jobe JB, Smith DM, Ball K, et al. ACTIVE: a cognitive intervention trial to promote independence in older adults. Control Clin Trials. 2001;22:453&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916177</ArticleId><ArticleId IdType="pubmed">11514044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA. 2002;288:2271&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916176</ArticleId><ArticleId IdType="pubmed">12425704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaridis EN, Rudberg MA, Furner SE, Cassel CK. Do activities of daily living have a hierarchical structure? an analysis using the longitudinal study of aging. J Gerontol A Biol Sci Med Sci. 1994;49:M47&#x2013;M51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky F, Miller D. Disability concepts and measurement: contributions of the epidemiology of disability to gerontological inquiry. In: Wilmoth J, Ferraro K, editors. Gerontology: Perspectives and Issues. 3rd ed Springer Publishing; New York, NY: 2006.</Citation></Reference><Reference><Citation>Roenker DL, Cissell GM, Ball KK, Wadley VG, Edwards JD. Speed-of-processing and driving simulator training result in improved driving performance. Hum Factors. 2003;45:218&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">14529195</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark F, Azen SP, Zemke R, et al. Occupational therapy for independent-living older adults: a randomized controlled trial. JAMA. 1997;278:1321&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343462</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis SL, Cornelius SW, Blow FC, Baltes PB. Training research in aging: attentional processes. J Educ Psychol. 1983;75:257&#x2013;270.</Citation></Reference><Reference><Citation>Rasmusson D, Rebok G, Bylsma F, Brandt J. Effects of three types of memory training in normal elderly. Aging Neuropsychol Cogn. 1999;6:56&#x2013;66.</Citation></Reference><Reference><Citation>Willis SL, Schaie KW. Training the elderly on the ability factors of spatial orientation and inductive reasoning. Psychol Aging. 1986;1:239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">3267404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball K. Increased mobility and reducing accidents of older drivers. In: Schaie K, Pietrucha M, editors. Mobility and Transportation in the Elderly. Vol 5. Springer; New York, NY: 2000. pp. 213&#x2013;250.</Citation></Reference><Reference><Citation>Edwards JD, Wadley VG, Myers RS, Roenker DL, Cissell GM, Ball KK. Transfer of a speed of processing intervention to near and far cognitive functions. Gerontology. 2002;48:329&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169801</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125&#x2013;142.</Citation></Reference><Reference><Citation>Rey A. L&#x2019;examen psychologique dans les cas d&#x2019;encephalopathie tramatique. Arch Psychol. 1941;28:286&#x2013;340.</Citation></Reference><Reference><Citation>Wilson B, Cockburn J, Baddeley A. The Rivermead Behavioral Memory Test. Thames Valley Test Co and National Rehabilitation Services; Reading, England and Gaylord, Mich: 1985.</Citation></Reference><Reference><Citation>Gonda J, Schaie K. Schaie-Thurstone Mental Abilities Test: Word Series Test. Consulting Psychologists Press; Palo Alto, Calif: 1985.</Citation></Reference><Reference><Citation>Thurstone L, Thurstone T. Examiner Manual for the SRA Primary Mental Abilities Test (Form 10-14) Science Research Associates; Chicago, III: 1949.</Citation></Reference><Reference><Citation>Ekstrom R, French J, Harman H, Derman D. Kit of Factor-Referenced Cognitive Tests. Revised ed Educational Testing Service; Princeton, NJ: 1976.</Citation></Reference><Reference><Citation>Owsley C, Ball K, Sloane ME, Roenker DL, Bruni JR. Visual/cognitive correlates of vehicle accidents in older drivers. Psychol Aging. 1991;6:403&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">1930757</ArticleId></ArticleIdList></Reference><Reference><Citation>Owsley C, Ball K, McGwin G, Jr, et al. Visual processing impairment and risk of motor vehicle crash among older adults. JAMA. 1998;279:1083&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball KK, Beard BL, Roenker DL, Miller RL, Griggs DS. Age and visual search: expanding the useful field of view. J Opt Soc Am A. 1988;5:2210&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pubmed">3230491</ArticleId></ArticleIdList></Reference><Reference><Citation>Teresi J, Lawton M, Holmes D, Ory M. Measurement in elderly chronic care populations. In: Morris J, Morris S, editors. ADL Assessment Measures for Use With Frail Elders. Springer Publishing Co; New York, NY: 1997.</Citation></Reference><Reference><Citation>Willis S, Marsiske M. Pennsylvania State University; University Park: 1993. Manual for the Everyday Problems Test.</Citation></Reference><Reference><Citation>Diehl M, Marsiske M, Horgas AL, Rosenberg A, Saczynski J, Willis SL. The Revised Observed Tasks of Daily Living: a performance-based assessment of everyday problem solving in older adults. J Appl Gerontol. 2005;24:211&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2153442</ArticleId><ArticleId IdType="pubmed">18160968</ArticleId></ArticleIdList></Reference><Reference><Citation>Owsley C, Sloane M, McGwin G, Jr, Ball K. Timed instrumental activities of daily living tasks: relationship to cognitive function and everyday performance assessments in older adults. Gerontology. 2002;48:254&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">12053117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med. 1997;16:2349&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351170</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom G. Statistical Estimates and Transformed Beta-Variables. Wiley; New York, NY: 1958.</Citation></Reference><Reference><Citation>Lehmann E. Nonparametrics: Statistical Methods Based on Ranks. Holden-Day; San Francisco, Calif: 1975.</Citation></Reference><Reference><Citation>Schafer J. Analysis of Incomplete Multivariate Data. Chapman &amp; Hall; London, England: 1997.</Citation></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed Lawrence Erlbaum Assoc; Mahwah, NJ: 1988.</Citation></Reference><Reference><Citation>Schupf N, Tang MX, Albert SM, et al. Decline in cognitive and functional skills increases mortality risk in nondemented elderly. Neurology. 2005;65:1218&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247048</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaire JC, Marsiske M. Well- and ill-defined measures of everyday cognition: relationship to older adults&#x2019; intellectual ability and functional status. Psychol Aging. 2002;17:101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909873</ArticleId><ArticleId IdType="pubmed">11931279</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis SL. Everyday cognitive competence in elderly persons: conceptual issues and empirical findings. Gerontologist. 1996;36:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">8942103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadley VG, Harrell LE, Marson DC. Self- and informant report of financial abilities in patients with Alzheimer&#x2019;s disease: reliable and valid? J Am Geriatr Soc. 2003;51:1621&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687393</ArticleId></ArticleIdList></Reference><Reference><Citation>Koltai DC, Welsh-Bohmer KA, Schmechel DE. Influence of anosognosia on treatment outcome among dementia patients. Neuropsychol Rehabil. 2001;11:455&#x2013;475.</Citation></Reference><Reference><Citation>Allaire JC, Marsiske M. Everyday cognition: age and intellectual ability correlates. Psychol Aging. 1999;14:627&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904910</ArticleId><ArticleId IdType="pubmed">10632150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky FD, Callahan CM, Fitzgerald JF, Johnson RJ. The risk of nursing home placement and subsequent death among older adults. J Gerontol. 1992;47:5173&#x2013;5182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1624712</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Paul RH, Moser DJ, Cohen RA. Executive impairments predict functional declines in vascular dementia. Clin Neuropsychol. 2004;18:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15595360</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60:185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580702</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001;285:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176911</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried TR, Bradley EH, Williams CS, Tinetti ME. Functional disability and health care expenditures for older persons. Arch Intern Med. 2001;161:2602&#x2013;2607.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718592</ArticleId></ArticleIdList></Reference><Reference><Citation>Plehn K, Marcopulos BA, McLain CA. The relationship between neuropsychological test performance, social functioning, and instrumental activities of daily living in a sample of rural older adults. Clin Neuropsychol. 2004;18:101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">15595362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane R, Kane R, Ladd R. The Heart of Long-Term Care. Oxford University Press; New York, NY: 1998.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17182789</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>51</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>13384</StartPage><EndPage>13389</EndPage><MedlinePgn>13384-9</MedlinePgn></Pagination><Abstract><AbstractText>Normal age-related testosterone depletion in men is a recently identified risk factor for Alzheimer's disease (AD), but how androgen loss affects the development of AD is unclear. To investigate the relationship between androgen depletion and AD, we compared how androgen status affects the progression of neuropathology in the triple transgenic mouse model of AD (3xTg-AD). Adult male 3xTg-AD mice were sham gonadectomized (GDX) or GDX to deplete endogenous androgens and then exposed for 4 months to either the androgen dihydrotestosterone (DHT) or to placebo. In comparison to gonadally intact 3xTg-AD mice, GDX mice exhibited robust increases in the accumulation of beta-amyloid (Abeta), the protein implicated as the primary causal factor in AD pathogenesis, in both hippocampus and amygdala. In parallel to elevated levels of Abeta, GDX mice exhibited significantly impaired spontaneous alternation behavior, indicating deficits in hippocampal function. Importantly, DHT treatment of GDX 3xTg-AD mice attenuated both Abeta accumulation and behavioral deficits. These data demonstrate that androgen depletion accelerates the development of AD-like neuropathology, suggesting that a similar mechanism may underlie the increased risk for AD in men with low testosterone. In addition, our finding that DHT protects against acceleration of AD-like neuropathology predicts that androgen-based hormone therapy may be a useful strategy for the prevention and treatment of AD in aging men.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosario</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Southern California, Los Angeles, California 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Jenna C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Christian J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG000093</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG23739</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00093</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023739</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS052143</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS52143</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17182789</ArticleId><ArticleId IdType="pmc">PMC6674990</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2514-06.2006</ArticleId><ArticleId IdType="pii">26/51/13384</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Hines M. Androgen&#x2013;behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav. 1998;33:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647934</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory, and depression in men. Psychoneuroendocrinology. 2004;29:1071&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219659</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal A&#x3b2; causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-&#x3b2; precursor protein and amyloid-&#x3b2; deposition. J Biol Chem. 2004;279:20539&#x2013;20545.</Citation><ArticleIdList><ArticleId IdType="pubmed">14871891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64:2063&#x2013;2068.</Citation><ArticleIdList><ArticleId IdType="pubmed">15985573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Almeida OP, Fonte J, Lim D, Waterreus A, Spry N, Flicker L, Martins RN. Chemical andropause and amyloid-&#x3b2; peptide. JAMA. 2001;285:2195&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325319</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillett MJ, Martins RN, Clarnette RM, Chubb SA, Bruce DG, Yeap BB. Relationship between testosterone, sex hormone binding globulin, and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis. 2003;5:267&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">14624021</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodenough S, Engert S, Behl C. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci Lett. 2000;296:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11099831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Wang R, Greengard P. Testosterone reduces neuronal secretion of Alzheimer's &#x3b2;-amyloid peptides. Proc Natl Acad Sci USA. 2000;97:1202&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15568</ArticleId><ArticleId IdType="pubmed">10655508</ArticleId></ArticleIdList></Reference><Reference><Citation>Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90:427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12175403</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield JP, Leung LW, Cai D, Kaasik K, Gross RS, Rodriguez-Boulan E, Greengard P, Xu H. Estrogen lowers Alzheimer &#x3b2;-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J Biol Chem. 2002;277:12128&#x2013;12136.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, Smith AD. Serum total testosterone is lower in men with Alzheimer's disease. Neuro Endocrinol Lett. 2001;22:163&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">11449190</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid &#x3b2; precursor protein. J Biol Chem. 1994;269:13065&#x2013;13068.</Citation><ArticleIdList><ArticleId IdType="pubmed">8175728</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138:1015&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310318</ArticleId></ArticleIdList></Reference><Reference><Citation>King D, Arendash GW. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav. 2002;75:627&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Kim JH, Hong SH, Cherny RA, Bush AI, Palmiter RD, Koh JY. Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. J Biol Chem. 2004;279:8602&#x2013;8607.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681234</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin-Allerhand JA, Lominska CE, Wang J, Smith JD. 17&#x3b1;-estradiol and 17&#x3b2;-estradiol treatments are effective in lowering cerebral amyloid-&#x3b2; levels in A&#x3b2;PPSWE transgenic mice. J Alzheimers Dis. 2002;4:449&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12515896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund TD, Hinds LR, Handa RJ. The androgen 5&#x3b1;-dihydrotestosterone and its metabolite 5&#x3b1;-androstan-3&#x3b2;, 17&#x3b2;-diol inhibit the hypothalamo&#x2013;pituitary&#x2013;adrenal response to stress by acting through estrogen receptor &#x3b2;-expressing neurons in the hypothalamus. J Neurosci. 2006;26:1448&#x2013;1456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675494</ArticleId><ArticleId IdType="pubmed">16452668</ArticleId></ArticleIdList></Reference><Reference><Citation>Manthey D, Heck S, Engert S, Behl C. Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur J Biochem. 2001;268:4285&#x2013;4291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11488923</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SM. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62:188&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745052</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE. Androgens and aging. Maturitas. 2001;38:61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311591</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of A&#x3b2;. Am J Pathol. 2006;168:184&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592652</ArticleId><ArticleId IdType="pubmed">16400022</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SC. The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: implications for Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:6612&#x2013;6617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21206</ArticleId><ArticleId IdType="pubmed">9192613</ArticleId></ArticleIdList></Reference><Reference><Citation>Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17&#x3b2;-estradiol modulate the levels of Alzheimer's amyloid &#x3b2; peptides in brain. Exp Gerontol. 2000;35:1317&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfankuch T, Rizk A, Olsen R, Poage C, Raber J. Role of circulating androgen levels in effects of apoE4 on cognitive function. Brain Res. 2005;1053:88&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054121</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ. Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons. Brain Res. 2001;919:160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Rosario ER, Nguyen TV. Androgens, aging, and Alzheimer's disease. Endocrine. 2006;29:233&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16785599</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Bongers G, LeFevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci. 2002;22:5204&#x2013;5209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757715</ArticleId><ArticleId IdType="pubmed">12077215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Nyborg AC, Murphy MP, Chang L, Stanczyk FZ, Golde TE, Pike CJ. Androgens modulate beta-amyloid levels in male rat brain. J Neurochem. 2003;87:1052&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age-related testosterone depletion and the risk for Alzheimer's disease. JAMA. 2004;292:1431&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383512</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer. 2005;103:1381&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15717315</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R. Brain estrogen deficiency accelerates A&#x3b2; plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA. 2005;102:19198&#x2013;19203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1323154</ArticleId><ArticleId IdType="pubmed">16365303</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Huang Y, Zhu YC, Yao T. Estrogen stimulates release of secreted amyloid precursor protein from primary rat cortical neurons via protein kinase C pathway. Acta Pharmacol Sin. 2005;26:171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15663894</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Xu H, Uljon SN, Gross R, Hardy K, Gaynor J, Lafrancois J, Simpkins J, Refolo LM, Petanceska S, Wang R, Duff K. Modulation of A&#x3b2; peptides by estrogen in mouse models. J Neurochem. 2002;80:191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796757</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17183151</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1387-2877</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>406</EndPage><MedlinePgn>399-406</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment with HMG-CoA reductase inhibitors ("statins") has been variably associated with a reduced risk of Alzheimer's disease (AD) in epidemiologic studies and reduced amyloid-beta (Abeta) deposition in animal models of AD. Putative neuroprotective effects of statins may vary in relation to their ability to penetrate into the central nervous system (CNS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We measured levels of cerebrospinal fluid (CSF) AD biomarkers following 14 weeks of treatment with simvastatin (a CNS permeant statin; n=10) at 40 mg/day or pravastatin (a CNS impermeant statin; n=13) at 80 mg/day in hypercholesterolemic subjects without dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Simvastatin, but not pravastatin, reduced CSF levels of phospho-tau-181 (p-tau181) in all subjects. There were no differences in CSF levels of total tau, Abeta42, Abeta40, soluble amyloid beta protein precursor (sAbetaPP) alpha or beta, or F2-isoprostanes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Statins may modulate the phosphorylation of tau in humans and this effect may depend on the CNS availability of the statin. These results suggest another mechanism by which statins may act to reduce the risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riekse</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Geriatric Medicine, University of Washington School of Medicine, and VA Puget Sound Health Care System, Seattle, WA 98108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Petrie</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Vavrek</LastName><ForeName>Darcy</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vuletic</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Albers</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Seubert</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Hazzard</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG023670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL30086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG20020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028441">F2-Isoprostanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C500436">amyloid beta-peptide (5-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>AGG2FN16EV</RegistryNumber><NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>KXO2KT9N0G</RegistryNumber><NameOfSubstance UI="D017035">Pravastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Alzheimers Dis. 2006 Dec;10(4):407-8. doi: 10.3233/jad-2006-10409.</RefSource><PMID Version="1">17183152</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028441" MajorTopicYN="N">F2-Isoprostanes</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017035" MajorTopicYN="N">Pravastatin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17183151</ArticleId><ArticleId IdType="doi">10.3233/jad-2006-10408</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17187063</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>148</EndPage><MedlinePgn>139-48</MedlinePgn></Pagination><Abstract><AbstractText>Hyperphosphorylated forms of the microtubule-associated protein (MAP) tau accumulate in Alzheimer's disease and related tauopathies and are thought to have an important role in neurodegeneration. However, the mechanisms through which phosphorylated tau induces neurodegeneration have remained elusive. Here, we show that tau-induced neurodegeneration is associated with accumulation of filamentous actin (F-actin) and the formation of actin-rich rods in Drosophila and mouse models of tauopathy. Importantly, modulating F-actin levels genetically leads to dramatic modification of tau-induced neurodegeneration. The ability of tau to interact with F-actin in vivo and in vitro provides a molecular mechanism for the observed phenotypes. Finally, we show that the Alzheimer's disease-linked human beta-amyloid protein (Abeta) synergistically enhances the ability of wild-type tau to promote alterations in the actin cytoskeleton and neurodegeneration. These findings raise the possibility that a direct interaction between tau and actin may be a critical mediator of tau-induced neurotoxicity in Alzheimer's disease and related disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fulga</LastName><ForeName>Tudor A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Harvard New Research Building Room 652, 77 Louis Pasteur Avenue, Boston, MA 02115, USA. Tudor_Fulga@hms.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elson-Schwab</LastName><ForeName>Ilan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Steinhilb</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Spires</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG19790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2007 Feb;9(2):133-4. doi: 10.1038/ncb0207-133.</RefSource><PMID Version="1">17268475</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId><ArticleId IdType="doi">10.1038/ncb1528</ArticleId><ArticleId IdType="pii">ncb1528</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17190607</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>127</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>29</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Neuronal transcriptome of Aplysia: neuronal compartments and circuitry.</ArticleTitle><Pagination><StartPage>1453</StartPage><EndPage>1467</EndPage><MedlinePgn>1453-67</MedlinePgn></Pagination><Abstract><AbstractText>Molecular analyses of Aplysia, a well-established model organism for cellular and systems neural science, have been seriously handicapped by a lack of adequate genomic information. By sequencing cDNA libraries from the central nervous system (CNS), we have identified over 175,000 expressed sequence tags (ESTs), of which 19,814 are unique neuronal gene products and represent 50%-70% of the total Aplysia neuronal transcriptome. We have characterized the transcriptome at three levels: (1) the central nervous system, (2) the elementary components of a simple behavior: the gill-withdrawal reflex-by analyzing sensory, motor, and serotonergic modulatory neurons, and (3) processes of individual neurons. In addition to increasing the amount of available gene sequences of Aplysia by two orders of magnitude, this collection represents the largest database available for any member of the Lophotrochozoa and therefore provides additional insights into evolutionary strategies used by this highly successful diversified lineage, one of the three proposed superclades of bilateral animals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moroz</LastName><ForeName>Leonid L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>The Whitney Laboratory for Marine Bioscience, University of Florida, 9505 Ocean Shore Boulevard, St. Augustine, FL 32080, USA. moroz@whitney.ufl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Puthanveettil</LastName><ForeName>Sathyanarayanan V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Kohn</LastName><ForeName>Andrea B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Heyland</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Bjarne</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sahni</LastName><ForeName>Anuj</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fahong</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jezzini</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lovell</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Iannucculli</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Minchen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tuan</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Huitao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Regina</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kalachikov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Panchin</LastName><ForeName>Yuri V</ForeName><Initials>YV</Initials></Author><Author ValidYN="Y"><LastName>Farmerie</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Jingyue</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kandel</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 HG002806</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH075026</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039103</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39103</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001048" MajorTopicYN="N">Aplysia</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020224" MajorTopicYN="N">Expressed Sequence Tags</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017952" MajorTopicYN="N">Ganglia, Invertebrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005880" MajorTopicYN="N">Gills</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="Y">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="Y">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17190607</ArticleId><ArticleId IdType="mid">NIHMS578064</ArticleId><ArticleId IdType="pmc">PMC4024467</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.09.052</ArticleId><ArticleId IdType="pii">S0092-8674(06)01595-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguinaldo AM, Turbeville JM, Linford LS, Rivera MC, Garey JR, Raff RA, Lake JA. Evidence for a clade of nematodes, arthropods and other moulting animals. Nature. 1997;387:489&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168109</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannvall K, Hjelm H, Korhonen L, Lahtinen U, Lehesjoki AE, Lindholm D. Cystatin-B is expressed by neural stem cells and by differentiated neurons and astrocytes. Biochem Biophys Res Commun. 2003;308:369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901878</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusca RC, Brusca GJ. Invertebrates. 2. Sunderland, MA: Sinauer Associates, Inc; 2003.</Citation></Reference><Reference><Citation>Cash D, Carew TJ. A quantitative analysis of the development of the central nervous system in juvenile Aplysia californica. J Neurobiol. 1989;20:25&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">2921607</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JY, Bottjer DJ, Oliveri P, Dornbos SQ, Gao F, Ruffins S, Chi H, Li CW, Davidson EH. Small bilaterian fossils from 40 to 55 million years before the Cambrian. Science. 2004;305:218&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178752</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary LJ, Byrne JH. Identification and characterization of a multifunction neuron contributing to defensive arousal in Aplysia. J Neurophysiol. 1993;70:1767&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">8294951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cravchik A, Subramanian G, Broder S, Venter JC. Sequence analysis of the human genome: implications for the understanding of nervous system function and disease. Arch Neurol. 2001;58:1772&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708983</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rosa R, Grenier JK, Andreeva T, Cook CE, Adoutte A, Akam M, Carroll SB, Balavoine G. Hox genes in brachiopods and priapulids and protostome evolution. Nature. 1999;399:772&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391241</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Rios M, Suess E, Miller MW. Localization of GABA-like immunoreactivity in the central nervous system of Aplysia californica. J Comp Neurol. 1999;413:255&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10524338</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald KK, Takacs CA, Carew TJ. Nonassociative and associative modification of head-waving produced by aversive tentacular stimuli in Aplysia. Learn Mem. 1997;3:366&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">10456104</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu GK, Starnes S, Stuve LL. Construction of uni-directionally cloned cDNA libraries from messenger RNA for improved 3&#x2032; end DNA sequencing. 6, 387,624 US patent. 2002 May;</Citation></Reference><Reference><Citation>Fujisawa Y, Furukawa Y, Ohta S, Ellis TA, Dembrow NC, Li L, Floyd PD, Sweedler JV, Minakata H, Nakamaru K, et al. The Aplysia mytilus inhibitory peptide-related peptides: identification, cloning, processing, distribution, and action. J Neurosci. 1999;19:9618&#x2013;9634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782896</ArticleId><ArticleId IdType="pubmed">10531464</ArticleId></ArticleIdList></Reference><Reference><Citation>Giller E, Jr, Schwartz JH. Choline acetyltransferase in identified neurons of abdominal ganglion of Aplysia californica. J Neurophysiol. 1971;34:93&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">5540582</ArticleId></ArticleIdList></Reference><Reference><Citation>Giribet G, Okusu A, Lindgren AR, Huff SW, Schrodl M, Nishiguchi MK. Evidence for a clade composed of molluscs with serially repeated structures: Monoplacophorans are related to chitons. Proc Natl Acad Sci USA. 2006;103:7723&#x2013;7728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472512</ArticleId><ArticleId IdType="pubmed">16675549</ArticleId></ArticleIdList></Reference><Reference><Citation>Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X, Golic KG, Jacobsen SE, Bestor TH. Methylation of tRNAAsp by the DNA Methyltransferase Homolog Dnmt2. Science. 2006;311:395&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424344</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande C, Templado J, Cervera JL, Zardoya R. Molecular phylogeny of Euthyneura (Mollusca: Gastropoda) Mol Biol Evol. 2004a;21:303&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">14660702</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande C, Templado J, Cervera JL, Zardoya R. Phylogenetic relationships among Opisthobranchia (Mollusca: Gastropoda) based on mitochondrial cox 1, trnV, and rrnL genes. Mol Phylogenet Evol. 2004b;33:378&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15336672</ArticleId></ArticleIdList></Reference><Reference><Citation>Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52:696&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">14530136</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag ES, Sly BJ, Andrews ME, Raff RA. Apextrin, a novel extracellular protein associated with larval ectoderm evolution in Heliocidaris erythrogramma. Dev Biol. 1999;211:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">10373306</ArticleId></ArticleIdList></Reference><Reference><Citation>Halanych KM. The new view of animal phylogeny. Annu Rev Ecol Syst. 2004;35:229&#x2013;256.</Citation></Reference><Reference><Citation>Haszprunar G. Is the Aplacophora monophyletic? A cladistic point of view. Amer Malacol Bull. 2000;15:115&#x2013;130.</Citation></Reference><Reference><Citation>Hening WA, Walters ET, Carew TJ, Kandel ER. Motorneuronal control of locomotion in Aplysia. Brain Res. 1979;179:231&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">509237</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyland A, Price AD, Bodnarova-Buganova M, Moroz LL. Thyroid hormone metabolism and peroxidase function in two non-chordate animals. J Exp Zoolog B Mol Dev Evol. 2006;306:551&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">16739141</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland ND. Early central nervous system evolution: an era of skin brains? Nat Rev Neurosci. 2003;4:617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12894237</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahan-Parwar B, Fredman SM. Neural control of locomotion in Aplysia: role of the central ganglia. Behav Neural Biol. 1979;27:39&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">496793</ArticleId></ArticleIdList></Reference><Reference><Citation>Jezzini SH, Moroz LL. Identification and distribution of a two-pore domain potassium channel in the CNS of Aplysia californica. Brain Res Mol Brain Res. 2004;127:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jezzini SH, Bodnarova M, Moroz LL. Two-color in situ hybridization in the CNS of Aplysia californica. J Neurosci Methods. 2005;149:15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16061289</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Taylor WR, Thornton JM. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci. 1992;8:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">1633570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER. Cellular Basis of Behavior. San Francisco: W.H. Freeman and Company; 1976.</Citation></Reference><Reference><Citation>Kandel ER. Behavioral Biology of Aplysia. San Francisco: W.H. Freeman and Company; 1979.</Citation></Reference><Reference><Citation>Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">11691980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER, Tauc L. Anomalous rectification in the meta-cerebral giant cells and its consequences for synaptic transmission. J Physiol. 1966;183:287&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1357579</ArticleId><ArticleId IdType="pubmed">5942815</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen B, Kohn AB, Nahir B, McFadden CS, Moroz LL. Complete DNA sequence of the mitochondrial genome of the sea-slug, Aplysia californica: conservation of the gene order in Euthyneura. Mol Phylogenet Evol. 2006;38:459&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortschak RD, Samuel G, Saint R, Miller DJ. EST analysis of the cnidarian Acropora millepora reveals extensive gene loss and rapid sequence divergence in the model invertebrates. Curr Biol. 2003;13:2190&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pubmed">14680636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupfermann I. Feeding behavior in Aplysia: a simple system for the study of motivation. Behav Biol. 1974;10:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">4815142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupfermann I, Kandel ER. Neuronal controls of a behavioral response mediated by the abdominal ganglion of Aplysia. Science. 1969;164:847&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">5767790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupfermann I, Weiss KR. Activity of an identified serotonergic neuron in free moving Aplysia correlates with behavioral arousal. Brain Res. 1982;241:334&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusserow A, Pang K, Sturm C, Hrouda M, Lentfer J, Schmidt HA, Technau U, von Haeseler A, Hobmayer B, Martindale MQ, Holstein TW. Unexpected complexity of the Wnt gene family in a sea anemone. Nature. 2005;433:156&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15650739</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehesjoki AE. Molecular background of progressive myoclonus epilepsy. EMBO J. 2003;22:3473&#x2013;3478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165608</ArticleId><ArticleId IdType="pubmed">12853462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell P, Moroz LL. The largest growth cones in the animal kingdom and dynamics of neuronal growth in cell culture of Aplysia. Integr Comp Biol. 2006;46:847&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">21672790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lydeard C, Holznagel WE, Schnare MN, Gutell RR. Phylogenetic analysis of molluscan mitochondrial LSU rDNA sequences and secondary structures. Mol Phylogenet Evol. 2000;15:83&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764537</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DJ, Ball EE, Technau U. Cnidarians and ancestral genetic complexity in the animal kingdom. Trends Genet. 2005;21:536&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098631</ArticleId></ArticleIdList></Reference><Reference><Citation>Moccia R, Chen D, Lyles V, Kapuya EEY, Kalachikov S, Spahn CM, Frank J, Kandel ER, Barad M, Martin KC. An unbiased cDNA library prepared from isolated Aplysia sensory neuron processes is enriched for cytoskeletal and translational mRNAs. J Neurosci. 2003;23:9409&#x2013;9417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740582</ArticleId><ArticleId IdType="pubmed">14561869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachin L, Nannmark U, Nystrom T. Differential roles of the universal stress proteins of Escherichia coli in oxidative stress resistance, adhesion, and motility. J Bacteriol. 2005;187:6265&#x2013;6272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1236625</ArticleId><ArticleId IdType="pubmed">16159758</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen C. Animal Evolution: Interrelationships of the Living Phyla. 2. Oxford: Oxford Univ. Press; 2001.</Citation></Reference><Reference><Citation>Nielsen C. Larval and adult brains. Evol Dev. 2005;7:483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">16174040</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamaneck Y, Halanych KM. Lophotrochozoan phylogeny assessed with LSU and SSU data: Evidence of lophophorate polyphyly. Mol Phylogenet Evol. 2006;40:20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556507</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamaneck YJ, Schander C, Halanych KM. Investigation of molluscan phylogeny using large-subunit and small-subunit nuclear rRNA sequences. Mol Phylogenet Evol. 2004;32:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186794</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson KJ, Eernisse DJ. Animal phylogeny and the ancestry of bilaterians: inferences from morphology and 18S rDNA gene sequences. Evol Dev. 2001;3:170&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440251</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip GK, Creevey CJ, McInerney JO. The Opisthokonta and the Ecdysozoa may not be clades: stronger support for the grouping of plant and animal than for animal and fungi and stronger support for the Coelomata than Ecdysozoa. Mol Biol Evol. 2005;22:1175&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703245</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippe H, Lartillot N, Brinkmann H. Multigene analyses of bilaterian animals corroborate the monophyly of ecdysozoa, lophotrochozoa, and protostomia. Mol Biol Evol. 2005;22:1246&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703236</ArticleId></ArticleIdList></Reference><Reference><Citation>Pojeta J, Runnegar B, Peel JS, Gordon MJ. Phylum Mollusca. In: Boardman RS, Chetham AH, Rowell AJ, editors. Fossil Invertebrates. Cambridge, MA: Blackwell Science; 1987. pp. 270&#x2013;435.</Citation></Reference><Reference><Citation>Rae PM, Steele RE. Absence of cytosine methylation at C-C-G-G and G-C-G-C sites in the rDNA coding regions and intervening sequences of Drosophila and the rDNA of other insects. Nucleic Acids Res. 1979;6:2987&#x2013;2995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327912</ArticleId><ArticleId IdType="pubmed">493131</ArticleId></ArticleIdList></Reference><Reference><Citation>Raible F, Tessmar-Raible K, Osoegawa K, Wincker P, Jubin C, Balavoine G, Ferrier D, Benes V, de Jong P, Weissenbach J, et al. Vertebrate-type intron-rich genes in the marine annelid Platynereis dumerilii. Science. 2005;310:1325&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">16311335</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokas A, Kruger D, Carroll SB. Animal evolution and the molecular signature of radiations compressed in time. Science. 2005;310:1933&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pubmed">16373569</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen SC, Weiss KR, Goldstein RS, Kupfermann I. The role of a modulatory neuron in feeding and satiation in Aplysia: effects of lesioning of the serotonergic metacerebral cells. J Neurosci. 1989;9:1562&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569832</ArticleId><ArticleId IdType="pubmed">2723741</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosado Fantappie M, Rodrigues Pereira Gimba E, Rumjanek FD. Lack of DNA Methylation in Schistosoma mansoni. Exp Parasitol. 2001;98:162&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakharov DA. Evolutionary aspects of transmitter heterogeneity. J Neural Transm Suppl. 1974;11:43&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">4154076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng G, dos Reis M, Stern CD. Churchill, a zinc finger transcriptional activator, regulates the transition between gastrulation and neurulation. Cell. 2003;115:603&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14651851</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson VJ, Johnson TE, Hammen RF. Caenorhabditis elegans DNA does not contain 5-methylcytosine at any time during development or aging. Nucleic Acids Res. 1986;14:6711&#x2013;6719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311675</ArticleId><ArticleId IdType="pubmed">3748820</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares MB, Bonaldo MF, Jelene P, Su L, Lawton L, Efstratiadis A. Construction and characterization of a normalized cDNA library. Proc Natl Acad Sci USA. 1994;91:9228&#x2013;9232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44785</ArticleId><ArticleId IdType="pubmed">7937745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, Koonin EV, Krylov DM, Mazumder R, Mekhedov SL, Nikolskaya AN, et al. The COG database: an updated version includes eukaryotes. BMC Bioinformatics. 2003;4:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC222959</ArticleId><ArticleId IdType="pubmed">12969510</ArticleId></ArticleIdList></Reference><Reference><Citation>Technau U, Rudd S, Maxwell P, Gordon PM, Saina M, Grasso LC, Hayward DC, Sensen CW, Saint R, Holstein TW, et al. Maintenance of ancestral complexity and non-metazoan genes in two basal cnidarians. Trends Genet. 2005;21:633&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">16226338</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine JW. On the origin of phyla. Chicago: The University of Chicago Press; 2004.</Citation></Reference><Reference><Citation>Vonnemann V, Schrodl M, Klushmann-Kolb A, Wagele H. Reconstruction of the phylogeny of Opisthobranchia (Mollusca, Gastropoda) by means of 18S and 28S rRNA gene sequences. J Molluscan Stud. 2005;71:113&#x2013;125.</Citation></Reference><Reference><Citation>Weiss KR, Kupfermann I. Homology of the giant serotonergic neurons (metacerebral cells) in Aplysia and pulmonate molluscs. Brain Res. 1976;117:33&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">990936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf YI, Rogozin IB, Koonin EV. Coelomata and not Ecdysozoa: evidence from genome-wide phylogenetic analysis. Genome Res. 2004;14:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314272</ArticleId><ArticleId IdType="pubmed">14707168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z. Estimating the pattern of nucleotide substitution. J Mol Evol. 1994;39:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">8064867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhulidov PA, Bogdanova EA, Shcheglov AS, Vagner LL, Khaspekov GL, Kozhemyako VB, Matz MV, Meleshkevitch E, Moroz LL, Lukyanov SA, Shagin DA. Simple cDNA normalization using kamchatka crab duplex-specific nuclease. Nucleic Acids Res. 2004;32:e37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373426</ArticleId><ArticleId IdType="pubmed">14973331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17190939</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>A genotype of exceptional longevity is associated with preservation of cognitive function.</ArticleTitle><Pagination><StartPage>2170</StartPage><EndPage>2175</EndPage><MedlinePgn>2170-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test whether cholesterol ester transfer protein (CETP) genotype (VV homozygosity for I405V) is associated with preservation of cognitive function in addition to its association with exceptional longevity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied Ashkenazi Jews with exceptional longevity (n = 158; age 99.2 +/- 0.3 years) for the associations of CETP VV genotype and lipoprotein phenotype, using the Mini-Mental State Examination (MMSE). To confirm the role of CETP in a younger cohort, we studied subjects from the Einstein Aging Study (EAS) for associations between CETP VV and cognitive impairment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects with MMSE &gt; 25 were twice as likely to have the CETP VV genotype (29% vs 14%, p = 0.02), and those with the VV genotype were more likely (61% vs 30%, p = 0.02) to have MMSE &gt; 25. Subjects with the VV genotype had lower levels of CETP (1.73 +/- 0.11 vs 2.12 +/- 0.10 mug/mL, p = 0.01), higher high-density lipoprotein (HDL) levels (p = 0.02), and larger lipoprotein particles (p = 0.03). In the EAS cohort, an approximately fivefold increase in the VV genotype (21% vs 4%, p = 0.02), higher HDL levels, and larger lipoprotein particle sizes were associated with less dementia and improved memory.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using two independent cohorts, we implicate the longevity CETP gene as a modulator of age-related cognitive function. A specific CETP genotype is associated with lower CETP levels and a favorable lipoprotein profile. It has not been determined whether modulation of this gene prevents age-related decline or AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barzilai</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Aging Research, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. barzilai@aecom.yu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atzmon</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Derby</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Bauman</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-021654</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-18728-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK 20541</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR12248</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053480">Cholesterol Ester Transfer Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053480" MajorTopicYN="N">Cholesterol Ester Transfer Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007585" MajorTopicYN="N">Jews</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17190939</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000249116.50854.65</ArticleId><ArticleId IdType="pii">67/12/2170</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17192927</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.</ArticleTitle><Pagination><StartPage>668</StartPage><EndPage>676</EndPage><MedlinePgn>668-76</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Despite progress in defining a pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, orally bioavailable compounds that prevent its effects on hippocampal synaptic plasticity and cognitive function have not yet emerged. A particularly attractive therapeutic strategy is to selectively neutralize small, soluble Abeta oligomers that have recently been shown to mediate synaptic dysfunction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using electrophysiological, biochemical, and behavioral assays, we studied how scyllo-inositol (AZD-103; molecular weight, 180) neutralizes the acutely toxic effects of Abeta on synaptic function and memory recall.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Scyllo-inositol, but not its stereoisomer, chiro-inositol, dose-dependently rescued long-term potentiation in mouse hippocampus from the inhibitory effects of soluble oligomers of cell-derived human Abeta. Cerebroventricular injection into rats of the soluble Abeta oligomers interfered with learned performance on a complex lever-pressing task, but administration of scyllo-inositol via the drinking water fully prevented oligomer-induced errors.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">A small, orally available natural product penetrates into the brain in vivo to rescue the memory impairment produced by soluble Abeta oligomers through a mechanism that restores hippocampal synaptic plasticity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleary</LastName><ForeName>James P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Tapan</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hofmeister</LastName><ForeName>Jacki</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lesne</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>O'Hare</LastName><ForeName>Eugene</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS07484</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>1VS4X81277</RegistryNumber><NameOfSubstance UI="C009217">scyllitol</NameOfSubstance></Chemical><Chemical><RegistryNumber>4L6452S749</RegistryNumber><NameOfSubstance UI="D007294">Inositol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007294" MajorTopicYN="N">Inositol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013237" MajorTopicYN="N">Stereoisomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17192927</ArticleId><ArticleId IdType="doi">10.1002/ana.21051</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17197420</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.</ArticleTitle><Pagination><StartPage>403</StartPage><EndPage>409</EndPage><MedlinePgn>403-9</MedlinePgn></Pagination><Abstract><AbstractText>Dominantly inherited mutations in the genes encoding presenilins (PS) and the amyloid precursor protein (APP) are the major causes of familial Alzheimer's disease (AD). The prevailing view of AD pathogenesis posits that accumulation of beta-amyloid (Abeta) peptides, particularly Abeta42, is the central event triggering neurodegeneration. Emerging evidence, however, suggests that loss of essential functions of PS could better explain dementia and neurodegeneration in AD. First, conditional inactivation of PS in the adult mouse brain causes progressive memory loss and neurodegeneration resembling AD, whereas mouse models based on overproduction of Abeta have failed to produce neurodegeneration. Second, whereas pathogenic PS mutations enhance Abeta42 production, they typically reduce Abeta40 generation and impair other PS-dependent activities. Third, gamma-secretase inhibitors can enhance the production of Abeta42 while blocking other gamma-secretase activities, thus mimicking the effects of PS mutations. Finally, PS mutations have been identified in frontotemporal dementia, which lacks amyloid pathology. Based on these and other observations, we propose that partial loss of PS function may underlie memory impairment and neurodegeneration in the pathogenesis of AD. We also speculate that Abeta42 may act primarily to antagonize PS-dependent functions, possibly by operating as an active site-directed inhibitor of gamma-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. jshen@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Raymond J</ForeName><Initials>RJ</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17197420</ArticleId><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="doi">10.1073/pnas.0608332104</ArticleId><ArticleId IdType="pii">0608332104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, III, Kandel ER, Duff K, Kirkwood A, Shen J. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M, Shen J. Neuroscientist. 2005;11:441&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">16151045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I. Proc Natl Acad Sci USA. 1996;93:14940&#x2013;14944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26241</ArticleId><ArticleId IdType="pubmed">8962160</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidner GA, Ye Y, Faraday MM, Alvord WG, Fortini ME. Curr Biol. 2006;16:1026&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713961</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proc Natl Acad Sci USA. 1999;96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkan AL, Martinez M, Wang J, Walker ES, Beher D, Shearman MS, Goate AM. J Neurochem. 2005;94:1315&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">16001967</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Gu Y, Hasegawa H, Ruan X, Arawaka S, Fraser P, Westaway D, Mount H, St George-Hyslop P. J Biol Chem. 2002;277:36521&#x2013;36526.</Citation><ArticleIdList><ArticleId IdType="pubmed">12119298</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H. Proc Natl Acad Sci USA. 2002;99:8025&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, et al. Proc Natl Acad Sci USA. 2003;100:13075&#x2013;13080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240747</ArticleId><ArticleId IdType="pubmed">14566063</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker ES, Martinez M, Brunkan AL, Goate A. J Neurochem. 2005;92:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">15663477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M. J Neurochem. 2005;94:1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992373</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y. Biochemistry. 2003;42:1042&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">12549925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C. Hum Mutat. 2006;27:686&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG. J Neurosci. 2000;20:8717&#x2013;8726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773081</ArticleId><ArticleId IdType="pubmed">11102478</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, et al. EMBO J. 2002;21:1948&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125968</ArticleId><ArticleId IdType="pubmed">11953314</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H. Neuron. 1998;20:611&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539133</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama O, Murayama M, Honda T, Sun X, Nihonmatsu N, Takashima A. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:905&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">10509383</ArticleId></ArticleIdList></Reference><Reference><Citation>Flood DG, Reaume AG, Dorfman KS, Lin YG, Lang DM, Trusko SP, Savage MJ, Annaert WG, De Strooper B, Siman R, Scott RW. Neurobiol Aging. 2002;23:335&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959395</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Romig H, Grim MG, Philipp U, Pesold B, Citron M, Baumeister R, Haass C. J Biol Chem. 1999;274:7615&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, Van Broeckhoven C, Merchiers P, Spittaels K, Annaert W, De Strooper B. J Biol Chem. 2003;278:43430&#x2013;43436.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH. J Neurosci. 1999;19:4229&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782616</ArticleId><ArticleId IdType="pubmed">10341227</ArticleId></ArticleIdList></Reference><Reference><Citation>Killick R, Pollard CC, Asuni AA, Mudher AK, Richardson JC, Rupniak HT, Sheppard PW, Varndell IM, Brion JP, Levey AI, et al. J Biol Chem. 2001;276:48554&#x2013;48561.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606587</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JA, Naruse S, Chen H, Eckman C, Younkin S, Price DL, Borchelt DR, Sisodia SS, Wong PC. Neuron. 1998;20:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539132</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. J Med Chem. 2001;44:2039&#x2013;2060.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405641</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Proc Natl Acad Sci USA. 1996;93:13170&#x2013;13175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24065</ArticleId><ArticleId IdType="pubmed">8917563</ArticleId></ArticleIdList></Reference><Reference><Citation>Durkin JT, Murthy S, Husten EJ, Trusko SP, Savage MJ, Rotella DP, Greenberg BD, Siman R. J Biol Chem. 1999;274:20499&#x2013;20504.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400678</ArticleId></ArticleIdList></Reference><Reference><Citation>Klafki H, Abramowski D, Swoboda R, Paganetti PA, Staufenbiel M. J Biol Chem. 1996;271:28655&#x2013;28659.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910499</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Proc Natl Acad Sci USA. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama H, Koo EH, Haass C, Takio K, et al. J Biol Chem. 2003;278:24294&#x2013;24301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707272</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. J Med Chem. 1998;41:6&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9438016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Moore CL, Leatherwood DD, Ostaszewski B, Rahmati T, Donkor IO, Selkoe DJ. Biochemistry. 1999;38:4720&#x2013;4727.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Haass C, Saido TC, Omura S, Ihara Y. Biochemistry. 1997;36:8377&#x2013;8383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9204885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Song L, Parker EM. J Biol Chem. 1999;274:8966&#x2013;8972.</Citation><ArticleIdList><ArticleId IdType="pubmed">10085142</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Song L, Terracina G, Liu Y, Pramanik B, Parker E. Biochemistry. 2001;40:5049&#x2013;5055.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305921</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CL, Diehl TS, Selkoe DJ, Wolfe MS. Ann NY Acad Sci. 2000;920:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhart JC, Pardee A. Cold Spring Harbor Symp Quant Biol. 1963;28:491&#x2013;96.</Citation></Reference><Reference><Citation>Jacobson GR, Stark GR. J Biol Chem. 1975;250:6852&#x2013;6860.</Citation><ArticleIdList><ArticleId IdType="pubmed">1099096</ArticleId></ArticleIdList></Reference><Reference><Citation>Amtul Z, Lewis PA, Piper S, Crook R, Baker M, Findlay K, Singleton A, Hogg M, Younkin L, Younkin SG, et al. Neurobiol Dis. 2002;9:269&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895378</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rademakers R, Saerens J, Pickut BA, Peeters K, van den Broeck M, Vennekens K, et al. Ann Neurol. 2004;55:617&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122701</ArticleId></ArticleIdList></Reference><Reference><Citation>Raux G, Gantier R, Thomas-Anterion C, Boulliat J, Verpillat P, Hannequin D, Brice A, Frebourg T, Campion D. Neurology. 2000;55:1577&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094121</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW, Jr, Morris JC. Arch Neurol. 2005;62:1821&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa A, Piao YS, Miyashita A, Kuwano R, Onodera O, Ohtake H, Suzuki M, Nishizawa M, Takahashi H. Ann Neurol. 2005;57:429&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">15732120</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, Crook R, Dolan RJ, McLaughlin J, Revesz T, Hardy J. Neurosci Lett. 2001;313:93&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11684347</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Proc Natl Acad Sci USA. 2002;99:13217&#x2013;13221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130613</ArticleId><ArticleId IdType="pubmed">12244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Thornton PL, Balazs R, Cotman CW. J Biol Chem. 2001;276:17301&#x2013;17306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278679</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuda N, Ohkubo N, Tamatani M, Lee YD, Taniguchi M, Namikawa K, Kiyama H, Yamaguchi A, Sato N, Sakata K, et al. J Biol Chem. 2001;276:9688&#x2013;9698.</Citation><ArticleIdList><ArticleId IdType="pubmed">11116137</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Remacle J, Killick R, Corsmit E, Vennekens K, Huylebroeck D, Cruts M, Van Broeckhoven C. Hum Mol Genet. 2003;12:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668610</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Del-Favero J, Dermaut B, van Duijn CM, Backhovens H, Van den Broeck MV, Serneels S, Corsmit E, Van Broeckhoven CV, Cruts M. Hum Mol Genet. 2000;9:325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655540</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, Kawarabayashi T, Younkin L, Fedeles B, Wilson MA, et al. Neuron. 2001;31:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DM, Levitan D, Yu G, Nishimura M, Chen F, Tandon A, Kawarai T, Arawaka S, Supala A, Song YQ, et al. NeuroReport. 2000;11:3227&#x2013;3230.</Citation><ArticleIdList><ArticleId IdType="pubmed">11043553</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Revesz T, Neumann M, Romig H, Grim MG, Pesold B, Kretzschmar HA, Hardy J, Holton JL, Baumeister R, et al. J Biol Chem. 2001;276:7233&#x2013;7239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11084029</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Beglopoulos V, Mattson MP, Shen J. Neurodegener Dis. 2005;2:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17210801</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>349</EndPage><MedlinePgn>343-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to discriminate early-stage Alzheimer disease (AD) (defined by clinical criteria and presence/absence of brain amyloid) from nondemented aging and to assess whether these biomarkers can predict future dementia in cognitively normal individuals.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Evaluation of CSF beta-amyloid(40) (Abeta(40)), Abeta(42), tau, phosphorylated tau(181), and plasma Abeta(40) and Abeta(42) and longitudinal clinical follow-up (from 1 to 8 years).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Longitudinal studies of healthy aging and dementia through an AD research center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Community-dwelling volunteers (n = 139) aged 60 to 91 years and clinically judged as cognitively normal (Clinical Dementia Rating [CDR], 0) or having very mild (CDR, 0.5) or mild (CDR, 1) AD dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Individuals with very mild or mild AD have reduced mean levels of CSF Abeta(42) and increased levels of CSF tau and phosphorylated tau(181). Cerebrospinal fluid Abeta(42) level completely corresponds with the presence or absence of brain amyloid (imaged with Pittsburgh Compound B) in demented and nondemented individuals. The CSF tau/Abeta(42) ratio (adjusted hazard ratio, 5.21; 95% confidence interval, 1.58-17.22) and phosphorylated tau(181)/Abeta(42) ratio (adjusted hazard ratio, 4.39; 95% confidence interval, 1.62-11.86) predict conversion from a CDR of 0 to a CDR greater than 0.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The very mildest symptomatic stage of AD exhibits the same CSF biomarker phenotype as more advanced AD. In addition, levels of CSF Abeta(42), when combined with amyloid imaging, augment clinical methods for identifying in individuals with brain amyloid deposits whether dementia is present or not. Importantly, CSF tau/Abeta(42) ratios show strong promise as antecedent (preclinical) biomarkers that predict future dementia in cognitively normal older adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, 660 S Euclid Ave, Box 8111, St Louis, MO 63110, USA. fagana@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01-RR00036</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2007 Sep;64(9):1356; author reply 1357-9. doi: 10.1001/archneur.64.9.1356.</RefSource><PMID Version="1">17846281</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2007 Sep;64(9):1357; author reply 1357-9. doi: 10.1001/archneur.64.9.1357-a.</RefSource><PMID Version="1">17846282</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.3.noc60123</ArticleId><ArticleId IdType="pii">64.3.noc60123</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17210817</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.</ArticleTitle><Pagination><StartPage>108</StartPage><EndPage>115</EndPage><MedlinePgn>108-15</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Individuals diagnosed as having mild cognitive impairment (MCI) have a high likelihood of progressing to dementia within 3 to 5 years, but not all individuals with MCI progress to dementia. Prognostic uncertainty suggests the need for additional measures to assist the clinician.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the added value of qualitative measures of medial temporal atrophy (MTA) to estimate the relative risk of progressing from MCI to dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory assessment centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 190 individuals with MCI.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Ratings of MTA performed using magnetic resonance images obtained at baseline. Log-rank tests and Cox proportional hazards ratios examining the significance of MTA estimates in predicting progression of MCI to dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A mean MTA score greater than 2.0 was associated with a greater than 2-fold increased likelihood of progression to dementia during the observation period (hazards ratio, 2.30; 95% confidence interval, 1.09-4.92; P = .03) after controlling for age, education, sex, and baseline Mini-Mental State Examination score.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adjusted estimates of MTA were associated with significantly increased risk of developing dementia within 3 years, suggesting that obtaining a magnetic resonance image during the evaluation of MCI may offer additional independent information about the risk of progression to dementia. Given the relatively high prevalence of MCI in the general population, use of this method as part of routine clinical evaluation may help identify individuals who might benefit from increased surveillance and future treatment.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00000173.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis, Sacramento 95817, USA. cdecarli@ucdavis.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Shelia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Cooperative Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00000173</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIA U01-10483</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arch Neurol. 2007 Mar;64(3):459</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17210817</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.1.108</ArticleId><ArticleId IdType="pii">64/1/108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17215356</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype.</ArticleTitle><Pagination><StartPage>823</StartPage><EndPage>828</EndPage><MedlinePgn>823-8</MedlinePgn></Pagination><Abstract><AbstractText>Cerebral angiopathy contributes to cognitive decline and dementia in Alzheimer's disease (AD) through cerebral blood flow (CBF) reductions and dysregulation. We report vascular smooth muscle cells (VSMC) in small pial and intracerebral arteries, which are critical for CBF regulation, express in AD high levels of serum response factor (SRF) and myocardin (MYOCD), two interacting transcription factors that orchestrate a VSMC-differentiated phenotype. Consistent with this finding, AD VSMC overexpressed several SRF-MYOCD-regulated contractile proteins and exhibited a hypercontractile phenotype. MYOCD overexpression in control human cerebral VSMC induced an AD-like hypercontractile phenotype and diminished both endothelial-dependent and -independent relaxation in the mouse aorta ex vivo. In contrast, silencing SRF normalized contractile protein content and reversed a hypercontractile phenotype in AD VSMC. MYOCD in vivo gene transfer to mouse pial arteries increased contractile protein content and diminished CBF responses produced by brain activation in wild-type mice and in two AD models, the Dutch/Iowa/Swedish triple mutant human amyloid beta-peptide (Abeta)-precursor protein (APP)- expressing mice and APPsw(+/-) mice. Silencing Srf had the opposite effect. Expression of SRF did not change in VSMC subjected to Alzheimer's neurotoxin, Abeta. Thus, SRF-MYOCD overexpression in small cerebral arteries appears to initiate independently of Abeta a pathogenic pathway mediating arterial hypercontractility and CBF dysregulation, which are associated with Alzheimer's dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Nienwen</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Socratech Research Laboratories L.L.C., Department of Neurosurgery, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Streb</LastName><ForeName>Jeffrey W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiyuan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Miano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R43 AG 024000</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL 62572</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43 AG024000</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG 023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL062572</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R41 AG 026950 01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026362">Serum Response Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C431508">myocardin</NameOfSubstance></Chemical><Chemical><RegistryNumber>660YQ98I10</RegistryNumber><NameOfSubstance UI="D011189">Potassium Chloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002536" MajorTopicYN="N">Cerebral Arteries</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011189" MajorTopicYN="N">Potassium Chloride</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026362" MajorTopicYN="N">Serum Response Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest: B.V.Z. is the scientific founder of Socratech L.L.C., a startup biotechnology company with a mission to develop neuroprotective strategies in the aging brain and for brain disorders such as stroke, Alzheimer's disease, and other neurodegenerative disorders. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17215356</ArticleId><ArticleId IdType="pmc">PMC1783398</ArticleId><ArticleId IdType="doi">10.1073/pnas.0608251104</ArticleId><ArticleId IdType="pii">0608251104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zlokovic BV. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Nat Neurosci Rev. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Gurol ME, Rosand J, Smith EE. Stroke. 2004;35:2616&#x2013;2619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459438</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, et al. Lancet Neurol. 2003;2:89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849265</ArticleId></ArticleIdList></Reference><Reference><Citation>Casserly I, Topol E. Lancet. 2004;353:1139&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15064035</ArticleId></ArticleIdList></Reference><Reference><Citation>Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, Young WG, Bloom FE. Proc Natl Acad Sci USA. 2003;100:1381&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298781</ArticleId><ArticleId IdType="pubmed">12552120</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. Nat Neurosci. 1999;2:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C. Proc Natl Acad Sci USA. 2000;97:9735&#x2013;9740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16934</ArticleId><ArticleId IdType="pubmed">10944232</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder LX, Avison MJ. Neurology. 1999;53:1391&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">10534240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM. Ann Neurol. 2005;57:789&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mies G, Ishimaru S, Xie Y, Seo K, Hossmann KA. J Cereb Blood Flow Metab. 1991;11:753&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">1874807</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin KC, Barad M, Kandel ER. Curr Opin Neurobiol. 2000;10:587&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">11084321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleim JA, Bruneau R, Calder K, Pocock D, VandenBerg PM, MacDonald E, Monfils MH, Sutherland RJ, Nader K. Neuron. 2003;40:167&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">14527441</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. J Am Med Assoc. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. N Engl J Med. 2003;348:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D-Z, Olson EN. Curr Opin Genet Dev. 2004;14:558&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380248</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano JM. J Mol Cell Cardiol. 2003;35:577&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788374</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J, Wei L, Otani T, Youker KA, Entman ML, Schwartz RJ. Circulation. 2003;108:407&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp PR, Metcalfe JC. Biochem J. 2000;345:445&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220776</ArticleId><ArticleId IdType="pubmed">10642500</ArticleId></ArticleIdList></Reference><Reference><Citation>Belaguli NS, Zhou W, Trinh TH, Majesky MW, Schwartz RJ. Mol Cell Biol. 1999;19:4582&#x2013;4591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84256</ArticleId><ArticleId IdType="pubmed">10373507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA, Olson EN. Cell. 2001;105:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11439182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Kitchen CM, Streb JW, Miano JM. J Mol Cell Cardiol. 2002;34:1345&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392995</ArticleId></ArticleIdList></Reference><Reference><Citation>Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Mol Cell Biol. 2003;23:2425&#x2013;2437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150745</ArticleId><ArticleId IdType="pubmed">12640126</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Circ Res. 2003;92:856&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang D-Z, Pipes GCT, Olson EN. Proc Natl Acad Sci USA. 2003;100:7129&#x2013;7134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165841</ArticleId><ArticleId IdType="pubmed">12756293</ArticleId></ArticleIdList></Reference><Reference><Citation>Streb JW, Miano JM. J Biol Chem. 2005;280:4125&#x2013;4134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15590635</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Chen G, Streb JW, Long X, Yang Y, Stoeckert CJ, Jr, Miano JM. Genome Res. 2006;16:197&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1361715</ArticleId><ArticleId IdType="pubmed">16365378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai N, Moien-Afshari F, Washio H, Min A, Laher I. Vasc Pharmacol. 2004;41:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380735</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang D-Z, Richardson JA, Olson EN. Proc Natl Acad Sci USA. 2003;100:9366&#x2013;9370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170924</ArticleId><ArticleId IdType="pubmed">12867591</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano JM, Ramanan N, Georger MA, de Mesy Bentley KL, Emerson RL, Balza RO, Jr, Xiao Q, Weiler H, Ginty DD, Misra RP. Proc Natl Acad Sci USA. 2004;101:17132&#x2013;17137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535359</ArticleId><ArticleId IdType="pubmed">15569937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Azhar G, Chai J, Sheridan P, Nagano K, Brown T, Yang J, Khrapko K, Borras AM, Lawitts J, et al. Am J Physiol. 2001;280:1782&#x2013;1792.</Citation><ArticleIdList><ArticleId IdType="pubmed">11247792</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE. J Biol Chem. 2004;279:20296&#x2013;20306.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. Ann Neurol. 2000;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Kawai-Kowase K, Owens GK. Arterioscler Thromb Vasc Biol. 2004;24:1596&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">15231515</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano JM. Circ Res. 2004;95:340&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">15321943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al. Nat Med. 2005;11:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Balazs R, Thornton PL, Cotman CW. J Neurosci. 2004;24:6799&#x2013;6809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729714</ArticleId><ArticleId IdType="pubmed">15282285</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Krause SM, Kretz O, Philippar U, Lemberger T, Casanova E, Wiebel FF, Schwarz H, Frotscher M, Schutz G, et al. Proc Natl Acad Sci USA. 2005;102:6148&#x2013;6153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087932</ArticleId><ArticleId IdType="pubmed">15837932</ArticleId></ArticleIdList></Reference><Reference><Citation>Etkin A, Alarcon JM, Weisberg SP, Touzani K, Huang YY, Nordheim A, Kandel ER. Neuron. 2006;50:127&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600861</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA. J Biol Chem. 2004;279:37124&#x2013;37132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15197188</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor DJ, Sabbagh M, Walker DG, Roher AE. Acta Neuropathol. 2007;113:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021755</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C. J Neurosci. 2005;25:1769&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725936</ArticleId><ArticleId IdType="pubmed">15716413</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. J Neuropathol Exp Neurol. 1997;56:1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE. J Biol Chem. 2003;278:19054&#x2013;19061.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754271</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland PM, Abramson RD, Watson R, Gelfand DH. Proc Natl Acad Sci USA. 1991;88:7276&#x2013;7280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52277</ArticleId><ArticleId IdType="pubmed">1871133</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda K, Nakane H, Heistad DD. J Cereb Blood Flow Metab. 2001;21:1125&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17215369</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Molecular markers of early Parkinson's disease based on gene expression in blood.</ArticleTitle><Pagination><StartPage>955</StartPage><EndPage>960</EndPage><MedlinePgn>955-60</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease (PD) progresses relentlessly and affects five million people worldwide. Laboratory tests for PD are critically needed for developing treatments designed to slow or prevent progression of the disease. We performed a transcriptome-wide scan in 105 individuals to interrogate the molecular processes perturbed in cellular blood of patients with early-stage PD. The molecular multigene marker here identified is associated with risk of PD in 66 samples of the training set comprising healthy and disease controls [third tertile cross-validated odds ratio of 5.7 (P for trend 0.005)]. It is further validated in 39 independent test samples [third tertile odds ratio of 5.1 (P for trend 0.04)]. Insights into disease-linked processes detectable in peripheral blood are offered by 22 unique genes differentially expressed in patients with PD versus healthy individuals. These include the co-chaperone ST13, which stabilizes heat-shock protein 70, a modifier of alpha-synuclein misfolding and toxicity. ST13 messenger RNA copies are lower in patients with PD (mean +/- SE 0.59 +/- 0.05) than in controls (0.96 +/- 0.09) (P = 0.002) in two independent populations. Thus, gene expression signals measured in blood can facilitate the development of biomarkers for PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA. cscherzer@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eklund</LastName><ForeName>Aron C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Morse</LastName><ForeName>Lee J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Zhixiang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Locascio</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Fefer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schwarzschild</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Sudarsky</LastName><ForeName>Lewis R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Standaert</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Roderick V</ForeName><Initials>RV</Initials></Author><Author ValidYN="Y"><LastName>Gullans</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE6613</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG024816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038372</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG 024816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 038372</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="Y">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: C.R.S., S.R.G., and R.V.J. are listed as coinventors on a U.S. Letters Patent application for identification of dysregulated genes in patients with neurologic diseases held by Brigham and Women's Hospital. C.R.S. is a consultant to Link Medicine Corporation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17215369</ArticleId><ArticleId IdType="pmc">PMC1766335</ArticleId><ArticleId IdType="doi">10.1073/pnas.0610204104</ArticleId><ArticleId IdType="pii">0610204104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manolio T. N Engl J Med. 2003;349:1587&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">14573728</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Circulation. 2002;106:3143&#x2013;3421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485966</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley JM, Lees AJ. Brain. 1991;114:2283&#x2013;2301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT., Jr Nat Med. 2004;10(Suppl):S51&#x2013;S57.</Citation><ArticleIdList><ArticleId IdType="pubmed">15298008</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Feany MB. Trends Genet. 2004;20:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219388</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB. Neurology. 2004;62:1835&#x2013;1838.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunada Y, Saito F, Matsumura K, Shimizu T. Neurosci Lett. 1998;254:180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10214987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, et al. Nat Genet. 2006;38:1184&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB, Beal MF. Curr Opin Neurol. 1994;7:333&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">7952242</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B, Calderaro C, Felici L, Stocchi F, Meco G, et al. Mov Disord. 1999;14:764&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">10495037</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozzi L, Lucetti C, Gambaccini G, Bernardini S, Del Dotto P, Migliore L, Scarpato R, Bonuccelli U. Neurol Sci. 2001;22:83&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487213</ArticleId></ArticleIdList></Reference><Reference><Citation>Caronti B, Antonini G, Calderaro C, Ruggieri S, Palladini G, Pontieri FE, Colosimo C. J Neural Transm. 2001;108:803&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">11515746</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T. Neurology. 1996;46:791&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618685</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, Guhathakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, et al. Nat Genet. 2005;37:710&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841396</ArticleId><ArticleId IdType="pubmed">15965475</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Jensen RV, Gullans SR. In: Principles of Molecular Neurosurgery. Freese A, Simeone FA, Leone P, Janson C, editors. Vol 18. Basel: Karger; 2004. pp. 246&#x2013;257.</Citation></Reference><Reference><Citation>Scherzer CR, Jensen RV, Gullans SR, Feany MB. Hum Mol Genet. 2003;12:2457&#x2013;2466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12915459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, et al. Arch Neurol. 2005;62:917&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956162</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB. Neurogenetics. 2006;7:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699787</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB. Ann NY Acad Sci. 2005;1053:356&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16179542</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. J Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, et al. Proc Natl Acad Sci USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. J Neurol Neurosurg Psychiatry. 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Nature. 2002;415:530&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823860</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D.  Gene Cards: Encyclopedia for Genes, Proteins and Diseases. Rehovot, Israel: Weizmann Inst Sci; 1997.  available at  www.genecards.org.</Citation></Reference><Reference><Citation>Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR. J Biol Chem. 1996;271:19385&#x2013;19394.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, Borlongan CV, Wang Y. Brain Res. 2001;904:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorkina T, Hoover BR, Zahniser NR, Sorkin A. Traffic. 2005;6:157&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15634215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Kim YI, Song C, Yoon I, Park JW, Choi YB, Kim HT, Lee KS. J Korean Med Sci. 2005;20:495&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782210</ArticleId><ArticleId IdType="pubmed">15953876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tusher VG, Tibshirani R, Chu G. Proc Natl Acad Sci USA. 2001;98:5116&#x2013;5121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33173</ArticleId><ArticleId IdType="pubmed">11309499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nollen EA, Kabakov AE, Brunsting JF, Kanon B, Hohfeld J, Kampinga HH. J Biol Chem. 2001;276:4677&#x2013;4682.</Citation><ArticleIdList><ArticleId IdType="pubmed">11076956</ArticleId></ArticleIdList></Reference><Reference><Citation>Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. J Biol Chem. 2004;279:25497&#x2013;25502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044495</ArticleId></ArticleIdList></Reference><Reference><Citation>Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. J Mol Biol. 2005;351:1081&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16051265</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Science. 2002;295:865&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Applied Biosystems. ABI Prism 7700 Sequence Detection System. Foster City, CA: Applied Biosystems; 2001. User Bulletin No 2.</Citation></Reference><Reference><Citation>Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, Sladek R, Xu F, et al. Proc Natl Acad Sci USA. 2003;100:605&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141043</ArticleId><ArticleId IdType="pubmed">12529507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. Neurology. 2001;57:S34&#x2013;S38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11775598</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Lee VM, Trojanowski JQ. Neuron. 2005;47:479&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff DF. Nat Rev Cancer. 2004;4:309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig JA, Weinstein JN. Nat Rev Cancer. 2005;5:845&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239904</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, et al. Nat Biotechnol. 2006;24:1151&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272078</ArticleId><ArticleId IdType="pubmed">16964229</ArticleId></ArticleIdList></Reference><Reference><Citation>Michiels S, Koscielny S, Hill C. Lancet. 2005;365:488&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohfeld J, Minami Y, Hartl FU. Cell. 1995;83:589&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585962</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunblatt E, Mandel S, Maor G, Youdim MB. J Neurochem. 2001;78:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432968</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. J Biol Chem. 2005;280:23727&#x2013;23734.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Maraganore DM, McDonnell SK, Schaid DJ. J Clin Epidemiol. 1998;51:517&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">9636001</ArticleId></ArticleIdList></Reference><Reference><Citation>Amersham Biosciences. CodeLink Expression Bioarrays Automated Target Preparation. Piscataway, NJ: Amersham Biosciences; 2003.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17220890</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1061-4036</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease.</ArticleTitle><Pagination><StartPage>168</StartPage><EndPage>177</EndPage><MedlinePgn>168-77</MedlinePgn></Pagination><Abstract><AbstractText>The recycling of the amyloid precursor protein (APP) from the cell surface via the endocytic pathways plays a key role in the generation of amyloid beta peptide (Abeta) in Alzheimer disease. We report here that inherited variants in the SORL1 neuronal sorting receptor are associated with late-onset Alzheimer disease. These variants, which occur in at least two different clusters of intronic sequences within the SORL1 gene (also known as LR11 or SORLA) may regulate tissue-specific expression of SORL1. We also show that SORL1 directs trafficking of APP into recycling pathways and that when SORL1 is underexpressed, APP is sorted into Abeta-generating compartments. These data suggest that inherited or acquired changes in SORL1 expression or function are mechanistically involved in causing Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative Diseases, Department of Medicine, Department, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Yongjun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kawarai</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Fanggeng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Katayama</LastName><ForeName>Taiichi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fusheng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Nobuto</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Pardossi-Piquard</LastName><ForeName>Raphaelle</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bohm</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wakutani</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Cuenco</LastName><ForeName>Karen T</ForeName><Initials>KT</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Pinessi</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rainero</LastName><ForeName>Innocenzo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Amalia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Inzelberg</LastName><ForeName>Rivka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hampe</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Bujo</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>You-Qiang</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Willnow</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Der</LastName><ForeName>Sandy D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Schmitt-Ulms</LastName><ForeName>Gerold</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-AG15473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HG/AG02213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG09029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419573">VPS35 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING INTERESTS</b>. The authors have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17220890</ArticleId><ArticleId IdType="mid">NIHMS88269</ArticleId><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="doi">10.1038/ng1943</ArticleId><ArticleId IdType="pii">ng1943</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate AM, et al. Segregation of a missense mutation in the amyloid precursor protein gene with Familial Alzheimer Disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer&#x2019;s disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, et al. Familial Alzheimer&#x2019;s disease in kindreds with missense mutations in a novel gene on chromosome 1 related to the Alzheimer&#x2019;s Disease type 3 gene. Nature. 1995;376:775&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A, et al. Association of Apoliprotein E allele e4 with the late-onset familial and sporadic Alzheimer Disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nature Genet. 1997;17:254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255:728&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738847</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993;75:1039&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">8261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer TA, et al. Key factors in Alzheimer&#x2019;s disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 2001;11:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098450</ArticleId><ArticleId IdType="pubmed">11145195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, et al. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci. 2003;116:3339&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, et al. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005;280:25892&#x2013;25900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201532</ArticleId><ArticleId IdType="pubmed">15886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, et al. Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann Neurol. 2005;58:909&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26:1596&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet. 2001;69:124&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226027</ArticleId><ArticleId IdType="pubmed">11404818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Cox NJ. The allelic architecture of human disease genes: common disease-common variant&#x2026;or not? Hum Mol Genet. 2002;11:2417&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12351577</ArticleId></ArticleIdList></Reference><Reference><Citation>Athan ES, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. Jama. 2001;286:2257&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">11710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer&#x2019;s type dementia in an elderly Arab population. Eur J Neurol. 2001;8:119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11284991</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, et al. Re-analysis of the association of Alpha-2-macroglobulin and Alzheimer&#x2019;s Disease. Nature Genet. 1999;22:19&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, et al. Evidence for an Alzheimer Disease susceptibility locus on chr 12, and for further locus heterogeneity. JAMA. 1998;280:614&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">9718052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, et al. Fine mapping of 10q and 18q for familial Alzheimer&#x2019;s disease in Caribbean Hispanics. Mol Psychiatry. 2004;9:1042&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1578737</ArticleId><ArticleId IdType="pubmed">15241431</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol. 2002;59:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939894</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. J Am Med Assoc. 2002;287:329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet. 2003;12:415&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Chakravarti A, Cutler DJ. Exhaustive allelic transmission disequilibrium tests as a new approach to genome-wide association studies. Nat Genet. 2004;36:1181&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, et al. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer&#x2019;s disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005;14:447&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, et al. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat. 2004;23:334&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15024728</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, et al. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;15:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Li F, Chang WP, Tang J. GGA proteins mediate the recycling pathway of memapsin 2 (BACE) J Biol Chem. 2005;280:11696&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Effects of age, sex, and ethnicity on the asscoiation between apolipoprotein E genotype and Alzheimer&#x2019;s Disease. A meta-analysis. APOE and Alzheimer&#x2019;s Disease Meta Analysis consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinowitz D, Laird N. A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information. Hum Hered. 2000;50:211&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782012</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeire S, Rutgeerts P. Current status of genetics research in inflammatory bowel disease. Genes Immun. 2005;6:637&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16107869</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen MJ, Craddock N, O&#x2019;Donovan MC. Schizophrenia: genes at last? Trends Genet. 2005;21:518&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009449</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S, et al. Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol. 2004;26:61&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14691957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM. PBAT: tools for family-based association studies. Am J Hum Genet. 2004;74:367&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181934</ArticleId><ArticleId IdType="pubmed">14740322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange C, Silverman EK, Xu X, Weiss ST, Laird NM. A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics. 2003;4:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange C, Laird NM. Power calculations for a general class of family-based association tests: dichotomous traits. Am J Hum Genet. 2002;71:575&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379194</ArticleId><ArticleId IdType="pubmed">12181775</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Steen K, et al. Genomic screening and replication using the same data set in family-based association testing. Nat Genet. 2005;37:683&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937480</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statistic Soc. 1995;B57:289&#x2013;300.</Citation></Reference><Reference><Citation>Jannot AS, Essioux L, Reese MG, Clerget-Darpoux F. Improved use of SNP information to detect the role of genes. Genet Epidemiol. 2003;25:158&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12916024</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwilliger JD, Weiss KM. Linkage disequilibrium mapping of complex disease: fantasy or reality? Curr Opin Biotechnol. 1998;9:578&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9889136</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384917</ArticleId><ArticleId IdType="pubmed">11791212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, et al. Nicastrin binds to membrane-tethered Notch. Nature Cell Biology. 2001;3:751&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483961</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjannet S, et al. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem. 2001;276:10879&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152688</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, et al. A Novel Protein (Nicastrin) Modulates Presenilin-Mediated Notch/Glp1 And betaAPP Processing. Nature. 2000;407:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, et al. The presenilin proteins are components of multiple membrane-bound complexes which have different biological activities. J Biol Chem. 2004;279:31329&#x2013;31336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa H, et al. Both the sequence and length of the C terminus of PEN-2 are critical for intermolecular interactions and function of presenilin complexes. J Biol Chem. 2004;279:46455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17224403</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction.</ArticleTitle><Pagination><StartPage>201</StartPage><EndPage>215</EndPage><MedlinePgn>201-15</MedlinePgn></Pagination><Abstract><AbstractText>Targeting of synaptic molecules to their proper location is essential for synaptic differentiation and plasticity. PSD-95/Dlg proteins have been established as key components of the postsynapse. However, the molecular mechanisms regulating the synaptic targeting, assembly, and disassembly of PSD-95/Dlg are not well understood. Here we show that PAR-1 kinase, a conserved cell polarity regulator, is critically involved in controlling the postsynaptic localization of Dlg. PAR-1 is prominently localized at the Drosophila neuromuscular junction (NMJ). Loss of PAR-1 function leads to increased synapse formation and synaptic transmission, whereas overexpression of PAR-1 has the opposite effects. PAR-1 directly phosphorylates Dlg at a conserved site and negatively regulates its mobility and targeting to the postsynapse. The ability of a nonphosphorylatable Dlg to largely rescue PAR-1-induced synaptic defects supports the idea that Dlg is a major synaptic substrate of PAR-1. Control of Dlg synaptic targeting by PAR-1-mediated phosphorylation thus constitutes a critical event in synaptogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yali</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, GRECC/VAPAHCS, Palo Alto, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Huifu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ji-Wu</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Kosek</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bingwei</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH080378</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS043167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>143513-41-1</RegistryNumber><NameOfSubstance UI="C070350">dlg1 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="C472496">Par-1 protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036681" MajorTopicYN="N">Fluorescence Recovery After Photobleaching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17224403</ArticleId><ArticleId IdType="mid">NIHMS16660</ArticleId><ArticleId IdType="pmc">PMC1855201</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.12.016</ArticleId><ArticleId IdType="pii">S0896-6273(06)01021-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2032;s disease. Acta Neuropathol (Berl) 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, Mandelkow EM. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell. 2002;13:4013&#x2013;4028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC133611</ArticleId><ArticleId IdType="pubmed">12429843</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenman JE, Topinka JR, Cooper EC, McGee AW, Rosen J, Milroy T, Ralston HJ, Bredt DS. Localization of postsynaptic density-93 to dendritic microtubules and interaction with microtubule-associated protein 1A. J Neurosci. 1998;18:8805&#x2013;8813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793550</ArticleId><ArticleId IdType="pubmed">9786987</ArticleId></ArticleIdList></Reference><Reference><Citation>Budnik V, Koh YH, Guan B, Hartmann B, Hough C, Woods D, Gorczyca M. Regulation of synapse structure and function by the Drosophila tumor suppressor gene dlg. Neuron. 1996;17:627&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661176</ArticleId><ArticleId IdType="pubmed">8893021</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Featherstone DE. Discs-large (DLG) is clustered by presynaptic innervation and regulates postsynaptic glutamate receptor subunit composition in Drosophila. BMC Biol. 2005;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545058</ArticleId><ArticleId IdType="pubmed">15638945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetkovich DM, Bunn RC, Kuo SH, Kawasaki Y, Kohwi M, Bredt DS. Postsynaptic targeting of alternative postsynaptic density-95 isoforms by distinct mechanisms. J Neurosci. 2002;22:6415&#x2013;6425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758133</ArticleId><ArticleId IdType="pubmed">12151521</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins CA, Wairkar YP, Johnson SL, DiAntonio A. Highwire restrains synaptic growth by attenuating a MAP kinase signal. Neuron. 2006;51:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815332</ArticleId></ArticleIdList></Reference><Reference><Citation>Craven SE, El-Husseini AE, Bredt DS. Synaptic targeting of the postsynaptic density protein PSD-95 mediated by lipid and protein motifs. Neuron. 1999;22:497&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197530</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis GW, Goodman CS. Genetic analysis of synaptic development and plasticity: homeostatic regulation of synaptic efficacy. Curr Opin Neurobiol. 1998;8:149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568402</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis GW, Schuster CM, Goodman CS. Genetic analysis of the mechanisms controlling target selection: target-derived Fasciclin II regulates the pattern of synapse formation. Neuron. 1997;19:561&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">9331349</ArticleId></ArticleIdList></Reference><Reference><Citation>DiAntonio A, Petersen SA, Heckmann M, Goodman CS. Glutamate receptor expression regulates quantal size and quantal content at the Drosophila neuromuscular junction. J Neurosci. 1999;19:3023&#x2013;3032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782296</ArticleId><ArticleId IdType="pubmed">10191319</ArticleId></ArticleIdList></Reference><Reference><Citation>Doerflinger H, Benton R, Torres IL, Zwart MF, St Johnston D. Drosophila anterior-posterior polarity requires actin-dependent PAR-1 recruitment to the oocyte posterior. Curr Biol. 2006;16:1090&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753562</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G. MARKing tau for tangles and toxicity. Trends Biochem Sci. 2004;29:548&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450610</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9108484</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Husseini AE, Craven SE, Chetkovich DM, Firestein BL, Schnell E, Aoki C, Bredt DS. Dual palmitoylation of PSD-95 mediates its vesiculotubular sorting, postsynaptic targeting, and ion channel clustering. J Cell Biol. 2000;148:159&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156213</ArticleId><ArticleId IdType="pubmed">10629226</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke L, Dakoji S, Bredt DS. Membrane-associated guanylate kinases regulate adhesion and plasticity at cell junctions. Annu Rev Biochem. 2005;74:219&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">15952887</ArticleId></ArticleIdList></Reference><Reference><Citation>Goda Y, Davis GW. Mechanisms of synapse assembly and disassembly. Neuron. 2003;40:243&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556707</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo HF, Zhong Y. Requirement of Akt to mediate long-term synaptic depression in Drosophila. J Neurosci. 2006;26:4004&#x2013;4014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673878</ArticleId><ArticleId IdType="pubmed">16611817</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo S, Kemphues KJ. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 1995;81:611&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. Synaptic changes in Alzheimer&#x2032;s disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol. 2004;165:1809&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618663</ArticleId><ArticleId IdType="pubmed">15509549</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghighi AP, McCabe BD, Fetter RD, Palmer JE, Hom S, Goodman CS. Retrograde control of synaptic transmission by postsynaptic CaMKII at the Drosophila neuromuscular junction. Neuron. 2003;39:255&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanada T, Lin L, Tibaldi EV, Reinherz EL, Chishti AH. GAKIN, a novel kinesin-like protein associates with the human homologue of the Drosophila discs large tumor suppressor in T lymphocytes. J Biol Chem. 2000;275:28774&#x2013;28784.</Citation><ArticleIdList><ArticleId IdType="pubmed">10859302</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert P, Russell S, Richardson H. Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. Bioessays. 2003;25:542&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">12766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan LY, Jan YN. L-glutamate as an excitatory transmitter at the Drosophila larval neuromuscular junction. J Physiol. 1976;262:215&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307638</ArticleId><ArticleId IdType="pubmed">186587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan LY, Jan YN. Antibodies to horseradish peroxidase as specific neuronal markers in Drosophila and in grasshopper embryos. Proc Natl Acad Sci U S A. 1982;79:2700&#x2013;2704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346269</ArticleId><ArticleId IdType="pubmed">6806816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemphues KJ, Priess JR, Morton DG, Cheng NS. Identification of genes required for cytoplasmic localization in early C. elegans embryos. Cell. 1988;52:311&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">3345562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MJ, Ehlers MD. Organelles and Trafficking Machinery for Postsynaptic Plasticity. Annu Rev Neurosci. 2006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876664</ArticleId><ArticleId IdType="pubmed">16776589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Naisbitt S, Hsueh YP, Rao A, Rothschild A, Craig AM, Sheng M. GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol. 1997;136:669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2134290</ArticleId><ArticleId IdType="pubmed">9024696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Sheng M. PDZ domain proteins of synapses. Nat Rev Neurosci. 2004;5:771&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378037</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, Gramates LS, Budnik V. Drosophila larval neuromuscular junction: molecular components and mechanisms underlying synaptic plasticity. Microsc Res Tech. 2000;49:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10757875</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, Popova E, Thomas U, Griffith LC, Budnik V. Regulation of DLG localization at synapses by CaMKII-dependent phosphorylation. Cell. 1999;98:353&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4656018</ArticleId><ArticleId IdType="pubmed">10458610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahey T, Gorczyca M, Jia XX, Budnik V. The Drosophila tumor suppressor gene dlg is required for normal synaptic bouton structure. Neuron. 1994;13:823&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661177</ArticleId><ArticleId IdType="pubmed">7946331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DM, Goodman CS. Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. Neuron. 1994;13:507&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">7917288</ArticleId></ArticleIdList></Reference><Reference><Citation>Lnenicka GA, Keshishian H. Identified motor terminals in Drosophila larvae show distinct differences in morphology and physiology. J Neurobiol. 2000;43:186&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10770847</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe BD, Marques G, Haghighi AP, Fetter RD, Crotty ML, Haerry TE, Goodman CS, O&#x2032;Connor MB. The BMP homolog Gbb provides a retrograde signal that regulates synaptic growth at the Drosophila neuromuscular junction. Neuron. 2003;39:241&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873382</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee AW, Bredt DS. Identification of an intramolecular interaction between the SH3 and guanylate kinase domains of PSD-95. J Biol Chem. 1999;274:17431&#x2013;17436.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza C, Olguin P, Lafferte G, Thomas U, Ebitsch S, Gundelfinger ED, Kukuljan M, Sierralta J. Novel isoforms of Dlg are fundamental for neuronal development in Drosophila. J Neurosci. 2003;23:2093&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742002</ArticleId><ArticleId IdType="pubmed">12657668</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito MA, Sheng M, Tsai LH. Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J Neurosci. 2004;24:865&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729809</ArticleId><ArticleId IdType="pubmed">14749431</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004;116:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006350</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnas D, Haghighi AP, Fetter RD, Kim SW, Goodman CS. Regulation of postsynaptic structure and protein localization by the Rho-type guanine nucleotide exchange factor dPix. Neuron. 2001;32:415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasse TM, Fouquet W, Schmid A, Kittel RJ, Mertel S, Sigrist CB, Schmidt M, Guzman A, Merino C, Qin G, et al. Glutamate receptor dynamics organizing synapse formation in vivo. Nat Neurosci. 2005;8:898&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136672</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2032;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H, Hsueh YP, Yang FC, Kim E, Sheng M. An intramolecular interaction between Src homology 3 domain and guanylate kinase-like domain required for channel clustering by postsynaptic density-95/SAP90. J Neurosci. 2000;20:3580&#x2013;3587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772679</ArticleId><ArticleId IdType="pubmed">10804199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Benton R, St Johnston D. The Drosophila homolog of C. elegans PAR-1 organizes the oocyte cytoskeleton and directs oskar mRNA localization to the posterior pole. Cell. 2000;101:377&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun TQ, Lu B, Feng JJ, Reinhard C, Jan YN, Fantl WJ, Williams LT. PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling. Nat Cell Biol. 2001;3:628&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">11433294</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas U, Ebitsch S, Gorczyca M, Koh YH, Hough CD, Woods D, Gundelfinger ED, Budnik V. Synaptic targeting and localization of discs-large is a stepwise process controlled by different domains of the protein. Curr Biol. 2000;10:1108&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658231</ArticleId><ArticleId IdType="pubmed">10996791</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas U, Kim E, Kuhlendahl S, Koh YH, Gundelfinger ED, Sheng M, Garner CC, Budnik V. Synaptic clustering of the cell adhesion molecule fasciclin II by discs-large and its role in the regulation of presynaptic structure. Neuron. 1997;19:787&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658217</ArticleId><ArticleId IdType="pubmed">9354326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomancak P, Piano F, Riechmann V, Gunsalus KC, Kemphues KJ, Ephrussi A. A Drosophila melanogaster homologue of Caenorhabditis elegans par-1 acts at an early step in embryonic-axis formation. Nat Cell Biol. 2000;2:458&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878812</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods DF, Bryant PJ. The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell. 1991;66:451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">1651169</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods DF, Hough C, Peel D, Callaini G, Bryant PJ. Dlg protein is required for junction structure, cell polarity, and proliferation control in Drosophila epithelia. J Cell Biol. 1996;134:1469&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120992</ArticleId><ArticleId IdType="pubmed">8830775</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinsmaier KE, Eberle KK, Buchner E, Walter N, Benzer S. Paralysis and early death in cysteine string protein mutants of Drosophila. Science. 1994;263:977&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">8310297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zito K, Parnas D, Fetter RD, Isacoff EY, Goodman CS. Watching a synapse grow: noninvasive confocal imaging of synaptic growth in Drosophila. Neuron. 1999;22:719&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">10230792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17227870</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.</ArticleTitle><Pagination><StartPage>1325</StartPage><EndPage>1330</EndPage><MedlinePgn>1325-30</MedlinePgn></Pagination><Abstract><AbstractText>Mitochondrial dysfunction is implicated in the pathophysiology of Parkinson's disease (PD), a common age-associated neurodegenerative disease characterized by intraneuronal inclusions (Lewy bodies) and progressive degeneration of the nigrostriatal dopamine (DA) system. It has recently been demonstrated that midbrain DA neurons of PD patients and elderly humans contain high levels of somatic mtDNA mutations, which may impair respiratory chain function. However, clinical studies have not established whether the respiratory chain deficiency is a primary abnormality leading to inclusion formation and DA neuron death, or whether generalized metabolic abnormalities within the degenerating DA neurons cause secondary damage to mitochondria. We have used a reverse genetic approach to investigate this question and created conditional knockout mice (termed MitoPark mice), with disruption of the gene for mitochondrial transcription factor A (Tfam) in DA neurons. The knockout mice have reduced mtDNA expression and respiratory chain deficiency in midbrain DA neurons, which, in turn, leads to a parkinsonism phenotype with adult onset of slowly progressive impairment of motor function accompanied by formation of intraneuronal inclusions and dopamine nerve cell death. Confocal and electron microscopy show that the inclusions contain both mitochondrial protein and membrane components. These experiments demonstrate that respiratory chain dysfunction in DA neurons may be of pathophysiological importance in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ekstrand</LastName><ForeName>Mats I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, S-14186 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terzioglu</LastName><ForeName>M&#xfc;gen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Galter</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shunwei</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hofstetter</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lindqvist</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Thams</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bergstrand</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Fredrik Sterky</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Trifunovic</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hoffer</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Cullheim</LastName><ForeName>Staffan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Abdul H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>Nils-G&#xf6;ran</ForeName><Initials>NG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015342">DNA Probes</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015342" MajorTopicYN="N">DNA Probes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004579" MajorTopicYN="Y">Electron Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: N.-G.L., L.O., and M.I.E. are coowners of a company owning commercial rights to the MitoPark mice.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17227870</ArticleId><ArticleId IdType="pmc">PMC1783140</ArticleId><ArticleId IdType="doi">10.1073/pnas.0605208103</ArticleId><ArticleId IdType="pii">0605208103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gaspari M, Larsson NG, Gustafsson CM. Biochim Biophys Acta. 2004;1659:148&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576046</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, Przedborski S. Neuron. 2003;39:889&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Cookson MR. Neuron. 2004;43:301&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294138</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Nature. 2006;441:1157&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Nature. 2006;441:1162&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyne RJ, Jackson-Lewis V. Brain Res Mol Brain Res. 2005;134:57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15790530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al. Nat Genet. 2006;38:515&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">16604074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell DA, Blakely EL, Johnson MA, Ince PG, Borthwick GM, Turnbull DM. Neurobiol Aging. 2001;22:265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182476</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor RW, Barron MJ, Borthwick GM, Gospel A, Chinnery PF, Samuels DC, Taylor GA, Plusa SM, Needham SJ, Greaves LC, et al. J Clin Invest. 2003;112:1351&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC228466</ArticleId><ArticleId IdType="pubmed">14597761</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly Y-M, Gidl&#xf6;f S, Oldfors A, Wibom R, et al. Nature. 2004;429:417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">15164064</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J. Am J Psychiatry. 1998;155:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">9501743</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, Barsh GS, Clayton DA. Nat Genet. 1998;18:231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">9500544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wilhelmsson H, Graff C, Li H, Oldfors A, Rustin P, Br&#xfc;ning JC, Kahn CR, Clayton DA, Barsh GS, Thoren P, Larsson NG. Nat Genet. 1999;21:133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, Larsson NG. Proc Natl Acad Sci USA. 2004;101:3136&#x2013;3141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365756</ArticleId><ArticleId IdType="pubmed">14978272</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva JP, Kohler M, Graff C, Oldfors A, Magnuson MA, Berggren PO, Larsson NG. Nat Genet. 2000;26:336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen L, Ekstrand M, Silva JP, Lindqvist E, Xu B, Rustin P, Olson L, Larsson NG. J Neurosci. 2001;21:8082&#x2013;8090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763882</ArticleId><ArticleId IdType="pubmed">11588181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wredenberg A, Wibom R, Wilhelmsson H, Graff C, Wiener HH, Burden SJ, Oldfors A, Westerblad H, Larsson NG. Proc Natl Acad Sci USA. 2002;99:15066&#x2013;15071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137544</ArticleId><ArticleId IdType="pubmed">12417746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Silva J, Gustafsson CM, Rustin P, Larsson NG. Proc Natl Acad Sci USA. 2001;98:4038&#x2013;4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31175</ArticleId><ArticleId IdType="pubmed">11259653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM, Larsson NG. Hum Mol Genet. 2004;13:935&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">15016765</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, Gustafsson CM. Nat Genet. 2002;31:289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">12068295</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan DM, Vandenbergh DJ, Perry MP, Bird GS, Ingersoll R, Nanthakumar E, Uhl GR. Brain Res Mol Brain Res. 1995;30:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7637582</ArticleId></ArticleIdList></Reference><Reference><Citation>Dymecki SM. Proc Natl Acad Sci USA. 1996;93:6191&#x2013;6196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39212</ArticleId><ArticleId IdType="pubmed">8650242</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano P. Nat Genet. 1999;21:70&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. J Neurosci. 2002;22:8797&#x2013;8807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults CW. Proc Natl Acad Sci USA. 2006;103:1661&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413649</ArticleId><ArticleId IdType="pubmed">16449387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL. J Biol Chem. 2002;277:6344&#x2013;6352.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F, Barcelo-Coblijn GC, Nussbaum RL. Mol Cell Biol. 2005;25:10190&#x2013;10201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1280279</ArticleId><ArticleId IdType="pubmed">16260631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. J Biol Chem. 1999;274:28849&#x2013;28852.</Citation><ArticleIdList><ArticleId IdType="pubmed">10506125</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D. J Mol Neurosci. 2002;18:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12059041</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifunovic A, Hansson A, Wredenberg A, Rovio AT, Dufour E, Khvorostov I, Spelbrink JN, Wibom R, Jacobs HT, Larsson NG. Proc Natl Acad Sci USA. 2005;102:17993&#x2013;17998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1312403</ArticleId><ArticleId IdType="pubmed">16332961</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugarli EI, Langer T. Trends Mol Med. 2006;12:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16647881</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson H, Luthman J, Lindqvist E, Olson L. Neurotoxicology. 1995;16:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17234951</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>315</Volume><Issue>5810</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Wandering minds: the default network and stimulus-independent thought.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>395</EndPage><MedlinePgn>393-5</MedlinePgn></Pagination><Abstract><AbstractText>Despite evidence pointing to a ubiquitous tendency of human minds to wander, little is known about the neural operations that support this core component of human cognition. Using both thought sampling and brain imaging, the current investigation demonstrated that mind-wandering is associated with activity in a default network of cortical regions that are active when the brain is "at rest." In addition, individuals' reports of the tendency of their minds to wander were correlated with activity in this network.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Malia F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Psychological and Brain Sciences, Dartmouth College, Hanover, NH 03755, USA. malia@nmr.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Michael I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Van Horn</LastName><ForeName>John D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Wegner</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Grafton</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Macrae</LastName><ForeName>C Neil</ForeName><Initials>CN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS033504</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH49127</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050614</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2007 Jul 6;317(5834):43; author reply 43. doi: 10.1126/science.317.5834.43.</RefSource><PMID Version="1">17615325</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005201" MajorTopicYN="N">Fantasy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="N">Thinking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17234951</ArticleId><ArticleId IdType="mid">NIHMS18906</ArticleId><ArticleId IdType="pmc">PMC1821121</ArticleId><ArticleId IdType="doi">10.1126/science.1131295</ArticleId><ArticleId IdType="pii">315/5810/393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer JL. Daydreaming. Plenum Press; New York: 1966.</Citation></Reference><Reference><Citation>Antrobus JS, Singer JL, Greenberg S. Percept Mot Skills. 1966;23:399.</Citation></Reference><Reference><Citation>Singer JL, McRaven V. Int J Soc Psychiatry. 1962;8:272.</Citation><ArticleIdList><ArticleId IdType="pubmed">13977604</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinger E. Structure and Functions of Fantasy. New York: Wiley; 1971.</Citation></Reference><Reference><Citation>Smallwood J, Schooler JW. Psychol Bull. 2006;132:946.</Citation><ArticleIdList><ArticleId IdType="pubmed">17073528</ArticleId></ArticleIdList></Reference><Reference><Citation>fMRI evidence suggests that, when deprived of variable sensory input, the mind recruits a discrete network of brain regions that includes the medial posterior cingulate (BAs 30 and 31); the precuneus (BA 7); paracentral lobule (BA 5); inferior parietal regions (BAs 40, 39, and 7); the angular gyri (BAs 19 and 39); the inferior frontal cortices (BAs 10, 47); superior and middle frontal gyri (BAs 8, 9, and 10); and a cluster spanning dorsal medial frontal regions (BAs 8, 9, 10, and 32) (8). These distributed foci have temporal coherence and constitute a tightly coupled, organized neural network.</Citation></Reference><Reference><Citation>McGuire PK, Paulesu E, Frackowiak RS, Frith CD. Neuroreport. 1996;7:2095.</Citation><ArticleIdList><ArticleId IdType="pubmed">8930966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard D, Raichle M. Nat Rev Neurosci. 2001;2:685.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>McKiernan KA, Kaufman JN, Kucera-Thompson J, Binder JR. J Cogn Neurosci. 2003;15:394.</Citation><ArticleIdList><ArticleId IdType="pubmed">12729491</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale JD, et al. Mem Cognit. 1995;23:551.</Citation><ArticleIdList><ArticleId IdType="pubmed">7476241</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiffrin RM, Schneider W. Psychol Rev. 1977;84:127.</Citation><ArticleIdList><ArticleId IdType="pubmed">6571425</ArticleId></ArticleIdList></Reference><Reference><Citation>Christoff K, Ream JM, Gabrieli JDE. Cortex. 2004;40:623.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505972</ArticleId></ArticleIdList></Reference><Reference><Citation>Materials and methods are available as supporting material. Science. Online.</Citation></Reference><Reference><Citation>Singer JL, Antrobus JS. In: The Function and Nature of Imagery. Sheehan P, editor. Academic Press; New York: 1972. pp. 175&#x2013;202.</Citation></Reference><Reference><Citation>Damasio A, Van Hoesen G. In: Neuropsychology of Human Emotion. Heilman K, Satz P, editors. Guilford; New York: 1983. pp. 85&#x2013;110.</Citation></Reference><Reference><Citation>Giambra LM. Psychol Aging. 1989;4:136.</Citation><ArticleIdList><ArticleId IdType="pubmed">2789741</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. J Neurosci. 2005;25:7709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. Proc Natl Acad Sci USA. 2001;98:676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Schooler JW. Trends Cogn Sci. 2002;6:339.</Citation><ArticleIdList><ArticleId IdType="pubmed">12140084</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig AD. Curr Opin Neurobiol. 2003;13:500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12965300</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasio AR, et al. Nat Neurosci. 2000;3:1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, et al. Proc Natl Acad Sci USA. 2001;98:4259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31213</ArticleId><ArticleId IdType="pubmed">11259662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley WM, et al. J Cogn Neurosci. 2002;14:785.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schooler JW, Reichle ED, Halpern DV. In: Thinking and Seeing: Visual Metacognition in Adults and Children. Levin DT, editor. MIT Press; Cambridge, MA: 2004. pp. 203&#x2013;226.</Citation></Reference><Reference><Citation>Wegner DM. In: Scientific Approaches to Consciousness. Cohen J, Schooler J, editors. Lawrence Erlbaum; Hillsdale, NJ: 1997. pp. 295&#x2013;316.</Citation></Reference><Reference><Citation>Tulving E. Can Psychol. 1985;26:1.</Citation></Reference><Reference><Citation>Maguire EA, et al. Philos Trans R Soc Lond B Biol Sci. 2001;356:1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088527</ArticleId><ArticleId IdType="pubmed">11571035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R, et al. J Cogn Neurosci. 2004;16:1583.</Citation><ArticleIdList><ArticleId IdType="pubmed">15622612</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, et al. J Neurophysiol. 2006;96:3517.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>This research was based on M.F.M.&#x2019;s doctoral dissertation, which was completed at Dartmouth College. The authors thank H. Gordon, D. Turk, J. Smallwood, T. Heatherton, M. Bar, J. Fugelsang, J. Cloutier, A. Krendl, D. Kraemer, J. Moran, M. Berryhill, G. Caplowitz, I. Kovelmanand three anonymous reviewers for their advice and assistance. C.N.M. was supported by a Royal Society&#x2013;Wolfson Fellowship.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17242369</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1691</StartPage><EndPage>1696</EndPage><MedlinePgn>1691-6</MedlinePgn></Pagination><Abstract><AbstractText>Neurogenesis is a subject of intense interest and extensive research, but it stands at the center of a bitter debate over ethical and practical problems. Neurodegenerative diseases, such as Alzheimer's disease (AD), accompanied by a shifting balance between neurogenesis and neurodegeneration, are suitable for stimulation of neurogenesis for the benefit of diseased patients. We have previously shown that Abs against the EFRH sequence of beta-amyloid peptide (AbetaP) prevent aggregation and disaggregate AbetaP both in vitro and in vivo. EFRH, located in the soluble tail of the N-terminal region, acts as a regulatory site controlling both solubilization and disaggregation processes in the AbetaP molecule. Here we show that anti-EFRH immunotherapy of a platelet-derived amyloid precursor protein transgenic mouse model of AD stimulates endogenous neurogenesis, suggested by elevated numbers of BrdU-incorporated cells, most of which are colocalized with a marker of mature neurons, NeuN. These newly born neurons expressed the activity-dependent gene Zif268, indicating their functional integration and participation in response to synaptic input in the brain. These findings suggest that anti-amyloid immunotherapy may promote recovery from AD or other diseases related to AbetaP overproduction and neurotoxicity by restoring neuronal population, as well as cognitive functions in treated patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavie</LastName><ForeName>Vered</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Beka</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17242369</ArticleId><ArticleId IdType="pmc">PMC1785268</ArticleId><ArticleId IdType="doi">10.1073/pnas.0610180104</ArticleId><ArticleId IdType="pii">0610180104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kempermann G, Jessberger S, Steiner B, Kronenberg G. Trends Neurosci. 2004;27:447&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15271491</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Buylla A. Semin Cell Dev Biol. 1997;8:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">15001097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornack DR, Rakic P. Proc Natl Acad Sci USA. 2001;98:4752&#x2013;4757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31906</ArticleId><ArticleId IdType="pubmed">11296302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois C, Alvarez-Buylla A. Science. 1994;264:1145&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8178174</ArticleId></ArticleIdList></Reference><Reference><Citation>Luskin MB. Neuron. 1993;11:173&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">8338665</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrous DN, Koehl M, Le Moal M. Physiol Rev. 2005;85:523&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15788705</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron HA, Woolley CS, McEwen BS, Gould E. Neuroscience. 1993;56:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247264</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen TM, Kristjansen PE, Bolwig TG, Wortwein G. Neuroscience. 2003;119:635&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">12809684</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje ML, Palmer T. Curr Opin Neurol. 2003;16:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">12644738</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D. Annu Rev Pharmacol Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, et al. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, et al. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Proc Natl Acad Sci USA. 1997;94:4109&#x2013;4112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20576</ArticleId><ArticleId IdType="pubmed">9108113</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D. Neurodegener Dis. 2005;2:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909007</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Balass M, Solomon B. J Neuroimmunol. 1998;88:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9688328</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Balass M, Katchalski-Katzir E, Solomon B. J Neuroimmunol. 1999;95:136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229123</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Hanan E, Katzav T. Proc Natl Acad Sci USA. 1996;93:452&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40256</ArticleId><ArticleId IdType="pubmed">8552659</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Dewachter I, Van Leuven F, Solomon B. Vaccine. 2003;21:1060&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, Hutter-Paier B, Solomon B. J Mol Neurosci. 2004;24:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">15314258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozon B, Davis S, Laroche S. Hippocampus. 2002;12:570&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440572</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ. J Comp Neurol. 2006;495:70&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessberger S, Kempermann G. Eur J Neurosci. 2003;18:2707&#x2013;2712.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656319</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Kitai ST. J Neurosci. 2000;20:5449&#x2013;5460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772329</ArticleId><ArticleId IdType="pubmed">10884328</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzowski JF. Hippocampus. 2002;12:86&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11918292</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Nat Med. 2002;8:963&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">12161747</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, Greenberg DA. Proc Natl Acad Sci USA. 2001;98:4710&#x2013;4715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31899</ArticleId><ArticleId IdType="pubmed">11296300</ArticleId></ArticleIdList></Reference><Reference><Citation>Felling RJ, Levison SW. J Neurosci Res. 2003;73:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12868061</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon J, Reid S, Kinyamu R, Opole I, Opole R, Baratta J, Korc M, Endo TL, Duong A, Nguyen G, et al. Proc Natl Acad Sci USA. 2000;97:14686&#x2013;14691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18979</ArticleId><ArticleId IdType="pubmed">11121069</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH. J Neurosci. 1997;17:3727&#x2013;3738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573703</ArticleId><ArticleId IdType="pubmed">9133393</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis MA, Penney EB, Pearson J, Dragunow M, Connor B, Faull RL. Neuroscience. 2005;132:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837138</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL. Proc Natl Acad Sci USA. 2003;100:9023&#x2013;9027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166431</ArticleId><ArticleId IdType="pubmed">12853570</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Proc Natl Acad Sci USA. 2004;101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA. Proc Natl Acad Sci USA. 2004;101:13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Prickaerts J, Koopmans G, Blokland A, Scheepens A. Neurobiol Learn Mem. 2004;81:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Development (Cambridge, UK) 2003;130:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12466205</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Markakis EA, Gage FH. J Comp Neurol. 1999;406:449&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">10205022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Kuhn CM, Kuhn HG. Brain Res Dev Brain Res. 2002;134:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11947933</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard-Riera N, Nait-Oumesmar B, Baron-Van Evercooren A. J Neurosci Res. 2004;76:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048920</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley JG, Mitchell BD, Kempermann G, Macklis JD. Prog Neurobiol. 2005;75:321&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">15913880</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemura NU. Neuroscience. 2005;134:121&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15964698</ArticleId></ArticleIdList></Reference><Reference><Citation>Magavi SS, Macklis JD. Brain Res Dev Brain Res. 2002;134:57&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11947937</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley JG, Mitchell BD, Magavi SS, Arlotta P, Macklis JD. NeuroRx. 2004;1:452&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534952</ArticleId><ArticleId IdType="pubmed">15717047</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ. Trends Neurosci. 2004;27:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363970</ArticleId><ArticleId IdType="pubmed">15111006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokoeva MV, Yin H, Flier JS. Science. 2005;310:679&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254185</ArticleId></ArticleIdList></Reference><Reference><Citation>Carleton A, Petreanu LT, Lansford R, Alvarez-Buylla A, Lledo PM. Nat Neurosci. 2003;6:507&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Toledano MA, Shelanski ML. J Neurosci. 2004;24:5439&#x2013;5444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729298</ArticleId><ArticleId IdType="pubmed">15190117</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Solomon B, Benhar I. J Neuroimmunol. 2000;106:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814779</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Katz O, Solomon B. Proc Natl Acad Sci USA. 2000;97:11455&#x2013;11459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17221</ArticleId><ArticleId IdType="pubmed">11027345</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MJ, Klyubin I, Wang Q, Anwyl R. Biochem Soc Trans. 2005;33:563&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042545</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje ML, Toda H, Palmer TD. Science. 2003;302:1760&#x2013;1765.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Proc Natl Acad Sci USA. 2003;100:13632&#x2013;13637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263865</ArticleId><ArticleId IdType="pubmed">14581618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak YD, Brannen CL, Qu T, Kim HM, Dong X, Soba P, Majumdar A, Kaplan A, Beyreuther K, Sugaya K. Stem Cells Dev. 2006;15:381&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">16846375</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Xie L, Mao XO, Greenberg DA. Brain Res. 2006;1085:183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16580645</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ. Trends Neurosci. 1999;22:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092043</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JM, Beckmann AM, Mason-Parker SE, Abraham WC, Wilce PA, Tate WP. Brain Res Mol Brain Res. 2000;77:258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17251419</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>796</StartPage><EndPage>807</EndPage><MedlinePgn>796-807</MedlinePgn></Pagination><Abstract><AbstractText>The basis for memory loss in early Alzheimer's disease (AD) seems likely to involve synaptic damage caused by soluble Abeta-derived oligomers (ADDLs). ADDLs have been shown to build up in the brain and CSF of AD patients and are known to interfere with mechanisms of synaptic plasticity, acting as gain-of-function ligands that attach to synapses. Because of the correlation between AD dementia and synaptic degeneration, we investigated here the ability of ADDLs to affect synapse composition, structure, and abundance. Using highly differentiated cultures of hippocampal neurons, a preferred model for studies of synapse cell biology, we found that ADDLs bound to neurons with specificity, attaching to presumed excitatory pyramidal neurons but not GABAergic neurons. Fractionation of ADDLs bound to forebrain synaptosomes showed association with postsynaptic density complexes containing NMDA receptors, consistent with observed attachment of ADDLs to dendritic spines. During binding to hippocampal neurons, ADDLs promoted a rapid decrease in membrane expression of memory-related receptors (NMDA and EphB2). Continued exposure resulted in abnormal spine morphology, with induction of long thin spines reminiscent of the morphology found in mental retardation, deafferentation, and prionoses. Ultimately, ADDLs caused a significant decrease in spine density. Synaptic deterioration, which was accompanied by decreased levels of the spine cytoskeletal protein drebrin, was blocked by the Alzheimer's therapeutic drug Namenda. The observed disruption of dendritic spines links ADDLs to a major facet of AD pathology, providing strong evidence that ADDLs in AD brain cause neuropil damage believed to underlie dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacor</LastName><ForeName>Pascale N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, USA. p-lacor@northwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buniel</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Furlow</LastName><ForeName>Paul W</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Clemente</LastName><ForeName>Antonio Sanz</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Pauline T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>Kirsten L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022237</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG018877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG022237</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048430" MajorTopicYN="Y">Cell Shape</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17251419</ArticleId><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3501-06.2007</ArticleId><ArticleId IdType="pii">27/4/796</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allison DW, Chervin AS, Gelfand VI, Craig AM. Postsynaptic scaffolds of excitatory and inhibitory synapses in hippocampal neurons: maintenance of core components independent of actin filaments and microtubules. J Neurosci. 2000;20:4545&#x2013;4554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772458</ArticleId><ArticleId IdType="pubmed">10844024</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso M, Medina JH, Pozzo-Miller L. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn Mem. 2004;11:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379687</ArticleId><ArticleId IdType="pubmed">15054132</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki C, Sekino Y, Hanamura K, Fujisawa S, Mahadomrongkul V, Ren Y, Shirao T. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses. J Comp Neurol. 2005;483:383&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">15700273</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer C, Schikorski T, Stevens CF. Comparison of hippocampal dendritic spines in culture and in brain. J Neurosci. 1998;18:5294&#x2013;5300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793498</ArticleId><ArticleId IdType="pubmed">9651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096&#x2013;9101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Jr, Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004;43:633&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442162</ArticleId><ArticleId IdType="pubmed">15339646</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlisle HJ, Kennedy MB. Spine architecture and synaptic plasticity. Trends Neurosci. 2005;28:182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808352</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Bakhos L, Wang Z, Venton DL, Klein WL. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci. 2003;20:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006;281:20315&#x2013;20325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16714296</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1&#x2013;42) into globular neurotoxins. Biochemistry. 2003;42:12749&#x2013;12760.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596589</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology. 2004;63:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477531</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of &#x3b2;-amyloid and prion proteins. J Neurosci. 1999;19:928&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782151</ArticleId><ArticleId IdType="pubmed">9920656</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol. 2006;65:592&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, Greenberg ME. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell. 2000;103:945&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136979</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd PR, Hardy JA, Oakley AE, Edwardson JA, Perry EK, Delaunoy JP. A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res. 1981;226:107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">7296283</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein G, Buranosky R, Crain BJ. Dendritic pathology of granule cells in Alzheimer's disease is unrelated to neuritic plaques. J Neurosci. 1994;14:5077&#x2013;5088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577187</ArticleId><ArticleId IdType="pubmed">8046469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ethell IM, Pasquale EB. Molecular mechanisms of dendritic spine development and remodeling. Prog Neurobiol. 2005;75:161&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Gullotta F. Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta Neuropathol (Berl) 1990;79:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">2141748</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala JC, Spacek J, Harris KM. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev. 2002;39:29&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086707</ArticleId></ArticleIdList></Reference><Reference><Citation>Futter M, Uematsu K, Bullock SA, Kim Y, Hemmings HC, Jr, Nishi A, Greengard P, Nairn AC. Phosphorylation of spinophilin by ERK and cyclin-dependent PK 5 (Cdk5) Proc Natl Acad Sci USA. 2005;102:3489&#x2013;3494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552943</ArticleId><ArticleId IdType="pubmed">15728359</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA. 2005;102:2273&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548981</ArticleId><ArticleId IdType="pubmed">15695586</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Haes AJ, Chang L, Klein WL, Van Duyne RP. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc. 2005;127:2264&#x2013;2271.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713105</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y, Shoji M, Shirao T, Hirai S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J Neurosci Res. 1996;43:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8838578</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Kater SB. Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function. Annu Rev Neurosci. 1994;17:341&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">8210179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999;19:8876&#x2013;8884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanpaa K, Isaacs KR, Shirao T, Brady DR, Rapoport SI. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:637&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">10374754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hering H, Lin CC, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci. 2003;23:3262&#x2013;3271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742299</ArticleId><ArticleId IdType="pubmed">12716933</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999;29:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Chae S, Lee D, Chromy B, Lee S, Park Y, Klein WL, Krafft GA, Hong S. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 2003;17:118&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424218</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Synaptic targeting by A&#x3b2; oligomers (ADDLs) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement. 2006;2:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595855</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Lacor PN, De Felice FG, Ferreira ST. Molecules that disrupt memory circuits in Alzheimer's disease: the attack on synapses by Abeta oligomers (ADDLs) In: Bontempi B, Silva A, Christen Y, Fondation Ipsen, editors. Memories: molecules and circuits. Paris: Springer; 2007.</Citation></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem. 2001;79:595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2007;100:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003;13:246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901839</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999;840:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10517949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Bhatia R, Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 2001;15:2433&#x2013;2444.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5:160&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. Actin-based plasticity in dendritic spines. Science. 2000;290:754&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052932</ArticleId></ArticleIdList></Reference><Reference><Citation>Matynia A, Kushner SA, Silva AJ. Genetic approaches to molecular and cellular cognition: a focus on LTP and learning and memory. Annu Rev Genet. 2002;36:687&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis. 2004;15:80&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751773</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokin M, Lindahl JS, Keifer J. Immediate-early gene-encoded protein Arc is associated with synaptic delivery of GluR4-containing AMPA receptors during in vitro classical conditioning. J Neurophysiol. 2006;95:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339507</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RGM, Davis M. The role of NMDA receptors in learning and memory. In: Collingridge GL, Watkins JC, editors. The NMDA receptor. Oxford: Oxford UP; 1994. pp. 340&#x2013;375.</Citation></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer G, Harrington CR, Wischik CM. Staging of cytoskeletal and &#x3b2;-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol. 2000;157:623&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850134</ArticleId><ArticleId IdType="pubmed">10934165</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006a;168:184&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592652</ArticleId><ArticleId IdType="pubmed">16400022</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006b;281:1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006;23:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Nagai T, Miyawaki A, Hayashi Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. Nat Neurosci. 2004;7:1104&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15361876</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan WS, Arndt K, Frank M, Gordon RE, Gawinowicz MA, Zhao Y, Colman DR. The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron. 2001;32:63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604139</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri L, Raiteri M. Synaptosomes still viable after 25 years of superfusion. Neurochem Res. 2000;25:1265&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers AB. Progress report on Alzheimer's disease 2004&#x2013;2005: new discoveries, new insights. Washington, DC: United States Department of Health and Human Services; 2005.</Citation></Reference><Reference><Citation>Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging. 2003;24:1029&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibel AB. Dendritic changes. In: Reisberg B, editor. Alzheimer's disease. New York: The Free Press; 1983. pp. 69&#x2013;73.</Citation></Reference><Reference><Citation>Segal M. Dendritic spines and long-term plasticity. Nat Rev Neurosci. 2005;6:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekino Y, Tanaka S, Hanamura K, Yamazaki H, Sasagawa Y, Xue Y, Hayashi K, Shirao T. Activation of N-methyl-d-aspartate receptor induces a shift of drebrin distribution: disappearance from dendritic spines and appearance in dendritic shafts. Mol Cell Neurosci. 2006;31:493&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368245</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M. Molecular organization of the postsynaptic specialization. Proc Natl Acad Sci USA. 2001;98:7058&#x2013;7061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34622</ArticleId><ArticleId IdType="pubmed">11416187</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett. 2002;324:209&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009525</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Standridge JB. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. Curr Alzheimer Res. 2006;3:95&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci. 2001;182:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:933&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258263</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Sekino Y, Tanaka S, Mizui T, Kishi S, Shirao T. Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J Neurosci. 2003;23:6586&#x2013;6595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740629</ArticleId><ArticleId IdType="pubmed">12878700</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Thornton PL, Balazs R, Cotman CW. Beta-amyloid-(1&#x2013;42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem. 2001;276:17301&#x2013;17306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278679</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres R, Firestein BL, Dong H, Staudinger J, Olson EN, Huganir RL, Bredt DS, Gale NW, Yancopoulos GD. PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron. 1998;21:1453&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883737</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (Lond) 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1&#x2013;42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, Bramham CR. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci. 2002;22:1532&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758896</ArticleId><ArticleId IdType="pubmed">11880483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zito K, Knott G, Shepherd GM, Shenolikar S, Svoboda K. Induction of spine growth and synapse formation by regulation of the spine actin cytoskeleton. Neuron. 2004;44:321&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17270731</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice.</ArticleTitle><Pagination><StartPage>325</StartPage><EndPage>335</EndPage><MedlinePgn>325-35</MedlinePgn></Pagination><Abstract><AbstractText>Currently, no treatment can prevent the cognitive and motor decline associated with widespread neurodegeneration in prion disease. However, we previously showed that targeting endogenous neuronal prion protein (PrP(C)) (the precursor of its disease-associated isoform, PrP(Sc)) in mice with early prion infection reversed spongiform change and prevented clinical symptoms and neuronal loss. We now show that cognitive and behavioral deficits and impaired neurophysiological function accompany early hippocampal spongiform pathology. Remarkably, these behavioral and synaptic impairments recover when neuronal PrP(C) is depleted, in parallel with reversal of spongiosis. Thus, early functional impairments precede neuronal loss in prion disease and can be rescued. Further, they occur before extensive PrP(Sc) deposits accumulate and recover rapidly after PrP(C) depletion, supporting the concept that they are caused by a transient neurotoxic species, distinct from aggregated PrP(Sc). These data suggest that early intervention in human prion disease may lead to recovery of cognitive and behavioral symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mallucci</LastName><ForeName>Giovanna R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom. g.mallucci@prion.ucl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Melanie D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Farmer</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Khatun</LastName><ForeName>Husna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jefferys</LastName><ForeName>John G R</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123160654</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U132692719</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018621">PrPC Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Feb 1;53(3):315-7. doi: 10.1016/j.neuron.2007.01.013.</RefSource><PMID Version="1">17270727</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004192" MajorTopicYN="N">Discrimination, Psychological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009425" MajorTopicYN="N">Nesting Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018621" MajorTopicYN="N">PrPC Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17270731</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.01.005</ArticleId><ArticleId IdType="pii">S0896-6273(07)00008-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17284452</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>14</Issue><PubDate><Year>2007</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.</ArticleTitle><Pagination><StartPage>10311</StartPage><EndPage>10324</EndPage><MedlinePgn>10311-24</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer disease is characterized by the abnormal aggregation of amyloid beta peptide into extracellular fibrillar deposits known as amyloid plaques. Soluble oligomers have been observed at early time points preceding fibril formation, and these oligomers have been implicated as the primary pathological species rather than the mature fibrils. A significant issue that remains to be resolved is whether amyloid oligomers are an obligate intermediate on the pathway to fibril formation or represent an alternate assembly pathway that may or may not lead to fiber formation. To determine whether amyloid beta oligomers are obligate intermediates in the fibrillization pathway, we characterized the mechanism of action of amyloid beta aggregation inhibitors in terms of oligomer and fibril formation. Based on their effects, the small molecules segregated into three distinct classes: compounds that inhibit oligomerization but not fibrillization, compounds that inhibit fibrillization but not oligomerization, and compounds that inhibit both. Several compounds selectively inhibited oligomerization at substoichiometric concentrations relative to amyloid beta monomer, with some active in the low nanomolar range. These results indicate that oligomers are not an obligate intermediate in the fibril formation pathway. In addition, these data suggest that small molecule inhibitors are useful for clarifying the mechanisms underlying protein aggregation and may represent potential therapeutic agents that target fundamental disease mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Necula</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, University of California, Irvine, California 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Milton</LastName><ForeName>Saskia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS-38298</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17284452</ArticleId><ArticleId IdType="doi">10.1074/jbc.M608207200</ArticleId><ArticleId IdType="pii">S0021-9258(19)57702-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17287515</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>1405</StartPage><EndPage>1410</EndPage><MedlinePgn>1405-10</MedlinePgn></Pagination><Abstract><AbstractText>Lewy bodies, the pathological hallmark of dementia with Lewy bodies (DLB), are large juxtanuclear inclusions of aggregated alpha-synuclein. However, the small number of cortical Lewy bodies relative to the total neuron count does not correlate with the extent of cognitive impairment. In contrast to dopaminergic neurons in Parkinson's disease, nerve cell loss is usually less prevalent in the cortex of DLB, suggesting a different mechanism of neurodegeneration. Because antibodies used for immunodetection per se do not generally differentiate the aggregated from the physiological and monomeric isoform of alpha-synuclein, we developed the paraffin-embedded tissue (PET) blot and the protein aggregate filtration (PAF) assay for the sensitive and selective detection of alpha-synuclein aggregates in tissue slides and brain homogenates, respectively. In contrast to common immunohistochemistry, the PET blot detected an enormous number of small alpha-synuclein aggregates, which, in contrast to the few Lewy bodies, may explain the cognitive impairment in DLB. Using the PAF assay, we demonstrate that the absolute majority of alpha-synuclein aggregates are located at presynaptic terminals, suggesting a severe pathological impact on synaptic function. Indeed, parallel to the massive presynaptic accumulation of alpha-synuclein aggregates, we observed significant synaptic pathology with almost complete loss of dendritic spines at the postsynaptic area. Our results provide strong evidence for a novel concept of neurodegeneration for DLB in which synaptic dysfunction is caused by presynaptic accumulation of alpha-synuclein aggregates. This concept may also be valid for Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Prion and Dementia Research Unit, Institute of Neuropathology, University of Goettingen, 37075 Goettingen, Germany. mkramer@med.uni-goettingen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz-Schaeffer</LastName><ForeName>Walter J</ForeName><Initials>WJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002499" MajorTopicYN="N">Centrifugation, Density Gradient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005374" MajorTopicYN="N">Filtration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="Y">Lewy Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016612" MajorTopicYN="N">Paraffin Embedding</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17287515</ArticleId><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4564-06.2007</ArticleId><ArticleId IdType="pii">27/6/1405</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burn DJ. Cortical Lewy body disease. J Neurol Neurosurg Psychiatry. 2004;75:175&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738936</ArticleId><ArticleId IdType="pubmed">14742580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123:383&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd PR, Watson WE, Morrison MM, Johnston GA, Bird ED, Cowburn RF, Hardy JA. Uptake of gamma-aminobutyric acid and l-glutamic acid by synaptosomes from postmortem human cerebral cortex: multiple sites, sodium dependence and effect of tissue preparation. Brain Res. 1989;490:320&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">2569904</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology. 1999;53:1284&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">10522886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Dodd PR, Oakley AE, Perry RH, Edwardson JA, Kidd AM. Metabolically active synaptosomes can be prepared from frozen rat and human brain. J Neurochem. 1983;40:608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">6827264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, Masliah E. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem. 1998;71:338&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648883</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttner WB, Schiebler W, Greengard P, De Camilli P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol. 1983;96:1374&#x2013;1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112660</ArticleId><ArticleId IdType="pubmed">6404912</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VM. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol. 1996;148:1517&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861579</ArticleId><ArticleId IdType="pubmed">8623921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamoto T, Shin RW, Doh-ura K, Tomokane N, Miyazono M, Muramoto T, Tateishi J. Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease. Am J Pathol. 1992;140:1285&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886543</ArticleId><ArticleId IdType="pubmed">1351366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10:524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, Kosaka K. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci. 2002;195:153&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897247</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002;16:2136&#x2013;2148.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473081</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and &#x3b1;-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. 2000;20:3214&#x2013;3220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773130</ArticleId><ArticleId IdType="pubmed">10777786</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron. 2004;44:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572108</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 1999;22:123&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202534</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol. 2005;57:82&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15562510</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RH, Irving D, Tomlinson BE. Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci. 1990;100:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">1965207</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz-Schaeffer WJ, Tschoke S, Kranefuss N, Drose W, Hause-Reitner D, Giese A, Groschup MH, Kretzschmar HA. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol. 2000;156:51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868648</ArticleId><ArticleId IdType="pubmed">10623653</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Sekino Y, Tanaka S, Mizui T, Kishi S, Shirao T. Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J Neurosci. 2003;23:6586&#x2013;6595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740629</ArticleId><ArticleId IdType="pubmed">12878700</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature. 2002;420:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda T, Greengard P, Berzins K, Cohen RS, Blomberg F, Grab DJ, Siekevitz P. Subcellular distribution in cerebral cortex of two proteins phosphorylated by a cAMP-dependent protein kinase. J Cell Biol. 1979;83:308&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111539</ArticleId><ArticleId IdType="pubmed">227912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology. 2005;64:545&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology. 2006;66:1591&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717229</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17289941</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>315</Volume><Issue>5815</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Reversal of neurological defects in a mouse model of Rett syndrome.</ArticleTitle><Pagination><StartPage>1143</StartPage><EndPage>1147</EndPage><MedlinePgn>1143-7</MedlinePgn></Pagination><Abstract><AbstractText>Rett syndrome is an autism spectrum disorder caused by mosaic expression of mutant copies of the X-linked MECP2 gene in neurons. However, neurons do not die, which suggests that this is not a neurodegenerative disorder. An important question for future therapeutic approaches to this and related disorders concerns phenotypic reversibility. Can viable but defective neurons be repaired, or is the damage done during development without normal MeCP2 irrevocable? Using a mouse model, we demonstrate robust phenotypic reversal, as activation of MeCP2 expression leads to striking loss of advanced neurological symptoms in both immature and mature adult animals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guy</LastName><ForeName>Jacky</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Cell Biology, Edinburgh University, King's Buildings, Edinburgh EH9 3JR, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Selfridge</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cobb</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>077224</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497393">Mecp2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002678" MajorTopicYN="N">Chimera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018390" MajorTopicYN="N">Gene Targeting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015518" MajorTopicYN="N">Rett Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17289941</ArticleId><ArticleId IdType="mid">EMS124480</ArticleId><ArticleId IdType="pmc">PMC7610836</ArticleId><ArticleId IdType="doi">10.1126/science.1138389</ArticleId><ArticleId IdType="pii">1138389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amir RE, et al. Nature Genet. 1999;23:185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508514</ArticleId></ArticleIdList></Reference><Reference><Citation>Neul JL, Zoghbi HY. Neuroscientist. 2004 Apr;10:118.</Citation><ArticleIdList><ArticleId IdType="pubmed">15070486</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong D, Dunn JK, Antalffy B, Trivedi R. J Neuropathol Exp Neurol. 1995 Mar;54:195.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi N, Macklis JD. Mol Cell Neurosci. 2004 Nov;27:306.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RZ, Akbarian S, Tudor M, Jaenisch R. Nat Genet. 2001;27:327.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242118</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy J, Hendrich B, Holmes M, Martin JE, Bird A. Nature Genetics. 2001;27:322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242117</ArticleId></ArticleIdList></Reference><Reference><Citation>Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Proc Natl Acad Sci U S A. 2004 Apr 20;101:6033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395918</ArticleId><ArticleId IdType="pubmed">15069197</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragatsis I, Zeitlin S. Nucleic Acids Res. 2001 Feb 1;29:E10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30411</ArticleId><ArticleId IdType="pubmed">11160912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, McMahon AP. Dev Biol. 2002 Apr 15;244:305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11944939</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins AL, et al. Hum Mol Genet. 2004 Nov 1;13:2679.</Citation><ArticleIdList><ArticleId IdType="pubmed">15351775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriaucionis S, Bird A. Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R221.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928486</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaka Y, Jugloff DG, Zhang L, Eubanks JH, Fitzsimonds RM. Neurobiol Dis. 2005 Aug 5;21:217.</Citation><ArticleIdList><ArticleId IdType="pubmed">16087343</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti P, et al. J Neurosci. 2006 Jan 4;26:319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674314</ArticleId><ArticleId IdType="pubmed">16399702</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan X, Campoy J, Bird A. Cell. 1997;88:471.</Citation><ArticleIdList><ArticleId IdType="pubmed">9038338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JD, et al. Cell. 1992;69:905.</Citation><ArticleIdList><ArticleId IdType="pubmed">1606614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17296549</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2007</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Response to: Pardossi-Piquard et al., "Presenilin-Dependent Transcriptional Control of the Abeta-Degrading Enzyme Neprilysin by Intracellular Domains of betaAPP and APLP." Neuron 46, 541-554.</ArticleTitle><Pagination><StartPage>479</StartPage><EndPage>483</EndPage><MedlinePgn>479-83</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Allen C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medial School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489697">APLP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neuron. 2005 May 19;46(4):541-54. doi: 10.1016/j.neuron.2005.04.008.</RefSource><PMID Version="1">15944124</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17296549</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.01.023</ArticleId><ArticleId IdType="pii">S0896-6273(07)00064-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17296550</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Response to correspondence: Pardossi-Piquard et al., "Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betAAPP and APLP." Neuron 46, 541-554.</ArticleTitle><Pagination><StartPage>483</StartPage><EndPage>486</EndPage><MedlinePgn>483-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pardossi-Piquard</LastName><ForeName>Rapha&#xeb;lle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IPMC, UMR6097 CNRS/UNSA, Equipe labellis&#xe9;e FRM, 660 Route des Lucioles, 06560 France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunys</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kawarai</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sunyach</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alves da Costa</LastName><ForeName>Cristine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>S&#xe9;valle</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pimplikar</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.-</RegistryNumber><NameOfSubstance UI="D000098830">AICDA (Activation-Induced Cytidine Deaminase)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.5</RegistryNumber><NameOfSubstance UI="D003564">Cytidine Deaminase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neuron. 2005 May 19;46(4):541-54. doi: 10.1016/j.neuron.2005.04.008.</RefSource><PMID Version="1">15944124</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003564" MajorTopicYN="N">Cytidine Deaminase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000098830" MajorTopicYN="N">AICDA (Activation-Induced Cytidine Deaminase)</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17296550</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.01.024</ArticleId><ArticleId IdType="pii">S0896-6273(07)00065-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17296554</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity.</ArticleTitle><Pagination><StartPage>519</StartPage><EndPage>533</EndPage><MedlinePgn>519-33</MedlinePgn></Pagination><Abstract><AbstractText>In Parkinson disease (PD), alpha-synuclein aggregates called Lewy bodies often involve and sequester Septin4 (Sept4), a polymerizing scaffold protein. However, the pathophysiological significance of this phenomenon is unclear. Here, we show the physiological association of Sept4 with alpha-synuclein, the dopamine transporter, and other presynaptic proteins in dopaminergic neurons; mice lacking Sept4 exhibit diminished dopaminergic neurotransmission due to scarcity of these presynaptic proteins. These data demonstrate an important role for septin scaffolds in the brain. In transgenic mice that express human alpha-synuclein(A53T) (a mutant protein responsible for familial PD), loss of Sept4 significantly enhances neuropathology and locomotor deterioration. In this PD model, insoluble deposits of Ser129-phosphorylated alpha-synuclein(A53T) are negatively correlated with the dosage of Sept4. In vitro, direct association with Sept4 protects alpha-synuclein against self-aggregation and Ser129 phosphorylation. Taken together, these data show that Sept4 may be involved in PD as a dual susceptibility factor, as its insufficiency can diminish dopaminergic neurotransmission and enhance alpha-synuclein neurotoxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biochemistry and Cell Biology Unit, HMRO, Kyoto University Graduate School of Medicine, Yoshida Konoe, Sakyo, Kyoto 606-8501, Japan. ihara@kuhp.kyoto-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hagiwara</LastName><ForeName>Akari</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tanigaki</LastName><ForeName>Ai</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kitano</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hikawa</LastName><ForeName>Rie</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Tomimoto</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takanashi</LastName><ForeName>Masashi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hideo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Miyakawa</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C492027">SEPTIN4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D058112">Septins</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Feb 15;53(4):469-70. doi: 10.1016/j.neuron.2007.02.002.</RefSource><PMID Version="1">17296545</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058112" MajorTopicYN="N">Septins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17296554</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.01.019</ArticleId><ArticleId IdType="pii">S0896-6273(07)00039-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17304350</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>117</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.</ArticleTitle><Pagination><StartPage>648</StartPage><EndPage>658</EndPage><MedlinePgn>648-58</MedlinePgn></Pagination><Abstract><AbstractText>A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here we report that inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation. A critical mediator of this mechanism was carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those of the mature Hsp90 refolding complex prevented this effect. This is the first demonstration to our knowledge that blockade of the refolding pathway promotes p-tau turnover through degradation. We also show that peripheral administration of a novel Hsp90 inhibitor promoted selective decreases in p-tau species in a mouse model of tauopathy, further suggesting a central role for the Hsp90 complex in the pathogenesis of tauopathies. When taken in the context of known high-affinity Hsp90 complexes in affected regions of the AD brain, these data implicate a central role for Hsp90 in the development of AD and other tauopathies and may provide a rationale for the development of novel Hsp90-based therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamal</LastName><ForeName>Adeela</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Klosak</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>Rachel M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Dunmore</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ash</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Shoraka</LastName><ForeName>Sareh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zlatkovic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Eckman</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Cam</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Nahman</LastName><ForeName>N Stanley</ForeName><Initials>NS</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Burrows</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS040256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG17216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-NS40256</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000619706">HSF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076249">Heat Shock Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C467728">STUB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Invest. 2007 Mar;117(3):590-2. doi: 10.1172/JCI31505.</RefSource><PMID Version="1">17332887</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076249" MajorTopicYN="N">Heat Shock Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17304350</ArticleId><ArticleId IdType="pmc">PMC1794119</ArticleId><ArticleId IdType="doi">10.1172/JCI29715</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hutton M., et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany M.B., Dickson D.W. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann. Neurol. 1996;40:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773594</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann. Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. (Berl.). 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M., et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. U. S. A. 2005;102:16801&#x2013;16806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275598</ArticleId><ArticleId IdType="pubmed">16260738</ArticleId></ArticleIdList></Reference><Reference><Citation>Waza M., et al. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. . J. Mol. Med. 2006;84:635&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741751</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N., et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 2005;94:1254&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamos J.E., et al. Expression of heat shock proteins in Alzheimer&#x2019;s disease. Neurology. 1991;41:345&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">2005999</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez N., et al. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer&#x2019;s disease. Brain Res. Mol. Brain Res. 1991;11:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">1661822</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H., Miura-Shimura Y., Kosik K.S. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. 2004;279:17957&#x2013;17962.</Citation><ArticleIdList><ArticleId IdType="pubmed">14963027</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C.A., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3&#x2013;cleaved tau species. J. Neurosci. 2006;26:6985&#x2013;6996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673930</ArticleId><ArticleId IdType="pubmed">16807328</ArticleId></ArticleIdList></Reference><Reference><Citation>Panaretou B., et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 1998;17:4829&#x2013;4836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170812</ArticleId><ArticleId IdType="pubmed">9707442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40:427&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">14556719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">14508491</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C.A., et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 2006;20:753&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">16464956</ArticleId></ArticleIdList></Reference><Reference><Citation>Biamonte M.A., et al. Orally active purine-based inhibitors of the heat shock protein 90. . J. Med. Chem. 2006;49:817&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420067</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C.A., et al. Development of a high throughput drug screening assay for the detection of changes in tau levels &#x2014; proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2005;2:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974923</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S.B., McDonough H., Boellmann F., Cyr D.M., Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature. 2006;440:551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112096</ArticleId><ArticleId IdType="pubmed">16554822</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.C., Nathan D.F., Lindquist S. In vivo analysis of the Hsp90 cochaperone Sti1 (p60). Mol. Cell. Biol. 1997;17:318&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231756</ArticleId><ArticleId IdType="pubmed">8972212</ArticleId></ArticleIdList></Reference><Reference><Citation>Frydman J., Hohfeld J. Chaperones get in touch: the Hip-Hop connection. Trends Biochem. Sci. 1997;22:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9066258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Smith D.F. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J. Biol. Chem. 1998;273:35194&#x2013;35200.</Citation><ArticleIdList><ArticleId IdType="pubmed">9857057</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.D., Schumacher R.J., Ross E.D., Toft D.O. Hop modulates Hsp70/Hsp90 interactions in protein folding. J. Biol. Chem. 1998;273:3679&#x2013;3686.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou Y.C., et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891359</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenert J.P., et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997;272:23843&#x2013;23850.</Citation><ArticleIdList><ArticleId IdType="pubmed">9295332</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">14765195</ArticleId></ArticleIdList></Reference><Reference><Citation>Soifer H.S., Zaragoza A., Peyvan M., Behlke M.A., Rossi J.J. A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res. 2005;33:846&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549394</ArticleId><ArticleId IdType="pubmed">15701756</ArticleId></ArticleIdList></Reference><Reference><Citation>Grelle G., et al. Identification of VCP/p97, carboxyl terminus of Hsp70-interacting protein (CHIP), and amphiphysin II interaction partners using membrane-based human proteome arrays. Mol. Cell. Proteomics. 2006;5:234&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275660</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C., et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronjanowski J.Q., Lee V.M. Pathological tau: a loss of normal function or a gain in toxicity? Nat. Neurosci. . 2005;8:1136&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., et al. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett. 1993;335:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">8253190</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M., Lee V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 1997;272:19547&#x2013;19553.</Citation><ArticleIdList><ArticleId IdType="pubmed">9235959</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrachina M., Maes T., Buesa C., Ferrer I. Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer&#x2019;s disease. Neuropathol. Appl. Neurobiol. 2006;32:505&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">16972884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E., Bieschke J., Perciavalle R.M., Kelly J.W., Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg A.L., Stein R., Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem. Biol. 1995;2:503&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">9383453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton W.S. The proteasome. Semin. Oncol. 2004;31(Suppl. 16):3&#x2013;9; discussion 33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Q., et al. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 2003;22:5446&#x2013;5458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC213783</ArticleId><ArticleId IdType="pubmed">14532117</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenert J.P., Johnson B.D., Toft D.O. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. J. Biol. Chem. 1999;274:17525&#x2013;17533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364185</ArticleId></ArticleIdList></Reference><Reference><Citation>Connell P., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 2001;3:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11146632</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver C.L., Espinoza M., Kress Y., Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer&#x2019;s disease. Neurobiol. Aging. 2000;21:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N., et al. Tau-66: evidence for a novel tau conformation in Alzheimer&#x2019;s disease. . J. Neurochem. 2001;77:1372&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11389188</ArticleId></ArticleIdList></Reference><Reference><Citation>Cripps D., et al. Alzheimer&#x2019;s disease&#x2013;specific conformation of hyperphosphorylated phf-tau is polyubiquitinated through lys-48, lys-11, and lys-6 ubiquitin conjugation. J. Biol. Chem. . 2006;281:10825&#x2013;10838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443603</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds M.R., Berry R.W., Binder L.I. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry. 2005;44:13997&#x2013;14009.</Citation><ArticleIdList><ArticleId IdType="pubmed">16229489</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J., et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell. 2002;13:4013&#x2013;4028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC133611</ArticleId><ArticleId IdType="pubmed">12429843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow, E.M. 2006. The modes and pathways of Tau&#x2019;s toxicity to neurons in neurodegeneration. Paper presented at the Keystone Symposia Conference on Alzheimer&#x2019;s Disease: Genes, Cellular Pathways and Therapies. February 21&#x2013;26. Breckenridge, Colorado, USA.</Citation></Reference><Reference><Citation>Sittler A., et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington&#x2019;s disease. Hum. Mol. Genet. 2001;10:1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406612</ArticleId></ArticleIdList></Reference><Reference><Citation>Waza M., et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 2005;11:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155577</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L., Dawson T.M. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann. Med. 2004;36:315&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">15224658</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro J.E., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005;106:2506&#x2013;2512..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895276</ArticleId><ArticleId IdType="pubmed">15972449</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17308309</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>15</Issue><PubDate><Year>2007</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.</ArticleTitle><Pagination><StartPage>11590</StartPage><EndPage>11601</EndPage><MedlinePgn>11590-601</MedlinePgn></Pagination><Abstract><AbstractText>Oxidative stress is a major aspect of Alzheimer disease (AD) pathology. We have investigated the relationship between oxidative stress and neuronal binding of Abeta oligomers (also known as ADDLs). ADDLs are known to accumulate in brain tissue of AD patients and are considered centrally related to pathogenesis. Using hippocampal neuronal cultures, we found that ADDLs stimulated excessive formation of reactive oxygen species (ROS) through a mechanism requiring N-methyl-d-aspartate receptor (NMDA-R) activation. ADDL binding to neurons was reduced and ROS formation was completely blocked by an antibody to the extracellular domain of the NR1 subunit of NMDA-Rs. In harmony with a steric inhibition of ADDL binding by NR1 antibodies, ADDLs that were bound to detergent-extracted synaptosomal membranes co-immunoprecipitated with NMDA-R subunits. The NR1 antibody did not affect ROS formation induced by NMDA, showing that NMDA-Rs themselves remained functional. Memantine, an open channel NMDA-R antagonist prescribed as a memory-preserving drug for AD patients, completely protected against ADDL-induced ROS formation, as did other NMDA-R antagonists. Memantine and the anti-NR1 antibody also attenuated a rapid ADDL-induced increase in intraneuronal calcium, which was essential for stimulated ROS formation. These results show that ADDLs bind to or in close proximity to NMDA-Rs, triggering neuronal damage through NMDA-R-dependent calcium flux. This response provides a pathologically specific mechanism for the therapeutic action of memantine, indicates a role for ROS dysregulation in ADDL-induced cognitive impairment, and supports the unifying hypothesis that ADDLs play a central role in AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Pauline T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Mary P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Sara J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Sergio T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG11385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG18877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG22547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId><ArticleId IdType="doi">10.1074/jbc.M607483200</ArticleId><ArticleId IdType="pii">S0021-9258(20)76737-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17322876</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.</ArticleTitle><Pagination><StartPage>411</StartPage><EndPage>413</EndPage><MedlinePgn>411-3</MedlinePgn></Pagination><Abstract><AbstractText>Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Nancy Pritzker Laboratory, Stanford University, Palo Alto, California 94304-5485, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Wade</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zuniga</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Blank</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Malenka</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Garner</LastName><ForeName>Craig C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018756">GABA Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>124-87-8</RegistryNumber><NameOfSubstance UI="D010852">Picrotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM5Z385K7T</RegistryNumber><NameOfSubstance UI="D010433">Pentylenetetrazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018756" MajorTopicYN="N">GABA Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010433" MajorTopicYN="N">Pentylenetetrazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010852" MajorTopicYN="N">Picrotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17322876</ArticleId><ArticleId IdType="doi">10.1038/nn1860</ArticleId><ArticleId IdType="pii">nn1860</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17336088</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1044-7431</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Molecular and cellular neurosciences</Title><ISOAbbreviation>Mol Cell Neurosci</ISOAbbreviation></Journal><ArticleTitle>The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>621</StartPage><EndPage>628</EndPage><MedlinePgn>621-8</MedlinePgn></Pagination><Abstract><AbstractText>Recent studies show that intracellular cholesterol levels can modulate the processing of amyloid precursor protein to Abeta peptide. Moreover, cholesterol-rich apoE-containing lipoproteins may also promote Abeta clearance. Agonists of the liver X receptor (LXR) transcriptionally induce genes involved in intracellular lipid efflux and transport, including apoE. Thus, LXR agonists have the potential to both inhibit APP processing and promote Abeta clearance. Here we show that LXR agonist, TO901317, increased hippocampal ABCA1 and apoE and decreased Abeta42 levels in APP transgenic mice. TO901317 had no significant effects on levels of Abeta40, full length APP, or the APP processing products. Next, we examined the effects of TO901317 in the contextual fear conditioning paradigm; TO901317 completely reversed the contextual memory deficit in these mice. These data demonstrate that LXR agonists do not directly inhibit APP processing but rather facilitate the clearance of Abeta42 and may represent a novel therapeutic approach to Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riddell</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA. riddeld@wyeh.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Comery</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Kouranova</LastName><ForeName>Evguenia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>C Frederick</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Warwick</LastName><ForeName>Helen K</ForeName><Initials>HK</Initials></Author><Author ValidYN="Y"><LastName>Ring</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Kirksey</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Aschmies</LastName><ForeName>Suzan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kubek</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hirst</LastName><ForeName>Warren D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vasylyev</LastName><ForeName>Dmytro</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Oganesian</LastName><ForeName>Aram</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Martone</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Pangalos</LastName><ForeName>Menelas N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Reinhart</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>J Steve</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Cell Neurosci</MedlineTA><NlmUniqueID>9100095</NlmUniqueID><ISSNLinking>1044-7431</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577836">ABCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423915">T0901317</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006845" MajorTopicYN="N">Hydrocarbons, Fluorinated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17336088</ArticleId><ArticleId IdType="doi">10.1016/j.mcn.2007.01.011</ArticleId><ArticleId IdType="pii">S1044-7431(07)00021-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17351623</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease.</ArticleTitle><Pagination><StartPage>432</StartPage><EndPage>438</EndPage><MedlinePgn>432-8</MedlinePgn></Pagination><Abstract><AbstractText>Microglia are the principal immune cells of the brain. In Alzheimer disease, these brain mononuclear phagocytes are recruited from the blood and accumulate in senile plaques. However, the role of microglia in Alzheimer disease has not been resolved. Microglia may be neuroprotective by phagocytosing amyloid-beta (Abeta), but their activation and the secretion of neurotoxins may also cause neurodegeneration. Ccr2 is a chemokine receptor expressed on microglia, which mediates the accumulation of mononuclear phagocytes at sites of inflammation. Here we show that Ccr2 deficiency accelerates early disease progression and markedly impairs microglial accumulation in a transgenic mouse model of Alzheimer disease (Tg2576). Alzheimer disease mice deficient in Ccr2 accumulated Abeta earlier and died prematurely, in a manner that correlated with Ccr2 gene dosage, indicating that absence of early microglial accumulation leads to decreased Abeta clearance and increased mortality. Thus, Ccr2-dependent microglial accumulation plays a protective role in the early stages of Alzheimer disease by promoting Abeta clearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El Khoury</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA. jelkhoury@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toft</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hickman</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Means</LastName><ForeName>Terry K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Terada</LastName><ForeName>Kinya</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Geula</LastName><ForeName>Changiz</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Luster</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515335">Ccr2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054390">Receptors, CCR2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2007 Apr;13(4):408-9. doi: 10.1038/nm0407-408.</RefSource><PMID Version="1">17415372</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018448" MajorTopicYN="Y">Models, Immunological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054390" MajorTopicYN="N">Receptors, CCR2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId><ArticleId IdType="doi">10.1038/nm1555</ArticleId><ArticleId IdType="pii">nm1555</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17353377</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.</ArticleTitle><Pagination><StartPage>354</StartPage><EndPage>362</EndPage><MedlinePgn>354-62</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To develop preventive therapy for Alzheimer disease (AD), it is essential to develop AD-related biomarkers that identify at-risk individuals in the same way that cholesterol levels identify persons at risk for heart disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether plasma levels of amyloid beta protein (Abeta40 and Abeta42) are useful for identifying cognitively normal elderly white subjects at increased risk for mild cognitive impairment (MCI) and AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Using well-established sandwich enzyme-linked immunosorbent assays, plasma Abeta40 and Abeta42 levels were analyzed at baseline in a prospective, elderly white cohort followed up for 2 to 12 (median, 3.7) years to detect incident cases of MCI or AD.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Cognitively normal, community-based white volunteers recruited from primary care settings into the Mayo Rochester Alzheimer Disease Patient Registry. Patients We followed up 563 cognitively normal white volunteers (median age, 78 years; 62% female) who had at least 1 follow-up visit after measurement of baseline plasma Abeta levels.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was time to development of MCI or AD. The secondary outcome was the annualized rate of cognitive change in patients for whom we had 2 Mattis Dementia Rating Scale evaluations 3 to 7 years apart.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During follow-up, 53 subjects developed MCI or AD. Subjects with plasma Abeta42/Abeta40 ratios in the lower quartiles showed significantly greater risk of MCI or AD (P = .04, adjusted for age and apolipoprotein E genotype). Comparison of subjects with plasma Abeta42/Abeta40 ratios in the lowest vs the highest quartile gave a relative risk of 3.1 (95% confidence interval, 1.1-8.3). After adjusting for age and apolipoprotein E genotype, regression analysis using annualized changes in the Dementia Rating Scale scores as an outcome variable showed that participants with lower Abeta42/Abeta40 ratios had greater cognitive decline (P = .02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The plasma Abeta42/Abeta40 ratio may be a useful premorbid biomarker for identifying cognitively normal elderly white subjects who are at increased risk for developing MCI or AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo College of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA. graffradford.neill@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Ivnik</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Glenn E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Linda H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG06656</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arch Neurol. 2007 Sep;64(9):1246</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="Y">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.3.354</ArticleId><ArticleId IdType="pii">64/3/354</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17353378</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.</ArticleTitle><Pagination><StartPage>366</StartPage><EndPage>370</EndPage><MedlinePgn>366-70</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides able to differentiate between patients with stable mild cognitive impairment (MCI) and those who will progress to Alzheimer disease (AD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Baseline cerebrospinal fluid samples from patients with MCI and healthy controls were profiled using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory disorder clinic.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Patients with MCI (n = 113), of whom 56 were cognitively stable and 57 progressed to AD with dementia during a 4- to 6-year follow-up, as well as 28 healthy controls who were followed up for 3 years. Main Outcome Measure During follow-up, 57 patients progressed to AD and 56 patients had stable MCI. Cerebrospinal fluid from these 2 groups of patients was compared using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified a panel of 17 potential biomarkers that could distinguish between patients with stable MCI and patients with MCI who progressed to AD. We have positively identified and characterized 5 of the potential biomarkers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Proteomic profiling of cerebrospinal fluid provided a novel panel of 17 potential biomarkers for prediction of MCI progression to AD. The 5 identified biomarkers are relevant to the pathogenesis of AD and could help gain an understanding of the molecular pathways in which they may function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simonsen</LastName><ForeName>Anja H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Biomarker Discovery Center Facility, Ciphergen Biosystems, Inc., 2100 Copenhagen O, Denmark. asimonsen@ciphergen.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Podust</LastName><ForeName>Vladimir N</ForeName><Initials>VN</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Huw A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Waldemar</LastName><ForeName>Gunhild</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17353378</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.3.366</ArticleId><ArticleId IdType="pii">64/3/366</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17353389</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.</ArticleTitle><Pagination><StartPage>431</StartPage><EndPage>434</EndPage><MedlinePgn>431-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the correspondence between uptake of Pittsburgh Compound B (PiB) in life and measures of beta-amyloid (Abeta) in postmortem tissue analysis. Patient A 76-year-old man with a clinical diagnosis of dementia with Lewy bodies underwent fluorodeoxyglucose (18)F and PiB positron emission tomographic brain scans. Imaging revealed marked region specific binding of PiB and abnormal fluorodeoxyglucose uptake. Intervention Autopsy was performed 3 months after the PiB scan.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Autopsy confirmed the clinical diagnosis; in addition, there was severe cerebral amyloid angiopathy and only moderate numbers of parenchymal Abeta plaques. Biochemical measures revealed a positive correlation between Abeta levels and regional PiB binding.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This report confirms that PiB detects Abeta in the living patient and demonstrates that amyloid deposited as cerebral amyloid angiopathy can be the dominant source of signal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Charlestown, MA 02129, USA. bbacskai@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Stefanie H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Scott B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Augustinack</LastName><ForeName>Jean C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Irizarry</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB00768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS038372</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2007 Mar;64(3):315-6. doi: 10.1001/archneur.64.3.315.</RefSource><PMID Version="1">17353372</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.3.431</ArticleId><ArticleId IdType="pii">64/3/431</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17359920</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Covalent modification of DNA regulates memory formation.</ArticleTitle><Pagination><StartPage>857</StartPage><EndPage>869</EndPage><MedlinePgn>857-69</MedlinePgn></Pagination><Abstract><AbstractText>DNA methylation is a covalent chemical modification of DNA catalyzed by DNA methyltransferases (DNMTs). DNA methylation is associated with transcriptional silencing and has been studied extensively as a lifelong molecular information storage mechanism put in place during development. Here we report that DNMT gene expression is upregulated in the adult rat hippocampus following contextual fear conditioning and that DNMT inhibition blocks memory formation. In addition, fear conditioning is associated with rapid methylation and transcriptional silencing of the memory suppressor gene PP1 and demethylation and transcriptional activation of the synaptic plasticity gene reelin, indicating both methyltransferase and demethylase activity during consolidation. DNMT inhibition prevents the PP1 methylation increase, resulting in aberrant transcription of the gene during the memory-consolidation period. These results demonstrate that DNA methylation is dynamically regulated in the adult nervous system and that this cellular mechanism is a crucial step in memory formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Courtney A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and the Evelyn F. McKnight Brain Institute,University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweatt</LastName><ForeName>J David</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 DA024761</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091042">Reelin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717129">Reln protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>776B62CQ27</RegistryNumber><NameOfSubstance UI="D000077209">Decitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.37</RegistryNumber><NameOfSubstance UI="D004248">DNA (Cytosine-5-)-Methyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D010749">Phosphoprotein Phosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>M801H13NRU</RegistryNumber><NameOfSubstance UI="D001374">Azacitidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2008 Sep 25;59(6):1051</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001374" MajorTopicYN="N">Azacitidine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003214" MajorTopicYN="N">Conditioning, Classical</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004248" MajorTopicYN="N">DNA (Cytosine-5-)-Methyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077209" MajorTopicYN="N">Decitabine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010749" MajorTopicYN="N">Phosphoprotein Phosphatases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091042" MajorTopicYN="N">Reelin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17359920</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.02.022</ArticleId><ArticleId IdType="pii">S0896-6273(07)00142-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17360474</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Spatial navigation deficit in amnestic mild cognitive impairment.</ArticleTitle><Pagination><StartPage>4042</StartPage><EndPage>4047</EndPage><MedlinePgn>4042-7</MedlinePgn></Pagination><Abstract><AbstractText>Patients with Alzheimer's disease (AD) frequently have difficulties with spatial orientation in their day-to-day life. Although AD is typically preceded by amnestic mild cognitive impairment (MCI), spatial navigation has not yet been studied in MCI. Sixty-five patients were divided into five groups: probable AD (n = 21); MCI, further classified as amnestic MCI single domain (n = 11); amnestic MCI multiple domain (n = 18), or nonamnestic MCI (n = 7), and subjective memory complaints (n = 8). These patients, together with a group of healthy control subjects (n = 26), were tested by using a four-subtests task that required them to locate an invisible goal inside a circular arena. Each subtest began with an overhead view of the arena showed on a computer monitor. This was followed by a real navigation inside of the actual space, an enclosed arena 2.9 m in diameter. Depending on the subtest, the subjects could use the starting position and/or cues on the wall for navigation. The subtests thus were focused on allocentric and egocentric navigation. The AD group and amnestic MCI multiple-domain group were impaired in all subtests. The amnestic MCI single-domain group was impaired significantly in subtests focused on allocentric orientation and at the beginning of the real space egocentric subtest, suggesting impaired memory for allocentric and real space configurations. Our results suggest that spatial navigation impairment occurs early in the development of AD and can be used for monitoring of the disease progression or for evaluation of presymptomiatic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hort</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Disorders Clinic, Department of Neurology, Second Medical School, Charles University, 150 18 Prague 5, Czech Republic. jakub.hort@seznam.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacz&#xf3;</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vyhn&#xe1;lek</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bojar</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bures</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vlcek</LastName><ForeName>Kamil</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="Y">Space Perception</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17360474</ArticleId><ArticleId IdType="pmc">PMC1820705</ArticleId><ArticleId IdType="doi">10.1073/pnas.0611314104</ArticleId><ArticleId IdType="pii">0611314104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Touchon J, Ritchie K. Int J Geriatr Psychiatry. 1999;14:556&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440976</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR, Zola-Morgan S. Science. 1991;253:1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mendez MF. Dementia: A Clinical Approach. Woburn, MA: Butterworth-Heinemann; 2003.</Citation></Reference><Reference><Citation>Braak H, Braak E. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, et al. Arch Neurol (Chicago) 2004;61:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732621</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, Arnold R, Mitchell J, Nestor PJ, Hodges JR. Psychol Med. 2006;36:507&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">16426486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Jagust WJ, Fitzpatrick A, Carlson MC, Dekosky ST, Breitner J, Lyketsos CG, Jones B, Kawas C, et al. J Neurol Neurosurg Psychiatry. 2006;77:159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077558</ArticleId><ArticleId IdType="pubmed">16103044</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos P, Grimmer T, Perneczky R, Domes G, Kurz A. Dement Geriatr Cogn Disord. 2006;22:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16679762</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai MC, Jacobs WJ. Int J Geriatr Psychiatry. 2004;19:250&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15027040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Mendez M, Perryman K. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">11513099</ArticleId></ArticleIdList></Reference><Reference><Citation>Monacelli AM, Cushman LA, Kavcic V, Duffy CJ. Neurology. 2003;61:1491&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pubmed">14663030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetewsky SJ, Duffy CJ. Neurology. 1999;52:958&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalova E, Vlcek K, Jarolimova E, Bures J. Behav Brain Res. 2005;159:175&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels RP, Feijen J, Postma A. Dement Geriatr Cogn Disord. 2005;20:184&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Steffenella TM, Duffy CJ. Neurology. 2003;60:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629237</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J, Dostrovsky J. Brain Res. 1971;34:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O'Keefe J. Nature. 1982;297:681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Astur RS, Taylor LB, Mamelak AN, Philpott L, Sutherland RJ. Behav Brain Res. 2002;132:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11853860</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigenbaum JD, Morris RG. Neuropsychology. 2004;18:462&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15291724</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Burgess N, Donnett JG, Frackowiak RS, Frith CD, O'Keefe J. Science. 1998;280:921&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572740</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Pickering A, Polkey CE, Morris RG. Neuropsychologia. 1997;35:11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981373</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre GK, Zarahn E, D'Esposito M. Proc Natl Acad Sci USA. 1998;95:839&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33806</ArticleId><ArticleId IdType="pubmed">9448249</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien HL, Tetewsky SJ, Avery LM, Cushman LA, Makous W, Duffy CJ. Cereb Cortex. 2001;11:1083&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590117</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdstock JS, Mayes AR, Cezayirli E, Isaac CL, Aggleton JP, Roberts N. Neuropsychologia. 2000;38:410&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohbot VD, Kalina M, Stepankova K, Spackova N, Petrides M, Nadel L. Neuropsychologia. 1998;36:1217&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842767</ArticleId></ArticleIdList></Reference><Reference><Citation>King JA, Burgess N, Hartley T, Vargha-Khadem F, O'Keefe J. Hippocampus. 2002;12:811&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542232</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Burke T, Phillips J, Staunton H. Neuropsychologia. 1996;34:993&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843066</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrone MC, Tosetti M, Montanaro D, Fiorentini A, Cioni G, Burr DC. Nat Neurosci. 2000;3:1322&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100154</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso MP, Hallikainen M, Vanhanen M, Nissinen A, Helkala EL, et al. Neurobiol Aging. 2004;25:303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123335</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A, Gustafson L. Arch Psychiatr Nervenkr. 1976;223:15&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">828039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Hindley NJ, Braak H, Braak E, Yilmazer-Hanke DM, Schultz C, Barnetson L, King EM, Jobst KA, Smith AD. Dement Geriatr Cogn Disord. 1999;10:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026385</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudic S, Barba GD, Thibaudet MC, Smagghe A, Remy P, Traykov L. Arch Clin Neuropsychol. 2006;21:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125364</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. CNS Spectr. 2005;10:22&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Arch Neurol. 2001;58:411&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255444</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Dement Geriatr Cogn Disord. 2006;22:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940725</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonker C, Geerlings MI, Schmand B. Int J Geriatr Psychiatry. 2000;15:983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113976</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Neurologia. 2000;15:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846869</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepankova K, Pastalkova E, Kalova E, Kalina M, Bures J. Behav Brain Res. 2003;147:95&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17360897</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation.</ArticleTitle><Pagination><StartPage>2751</StartPage><EndPage>2759</EndPage><MedlinePgn>2751-9</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) neuropathology is characterized by the accumulation of phosphorylated tau and amyloid-beta peptides derived from the amyloid precursor protein (APP). Elevated blood levels of homocysteine are a significant risk factor for many age-related diseases, including AD. Impaired homocysteine metabolism favors the formation of S-adenosylhomocysteine, leading to inhibition of methyltransferase-dependent reactions. Here, we show that incubation of neuroblastoma cells with S-adenosylhomocysteine results in reduced methylation of protein phosphatase 2A (PP2A), a major brain Ser/Thr phosphatase, most likely by inhibiting PP2A methyltransferase (PPMT). PP2A methylation levels are also decreased after ectopic expression of PP2A methylesterase in Neuro-2a (N2a) cells. Reduced PP2A methylation promotes the downregulation of B alpha-containing holoenzymes, thereby affecting PP2A substrate specificity. It is associated with the accumulation of both phosphorylated tau and APP isoforms and increased secretion of beta-secretase-cleaved APP fragments and amyloid-beta peptides. Conversely, incubation of N2a cells with S-adenosylmethionine and expression of PPMT enhance PP2A methylation. This leads to the accumulation of dephosphorylated tau and APP species and increased secretion of neuroprotective alpha-secretase-cleaved APP fragments. Remarkably, hyperhomocysteinemia induced in wild-type and cystathionine-beta-synthase +/- mice by feeding a high-methionine, low-folate diet is associated with increased brain S-adenosylhomocysteine levels, PPMT downregulation, reduced PP2A methylation levels, and tau and APP phosphorylation. We reported previously that downregulation of neuronal PPMT and PP2A methylation occur in affected brain regions from AD patients. The link between homocysteine, PPMT, PP2A methylation, and key CNS proteins involved in AD pathogenesis provides new mechanistic insights into this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sontag</LastName><ForeName>Estelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. estelle.sontag@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunbhakdi-Craig</LastName><ForeName>Viyada</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Sontag</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ogris</LastName><ForeName>Egon</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dayal</LastName><ForeName>Sanjana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lentz</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Arning</LastName><ForeName>Erland</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bottiglieri</LastName><ForeName>Teodoro</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG018883</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18883</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AT002311</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS024621</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG018883</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS24621</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AT002311</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL063943</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.-</RegistryNumber><NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D010749">Phosphoprotein Phosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008780" MajorTopicYN="N">Methyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041681" MajorTopicYN="N">NIH 3T3 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010749" MajorTopicYN="N">Phosphoprotein Phosphatases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17360897</ArticleId><ArticleId IdType="pmc">PMC6672573</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3316-06.2007</ArticleId><ArticleId IdType="pii">27/11/2751</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ando K, Iijima KI, Elliott JI, Kirino Y, Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem. 2001;276:40353&#x2013;40361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11517218</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Phosphorylation of tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol Aging. 1998;19:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562497</ArticleId></ArticleIdList></Reference><Reference><Citation>Baharians Z, Schonthal AH. Autoregulation of protein phosphatase type 2A expression. J Biol Chem. 1998;273:19019&#x2013;19024.</Citation><ArticleIdList><ArticleId IdType="pubmed">9668082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottiglieri T. The effect of storage on rat tissues and human plasma amino acid levels determined by HPLC. Biomed Chromatogr. 1987;2:195&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">3507236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottiglieri T. Isocratic high performance liquid chromatographic analysis of S-adenosylmethionine and S-adenosylhomo-cysteine in animal tissues: the effect of exposure to nitrous oxide. Biomed Chromatogr. 1990;4:239&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">2289047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottiglieri T, Reynolds EH, Toone BK, Carney MW. CSF S-adenosylmethionine in neuropsychiatric disorders. Lancet. 1991;338:121.</Citation><ArticleIdList><ArticleId IdType="pubmed">1676448</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Hundelt M, Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta. 2005;1739:331&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615650</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Koo EH, Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc Natl Acad Sci USA. 1993;90:9195&#x2013;9198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47529</ArticleId><ArticleId IdType="pubmed">8415676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, Jeong YH, Lee JP, Park CH, Kim S, Baik TK, Suh YH. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol. 2006;26:4327&#x2013;4338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489099</ArticleId><ArticleId IdType="pubmed">16705182</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cruz e Silva EF, da Cruz e Silva OA. Protein phosphorylation and APP metabolism. Neurochem Res. 2003;28:1553&#x2013;1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570401</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cruz e Silva EF, da Cruz e Silva OA, Zaia CT, Greengard P. Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. Mol Med. 1995;1:535&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2229959</ArticleId><ArticleId IdType="pubmed">8529119</ArticleId></ArticleIdList></Reference><Reference><Citation>De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, Goris J. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry. 1999;38:16539&#x2013;16547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600115</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin AM, Bottiglieri T, Domann FE, Lentz SR. Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J Biol Chem. 2005;280:25506&#x2013;25511.</Citation><ArticleIdList><ArticleId IdType="pubmed">15899898</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med. 2005;5:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16047261</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci. 2005;28:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy SE, Caporaso GL, Buxbaum JD, de Cruz SO, Iverfeldt K, Nordstedt C, Suzuki T, Czernik AJ, Nairn AC, Greengard P. Protein phosphorylation regulates relative utilization of processing pathways for Alzheimer beta/A4 amyloid precursor protein. Ann NY Acad Sci. 1993;695:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239268</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Satumtira S, Jakes R, Smith MJ, Kamibayashi C, White CL, Sontag E. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J Neurochem. 2000;75:2155&#x2013;2162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032905</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques AG, Domingues SC, Fardilha M, da Cruz e Silva EF, da Cruz e Silva OA. Sodium azide and 2-deoxy-d-glucose-induced cellular stress affects phosphorylation-dependent AbetaPP processing. J Alzheimers Dis. 2005;7:201&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002;70:694&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB, Rogers E. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis. 2003;14:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678664</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer M, Bruckner MK, Beck M, Bigl V, Arendt T. Modulation of APP processing and secretion by okadaic acid in primary guinea pig neurons. J Neural Transm. 2000;107:451&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">11215756</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen RE, Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem. 2002;9:2055&#x2013;2075.</Citation><ArticleIdList><ArticleId IdType="pubmed">12369870</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bottiglieri T. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology. 2005;65:1402&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhee KH, Kruger WD. The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal. 2005;7:813&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm. 2004;111:547&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, Fahrenholz F. The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem. 2005;38:105&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA. 1999;96:3922&#x2013;3927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22396</ArticleId><ArticleId IdType="pubmed">10097139</ArticleId></ArticleIdList></Reference><Reference><Citation>Latasa MJ, Belandia B, Pascual A. Thyroid hormones regulate beta-amyloid gene splicing and protein secretion in neuroblastoma cells. Endocrinology. 1998;139:2692&#x2013;2698.</Citation><ArticleIdList><ArticleId IdType="pubmed">9607774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173445</ArticleId><ArticleId IdType="pubmed">14557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, Faraci FM. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol Heart Circ Physiol. 2000;279:H970&#x2013;H975.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993757</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Su Y, Li B, Zhou Y, Ryder J, Gonzalez-DeWhitt P, May PC, Ni B. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 2003;547:193&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860412</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, Calatayud MT, Blazquez MB. APP processing and the APP-KPI domain involvement in the amyloid cascade. Neurodegener Dis. 2005;2:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909010</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18:3587&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC331014</ArticleId><ArticleId IdType="pubmed">2194165</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol. 2003;2:425&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849121</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem. 1996;67:1328&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder C, Schoonenboom NS, Jansen EE, Verhoeven NM, van Kamp GJ, Jakobs C, Scheltens P. The transmethylation cycle in the brain of Alzheimer patients. Neurosci Lett. 2005;386:69&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16040194</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa K, Kitazume S, Oka R, Maruyama K, Saido TC, Sato Y, Endo T, Hashimoto Y. Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. J Neurochem. 2006;96:924&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">16412100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurk E, Refsum H, Tell GS, Engedal K, Vollset SE, Ueland PM, Nygaard HA, Smith AD. Plasma total homocysteine and memory in the elderly: The Hordaland Homocysteine study. Ann Neurol. 2005;58:847&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogris E, Du X, Nelson KC, Mak EK, Yu XX, Lane WS, Pallas DC. A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J Biol Chem. 1999;274:14382&#x2013;14391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503312</ArticleId><ArticleId IdType="pubmed">10318862</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco-Quinto J, Rodriguez de Turco EB, Derosa S, Howard A, Cruz-Sanchez F, Sambamurti K, Refolo L, Petanceska S, Pappolla MA. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22:651&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">16516482</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrot N, Santos SF, Feyt C, Morel M, Brion JP, Octave JN. Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. J Biol Chem. 2006;281:39907&#x2013;39914.</Citation><ArticleIdList><ArticleId IdType="pubmed">17085446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82:636&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155278</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844848</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal. 2001;13:7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11257442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron. 1996;17:1201&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL, III, Mumby MC, Bloom GS. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem. 1999;274:25490&#x2013;25498.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464280</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL., III Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol. 2004a;63:287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">15099019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, White CL., III Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol. 2004b;63:1080&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">15535135</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta. 2005;1739:280&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Cole GM, Chu T, Xia W, Galasko D, Yamaguchi H, Tanemura K, Frautschy SA, Takashima A. Intracellular Abeta is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines. Neurobiol Aging. 2002;23:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">11804703</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolstykh T, Lee J, Vafai S, Stock JB. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J. 2000;19:5682&#x2013;5691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305779</ArticleId><ArticleId IdType="pubmed">11060019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">1874890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vafai SB, Stock JB. Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's disease. FEBS Lett. 2002;518:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11997007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R. beta-Secretase, APP and Abeta in Alzheimer's disease. Subcell Biochem. 2005;38:79&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709474</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingtdeux V, Hamdane M, Gompel M, Begard S, Drobecq H, Ghestem A, Grosjean ME, Kostanjevecki V, Grognet P, Vanmechelen E, Buee L, Delacourte A, Sergeant N. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis. 2005;20:625&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">15936948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SY, Choi JE, Yoon JH, Huh JW, Kim DH. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol Dis. 2006;22:435&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">16480887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu XX, Du X, Moreno CS, Green RE, Ogris E, Feng Q, Chou L, McQuoid MJ, Pallas DC. Methylation of the protein phosphatase 2A catalytic subunit is Essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Mol Biol Cell. 2001;12:185&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30577</ArticleId><ArticleId IdType="pubmed">11160832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17360908</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.</ArticleTitle><Pagination><StartPage>2866</StartPage><EndPage>2875</EndPage><MedlinePgn>2866-75</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by decreased synapse density in hippocampus and neocortex, and synapse loss is the strongest anatomical correlate of the degree of clinical impairment. Although considerable evidence supports a causal role for the amyloid-beta protein (Abeta) in AD, a direct link between a specific form of Abeta and synapse loss has not been established. We demonstrate that physiological concentrations of naturally secreted Abeta dimers and trimers, but not monomers, induce progressive loss of hippocampal synapses. Pyramidal neurons in rat organotypic slices had markedly decreased density of dendritic spines and numbers of electrophysiologically active synapses after exposure to picomolar levels of soluble oligomers. Spine loss was reversible and was prevented by Abeta-specific antibodies or a small-molecule modulator of Abeta aggregation. Mechanistically, Abeta-mediated spine loss required activity of NMDA-type glutamate receptors (NMDARs) and occurred through a pathway involving cofilin and calcineurin. Furthermore, NMDAR-mediated calcium influx into active spines was reduced by Abeta oligomers. Partial blockade of NMDARs by pharmacological antagonists was sufficient to trigger spine loss. We conclude that soluble, low-n oligomers of human Abeta trigger synapse loss that can be reversed by therapeutic agents. Our approach provides a quantitative cellular model for elucidating the molecular basis of Abeta-induced neuronal dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Ganesh M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloodgood</LastName><ForeName>Brenda L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>Bernardo L</ForeName><Initials>BL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046579</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17360908</ArticleId><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4970-06.2007</ArticleId><ArticleId IdType="pii">27/11/2866</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bloodgood BL, Sabatini BL. Nonlinear regulation of unitary synaptic signals by CaV(2.3) voltage-sensitive calcium channels located in dendritic spines. Neuron. 2007;53:249&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17224406</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter AG, Sabatini BL. State-dependent calcium signaling in dendritic spines of striatal medium spiny neurons. Neuron. 2004;44:483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">15504328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem. 2002;77:354&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">11991763</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JA, Mulkey RM, Nicoll RA, Malenka RC. Ca2+ signaling requirements for long-term depression in the hippocampus. Neuron. 1996;16:825&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">8608000</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci. 1987;78:151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Stevens JK. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. J Neurosci. 1989;9:2982&#x2013;2997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569708</ArticleId><ArticleId IdType="pubmed">2769375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdain P, Fukunaga K, Muller D. Calcium/calmodulin-dependent protein kinase II contributes to activity-dependent filopodia growth and spine formation. J Neurosci. 2003;23:10645&#x2013;10649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740921</ArticleId><ArticleId IdType="pubmed">14627649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG. Dimeric amyloid &#x3b2; protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2004;24:3801&#x2013;3809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729359</ArticleId><ArticleId IdType="pubmed">15084661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH. Clinical practice. Early Alzheimer's disease. N Engl J Med. 2003;349:1056&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">12968090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Miller DL, Sapienza VJ, Chen C-MJ, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun. 1988;2:121&#x2013;130.</Citation></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk Y, Eilers J, Lisman J, Konnerth A. NMDA receptor-mediated subthreshold Ca2+ signals in spines of hippocampal neurons. J Neurosci. 2000;20:1791&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772937</ArticleId><ArticleId IdType="pubmed">10684880</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science. 1999;283:1923&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082466</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney MT, Minamide LS, Kinley AW, Boyle JA, Bamburg JR. &#x3b2;-Secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid &#x3b2;: a feedforward mechanism for Alzheimer's disease. J Neurosci. 2005;25:11313&#x2013;11321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725891</ArticleId><ArticleId IdType="pubmed">16339026</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001;56:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature. 2004;429:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158816</ArticleId><ArticleId IdType="pubmed">15190253</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000;275:18495&#x2013;18502.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764800</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MHL, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SSN, Mount HTJ, Fraser PE, Westaway D, George-Hyslop PS. Cyclohexanehexol inhibitors of A[beta] aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767098</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2; 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron. 2004;44:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572108</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Neveu D, Zucker RS. Postsynaptic levels of [Ca2+]i needed to trigger LTD and LTP. Neuron. 1996;16:619&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">8785059</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll RA, Malenka RC. Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann NY Acad Sci. 1999;868:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10414328</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimchinsky EA, Yasuda R, Oertner TG, Svoboda K. The number of glutamate receptors opened by synaptic stimulation in single hippocampal spines. J Neurosci. 2004;24:2054&#x2013;2064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730404</ArticleId><ArticleId IdType="pubmed">14985448</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci. 2006;33:274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">16962789</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci. 2005;8:1727&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286931</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid {beta}-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (Lond) 2006a;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006b;60:668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192927</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61:1965&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229004</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid &#x3b2;-peptide (A&#x3b2;) fibrillogenesis block oligomerization of natural A&#x3b2; and thereby rescue long-term potentiation. J Neurosci. 2005;25:2455&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725159</ArticleId><ArticleId IdType="pubmed">15758153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SN, Tang YG, Zucker RS. Selective induction of LTP and LTD by postsynaptic [Ca2+]i elevation. J Neurophysiol. 1999;81:781&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">10036277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci. 2006;9:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415866</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron. 2004;44:749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17360912</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1.</ArticleTitle><Pagination><StartPage>2896</StartPage><EndPage>2907</EndPage><MedlinePgn>2896-907</MedlinePgn></Pagination><Abstract><AbstractText>Early hallmarks of Alzheimer's disease include the loss of synapses, which precedes the loss of neurons and the pathological phosphorylation and aggregation of tau protein. Mitochondrial dysfunction has been suggested as a reason, but evidence on the role of tau was lacking. Here, we show that transfection of tau in mature hippocampal neurons leads to an improper distribution of tau into the somatodendritic compartment with concomitant degeneration of synapses, as seen by the disappearance of spines and of presynaptic and postsynaptic markers. This is accompanied by transport inhibition of vesicles and organelles, concomitant with an increase and bundling of microtubules. Mitochondria degenerate, thus causing ATP levels to decrease. The tau-induced synaptic decay can be relieved by the activation of the kinase MARK2 (microtubule-associated protein/microtubule affinity regulating kinase 2)/Par-1 (protease-activated receptor 1), which can remove tau from the microtubule tracks and reverses the transport block. This leads to the rescue of dendritic spines, synapses, mitochondrial transport and ATP levels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thies</LastName><ForeName>Edda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044463">Receptor, PAR-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C094670">MARK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001693" MajorTopicYN="N">Biological Transport, Active</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044463" MajorTopicYN="N">Receptor, PAR-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17360912</ArticleId><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4674-06.2007</ArticleId><ArticleId IdType="pii">27/11/2896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aronov S, Aranda G, Behar L, Ginzburg I. Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J Neurosci. 2001;21:6577&#x2013;6587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763080</ArticleId><ArticleId IdType="pubmed">11517247</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas PW, Pienkowski TP, Kosik KS. Processes induced by tau expression in Sf9 cells have an axon-like microtubule organization. J Cell Biol. 1991;115:1333&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289232</ArticleId><ArticleId IdType="pubmed">1955477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett WP, Banker GA. An electron microscopic study of the development of axons and dendrites by hippocampal neurons in culture. II. Synaptic relationships. J Neurosci. 1984;4:1954&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564956</ArticleId><ArticleId IdType="pubmed">6470763</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">16178023</ArticleId></ArticleIdList></Reference><Reference><Citation>Berliocchi L, Fava E, Leist M, Horvat V, Dinsdale D, Read D, Nicotera P. Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis. J Cell Biol. 2005;168:607&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171755</ArticleId><ArticleId IdType="pubmed">15716378</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, Mandelkow EM. Protein kinase MARK/par-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell. 2002;13:4013&#x2013;4028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC133611</ArticleId><ArticleId IdType="pubmed">12429843</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun L. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee FC, Mudher A, Cuttle MF, Newman TA, Mackay D, Lovestone S, Shepherd D. Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis. 2005;20:918&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Kanai Y, Cowan NJ, Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature. 1992;360:674&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Pittenger MF, Feramisco JR. Elevation of tubulin levels by microinjection suppresses new tubulin synthesis. Nature. 1983;305:738&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">6633643</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Buee L. Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol. 2000;13:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10970052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresbach T, Hempelmann A, Spilker C, tom Dieck S, Altrock WD, Zuschratter W, Garner CC, Gundelfinger ED. Functional regions of the presynaptic cytomatrix protein bassoon: significance for synaptic targeting and cytomatrix anchoring. Mol Cell Neurosci. 2003;23:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12812759</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic. 3:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15163359</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia ML, Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol. 2001;13:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hering H, Sheng M. Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci. 2001;2:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11733795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science. 1998;279:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">9438838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y. Selective stabilization of tau in axons and microtubule-associated protein 2c in cell-bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol. 1996;132:667&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199865</ArticleId><ArticleId IdType="pubmed">8647897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci. 2005;118:5411&#x2013;5419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1533994</ArticleId><ArticleId IdType="pubmed">16306220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Krichevsky AM. The message and the messenger: delivering RNA in neurons. Science STKE. 2002;2002:PE16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11930084</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Oddo S. Alzheimer's disease: A&#x3b2;, tau and synaptic dysfunction. Trends Mol Med. 2005;11:170&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell. 2004;119:873&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607982</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lillo C, Jonsson PA, Vande Velde C, Ward CM, Miller TM, Subramaniam JR, Rothstein JD, Marklund S, Andersen PM, Brannstrom T, Gredal O, Wong PC, Williams DS, Cleveland DW. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 2004;43:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233913</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E-M, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR-1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol. 2004;167:99&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172520</ArticleId><ArticleId IdType="pubmed">15466480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus A. Actin-based plasticity in dendritic spine. Science. 2000;290:754&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, Fischer I, Kosik KS, Nixon RA. Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo. J Neurosci. 1995;15:8259&#x2013;8267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577949</ArticleId><ArticleId IdType="pubmed">8613759</ArticleId></ArticleIdList></Reference><Reference><Citation>Overly CC, Hollenbeck PJ. Dynamic organization of endocytic pathways in axons of cultured sympathetic neurons. J Neurosci. 1996;16:6056&#x2013;6064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579168</ArticleId><ArticleId IdType="pubmed">8815888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakakibara T, Murakami S, Eisaki N, Nakajima M, Imai K. An enzymatic cycling method using pyruvate orthophosphate dikinase and firefly luciferase for the simultaneous determination of ATP and AMP. Anal Biochem. 1999;268:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">10036167</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmiere PD, Bamburg JR. Regulation of the neuronal actin cytoskeleton by ADF/cofilin. J Neurobiol. 2004;58:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598374</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz A, Kojima H, Oiwa K, Mandelkow E-M, Song YH, Mandelkow E. Single-molecule investigation of the interference between kinesin and tau on microtubules. EMBO J. 2002;21:4896&#x2013;4905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126299</ArticleId><ArticleId IdType="pubmed">12234929</ArticleId></ArticleIdList></Reference><Reference><Citation>Setou M, Nakagawa T, Seog DH, Hirokawa N. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science. 2000;288:1796&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846156</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Subramaniam S, Wolf T, Tackenberg C, Brandt R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J Neurosci. 2006;26:6103&#x2013;6114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675219</ArticleId><ArticleId IdType="pubmed">16738255</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Hyman BT. Neuronal structure is altered by amyloid plaques. Rev Neurosci. 2004;15:267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15526551</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002;156:1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Goldstein LS. Axonal transport and Alzheimer's disease. Annu Rev Biochem. 2006;75:607&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756504</ArticleId></ArticleIdList></Reference><Reference><Citation>Terman A, Brunk UT. Autophagy in cardiac myocyte homeostasis, aging, and pathology. Cardiovasc Res. 2005;68:355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">16213475</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm T, Li X, Biernat J, Jiao J, Mandelkow E, Vandekerckhove J, Mandelkow E-M. MARKK, a Ste-20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. EMBO J. 2003;22:5090&#x2013;5101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC204455</ArticleId><ArticleId IdType="pubmed">14517247</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuste R, Bonhoeffer T. Genesis of dendritic spines: insights from ultrastructural and imaging studies. Nat Rev Neurosci. 2004;5:24&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1736183</PMID><DateCompleted><Year>1992</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>2</Issue><PubDate><Year>1992</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease.</ArticleTitle><Pagination><StartPage>447</StartPage><EndPage>449</EndPage><MedlinePgn>447-9</MedlinePgn></Pagination><Abstract><AbstractText>Postmortem analyses of Alzheimer's disease (AD) brain tissue reveal reactive microglia expressing high levels of major histocompatibility complex (MHC) glycoproteins, immunoglobulin receptors, and complement receptors; small but significant numbers of T-lymphocytes infiltrating tissue; enhanced cytokine and cytokine receptor expression; and profuse immunoreactivity for complement proteins of the classic pathway colocalized with senile plaques, dystrophic neurites, and some neurofibrillary tangles. Protectin, clusterin, and vitronectin, three proteins designed to defend host cells against "bystander lysis" caused by the membrane attack complex of complement, are all expressed at high levels in AD tissue but not in normal tissue. Taken together, these findings indicate that immune-mediated autodestructive processes may occur in AD. In view of the urgency to find treatments for AD and disappointing results with the many classes of pharmacologic agents that have so far been given clinical trials, exploration of the effectiveness of anti-inflammatory agents may now be warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>P L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AGO 7367</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1736183</ArticleId><ArticleId IdType="doi">10.1212/wnl.42.2.447</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17366635</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.</ArticleTitle><Pagination><StartPage>446</StartPage><EndPage>453</EndPage><MedlinePgn>446-53</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Aggregation and deposition of amyloid beta (Abeta) in the brain is thought to be central to the pathogenesis of Alzheimer's disease (AD). Recent studies suggest that cerebrospinal fluid (CSF) Abeta levels are strongly correlated with AD status and progression, and may be a meaningful endophenotype for AD. Mutations in presenilin 1 (PSEN1) are known to cause AD and change Abeta levels. In this study, we have investigated DNA sequence variation in the presenilin (PSEN1) gene using CSF Abeta levels as an endophenotype for AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We sequenced the exons and flanking intronic regions of PSEN1 in clinically characterized research subjects with extreme values of CSF Abeta levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This novel approach led directly to the identification of a disease-causing mutation in a family with late-onset AD.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">This finding suggests that CSF Abeta may be a useful endophenotype for genetic studies of AD. Our results also suggest that PSEN1 mutations can cause AD with a large range in age of onset, spanning both early- and late-onset AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquart</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chakraverty</LastName><ForeName>Sumi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00036</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId><ArticleId IdType="doi">10.1002/ana.21099</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17367539</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2007</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6</StartPage><MedlinePgn>6</MedlinePgn></Pagination><Abstract><AbstractText>Alpha-synuclein is a small soluble, cytosolic protein which associates with vesicular membranes. It is a component of intracellular Lewy bodies present in Parkinson's disease and a subset of Alzheimer's disease (AD). In addition, early studies identified a fragment of alpha-synuclein in the amyloid plaques of AD patients. Hypothesizing that alpha-synuclein might modify the AD pathogenic process, we crossed the Tg2576 strain of APP transgenic mice onto an alpha-synuclein knockout background to determine the effects of alpha-synuclein on Abeta production and plaque deposition. We found that alpha-synuclein deficiency does not affect the Abeta levels, nor does it alter the age of onset of plaque pathology. To our surprise, however, loss of alpha-synuclein leads to a significant increase in plaque load in all areas of the forebrain at 18 months of age. This is associated with an increase in another synaptic protein, synaptophysin. We thus conclude that alpha-synuclein is not involved in seeding of the plaques, but rather suppresses the progression of plaque pathology at advanced stages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kallhoff</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA. vk144297@bcm.tmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peethumnongsin</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021141</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS040039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17367539</ArticleId><ArticleId IdType="pmc">PMC1832188</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-2-6</ArticleId><ArticleId IdType="pii">1750-1326-2-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Rub U, Schultz C, Del Tredici K. Vulnerability of Cortical Neurons to Alzheimer's and Parkinson's Diseases. J Alzheimers Dis. 2006;9:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914843</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D, Kopan R. Notch and Presenilin: Regulated Intramembrane Proteolysis Links Development and Degeneration. Annu Rev Neurosci. 2003;26:565&#x2013;97. doi: 10.1146/annurev.neuro.26.041002.131334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.26.041002.131334</ArticleId><ArticleId IdType="pubmed">12730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the Act: Alpha-Synuclein Is the Culprit in Parkinson's Disease. Neuron. 2003;40:453&#x2013;6. doi: 10.1016/S0896-6273(03)00684-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00684-6</ArticleId><ArticleId IdType="pubmed">14642269</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Lee VM. Parkin and the Molecular Pathways of Parkinson's Disease. Neuron. 2001;31:885&#x2013;8. doi: 10.1016/S0896-6273(01)00439-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00439-1</ArticleId><ArticleId IdType="pubmed">11580890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular Cloning of Cdna Encoding an Unrecognized Component of Amyloid in Alzheimer Disease. Proc Natl Acad Sci USA. 1993;90:11282&#x2013;6. doi: 10.1073/pnas.90.23.11282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.23.11282</ArticleId><ArticleId IdType="pmc">PMC47966</ArticleId><ArticleId IdType="pubmed">8248242</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The Precursor Protein of Non-a Beta Component of Alzheimer's Disease Amyloid Is a Presynaptic Protein of the Central Nervous System. Neuron. 1995;14:467&#x2013;75. doi: 10.1016/0896-6273(95)90302-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90302-X</ArticleId><ArticleId IdType="pubmed">7857654</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-a Beta Component of Alzheimer's Disease Amyloid (Nac) Is Amyloidogenic. Biochemistry. 1995;34:10139&#x2013;45. doi: 10.1021/bi00032a006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00032a006</ArticleId><ArticleId IdType="pubmed">7640267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta Peptide and Alpha Synuclein: Molecular Mechanisms in Overlapping Pathology of Alzheimer's and Parkinson's in Dementia with Lewy Body Disease. Neurochem Res. 2006;31:1153&#x2013;62. doi: 10.1007/s11064-006-9140-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9140-9</ArticleId><ArticleId IdType="pubmed">16947080</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ueda K, Chen P, Ashe KH, Cole GM. Plaque-Associated Alpha-Synuclein (Nacp) Pathology in Aged Transgenic Mice Expressing Amyloid Precursor Protein. Brain Res. 2000;853:381&#x2013;3. doi: 10.1016/S0006-8993(99)02207-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(99)02207-6</ArticleId><ArticleId IdType="pubmed">10640638</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. Beta-Amyloid Peptides Enhance Alpha-Synuclein Accumulation and Neuronal Deficits in a Transgenic Mouse Model Linking Alzheimer's Disease and Parkinson's Disease. Proc Natl Acad Sci USA. 2001;98:12245&#x2013;50. doi: 10.1073/pnas.211412398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.211412398</ArticleId><ArticleId IdType="pmc">PMC59799</ArticleId><ArticleId IdType="pubmed">11572944</ArticleId></ArticleIdList></Reference><Reference><Citation>Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX. Non-Abeta Component of Alzheimer's Disease Amyloid (Nac) Revisited. Nac and Alpha-Synuclein Are Not Associated with Abeta Amyloid. Am J Pathol. 1999;155:1173&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867017</ArticleId><ArticleId IdType="pubmed">10514400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming SM, Fernagut PO, Chesselet MF. Genetic Mouse Models of Parkinsonism: Strengths and Limitations. NeuroRx. 2005;2:495&#x2013;503. doi: 10.1602/neurorx.2.3.495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1602/neurorx.2.3.495</ArticleId><ArticleId IdType="pmc">PMC1144493</ArticleId><ArticleId IdType="pubmed">16389313</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice Lacking Alpha-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System. Neuron. 2000;25:239&#x2013;52. doi: 10.1016/S0896-6273(00)80886-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80886-7</ArticleId><ArticleId IdType="pubmed">10707987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking Alpha-Synuclein. J Neurosci. 2002;22:8797&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC. Double-Knockout Mice for Alpha- and Beta-Synucleins: Effect on Synaptic Functions. Proc Natl Acad Sci USA. 2004;101:14966&#x2013;71. doi: 10.1073/pnas.0406283101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0406283101</ArticleId><ArticleId IdType="pmc">PMC522043</ArticleId><ArticleId IdType="pubmed">15465911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-Synuclein Cooperates with Cspalpha in Preventing Neurodegeneration. Cell. 2005;123:383&#x2013;96. doi: 10.1016/j.cell.2005.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.09.028</ArticleId><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid Rafts Mediate the Synaptic Localization of Alpha-Synuclein. J Neurosci. 2004;24:6715&#x2013;23. doi: 10.1523/JNEUROSCI.1594-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1594-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729723</ArticleId><ArticleId IdType="pubmed">15282274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL. A Combinatorial Code for the Interaction of Alpha-Synuclein with Membranes. J Biol Chem. 2005;280:31664&#x2013;72. doi: 10.1074/jbc.M504894200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M504894200</ArticleId><ArticleId IdType="pubmed">16020543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The Gamma-Secretase Complex: Membrane-Embedded Proteolytic Ensemble. Biochemistry. 2006;45:7931&#x2013;9. doi: 10.1021/bi060799c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi060799c</ArticleId><ArticleId IdType="pubmed">16800619</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered Presynaptic Protein Nacp Is Associated with Plaque Formation and Neurodegeneration in Alzheimer's Disease. Am J Pathol. 1996;148:201&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861620</ArticleId><ArticleId IdType="pubmed">8546207</ArticleId></ArticleIdList></Reference><Reference><Citation>Gispert-Sanchez S, Auburger G. The Role of Protein Aggregates in Neuronal Pathology: Guilty, Innocent, or Just Trying to Help? J Neural Transm Suppl. 2006:111&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17017517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Takenouchi T, Mallory M, Masliah E, Takeda A. The Role of Nac in Amyloidogenesis in Alzheimer's Disease. Am J Pathol. 2000;156:734&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850022</ArticleId><ArticleId IdType="pubmed">10667911</ArticleId></ArticleIdList></Reference><Reference><Citation>Quilty MC, King AE, Gai WP, Pountney DL, West AK, Vickers JC, Dickson TC. Alpha-Synuclein Is Upregulated in Neurones in Response to Chronic Oxidative Stress and Is Associated with Neuroprotection. Exp Neurol. 2006;199:249&#x2013;56. doi: 10.1016/j.expneurol.2005.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.10.018</ArticleId><ArticleId IdType="pubmed">16310772</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu A, Wersinger C, Moussa CE, Vernier P. The Role of Alpha-Synuclein in Both Neuroprotection and Neurodegeneration. Ann N Y Acad Sci. 2004;1035:250&#x2013;70. doi: 10.1196/annals.1332.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1332.016</ArticleId><ArticleId IdType="pubmed">15681812</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Iseki E, Katsuse O, Yamaguchi A, Katsuyama K, Aoki I, Yamanaka S, Kosaka K. Neuronal Accumulation of Alpha- and Beta-Synucleins in the Brain of a Gm2 Gangliosidosis Mouse Model. Neuroreport. 2003;14:551&#x2013;4. doi: 10.1097/00001756-200303240-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200303240-00004</ArticleId><ArticleId IdType="pubmed">12657883</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Wang B, He W, Zheng H. Wild-Type Presenilin 1 Protects against Alzheimer Disease Mutation-Induced Amyloid Pathology. J Biol Chem. 2006;281:15330&#x2013;6. doi: 10.1074/jbc.M512574200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M512574200</ArticleId><ArticleId IdType="pubmed">16574645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17376970</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia.</ArticleTitle><Pagination><StartPage>3090</StartPage><EndPage>3097</EndPage><MedlinePgn>3090-7</MedlinePgn></Pagination><Abstract><AbstractText>Postoperative cognitive dysfunction, confusion, and delirium are common after general anesthesia in the elderly, with symptoms persisting for months or years in some patients. Even middle-aged patients are likely to have postoperative cognitive dysfunction for months after surgery, and Alzheimer's disease (AD) patients appear to be particularly at risk of deterioration after anesthesia. Several investigators have thus examined whether general anesthesia is associated with AD, with some studies suggesting that exposure to anesthetics may increase the risk of AD. However, little is known on the biochemical consequences of anesthesia on pathogenic pathways in vivo. Here, we investigated the effect of anesthesia on tau phosphorylation and amyloid precursor protein (APP) metabolism in mouse brain. We found that, regardless of the anesthetic used, anesthesia induced rapid and massive hyperphosphorylation of tau, rapid and prolonged hypothermia, inhibition of Ser/Thr PP2A (protein phosphatase 2A), but no changes in APP metabolism or Abeta (beta-amyloid peptide) accumulation. Reestablishing normothermia during anesthesia completely rescued tau phosphorylation to normal levels. Our results indicate that changes in tau phosphorylation were not a result of anesthesia per se, but a consequence of anesthesia-induced hypothermia, which led to inhibition of phosphatase activity and subsequent hyperphosphorylation of tau. These findings call for careful monitoring of core temperature during anesthesia in laboratory animals to avoid artifactual elevation of protein phosphorylation. Furthermore, a thorough examination of the effect of anesthesia-induced hypothermia on the risk and progression of AD is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Planel</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, Department of Pathology, Taub Institute for Alzheimer's Disease Research, New York, New York 10032, USA. emmanuel@planel.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Karl E G</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Charles E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Finley</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Krishnamurthy</LastName><ForeName>Pavan</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lili</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Schachter</LastName><ForeName>Joel B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Lit-Fui</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D010749">Phosphoprotein Phosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="N">Anesthetics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007035" MajorTopicYN="N">Hypothermia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010749" MajorTopicYN="N">Phosphoprotein Phosphatases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17376970</ArticleId><ArticleId IdType="pmc">PMC6672474</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4854-06.2007</ArticleId><ArticleId IdType="pii">27/12/3090</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso AC, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA. 2001;98:6923&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34454</ArticleId><ArticleId IdType="pubmed">11381127</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaducci LA, Fratiglioni L, Rocca WA, Fieschi C, Livrea P, Pedone D, Bracco L, Lippi A, Gandolfo C, Bino G, Prencipe M, Bonatti ML, Girotti F, Carella F, Tavola B, Ferla S, Lenzi GL, Carolei A, Gambi A, Grigoletto F, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology. 1986;36:922&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">3714054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancelin ML, de Roquefeuil G, Ledesert B, Bonnel F, Cheminal JC, Ritchie K. Exposure to anaesthetic agents, cognitive functioning and depressive symptomatology in the elderly. Br J Psychiatry. 2001;178:360&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282816</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 2006;580:2922&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pubmed">16529745</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Diaz-Nido J. Tangling with hypothermia. Nat Med. 2004;10:460&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989;477:90&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">2495152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford PD. Adverse cerebral effects of anaesthesia on old people. Lancet. 1955;269:259&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">13243706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennecib M, Gong C, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000;485:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnen N, Warner MA, Kokmen E, Kurland LT. Early and midlife exposure to anesthesia and age of onset of Alzheimer's disease. Int J Neurosci. 1994a;77:181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">7814211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT. Alzheimer's disease and cumulative exposure to anesthesia: a case-control study. J Am Geriatr Soc. 1994b;42:198&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone I, Rosen M. Alzheimer's disease and anaesthesia. Anaesthesia. 2000;55:592&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">10866728</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Braak H, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994;87:554&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA. Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(Suppl 2):S36&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833352</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40:1698&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">2146525</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci. 2003;23:5645&#x2013;5649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741250</ArticleId><ArticleId IdType="pubmed">12843267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussiere T, Hof PR, Mailliot C, Brown CD, Caillet-Boudin ML, Perl DP, Buee L, Delacourte A. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol (Berl) 1999;97:221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem. 1989;58:453&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">2549856</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Planel E. Untangling memory deficits. Nat Med. 2005;11:826&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">16079873</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology. 2004;101:703&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329595</ArticleId></ArticleIdList></Reference><Reference><Citation>French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol. 1985;121:414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">4014131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini M, Vanacore N, Schiaffini C, Brusa L, Panella M, Talarico G, Bruno G, Meco G, Lenzi GL. A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci. 2002;23:11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111615</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Cohen ES, Jakes R, Cohen P. p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease. FEBS Lett. 1992;312:95&#x2013;99. [Erratum (1992) 313:203]</Citation><ArticleIdList><ArticleId IdType="pubmed">1330687</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem. 1993;61:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem. 1995;65:732&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem. 2000;275:5535&#x2013;5544.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681533</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB, Raskind M. A case-control study of Alzheimer's disease. Ann Neurol. 1990;28:766&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">2285263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson Y, Berggren D, Brannstrom B, Bucht G, Norberg A, Hansson LI, Winblad B. Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc. 1988;36:525&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem. 2002;277:44525&#x2013;44530.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226093</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman A, Simon EW. Body temperature as a risk factor for Alzheimer's disease. Med Hypotheses. 2000;55:440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">11058425</ArticleId></ArticleIdList></Reference><Reference><Citation>Huitron-Resendiz S, Sanchez-Alavez M, Gallegos R, Berg G, Crawford E, Giacchino JL, Games D, Henriksen SJ, Criado JR. Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Brain Res. 2002;928:126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844479</ArticleId></ArticleIdList></Reference><Reference><Citation>Iivonen H, Nurminen L, Harri M, Tanila H, Puolivali J. Hypothermia in mice tested in Morris water maze. Behav Brain Res. 2003;141:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Lane E, Vincent I, Otvos L, Jr, Hoffmann R, Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem. 1997;69:2087&#x2013;2095.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349554</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) 1996;8:189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">8862194</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T, Monk T, Rasmussen LS, Abildstrom H, Houx P, Korttila K, Kuipers HM, Hanning CD, Siersma VD, Kristensen D, Canet J, Ibanaz MT, Moller JT. Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology. 2002;96:1351&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">12170047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer's disease: a population-based case-control study. Neurology. 1991;41:1393&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">1891088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H, Pyo HK, Feinstein B, Pasinetti GM. Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim Biophys Acta. 2003;1639:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">14636947</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Friedman AB, Roh MS, Jope RS. Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem. 2005;92:701&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850892</ArticleId><ArticleId IdType="pubmed">15659239</ArticleId></ArticleIdList></Reference><Reference><Citation>Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M, Seubert P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J. 1996;316:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217397</ArticleId><ArticleId IdType="pubmed">8687413</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccioni RB, Otth C, Concha II, Munoz JP. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem. 2001;268:1518&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pubmed">11248668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of clapains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem. 2002;277:36415&#x2013;36424.</Citation><ArticleIdList><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, Lee VM. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13:989&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946342</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurage CA, Sergeant N, Ruchoux MM, Hauw JJ, Delacourte A. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol (Berl) 2003;105:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12536218</ArticleId></ArticleIdList></Reference><Reference><Citation>McKintosh C. Assay and purification of protein (serine/threonine) phosphatases. In: Grahame Hardie D, editor. Protein phosphorylation: a practical approach. Oxford: Oxford UP; 1993. pp. 197&#x2013;230.</Citation></Reference><Reference><Citation>Moller JT, Cluitmans P, Rasmussen LS, Houx P, Rasmussen H, Canet J, Rabbitt P, Jolles J, Larsen K, Hanning CD, Langeron O, Johnson T, Lauven PM, Kristensen PA, Biedler A, van Beem H, Fraidakis O, Silverstein JH, Beneken JE, Gravenstein JS. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet. 1998;351:857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">9525362</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990&#x2013;6995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088065</ArticleId><ArticleId IdType="pubmed">15867159</ArticleId></ArticleIdList></Reference><Reference><Citation>Okawa Y, Ishiguro K, Fujita SC. Stress-induced hyperphosphorylation of tau in the mouse brain. FEBS Lett. 2003;535:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12560101</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keeffe ST, Ni Chonchubhair A. Postoperative delirium in the elderly. Br J Anaesth. 1994;73:673&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826799</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Palotas M, Palotas A, Bjelik A, Pakaski M, Hugyecz M, Janka Z, Kalman J. Effect of general anesthetics on amyloid precursor protein and mRNA levels in the rat brain. Neurochem Res. 2005;30:1021&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">16258851</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides Tau protein kinase I/glycogen synthase kinase 3beta and Cyclin-dependant kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem. 2001;276:34298&#x2013;34306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441005</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Sun X, Takashima A. Role of GSK-3 beta in Alzheimer's disease pathology. Drug Dev Res. 2002;56:491&#x2013;510.</Citation></Reference><Reference><Citation>Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci. 2004;24:2401&#x2013;2411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729502</ArticleId><ArticleId IdType="pubmed">15014115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees DI, Gaines GY., III Anesthetic considerations for patients with Alzheimer's disease. Tex Med. 1985;81:45&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">3885463</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem. 2000;74:1587&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Polge C, de Roquefeuil G, Djakovic M, Ledesert B. Impact of anesthesia on the cognitive functioning of the elderly. Int Psychogeriatr. 1997;9:309&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9513030</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Nixon RA, Mathews PM. ELISA method for measurement of amyloid-beta levels. Methods Mol Biol. 2005;299:279&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, David JP, Champain D, Ghestem A, Wattez A, Delacourte A. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem. 2002;81:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi JJ, Yen SH, Gondal JA, Wu Q, Grundke-Iqbal I, Iqbal K. Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett. 1998;436:471&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9801171</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Cummings BJ, Cotman CW. Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites. NeuroReport. 1994;5:2358&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">7533559</ArticleId></ArticleIdList></Reference><Reference><Citation>Szendrei GI, Lee VM, Otvos L., Jr Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J Neurosci Res. 1993;34:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680727</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi A, Kurz A. Thermal management of the patient: where does the patient lose and/or gain temperature? Curr Opin Anaesthesiol. 2005;18:632&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534304</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi S, Fujita Y, Hayashi S, Kakita A, Takahashi H, Murayama S, Saido TC, Hisanaga S, Iwatsubo T, Hasegawa M. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett. 2001;489:46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231011</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol. 2005;166:1761&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602412</ArticleId><ArticleId IdType="pubmed">15920161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Q, Wang J. Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals. 2002;11:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566927</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Paired helical filament tau in Alzheimer's disease. The kinase connection. Am J Pathol. 1994;144:449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887092</ArticleId><ArticleId IdType="pubmed">8129030</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol. 2001;168:402&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, Iqbal K. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, - 2B and -1. Brain Res. 1996;38:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">8793108</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Tanzi RE. Alzheimer's disease and post-operative cognitive dysfunction. Exp Gerontol. 2006;41:346&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564662</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G, Tanzi RE. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology. 2006;104:988&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">16645451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals. 2002;11:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17400334</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1190</StartPage><EndPage>1198</EndPage><MedlinePgn>1190-8</MedlinePgn></Pagination><Abstract><AbstractText>Genetic studies have demonstrated very high heritability for Alzheimer's disease (AD) risk in humans; however, these genetic contributions have proven extremely challenging to map in large studies of AD patients. Processing of the amyloid precursor protein (APP) to produce amyloid-beta (Abeta) peptide is increasingly believed to be of central importance in AD pathogenesis. Intriguingly, mice from the C57BL/6J and DBA2/J inbred strains carrying the R1.40 APP transgene produce identical levels of unprocessed APP, but demonstrate significant, heritable differences in Abeta levels. To identify specific loci responsible for the observed genetic control of Abeta metabolism in this model system, we have performed a whole-genome quantitative trait locus (QTL) mapping experiment on a total of 516 animals from a C57BL/6JxDBA/2J intercross using a dense set of SNP genetic markers. Our studies have identified three loci on mouse chromosomes 1, 2, and 7 showing significant or suggestive associations with brain Abeta levels, several of which contain regions syntenic to previous reports of linkage in human AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryman</LastName><ForeName>Davis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Lerner Research Institute, Cleveland Clinic Foundation, Department of Neurosciences, NC3-164, 9500 Euclid Avenue, Cleveland, OH 44195 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008613</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA043703</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA43703</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM07250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019655" MajorTopicYN="N">Quantitative Trait, Heritable</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17400334</ArticleId><ArticleId IdType="mid">NIHMS479189</ArticleId><ArticleId IdType="pmc">PMC3745768</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.017</ArticleId><ArticleId IdType="pii">S0197-4580(07)00059-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum. Mol. Genet. 2003;12:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 2007;44:999&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698083</ArticleId></ArticleIdList></Reference><Reference><Citation>Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, Jin LW, Mumby M, Churchill G, Herz J, Cooper JA. Genetic modulation of tau phosphorylation in the mouse. J. Neurosci. 2003;23:187&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742161</ArticleId><ArticleId IdType="pubmed">12514215</ArticleId></ArticleIdList></Reference><Reference><Citation>Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J. Biol. Chem. 2004;279:29639&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126508</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics. 1994;138:963&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1206241</ArticleId><ArticleId IdType="pubmed">7851788</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan R, Tenner AJ. Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. Exp. Neurol. 2004;185:241&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Fratiglioni L, Johansson B, Berg S, Mortimer JA, Reynolds CA, Fiske A, Pedersen NL. Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study. Neurobiol. Aging. 2005;26:439&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653172</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry. 2006;63:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, Lammert F. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 2005;37:835&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15995705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI. Molecular genetics of late-onset Alzheimer's disease. Ann. Hum. Genet. 2004;68:381&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15225164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ. A full genome scan for late onset Alzheimer's disease. Hum. Mol. Genet. 1999;8:237&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Krezowski J, Knudson D, Ebeling C, Pitstick R, Giri RK, Schenk D, Westaway D, Younkin L, Younkin SG, Ashe KH, Carlson GA. Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression. Hum. Mol. Genet. 2004;13:1989&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Sisodia SS, Lawler AM, Slunt HH, Kitt CA, Kearns WG, Pearson PL, Price DL, Gearhart JD. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. 1993;5:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Mayeux R, Mayo D, Mo J, Santana V, Williamson J, Flaquer A, Ciappa A, Rondon H, Estevez P, Lantigua R, Kawarai T, Toulina A, Medrano M, Torres M, Stern Y, Tycko B, Rogaeva E, St George-Hyslop P, Knowles JA. Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics. Mol. Psychiatry. 2004;9:1042&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1578737</ArticleId><ArticleId IdType="pubmed">15241431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum. Mol. Genet. 2003;12:2949&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, Catanese J, White TJ, Maxwell TJ, Hollingworth P, Abraham R, Rubinsztein DC, Brayne C, Wavrant-De Vrieze F, Hardy J, O'Donovan M, Lovestone S, Morris JC, Thal LJ, Owen M, Williams J, Goate A. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum. Mol. Genet. 2006;15:2560&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847012</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FA, Jr., Goetz CG, Mastaglia F, Stajich JM, Gibson RA, Middleton LT, Saunders AM, Scott BL, Small GW, Nicodemus KK, Reed AD, Schmechel DE, Welsh-Bohmer KA, Conneally PM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA. Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 2002;70:985&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379130</ArticleId><ArticleId IdType="pubmed">11875758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch M, Walsh B. Genetics and Analysis of Quantitative Traits. Sinauer Associates, Inc.; Sunderland, Massachusettes: 1998.</Citation></Reference><Reference><Citation>Manly KF, Olson JM. Overview of QTL mapping software and introduction to map manager QT. Mamm. Genome. 1999;10:327&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10087288</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschang P, Brich J, Weeber EJ, Sweatt JD, Shelton JM, Richardson JA, Hammer RE, Herz J. Normal development and fertility of knockout mice lacking the tumor suppressor gene LRP1b suggest functional compensation by LRP1. Mol. Cell Biol. 2004;24:3782&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387731</ArticleId><ArticleId IdType="pubmed">15082773</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin MV, Dong H, Vallera D, Lee D, Lu L, Williams RW, Rosen GD, Cheverud JM, Csernansky JG. Independent quantitative trait loci influence ventral and dorsal hippocampal volume in recombinant inbred strains of mice. Genes Brain Behav. 2006;5:614&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17081266</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers. Dis. 2006;9:271&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914866</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CC, McLoughlin DM, Lau KF, Tennant ME, Rogelj B. The X11 proteins, Abeta production and Alzheimer's disease. Trends Neurosci. 2006;29:280&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545469</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D, Marshall H, Meyer D, Shears S, Booth J, Ramic D, Knowles H, Morris JC, Williams N, Norton N, Abraham R, Kehoe P, Williams H, Rudrasingham V, Rice F, Giles P, Tunstall N, Jones L, Lovestone S, Williams J, Owen MJ, Hardy J, Goate A. Full genome screen for Alzheimer disease: stage II analysis. Am. J. Med. Genet. 2002;114:235&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11857588</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng T, Hao L, Madri JA, Su X, Elias JA, Stahl GL, Squinto S, Wang Y. Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J. Clin. Invest. 2005;115:1590&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1090470</ArticleId><ArticleId IdType="pubmed">15902311</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bass ML, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, Conneally PM, Small GW, Saunders AM, Roses AD, Haines JL. Complete genomic screen in late-onset familial Alzheimer's disease. Neurobiol. Aging. 1998;19:S39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL. Identification of novel genes in late-onset Alzheimer's disease. Exp. Gerontol. 2000;35:1343&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113612</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters LL, Robledo RF, Bult CJ, Churchill GA, Paigen BJ, Svenson KL. The mouse as a model for human biology: a resource guide for complex trait analysis. Nat. Rev. Genet. 2007;8:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17173058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc. Natl. Acad. Sci. U S A. 2006;103:9649&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1476693</ArticleId><ArticleId IdType="pubmed">16769899</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM, St George-Hyslop PH. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani G, Krzywkowski P, Dudal S, Yu M, Paquette J, Malo D, Gervais F, Tremblay P. Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice. Hum. Mol. Genet. 2006;15:2313&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16785251</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva AR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Newman TT, Breitner JC. APOE and AD concordance in twin pairs as predictors of AD in first-degree relatives. Neurology. 2000;54:593&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680788</ArticleId></ArticleIdList></Reference><Reference><Citation>Warwick Daw E, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM. The number of trait loci in late-onset Alzheimer disease. Am. J. Hum. Genet. 2000;66:196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288326</ArticleId><ArticleId IdType="pubmed">10631151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetsel RA, Fleischer DT, Haviland DL. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J. Biol. Chem. 1990;265:2435&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">2303408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 1999;154:927&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866427</ArticleId><ArticleId IdType="pubmed">10079271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Hughes HB, Stiffler JS, Hurtt MR, Kaplan BB. A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution. Genomics. 1998;50:121&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9653640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17410168</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>446</Volume><Issue>7136</Issue><PubDate><Year>2007</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Multimodal fast optical interrogation of neural circuitry.</ArticleTitle><Pagination><StartPage>633</StartPage><EndPage>639</EndPage><MedlinePgn>633-9</MedlinePgn></Pagination><Abstract><AbstractText>Our understanding of the cellular implementation of systems-level neural processes like action, thought and emotion has been limited by the availability of tools to interrogate specific classes of neural cells within intact, living brain tissue. Here we identify and develop an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking. NpHR is compatible with ChR2, the previous optical excitation technology we have described, in that the two opposing probes operate at similar light powers but with well-separated action spectra. NpHR, like ChR2, functions in mammals without exogenous cofactors, and the two probes can be integrated with calcium imaging in mammalian brain tissue for bidirectional optical modulation and readout of neural activity. Likewise, NpHR and ChR2 can be targeted together to Caenorhabditis elegans muscle and cholinergic motor neurons to control locomotion bidirectionally. NpHR and ChR2 form a complete system for multimodal, high-speed, genetically targeted, all-optical interrogation of living neural circuits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-Ping</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Brauner</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liewald</LastName><ForeName>Jana F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Watzke</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Phillip G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Bamberg</LastName><ForeName>Ernst</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Nagel</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gottschalk</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Deisseroth</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002712">Chlorides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025602">Halorhodopsins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9009-81-8</RegistryNumber><NameOfSubstance UI="D012243">Rhodopsin</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2007 Apr 5;446(7136):617-9. doi: 10.1038/446617a.</RefSource><PMID Version="1">17410162</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002712" MajorTopicYN="N">Chlorides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025602" MajorTopicYN="N">Halorhodopsins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="Y">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009865" MajorTopicYN="N">Oocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055095" MajorTopicYN="N">Optics and Photonics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012243" MajorTopicYN="N">Rhodopsin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17410168</ArticleId><ArticleId IdType="doi">10.1038/nature05744</ArticleId><ArticleId IdType="pii">nature05744</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17420311</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort.</ArticleTitle><Pagination><StartPage>501</StartPage><EndPage>506</EndPage><MedlinePgn>501-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the association between Alzheimer disease (AD) and variant alleles in SORL1 using a series of single nucleotide polymorphisms (SNPs) in an urban, multiethnic, community-based population.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We used a nested case-control analysis in a population-based, prospective study of aging and dementia in Medicare recipients, 65 years and older.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Northern Manhattan, NY.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">There were 296 patients with probable AD and 428 healthy, elderly controls. The participants were African American (34%), Caribbean Hispanic (51%), or non-Hispanic white (15%).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">We genotyped all 29 SNPs in SORL1 that were examined in the earlier report. We assessed allelic association with AD using standard case-control methods, which included apolipoprotein E genotype as a covariate.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Several individual SNPs and SNP haplotypes were significantly associated with AD in this prospectively collected community-based cohort, confirming the previously reported positive association of SORL1 with AD. Single nucleotide polymorphism 12, near the 5' region, was associated with AD in African American and Hispanic individuals. Two SNPs in the 3' region were also associated with AD in African American (SNP 26) and non-Hispanic white (SNP 20) individuals. A single haplotype in the 3' region was associated with AD in Hispanic individuals. However, several different haplotypes were associated with AD in African American and white individuals, including the TTC haplotypes at SNPs 23 through 25 (P = .035), which was significantly associated with AD in the North European white individuals in our previous report.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirms the association between genetic variants in SORL1 and AD. While the associations observed in these data sets overlap with those previously reported, the finding of novel SNP and haplotype associations suggests that there may be extensive allelic heterogeneity in SORL1. Broad regions of the SORL1 gene will therefore need to be scrutinized for functional pathogenic variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schupf</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lantigua</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wakutani</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG09029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-AG15473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17420311</ArticleId><ArticleId IdType="mid">NIHMS88266</ArticleId><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.4.501</ArticleId><ArticleId IdType="pii">64/4/501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007 Jan 14;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurland BJ, Wilder DE, Lantigua R, et al. Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatry. 1999 Jun;14(6):481&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">10398359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001 Jan 9;56(1):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman J, Andrews H, Tatemichi T, et al. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician&#x2019;s diagnosis. Arch Neurol. 1992;49(5):461&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580807</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992 May;49(5):453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580806</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricks L, Pittman J, Jacobs DM, Sano M, Stern Y. Normative data for a brief neuropsychological battery administered to English- and Spanish-speaking community-dwelling elders. J Int Neuropsychol Soc. 1998 Jul;4(4):311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">9656604</ArticleId></ArticleIdList></Reference><Reference><Citation>Census of Population and Housing Summary Tape File1, Technical Documentation. Washington, DC: Bureau of the Census; 1991.</Citation></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D, Heath SC, Liu X, Ott J. A transmission/disequilibrium test that allows for genotyping errors in the analysis of single-nucleotide polymorphism data. Am J Hum Genet. 2001 Aug;69(2):371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235309</ArticleId><ArticleId IdType="pubmed">11443542</ArticleId></ArticleIdList></Reference><Reference><Citation>DSM-III and IV American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3. Washington, DC: American Psychiatric Association; 1987.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990 Mar;31(3):545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer&#x2019;s disease: ethnic variation in genotypic risks. Ann Neurol. 1995;37(2):254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847867</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005 Jan 15;21(2):263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott J. Analysis of human genetic linkage. Baltimore: Johns Hopkins University Press; 1999.</Citation></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993 Aug;43(8):1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17420320</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Relation of diabetes to mild cognitive impairment.</ArticleTitle><Pagination><StartPage>570</StartPage><EndPage>575</EndPage><MedlinePgn>570-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Type 2 diabetes mellitus is an important risk factor for Alzheimer disease and is more prevalent in elderly minority persons compared with non-Hispanic white persons.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether diabetes is related to a higher risk of mild cognitive impairment (MCI), a transitional stage between normal cognition and Alzheimer disease, in a multiethnic cohort with a high prevalence of diabetes.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Longitudinal cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Northern Manhattan in New York, NY.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">We studied persons without prevalent MCI or dementia at baseline and with at least 1 follow-up interval. Of 1772 participants with a complete neuropsychological evaluation, 339 (19.1%) were excluded because of prevalent dementia, 304 were excluded because of prevalent MCI (17.2%), and 211 were excluded because of loss to follow-up (11.9%), resulting in a final sample of 918 participants for longitudinal analyses.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">We related diabetes defined by self-report to incident all-cause MCI, amnestic MCI, and nonamnestic MCI. We conducted multivariate analyses with proportional hazards regression adjusting for age, sex, years of education, ethnic group, apolipoprotein E (APOE) epsilon4 allele, hypertension, low-density lipoprotein level, current smoking, heart disease, and stroke.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 334 persons had incident MCI, 160 (47.9%) had amnestic MCI, and 174 (52.1%) had nonamnestic MCI. Diabetes was related to a significantly higher risk of all-cause MCI and amnestic MCI after adjustment for all covariates. Diabetes was also related to a higher risk of nonamnestic MCI, but this association was appreciably attenuated after adjustment for socioeconomic variables and vascular risk factors. The risk of MCI attributable to diabetes was 8.8% for the whole sample and was higher for African American persons (8.4%) and Hispanic persons (11.0%) compared with non-Hispanic white persons (4.6%), reflecting the higher prevalence of diabetes in minority populations in the United States.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Diabetes is related to a higher risk of amnestic MCI in a population with a high prevalence of this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luchsinger</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Taub Institute for Research of Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA. jal94@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Bindu</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Ming-Xin</ForeName><Initials>MX</Initials></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1K08AG20856-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG07702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17420320</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.4.570</ArticleId><ArticleId IdType="pii">64/4/570</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17420446</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>16</Issue><PubDate><Year>2007</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Regulation of CNS synapses by neuronal MHC class I.</ArticleTitle><Pagination><StartPage>6828</StartPage><EndPage>6833</EndPage><MedlinePgn>6828-33</MedlinePgn></Pagination><Abstract><AbstractText>Until recently, neurons in the healthy brain were considered immune-privileged because they did not appear to express MHC class I (MHCI). However, MHCI mRNA was found to be regulated by neural activity in the developing visual system and has been detected in other regions of the uninjured brain. Here we show that MHCI regulates aspects of synaptic function in response to activity. MHCI protein is colocalized postsynaptically with PSD-95 in dendrites of hippocampal neurons. In vitro, whole-cell recordings of hippocampal neurons from beta2m/TAP1 knockout (KO) mice, which have reduced MHCI surface levels, indicate a 40% increase in mini-EPSC (mEPSC) frequency. mEPSC frequency is also increased 100% in layer 4 cortical neurons. Similarly, in KO hippocampal cultures, there is a modest increase in the size of presynaptic boutons relative to WT, whereas postsynaptic parameters (PSD-95 puncta size and mEPSC amplitude) are normal. In EM of intact hippocampus, KO synapses show a corresponding increase in vesicles number. Finally, KO neurons in vitro fail to respond normally to TTX treatment by scaling up synaptic parameters. Together, these results suggest that postsynaptically localized MHCl acts in homeostatic regulation of synaptic function and morphology during development and in response to activity blockade. The results also imply that MHCI acts retrogradely across the synapse to translate activity into lasting change in structure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>C Alex</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butts</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Shatz</LastName><ForeName>Carla J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH071666</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH020017</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH20017</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17420446</ArticleId><ArticleId IdType="pmc">PMC1871870</ArticleId><ArticleId IdType="doi">10.1073/pnas.0702023104</ArticleId><ArticleId IdType="pii">0702023104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Katz LC, Shatz CJ. Science. 1996;274:1133&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">8895456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Hohn A, Shatz CJ. J Comp Neurol. 2000;420:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">10745216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabelli RJ, Shelton DL, Segal RA, Shatz CJ. Neuron. 1997;19:63&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9247264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman J, Schulman H, Cline H. Nat Rev Neurosci. 2002;3:175&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994750</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW. Nature. 1984;310:688&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">6433204</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KA, Hart DN, Fabre JW, Morris PJ. Transplantation. 1980;29:274&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">6989046</ArticleId></ArticleIdList></Reference><Reference><Citation>Corriveau RA, Huh GS, Shatz CJ. Neuron. 1998;21:505&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768838</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco A, Patterson S, Alarcon JM, Gromova P, Mata-Roig M, Morozov A, Kandel ER. Neuron. 2005;48:123&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">16202713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt C, Kaltschmidt B, Baeuerle PA. Proc Natl Acad Sci USA. 1995;92:9618&#x2013;9622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40853</ArticleId><ArticleId IdType="pubmed">7568184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Hirota J, Mombaerts P. Curr Biol. 2003;13:394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">12620187</ArticleId></ArticleIdList></Reference><Reference><Citation>Loconto J, Papes F, Chang E, Stowers L, Jones EP, Takada T, Kumanovics A, Fischer Lindahl K, Dulac C. Cell. 2003;112:607&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628182</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiagarajan TC, Piedras-Renteria ES, Tsien RW. Neuron. 2002;36:1103&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">12495625</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth K, Bito H, Schulman H, Tsien RW. Curr Biol. 1995;5:1334&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">8749377</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer Lindahl K. Immunogenetics. 1997;46:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9148789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijlmakers MJ, Ploegh HL. Curr Opin Immunol. 1993;5:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">8095788</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. Cell. 1992;71:1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">1473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Nature. 1990;344:742&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">2139497</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes JJ, Momburg F. Curr Opin Immunol. 1993;5:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680870</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Science. 2000;290:2155&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175035</ArticleId><ArticleId IdType="pubmed">11118151</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton AL, Salichon N, Lebrand C, Ravary A, Blakely R, Seif I, Gaspar P. J Neurosci. 1999;19:7007&#x2013;7024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782873</ArticleId><ArticleId IdType="pubmed">10436056</ArticleId></ArticleIdList></Reference><Reference><Citation>Godement P, Salaun J, Imbert M. J Comp Neurol. 1984;230:552&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">6520251</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D, Shatz CJ. Neuron. 2002;33:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832224</ArticleId></ArticleIdList></Reference><Reference><Citation>Syken J, Grandpre T, Kanold PO, Shatz CJ. Science. 2006;313:1795&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917027</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulanger LM, Shatz CJ. Nat Rev Neurosci. 2004;5:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">15208694</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H, Schmidt H, Cavalie A, Jenne D, Wekerle H. J Exp Med. 1997;185:305&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196130</ArticleId><ArticleId IdType="pubmed">9016879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MB. Trends Neurosci. 1997;20:264&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">9185308</ArticleId></ArticleIdList></Reference><Reference><Citation>Greengard P, Browning MD, McGuinness TL, Llinas R. Adv Exp Med Biol. 1987;221:135&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2893522</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J, Zhang T, Bloch LM. BMC Neurosci. 2006;7:17&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386695</ArticleId><ArticleId IdType="pubmed">16503994</ArticleId></ArticleIdList></Reference><Reference><Citation>Linda H, Hammarberg H, Cullheim S, Levinovitz A, Khademi M, Olsson T. Exp Neurol. 1998;150:282&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">9527898</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. Science. 2000;290:1364&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">11082065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopf FW, Waters J, Mehta S, Smith SJ. J Neurosci. 2002;22:775&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758526</ArticleId><ArticleId IdType="pubmed">11826107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieribone VA, Shupliakov O, Brodin L, Hilfiker-Rothenfluh S, Czernik AJ, Greengard P. Nature. 1995;375:493&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">7777058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploegh HL, Cannon LE, Strominger JL. Proc Natl Acad Sci USA. 1979;76:2273&#x2013;2277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC383581</ArticleId><ArticleId IdType="pubmed">287067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fremeau RT, Jr, Kam K, Qureshi T, Johnson J, Copenhagen DR, Storm-Mathisen J, Chaudhry FA, Nicoll RA, Edwards RH. Science. 2004;304:1815&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">15118123</ArticleId></ArticleIdList></Reference><Reference><Citation>Fremeau RT, Jr, Voglmaier S, Seal RP, Edwards RH. Trends Neurosci. 2004;27:98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E, Sheng M. Nat Rev Neurosci. 2004;5:771&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T, Futai K, Lashuel HA, Lo I, Okamoto K, Walz T, Hayashi Y, Sheng M. Neuron. 2004;44:453&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">15504326</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrone J, O'Byrne M, Murthy VN. Nature. 2002;420:414&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama K, Kiyosue K, Taguchi T. J Neurosci. 2005;25:4040&#x2013;4051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724957</ArticleId><ArticleId IdType="pubmed">15843606</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy VN, Schikorski T, Stevens CF, Zhu Y. Neuron. 2001;32:673&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719207</ArticleId></ArticleIdList></Reference><Reference><Citation>De Gois S, Schafer MK, Defamie N, Chen C, Ricci A, Weihe E, Varoqui H, Erickson JD. J Neurosci. 2005;25:7121&#x2013;7133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725238</ArticleId><ArticleId IdType="pubmed">16079394</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC. Science. 2002;295:2282&#x2013;2285.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910117</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrone J, Murthy VN. Curr Opin Neurobiol. 2003;13:560&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630218</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano GG. Trends Neurosci. 1999;22:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322495</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB. Nature. 1998;391:892&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">9495341</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Nicoll RA. Neuron. 1997;19:473&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">9331339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wierenga CJ, Walsh MF, Turrigiano GG. J Neurophysiol. 2006;96:2127&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16760351</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller GL, Knudsen EI. J Neurophysiol. 2001;85:2184&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11353033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacci A, Huguenard JR. Neuron. 2006;49:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">16387644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman KN, Pal SK, Burrone J, Murthy VN. Nat Neurosci. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16582905</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D, Malenka RC. Nature. 2006;440:1054&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">16547515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler WJ, Pozzo-Miller LD. J Neurosci. 2001;21:4249&#x2013;4258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806848</ArticleId><ArticleId IdType="pubmed">11404410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford LC, Nelson SB, Turrigiano GG. Neuron. 1998;21:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768839</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker G, Goslin K. Cambridge, MA: MIT Press; 1998.</Citation></Reference><Reference><Citation>Neumann H, Cavalie A, Jenne DE, Wekerle H. Science. 1995;269:549&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17435754</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.</ArticleTitle><Pagination><StartPage>608</StartPage><EndPage>614</EndPage><MedlinePgn>608-14</MedlinePgn></Pagination><Abstract><AbstractText>Here we report an in vitro model system for studying the molecular and cellular mechanisms that underlie the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Embryonic stem cells (ESCs) derived from mice carrying normal or mutant transgenic alleles of the human SOD1 gene were used to generate motor neurons by in vitro differentiation. These motor neurons could be maintained in long-term coculture either with additional cells that arose during differentiation or with primary glial cells. Motor neurons carrying either the nonpathological human SOD1 transgene or the mutant SOD1(G93A) allele showed neurodegenerative properties when cocultured with SOD1(G93A) glial cells. Thus, our studies demonstrate that glial cells carrying a human SOD1(G93A) mutation have a direct, non-cell autonomous effect on motor neuron survival. More generally, our results show that ESC-based models of disease provide a powerful tool for studying the mechanisms of neural degeneration. These phenotypes displayed in culture could provide cell-based assays for the identification of new ALS drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Giorgio</LastName><ForeName>Francesco Paolo</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>The Stowers Medical Institute, the Harvard Stem Cell Institute. Harvard University, 7 Divinity Ave., Cambridge, Massachusetts 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasco</LastName><ForeName>Monica A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Siao</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Maniatis</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD046732</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD046732-01A1</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2007 May;10(5):535-7. doi: 10.1038/nn0507-535.</RefSource><PMID Version="1">17453052</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2019 Apr;22(4):512-513. doi: 10.1038/s41593-019-0367-6.</RefSource><PMID Version="1">30858602</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17435754</ArticleId><ArticleId IdType="mid">NIHMS306731</ArticleId><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="doi">10.1038/nn1885</ArticleId><ArticleId IdType="pii">nn1885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH., Jr. Amyotrophic lateral sclerosis. Insights from genetics. Arch. Neurol. 1997;54:1246&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole N, Siddique T. Genetic disorders of motor neurons. Semin. Neurol. 1999;19:407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci. 2001;21:9246&#x2013;9254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004;27:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002;110:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176325</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber S, et al. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. Neuron. 1999;23:659&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482234</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaler J, et al. Active suppression of interneuron programs within developing motor neurons revealed by analysis of homeodomain factor HB9. Neuron. 1999;23:675&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince PG, Tomkins J, Slade JY, Thatcher NM, Shaw PJ. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J. Neuropathol. Exp. Neurol. 1998;57:895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">9786240</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. Copper-binding&#x2013;site null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum. Mol. Genet. 2003;12:2753&#x2013;2764.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966034</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis. 2001;8:933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Houseweart MK, Brown RH, Jr., Cleveland DW. Caspase-1 and 3 are sequentially activated in motor neuron death in Cu/Zn superoxide dismutase&#x2013;mediated familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2000;97:13901&#x2013;13906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17673</ArticleId><ArticleId IdType="pubmed">11095709</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C, et al. Motoneuron death triggered by a specific pathway downstream of Fas potentiation by ALS-linked SOD1 mutations. Neuron. 2002;35:1067&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354397</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2006;103:16021&#x2013;16026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Anderson DJ. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell. 2002;109:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignami A, Dahl D. Astrocyte-specific protein and neuroglial differentiation. An immunofluorescence study with antibodies to the glial fibrillary acidic protein. J. Comp. Neurol. 1974;153:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">4593733</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker G, Goslin K. Culturing Nerve Cells. 2nd ed. MIT Press; Cambridge, Massachusetts: 1998.</Citation></Reference><Reference><Citation>Ullian EM, Harris BT, Wu A, Chan JR, Barres BA. Schwann cells and astrocytes induce synapse formation by spinal motor neurons in culture. Mol. Cell. Neurosci. 2004;25:241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019941</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ, Barres BA. Signaling between glia and neurons: focus on synaptic plasticity. Curr. Opin. Neurobiol. 2005;15:542&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16144764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullian EM, Christopherson KS, Barres BA. Role for glia in synaptogenesis. Glia. 2004;47:209&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">15252809</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">7242681</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA. 1981;78:7634&#x2013;7638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC349323</ArticleId><ArticleId IdType="pubmed">6950406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev. 2005;19:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Nun IF, Benvenisty N. Human embryonic stem cells as a cellular model for human disorders. Mol. Cell. Endocrinol. 2006;252:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690205</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. advance online publication, 15 April 2007 (doi:10.1038/nn1876)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan B, Beddington R, Costantini F, Lacey E. Manipulating the Mouse Embryo: A Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, New York: 1994.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17463094</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>18</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons.</ArticleTitle><Pagination><StartPage>7319</StartPage><EndPage>7326</EndPage><MedlinePgn>7319-26</MedlinePgn></Pagination><Abstract><AbstractText>Global, age-dependent changes in gene expression from rodent models of inherited ALS caused by dominant mutations in superoxide-dismutase 1 (SOD1) were identified by using gene arrays and RNAs isolated from purified embryonic and adult motor neurons. Comparison of embryonic motor neurons expressing a dismutase active ALS-linked mutant SOD1 with those expressing comparable levels of wild-type SOD1 revealed the absence of mutant-induced mRNA changes. An age-dependent mRNA change that developed presymptomatically in adult motor neurons collected by laser microdissection from mice expressing dismutase active ALS-linked mutants was dysregulation of the d/l-serine biosynthetic pathway, previously linked to both excitotoxic and neurotrophic effects. An unexpected dysregulation common to motor neurons expressing either dismutase active or inactive mutants was induction of neuronally derived components of the classic complement system and the regenerative/injury response. Alteration of these mutant SOD1-induced pathways identified a set of targets for therapies for inherited ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lobsiger</LastName><ForeName>Christian S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Ludwig Institute and Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boill&#xe9;e</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 27036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606292">Sod1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17463094</ArticleId><ArticleId IdType="pmc">PMC1863491</ArticleId><ArticleId IdType="doi">10.1073/pnas.0702230104</ArticleId><ArticleId IdType="pii">0702230104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu ZS, Wong PC, Brown RH, Jr, Price DL, Sisodia SS, Cleveland DW. Proc Natl Acad Sci USA. 1994;91:8292&#x2013;8296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, et al. Neuron. 1997;18:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. Neuron. 1995;14:1105&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, Erickson J, Kulik J, DeVito L, Psaltis G, et al. Proc Natl Acad Sci USA. 2002;99:1604&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, et al. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen MK, Roberds SL, Ellerbrock BR, Fleck TJ, McKinley DK, Gurney ME. Ann Neurol. 2001;50:730&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">11761470</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G. J Neurochem. 2002;80:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796754</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin FE, Boisset G, Docquier M, Schaad O, Descombes P, Kato AC. Hum Mol Genet. 2005;14:3309&#x2013;3320.</Citation><ArticleIdList><ArticleId IdType="pubmed">16192287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lillo C, Jonsson PA, Vande Velde C, Ward CM, Miller TM, Subramaniam JR, Rothstein JD, Marklund S, Andersen PM, et al. Neuron. 2004;43:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappert A, Bechmann I, Pivneva T, Mahlo J, Biber K, Nolte C, Kovac AD, Gerard C, Boddeke HW, Nitsch R, et al. J Neurosci. 2004;24:8500&#x2013;8509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729901</ArticleId><ArticleId IdType="pubmed">15456824</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, Albo F, Gaetti C, Spalloni A, Bengtson CP, Longone P, Cavalcanti S, Zona C. Neurosci Lett. 2003;351:153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">14623129</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalloni A, Albo F, Ferrari F, Mercuri N, Bernardi G, Zona C, Longone P. Neurobiol Dis. 2004;15:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006704</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C, Estevez AG, Nishimune H, Cleveland DW, deLapeyriere O, Henderson CE, Haase G, Pettmann B. Neuron. 2002;35:1067&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354397</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C, Buhler E, Sadeghi C, Jacquier A, Aebischer P, Pettmann B, Henderson CE, Haase G. Proc Natl Acad Sci USA. 2006;103:6007&#x2013;6012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458688</ArticleId><ArticleId IdType="pubmed">16581901</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Shinobu LA, Ward CM, Young D, Cleveland DW. J Neurochem. 2005;93:875&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857390</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wong WH. Proc Natl Acad Sci USA. 2001;98:31&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14539</ArticleId><ArticleId IdType="pubmed">11134512</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya S, Watanabe M. Arch Histol Cytol. 2003;66:109&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">12846552</ArticleId></ArticleIdList></Reference><Reference><Citation>Raivich G, Bohatschek M, Da Costa C, Iwata O, Galiano M, Hristova M, Nateri AS, Makwana M, Riera-Sans L, Wolfer DP, et al. Neuron. 2004;43:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishore U, Reid KB. Immunopharmacology. 2000;49:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">10904115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Science. 1998;281:1851&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld EF. J Biol Chem. 1989;264:10927&#x2013;10930.</Citation><ArticleIdList><ArticleId IdType="pubmed">2525553</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, et al. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, Yonenobu K, Ochi T, Noguchi K. Mol Cell Neurosci. 2000;15:170&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10673325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla IE, Tanabe K, Strittmatter SM. J Neurosci. 2002;22:1303&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757578</ArticleId><ArticleId IdType="pubmed">11850458</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlug AS, Teuling E, Haasdijk ED, French P, Hoogenraad CC, Jaarsma D. Eur J Neurosci. 2005;22:1881&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">16262628</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P. Nat Neurosci. 2006;9:408&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati DM, Kishore U. Mol Immunol. 2007;44:999&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698083</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H. J Neuroimmunol. 1984;6:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ. Neurobiol Dis. 2004;15:40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751769</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldknopf IL, Sheta EA, Bryson J, Folsom B, Wilson C, Duty J, Yen AA, Appel SH. Biochem Biophys Res Commun. 2006;342:1034&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">16516157</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal RP, Morgan TE, Finch CE. Neurosci Lett. 1999;271:65&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan R, Tenner AJ. J Neuroinflammation. 2005;2:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545941</ArticleId><ArticleId IdType="pubmed">15642121</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Li R, McGeer EG, McGeer PL. Brain Res. 1997;769:391&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">9374212</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai K, Walker DG, McGeer EG, McGeer PL. Brain Res. 1997;769:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9374211</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Kim LJ, Mealey R, Marsh HC, Jr, Zhang Y, Tenner AJ, Connolly ES, Jr, Pinsky DJ. Science. 1999;285:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">10417391</ArticleId></ArticleIdList></Reference><Reference><Citation>Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Exp Neurol. 1996;138:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8593893</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ. J Neurosci. 2004;24:6457&#x2013;6465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Nat Neurosci. 2006;9:108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartvelishvily E, Shleper M, Balan L, Dumin E, Wolosker H. J Biol Chem. 2006;281:14151&#x2013;14162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551623</ArticleId></ArticleIdList></Reference><Reference><Citation>Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA, Oliet SH. Cell. 2006;125:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan PH, Kawase M, Murakami K, Chen SF, Li Y, Calagui B, Reola L, Carlson E, Epstein CJ. J Neurosci. 1998;18:8292&#x2013;8299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792858</ArticleId><ArticleId IdType="pubmed">9763473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger CS, Garcia ML, Ward CM, Cleveland DW. Proc Natl Acad Sci USA. 2005;102:10351&#x2013;10356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177385</ArticleId><ArticleId IdType="pubmed">16002469</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennica D, Arce V, Swanson TA, Vejsada R, Pollock RA, Armanini M, Dudley K, Phillips HS, Rosenthal A, Kato AC, et al. Neuron. 1996;17:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755479</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17468743</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>447</Volume><Issue>7141</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Recovery of learning and memory is associated with chromatin remodelling.</ArticleTitle><Pagination><StartPage>178</StartPage><EndPage>182</EndPage><MedlinePgn>178-82</MedlinePgn></Pagination><Abstract><AbstractText>Neurodegenerative diseases of the central nervous system are often associated with impaired learning and memory, eventually leading to dementia. An important aspect in pre-clinical research is the exploration of strategies to re-establish learning ability and access to long-term memories. By using a mouse model that allows temporally and spatially restricted induction of neuronal loss, we show here that environmental enrichment reinstated learning behaviour and re-established access to long-term memories after significant brain atrophy and neuronal loss had already occurred. Environmental enrichment correlated with chromatin modifications (increased histone-tail acetylation). Moreover, increased histone acetylation by inhibitors of histone deacetylases induced sprouting of dendrites, an increased number of synapses, and reinstated learning behaviour and access to long-term memories. These data suggest that inhibition of histone deacetylases might be a suitable therapeutic avenue for neurodegenerative diseases associated with learning and memory impairment, and raises the possibility of recovery of long-term memories in patients with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge 02139, USA. andre.fischer@mpi-mail.mpg.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sananbenesi</LastName><ForeName>Farahnaz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Dobbin</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002087">Butyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2007 May 10;447(7141):151-2. doi: 10.1038/nature05716.</RefSource><PMID Version="1">17468746</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042002" MajorTopicYN="Y">Chromatin Assembly and Disassembly</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="Y">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17468743</ArticleId><ArticleId IdType="doi">10.1038/nature05772</ArticleId><ArticleId IdType="pii">nature05772</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17470753</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>18</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.</ArticleTitle><Pagination><StartPage>1501</StartPage><EndPage>1508</EndPage><MedlinePgn>1501-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the total number of synapses in the stratum radiatum (str rad) of the human hippocampal CA1 subfield in individuals with mild Alzheimer disease (mAD), mild cognitive impairment (MCI), or no cognitive impairment (NCI) and determine if synapse loss is an early event in the progression of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Short postmortem autopsy tissue was obtained, and an unbiased stereologic sampling scheme coupled with transmission electron microscopy was used to directly visualize synaptic contacts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Individuals with mAD had fewer synapses (55%) than the other two diagnostic groups. Individuals with MCI had a mean synaptic value that was 18% lower than the NCI group mean. The total number of synapses showed a correlation with several cognitive tests including those involving both immediate and delayed recall. Total synaptic numbers showed no relationship to the subject's Braak stage or to APOE genotype. The volume of the str rad was reduced in mAD vs the other two diagnostic groups that were not different from each other.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results strongly support the concept that synapse loss is a structural correlate involved very early in cognitive decline in mild Alzheimer disease (mAD) and supports mild cognitive impairment as a transitional stage between mAD and no cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheff</LastName><ForeName>S W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging and Alzheimer Disease Research Center, University of Kentucky College of Medicine, Lexington, KY 40536-0230, USA. sscheff@email.uky.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>F A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Mufson</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000260698.46517.8f</ArticleId><ArticleId IdType="pii">68/18/1501</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17474819</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>618</EndPage><MedlinePgn>613-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">While the apolipoprotein E (APOE) epsilon allele is a well-established risk factor for late-onset Alzheimer's disease (AD), initial genome scans using microsatellite markers in late-onset AD failed to identify this locus on chromosome 19. Recently developed methods for the simultaneous assessment of hundreds of thousands of single nucleotide polymorphisms (SNPs) promise to help more precisely identify loci that contribute to the risk of AD and other common multigenic conditions. We sought here to demonstrate that more precise identification of loci that are associated with complex, multi-genic genetic disorders can be achieved using ultra-high-density whole-genome associations by demonstrating their ability to identify the APOE locus as a major susceptibility gene for late-onset AD, despite the absence of SNPs within the APOE locus itself, as well as to refine odds ratios (ORs) based on gold-standard phenotyping of the study population.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">An individualized genome-wide association study using 502,627 SNPs was performed in 1086 his-topathologically verified AD cases and controls to determine the OR associated with genes predisposing to Alzheimer's disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As predicted, ultra-high-density SNP genotyping, in contrast to traditional microsatellite-based genome screening approaches, precisely identified the APOE locus as having a significant association with late-onset AD. SNP rs4420638 on chromosome 19, located 14 kilobase pairs distal to the APOE epsilon variant, significantly distinguished between AD cases and controls (Bonferroni corrected p value = 5.30 x 10(-34), OR = 4.01) and was far more strongly associated with the risk of AD than any other SNP of the 502,627 tested.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study provides empirical support for the suggestion that the APOE locus is the major susceptibility gene for late-onset AD in the human genome, with an OR significantly greater than any other locus in the human genome. It also supports the feasibility of the ultra-high-density whole-genome association approach to the study of AD and other heritable phenotypes. These whole-genome association studies show great promise to identify additional genes that contribute to the risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coon</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Ariz. 85004, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>John V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Lince</LastName><ForeName>Diane Hu</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Zismann</LastName><ForeName>Victoria L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Doris</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bryden</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Halperin</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Marlowe</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kaleem</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Douglas G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Ravid</LastName><ForeName>Rivka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Heward</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Papassotiropoulos</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychiatry. 2007 Apr;68(4):611-2. doi: 10.4088/jcp.v68n0418.</RefSource><PMID Version="1">17474818</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002888" MajorTopicYN="Y">Chromosomes, Human, Pair 19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId><ArticleId IdType="doi">10.4088/jcp.v68n0419</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17502554</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>20</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Imaging beta-amyloid burden in aging and dementia.</ArticleTitle><Pagination><StartPage>1718</StartPage><EndPage>1725</EndPage><MedlinePgn>1718-25</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare brain beta-amyloid (Abeta) burden measured with [(11)C]Pittsburgh Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-three subjects with dementia (17 AD, 10 dementia with Lewy bodies [DLB], 6 frontotemporal dementia [FTD]), 9 subjects with mild cognitive impairment (MCI), and 27 age-matched healthy control subjects (HCs) were studied. Abeta burden was quantified using PIB distribution volume ratio.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cortical PIB binding was markedly elevated in every AD subject regardless of disease severity, generally lower and more variable in DLB, and absent in FTD, whereas subjects with MCI presented either an "AD-like" (60%) or normal pattern. Binding was greatest in the precuneus/posterior cingulate, frontal cortex, and caudate nuclei, followed by lateral temporal and parietal cortex. Six HCs (22%) showed cortical uptake despite normal neuropsychological scores. PIB binding did not correlate with dementia severity in AD or DLB but was higher in subjects with an APOE-epsilon4 allele. In DLB, binding correlated inversely with the interval from onset of cognitive impairment to diagnosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pittsburgh Compound B PET findings match histopathologic reports of beta-amyloid (Abeta) distribution in aging and dementia. Noninvasive longitudinal studies to better understand the role of amyloid deposition in the course of neurodegeneration and to determine if Abeta deposition in nondemented subjects is preclinical AD are now feasible. Our findings also suggest that Abeta may influence the development of dementia with Lewy bodies, and therefore strategies to reduce Abeta may benefit this condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia. christopher.rowe@austin.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ackermann</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cowie</LastName><ForeName>T F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Darby</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Merory</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tochon-Danguy</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>V L</ForeName><Initials>VL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2008 Apr 29;70(18):1649; author reply 1650. doi: 10.1212/01.wnl.0000318046.06992.24.</RefSource><PMID Version="1">18443321</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="Y">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000261919.22630.ea</ArticleId><ArticleId IdType="pii">68/20/1718</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17506994</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2007</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-291X</ISSN><JournalIssue CitedMedium="Print"><Volume>358</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation.</ArticleTitle><Pagination><StartPage>777</StartPage><EndPage>782</EndPage><MedlinePgn>777-82</MedlinePgn></Pagination><Abstract><AbstractText>In recent years, transgenic mice have become valuable tools for studying mechanisms of Alzheimer's disease (AD). With the aim of developing an animal model better for memory and neurobehavioural testing, we have generated a transgenic rat model of AD. These animals express human amyloid precursor protein (APP) containing the Swedish AD mutation. The highest level of expression in the brain is found in the cortex, hippocampus, and cerebellum. Starting after the age of 15 months, the rats show increased tau phosphorylation and extracellular Abeta staining. The Abeta is found predominantly in cerebrovascular blood vessels with very rare diffuse plaques. We believe that crossing these animals with mutant PS1 transgenic rats will result in accelerated plaque formation similar to that seen in transgenic mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Folkesson</LastName><ForeName>Ronnie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Department of Neurobiology, Caring Sciences and Society, Novum, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malkiewicz</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kloskowska</LastName><ForeName>Ewa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Popova</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bogdanovic</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ganten</LastName><ForeName>Ursula</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Ganten</LastName><ForeName>Detlev</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bader</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Benedikz</LastName><ForeName>Eirikur</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005821" MajorTopicYN="N">Genetic Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17506994</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2007.04.195</ArticleId><ArticleId IdType="pii">S0006-291X(07)00925-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17517623</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>22</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.</ArticleTitle><Pagination><StartPage>9511</StartPage><EndPage>9516</EndPage><MedlinePgn>9511-6</MedlinePgn></Pagination><Abstract><AbstractText>Neurodegeneration, a result of multiple dysregulatory events, is a lengthy multistep process manifested by accrual of mutant variants and abnormal expression, posttranslational modification, and processing of certain proteins. Accumulation of these dysregulated processes requires a mechanism that maintains their functional stability and allows the evolution of the neurodegenerative phenotype. In malignant cells, the capacity to buffer transformation has been attributed to heat-shock protein 90 (Hsp90). Although normal proteins seem to require limited assistance from the chaperone, their aberrant counterparts seem to be highly dependent on Hsp90. Whereas enhanced Hsp90 affinity for mutated or functionally deregulated client proteins has been observed for several oncoproteins, it is unknown whether Hsp90 plays a similar role for neuronal proteins and thus maintains and facilitates the transformed phenotype in neurodegenerative diseases. Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, leading to a time-dependent accumulation of Tau aggregates and subsequent neuronal death. Here, we show that the stability of p35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90. Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a reduction of the pathogenic activity of these proteins and results in elimination of aggregated Tau. The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University and Fisher Foundation for Alzheimer's Disease, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dou</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rodina</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chip</LastName><ForeName>Sophorn</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joungnam</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Moulick</LastName><ForeName>Kamalika</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Nian</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chiosis</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>90 AZ 279102</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17517623</ArticleId><ArticleId IdType="pmc">PMC1890525</ArticleId><ArticleId IdType="doi">10.1073/pnas.0701055104</ArticleId><ArticleId IdType="pii">0701055104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neckers L. Handb Exp Pharmacol. 2006;172:259&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">16610363</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald E, Workman P, Jones K. Curr Top Med Chem. 2006;6:1091&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842148</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiosis G. Expert Opin Ther Targets. 2006;10:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16441227</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JC, Hartl FU. EMBO J. 2000;19:5930&#x2013;5940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305790</ArticleId><ArticleId IdType="pubmed">11060043</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray B, Lynch T, Farrell M. Biochem Soc Trans. 2005;33:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Shimura H. Biochim Biophys Acta. 2005;1739:298&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615647</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Leschik J. Curr Alzheimer Res. 2004;1:255&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975055</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C. Trends Genet. 2005;21:664&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16221505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau LF, Schachter JB, Seymour PA, Sanner MA. Curr Top Med Chem. 2002;4:395&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966463</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Biochim Biophys Acta. 2005;1739:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YL, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC. EMBO J. 2005;24:209&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544899</ArticleId><ArticleId IdType="pubmed">15592431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YL, Li BS, Amin ND, Albers W, Pant HC. Eur J Biochem. 2002;269:4427&#x2013;4434.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Sleegers K, Theuns J, Van den Broeck M, Bel Kacem S, Nilsson LG, Adolfsson R, van Duijn CM, Van Broeckhoven C, Cruts M. Neurobiol Aging. 2005;26:1145&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. Am J Pathol. 2004;165:843&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618588</ArticleId><ArticleId IdType="pubmed">15331409</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A., DeTure M, Ramsden M, McGowan E, et al. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiosis G, Caldas Lopes E, Solit D. Curr Opin Invest Drugs. 2006;6:534&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">16784024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Chem Biol. 2004;11:787&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimnaugh E, Chavany C, Neckers LM. J Biol Chem. 1996;271:22796&#x2013;22801.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanemaru K, Takio K, Miura R, Titani K, Ihara Y. J Neurochem. 1992;58:1667&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">1560225</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel G, Mercken M, Murayama M, Noguchi K, Ishiguro K, Imahori K, Takashima A. Biochim Biophys Acta. 1998;1380:177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9565682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Delalle I, Caviness VS, Jr, Chae T, Harlow E. Nature. 1994;371:419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Yeung J, Lee KY, Matsushita M, Matsui H, Tomizawa K, Hatase O, Wang JH. J Biol Chem. 1995;270:26897&#x2013;26903.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592934</ArticleId></ArticleIdList></Reference><Reference><Citation>Paglini G, Pigino G, Kunda P, Morfini G, Maccioni R, Quiroga S, Ferreira A, Caceres A. J Neurosci. 1998;18:9858&#x2013;9869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793278</ArticleId><ArticleId IdType="pubmed">9822744</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Ohshima T, Cho A, Sreenath T, Iadarola MJ, Pant HC, Kim Y, Nairn AC, Brady RO, Greengard P, et al. Proc Natl Acad Sci USA. 2005;102:1737&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547862</ArticleId><ArticleId IdType="pubmed">15665076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro K, Omori A, Sato K, Tomizawa K, Imahori K, Uchida T. Neurosci Lett. 1991;128:195&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1658692</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. FEBS Lett. 1993;336:417&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">8282104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HC, Zhou Y, Shen Y, Tsai LH. FEBS Lett. 2002;523:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12123804</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K. FEBS Lett. 1995;358:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7821426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Q, Wang J. Neurosignals. 2002;11:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566927</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE. Hum Mol Genet. 2001;10:1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406612</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Bonini NM. Nat Med. 2002;11:1185&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411925</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H. Proc Natl Acad Sci USA. 2003;100:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141063</ArticleId><ArticleId IdType="pubmed">12522269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Cell. 1998;94:471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">9727490</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudeau J, Deak M, Lawlor MA, Morrice NA, Alessi DR. Biochem J. 2003;370:849&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1223241</ArticleId><ArticleId IdType="pubmed">12489981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamphere L, Fiore F, Xu X, Brizuela L, Keezer S, Sardet C, Draetta GF, Gyuris J. Oncogene. 1997;14:1999&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, et al. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH. J Neurochem. 2002;83:1498&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, Murata S, Tanaka K, Takashima A. J Neurochem. 2005;94:1254&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111477</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G. J Med Chem. 2006;49:381&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">16392823</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cruz e Silva EF, Fox CA, Ouimet CC, Gustafson E, Watson SJ, Greengard P. J Neurosci. 1995;15:3375&#x2013;3389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578208</ArticleId><ArticleId IdType="pubmed">7751917</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, et al. Nat Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Ma XH, Ule J, Bibb JA, Nishi A, DeMaggio AJ, Yan Z, Nairn AC, Greengard P. Proc Natl Acad Sci USA. 2001;98:11062&#x2013;11068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58683</ArticleId><ArticleId IdType="pubmed">11572969</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. Proc Natl Acad Sci USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17522104</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>Pt 7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations.</ArticleTitle><Pagination><StartPage>1767</StartPage><EndPage>1776</EndPage><MedlinePgn>1767-76</MedlinePgn></Pagination><Abstract><AbstractText>Measures are needed that identify persons that will develop Alzheimer's disease in order to target them for preventative interventions. There is evidence from animal, pathological and imaging studies that disruption of white matter occurs in the course of Alzheimer's disease and may be an early event. Prior studies have suggested that late-myelinating regions or white matter connecting limbic structures are particularly susceptible to degradation. Persons destined to develop the disease by virtue of fully penetrant genetic alterations (familial Alzheimer's disease or FAD) provide a model in which early and even presymptomatic changes of the disease may be identified. In this study we performed diffusion tensor imaging (DTI) on 2 demented and 21 subjects at-risk for inheriting an FAD mutation. We compared global and localized fractional anisotropy (FA) measures in white matter between FAD mutation carriers and non-carriers in the preclinical (clinical dementia rating &lt;1, n = 20) and presymptomatic (clinical dementia rating = 0, n = 15) stages of the disease. There were no significant differences between mutation carriers and non-carriers with regard to absolute age, age relative to the typical age of disease diagnosis in their family, gender or Mini-Mental Status Examination Score. Among preclinical FAD mutation carriers (n = 12), mean whole brain white-matter FA (P = 0.045), FA of the columns of the fornix (P = 0.012), area of the perforant pathways bilaterally (right side: P = 0.028, left side: P = 0.027) and left orbitofrontal lobe (P = 0.024) were decreased relative to that of non-carriers (n = 8). We also found that FA in the columns of the fornix (P = 0.008) and left orbitofrontal lobe white matter (P = 0.045) were decreased in the eight presymptomatic mutation carriers compared to seven non-carriers. Logistic regression demonstrated that FA of the columns of the fornix was a better predictor of mutation status than was cross-sectional area of the fornix, global mean white-matter FA and left frontal lobe white-matter FA. In a linear regression analysis, white-matter volume (P = 0.002), hippocampal volume (P = 0.023) and mutation status (P = 0.032) significantly predicted fornix FA. We conclude that FA is decreased in the white matter in preclinical and even presymptomatic FAD mutation carriers, particularly in the late-myelinating tracts connecting limbic structures. Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>UCLA Department of Neurology, Alzheimer's Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095-7226, USA. jringman@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Yaneth</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Varpetian</LastName><ForeName>Arousiak</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Freddy</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fitten</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG-22228</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020712" MajorTopicYN="N">Fornix, Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17522104</ArticleId><ArticleId IdType="doi">10.1093/brain/awm102</ArticleId><ArticleId IdType="pii">awm102</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17529984</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>886</EndPage><MedlinePgn>880-886</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn1914</ELocationID><Abstract><AbstractText>Learning is accompanied by modulation of postsynaptic signal transduction pathways in neurons. Although the neuronal protein kinase cyclin-dependent kinase 5 (Cdk5) has been implicated in cognitive disorders, its role in learning has been obscured by the perinatal lethality of constitutive knockout mice. Here we report that conditional knockout of Cdk5 in the adult mouse brain improved performance in spatial learning tasks and enhanced hippocampal long-term potentiation and NMDA receptor (NMDAR)-mediated excitatory postsynaptic currents. Enhanced synaptic plasticity in Cdk5 knockout mice was attributed to reduced NR2B degradation, which caused elevations in total, surface and synaptic NR2B subunit levels and current through NR2B-containing NMDARs. Cdk5 facilitated the degradation of NR2B by directly interacting with both it and its protease, calpain. These findings reveal a previously unknown mechanism by which Cdk5 facilitates calpain-mediated proteolysis of NR2B and may control synaptic plasticity and learning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hawasli</LastName><ForeName>Ammar H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Benavides</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Chan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kansy</LastName><ForeName>Janice W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Kanehiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chambon</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut de G&#xe9;n&#xe9;tique et de Biologie Mol&#xe9;culaire et Cellulaire, 67404 Illkirch Cedex, Centre Universitaire de Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, New York 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Craig M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Donald C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibb</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 DA020199</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 DA017750</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 MH065975</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17529984</ArticleId><ArticleId IdType="mid">NIHMS64520</ArticleId><ArticleId IdType="pmc">PMC3910113</ArticleId><ArticleId IdType="doi">10.1038/nn1914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sweatt JD. Mechanisms of Memory. Elsevier; San Diego, California: 2003.</Citation></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibb JA, et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature. 2001;410:376&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibb JA, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999;402:669&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604473</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung ZH, Fu AKY, Ip NY. Synaptic roles of Cdk5: implications in higher cognitive functions and neurodegenerative diseases. Neuron. 2006;50:13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48:825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J. Cyclin-dependent kinase 5 is required for associative learning. J. Neurosci. 2002;22:3700&#x2013;3707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758363</ArticleId><ArticleId IdType="pubmed">11978846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore EC, Ohshima T, Goffinet AM, Kulkarni AB, Herrup K. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. J. Neurosci. 1998;18:6370&#x2013;6377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793186</ArticleId><ArticleId IdType="pubmed">9698328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, et al. Impairment of hippocampal long-term depression and defective spatial learning and memory in p35 mice. J. Neurochem. 2005;94:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. USA. 1996;93:11173&#x2013;11178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38303</ArticleId><ArticleId IdType="pubmed">8855328</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei FY, et al. Control of cyclin-dependent kinase 5 (Cdk5) activity by glutamatergic regulation of p35 stability. J. Neurochem. 2005;93:502&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">15816873</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J. Physiol. (Lond.) 2002;540:761&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290289</ArticleId><ArticleId IdType="pubmed">11986366</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber P, Metzger D, Chambon P. Temporally controlled targeted somatic mutagenesis in the mouse brain. Eur. J. Neurosci. 2001;14:1777&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">11860472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, et al. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996;87:1327&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernasconi-Guastalla S, Wolfer DP, Lipp HP. Hippocampal mossy fibers and swimming navigation in mice: correlations with size and left-right asymmetries. Hippocampus. 1994;4:53&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8061752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa K, et al. Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one-time experience. Neuron. 2003;38:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718863</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelo M, Plattner F, Irvine EE, Giese KP. Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci. 2003;18:423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887424</ArticleId></ArticleIdList></Reference><Reference><Citation>Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">7512349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenard BL, Menniti FS. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 1999;5:381&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213801</ArticleId></ArticleIdList></Reference><Reference><Citation>Picconi B, et al. NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke. 2006;37:1895&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science. 2004;304:1021&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">15143284</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttmann RP, et al. Specific proteolysis of the NR2 subunit at multiple sites by calpain. J. Neurochem. 2001;78:1083&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553682</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttmann RP, et al. Proteolysis of the N-methyl-d-aspartate receptor by calpain in situ. J. Pharmacol. Exp. Ther. 2002;302:1023&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">12183659</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpkins KL, et al. Selective activation induced cleavage of the NR2B subunit by calpain. J. Neurosci. 2003;23:11322&#x2013;11331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740527</ArticleId><ArticleId IdType="pubmed">14672996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao MG, et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron. 2005;47:859&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutsuwada T, et al. Impairment of suckling response, trigeminal neuronal pattern formation and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Neuron. 1996;16:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">8789948</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung HJ, Huang YH, Lau LF, Huganir RL. Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J. Neurosci. 2004;24:10248&#x2013;10259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730169</ArticleId><ArticleId IdType="pubmed">15537897</ArticleId></ArticleIdList></Reference><Reference><Citation>Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 2000;3:661&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MC, et al. Comparing calpain- and caspase-3&#x2013;mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem. J. 2006;394:715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383722</ArticleId><ArticleId IdType="pubmed">16351572</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong YN, Waxman EA, Lynch DR. Interactions of postsynaptic density-95 and the NMDA receptor 2 subunit control calpain-mediated cleavage of the NMDA receptor. J. Neurosci. 2004;24:11035&#x2013;11045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730266</ArticleId><ArticleId IdType="pubmed">15590920</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito MA, Sheng M, Tsai LH. Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J. Neurosci. 2004;24:865&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729809</ArticleId><ArticleId IdType="pubmed">14749431</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, et al. Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature. 2005;436:1166&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464117</ArticleId><ArticleId IdType="pubmed">16121183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyama Y, et al. Increased thresholds for long-term potentiation and contextual learning in mice lacking the NMDA-type glutamate receptor epsilon1 subunit. J. Neurosci. 1998;18:6704&#x2013;6712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792962</ArticleId><ArticleId IdType="pubmed">9712642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattler S, Kelly M, Nehls M. Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques. 1999;26:1150&#x2013;6. 1158, 1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">10376154</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold SJ, Ni YG, Dohlman HG, Nestler EJ. Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J. Neurosci. 1997;17:8024&#x2013;8037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793903</ArticleId><ArticleId IdType="pubmed">9315921</ArticleId></ArticleIdList></Reference><Reference><Citation>Berton O, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006;311:864&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469931</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi A, et al. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J. Neurochem. 2002;81:832&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065642</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell CM, et al. The presynaptic active zone protein RIM1alpha is critical for normal learning and memory. Neuron. 2004;42:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910111</ArticleId><ArticleId IdType="pubmed">15066271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DC, Chung S, Spruston N. Output-mode transitions are controlled by prolonged inactivation of sodium channels in pyramidal neurons of subiculum. PLoS Biol. 2005;3:e175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088280</ArticleId><ArticleId IdType="pubmed">15857153</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K, Shimono K, Lemmon V. Dephosphorylation and internalization of cell adhesion molecule L1 induced by theta burst stimulation in rat hippocampus. Mol. Cell. Neurosci. 2005;29:245&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382274</ArticleId><ArticleId IdType="pubmed">15911348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17533169</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>Pt 7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1777</StartPage><EndPage>1786</EndPage><MedlinePgn>1777-86</MedlinePgn></Pagination><Abstract><AbstractText>Mild cognitive impairment (MCI), particularly the amnestic subtype (aMCI), is considered as a transitional stage between normal aging and a diagnosis of clinically probable Alzheimer's disease (AD). The aMCI construct is particularly useful as it provides an opportunity to assess a clinical stage which in most subjects represents prodromal AD. The aim of this study was to assess the progression of cerebral atrophy over multiple serial MRI during the period from aMCI to progression to AD. Thirty-three subjects were selected that fulfilled clinical criteria for aMCI and had three serial MRI scans: the first scan approximately 3 years before the diagnosis of AD, the second scan approximately 1 year before, and the third scan at the time of the diagnosis of AD. A group of 33 healthy controls were age and gender-matched to the study cohort. Voxel-based morphometry (VBM) was used to assess patterns of grey matter atrophy in the aMCI subjects at each time-point compared to the control group. Customized templates and prior probability maps were used to avoid normalization and segmentation bias. The pattern of grey matter loss in the aMCI subject scans that were 3 years before the diagnosis of AD was focused primarily on the medial temporal lobes, including the amygdala, anterior hippocampus and entorhinal cortex, with some additional involvement of the fusiform gyrus, compared to controls. The extent and magnitude of the cerebral atrophy further progressed by the time the subjects were 1 year before the diagnosis of AD. At this point atrophy in the temporal lobes spread to include the middle temporal gyrus, and extended into more posterior regions of the temporal lobe to include the entire extent of the hippocampus. The parietal lobe also started to become involved. By the time the subjects had progressed to a clinical diagnosis of AD the pattern of grey matter atrophy had become still more widespread with more severe involvement of the medial temporal lobes and the temporoparietal association cortices and, for the first time, substantial involvement of the frontal lobes. This pattern of progression fits well with the Braak and Braak neurofibrillary pathological staging scheme in AD. It suggests that the earliest changes occur in the anterior medial temporal lobe and fusiform gyrus, and that these changes occur at least 3 years before progression to the diagnosis of AD. These results also suggest that 3D patterns of grey matter atrophy may help to predict the time to the first diagnosis of AD in subjects with aMCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whitwell</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przybelski</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17533169</ArticleId><ArticleId IdType="mid">NIHMS137139</ArticleId><ArticleId IdType="pmc">PMC2752411</ArticleId><ArticleId IdType="doi">10.1093/brain/awm112</ArticleId><ArticleId IdType="pii">awm112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adak S, Illouz K, Gorman W, Tandon R, Zimmerman EA, Guariglia R, et al. Predicting the rate of cognitive decline in aging and early Alzheimer disease. Neurology. 2004;63:108&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000;11:805&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage. 2001;14:298&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell-McGinty S, Lopez OL, Meltzer CC, Scanlon JM, Whyte EM, Dekosky ST, et al. Differential cortical atrophy in subgroups of mild cognitive impairment. Arch Neurol. 2005;62:1393&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottino CM, Castro CC, Gomes RL, Buchpiguel CA, Marchetti RL, Neto MR. Volumetric MRI measurements can differentiate Alzheimer's disease, mild cognitive impairment, and normal aging. Int Psychogeriatr. 2002;14:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094908</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Rankin KP, Miller BL, Schuff N, Weiner M, Gorno-Tempini ML, et al. Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia. Archives of Neurology. 2003;60:949&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzali M, Filippi M, Magnani G, Cercignani M, Franceschi M, Schiatti E, et al. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology. 2006;67:453&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894107</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Burges CJC. A tutorial on support vector machines for pattern recognition. Data Mining and Knowledge Discovery. 1998;2:121&#x2013;167.</Citation></Reference><Reference><Citation>Busatto GF, Garrido GE, Almeida OP, Castro CC, Camargo CH, Cid CG, et al. A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease. Neurobiol Aging. 2003;24:221&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas VA, Du AT, Hardin D, Ezekiel F, Weber P, Jagust WJ, et al. Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia. Neurobiol Aging. 2003;24:537&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang F, Parisi JE, Jack CR, Petersen RC. Morphometric analysis of the hippocampus in Alzheimer's disease: post-mortem MRI and histological correlates. Ann Neurol. 1992;32:268.</Citation></Reference><Reference><Citation>Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport. 2002;13:1939&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage. 2005;27:934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979341</ArticleId></ArticleIdList></Reference><Reference><Citation>Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging. 2000;21:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794844</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994;53:125&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7823614</ArticleId></ArticleIdList></Reference><Reference><Citation>Davatzikos C, Fan Y, Wu X, Shen D, Resnick SM. Detection of prodromal Alzheimer's disease via pattern classification of MRI. Neurobiol Aging. 2006 Dec 13; Epub.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323584</ArticleId><ArticleId IdType="pubmed">17174012</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Golomb J, George AE, Convit A, Tarshish CY, McRae T, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol. 1993;14:897&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8333817</ArticleId><ArticleId IdType="pubmed">8352162</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210817</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology. 2004;63:220&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820872</ArticleId><ArticleId IdType="pubmed">15277612</ArticleId></ArticleIdList></Reference><Reference><Citation>deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging. 2004;25:1197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312965</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22:747&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;71:441&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1763497</ArticleId><ArticleId IdType="pubmed">11561025</ArticleId></ArticleIdList></Reference><Reference><Citation>Erten-Lyons D, Howieson D, Moore MM, Quinn J, Sexton G, Silbert L, et al. Brain volume loss in MCI predicts dementia. Neurology. 2006;66:233&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434660</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain. 1996;119(Pt 6):2001&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry. 2005;76:112&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739332</ArticleId><ArticleId IdType="pubmed">15608008</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, et al. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry. J Neurol Neurosurg Psychiatry. 2002;73:657&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757361</ArticleId><ArticleId IdType="pubmed">12438466</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2006;77:1219&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077364</ArticleId><ArticleId IdType="pubmed">16891386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, et al. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett. 2005;382:269&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15925102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii K, Kawachi T, Sasaki H, Kono AK, Fukuda T, Kojima Y, et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol. 2005;26:333&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7974092</ArticleId><ArticleId IdType="pubmed">15709131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42:183&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724764</ArticleId><ArticleId IdType="pubmed">10953178</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63:674&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O'Brien JT, Scheltens P, et al. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage. 2003;18:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725765</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage. 2004;23:708&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488420</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58:1188&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249617</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda H, Kitayama N, Ohnishi T, Asada T, Nakano S, Sakamoto S, et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med. 2002;43:304&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11884488</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TE, editors. Geriatric Psychiatry. Grune and Stratton; New York: 1976. pp. 77&#x2013;121.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan AB, Hermann BP, Johnson SC, Hansen RR, Seidenberg M, Meyerand ME. Voxel-based morphometry of unilateral temporal lobe epilepsy reveals abnormalities in cerebral white matter. Neuroimage. 2004;23:167&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325363</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno K, Wakai M, Takeda A, Sobue G. Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volumetric and memory assessment study. J Neurol Sci. 2000;173:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10675575</ArticleId></ArticleIdList></Reference><Reference><Citation>Morys J, Bobek-Billewicz B, Dziewiatkowski J, Bidzan L, Ussorowska D, Narklewicz O. Changes in the volume of temporal lobe structures related to Alzheimer's type dementia. Folia Neuropathol. 2002;40:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230256</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso MP, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging. 2004;25:303&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123335</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen C, Testa C, Laakso MP, Hallikainen M, Helkala EL, Hanninen T, et al. A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2005;76:11&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739300</ArticleId><ArticleId IdType="pubmed">15607988</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cogntiive impairment. Arch Neurol. 2006;63:665&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682536</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006;5:828&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99:4703&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol. 2003;53:181&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12557284</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR., Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage. 2005;26:600&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739382</ArticleId><ArticleId IdType="pubmed">15907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiino A, Watanabe T, Maeda K, Kotani E, Akiguchi I, Matsuda M. Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. Neuroimage. 2006;33:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904912</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology. 2005;64:1520&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883311</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Alexander GE, Schapiro MB, Moller HJ, Rapoport SI, Hampel H. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain. 2004;127:811&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985261</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol. 1999;246:477&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431775</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA, Vogt LJ, Vrana KE, Gioia L, Meadows RS, Challa VR, et al. Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp Neurol. 1998;153:8&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Swank JS, Glick IE, Gado MH, Miller MI, Morris JC, et al. Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage. 2003;20:667&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568443</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Petersen RC, Negash S, Weigand SD, Kantarci K, Ivnik RI, et al. Patterns of Atrophy differ among Specific Subtypes of Mild Cognitive Impairment. Arch Neurol. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735186</ArticleId><ArticleId IdType="pubmed">17698703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf H, Hensel A, Kruggel F, Riedel-Heller SG, Arendt T, Wahlund LO, et al. Structural correlates of mild cognitive impairment. Neurobiol Aging. 2004;25:913&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212845</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Jack CR, Jr., O'Brien PC, Kokmen E, Smith GE, Ivnik RJ, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology. 2000;54:1760&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10802781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17544378</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The effects of prolonged stress and APOE genotype on memory and cortisol in older adults.</ArticleTitle><Pagination><StartPage>472</StartPage><EndPage>478</EndPage><MedlinePgn>472-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic elevations in cortisol associated with prolonged stress have been associated with memory loss, as has the apolipoprotein E gene (APOE-epsilon4) genotype. Combined effects of stress and APOE status on memory and cortisol in humans have not been studied.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A semistructured interview with standardized scoring was used to measure stress level and univariate analysis of variance to assess effects of stress and APOE-epsilon4 status on memory and salivary cortisol in 91 nondemented subjects (mean age 78.8 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Low-stress subjects performed better than high-stress subjects on delayed recall of stories (p = .04), word lists (p = .02), and visual designs (p = .04). APOE-epsilon4-negative subjects obtained better scores than epsilon4-positive subjects on immediate (p = &lt; .01) and delayed (p &lt; .01) recall of visual designs. Significant stress by APOE-epsilon4 interaction effects on memory (p = .03) and cortisol (p &lt; .01) resulted from consistently worse memory and higher cortisol concentrations in the high stress, epsilon4-positive group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings are consistent with a model in which prolonged exposure of older, nondemented individuals to stress in the presence of an epsilon4 allele leads to memory decline. Further studies will assess whether stress and APOE-epsilon4 interact to increase the risk of developing Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peavy</LastName><ForeName>Guerry M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, California, USA. gpeavy@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Sherry</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Khandrika</LastName><ForeName>Srikrishna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01MH063782-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR 000827</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH063782</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000827</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="Y">Stress, Psychological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17544378</ArticleId><ArticleId IdType="mid">NIHMS29348</ArticleId><ArticleId IdType="pmc">PMC2002507</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2007.03.013</ArticleId><ArticleId IdType="pii">S0006-3223(07)00256-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Swan GE, Reed T, Jack LM, Miller BL, Markee T, Wolf PA, et al. Differential genetic influence for components of memory in aging adult twins. Arch Neurol. 1999;56:1127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10488814</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Kawas C. The epidemiology of dementia and Alzheimer&#x2019;s disease. In: Terry RD, Katzman Robert, Bick Katherine L, editors. Alzheimer&#x2019;s disease. Raven Press; New York: 1994. pp. 105&#x2013;122.</Citation></Reference><Reference><Citation>Lindauer R, Olff M, van Meijel E, Carlier I, Gersons B. Cortisol, learning, memory, and attention, in relation to smaller hippocampal volume in police officers with posttraumatic stress disorder. Biol Psychiatry. 2006;59:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">16154543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair NP, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci. 1998;1:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschbaum C, Wolf OT, May M, Wippich W, Hellhammer DH. Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sci. 1996;58:1475&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8622574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NP, Meaney MJ. Basal cortisol levels and cognitive deficits in human aging. J Neurosci. 1994;14:2893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577490</ArticleId><ArticleId IdType="pubmed">8182446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupien SJ, Wilkinson CW, Briere S, Menard C, Ng Ying Kin NM, Nair NP. The modulatory effects of corticosteroids on cognition: studies in young human populations. Psychoneuroendocrinology. 2002;27:401&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11818174</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS, Sapolsky RM. Stress and cognitive function. Curr Opin Neurobiol. 1995;5:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann S, Piel M, Wolf OT. Impaired memory retrieval after psychosocial stress in healthy young men. J Neurosci. 2005;25:2977&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725125</ArticleId><ArticleId IdType="pubmed">15772357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupien SJ, Gaudreau S, Tchiteya BM, Maheu F, Sharma S, Nair NP, et al. Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. J Clin Endocrinol Metab. 1997;82:2070&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9215274</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Rosnick CB, Fratiglioni L, Backman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004;19:592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer&#x2019;s disease. Psychol Aging. 1999;14:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">10403716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Salmon DP, Monsch AU, Galasko D, Butters N, Klauber MR, et al. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology. 1995;45:2203&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8848194</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004;63:1898&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol. 2002;59:1154&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12117364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, et al. Decline in verbal memory during preclinical Alzheimer&#x2019;s disease: examination of the effect of APOE genotype. J Int Neuropsychol Soc. 2002;8:943&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1621042</ArticleId><ArticleId IdType="pubmed">12405546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschanz J, Welsh-Bohmer K, Lyketsos C, Corcoran C, Green R, Hayden K, et al. Conversion to dementia from mild cognitive disorder. Neurology. 2006;67:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16864813</ArticleId></ArticleIdList></Reference><Reference><Citation>den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, Breteler MM. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology. 2002;59:746&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221169</ArticleId></ArticleIdList></Reference><Reference><Citation>Grootendorst J, Bour A, Vogel E, Kelche C, Sullivan PM, Dodart JC, et al. Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav Brain Res. 2005;159:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15794991</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology. 2001;56:1094&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11320185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon I, Ben-Eliyahu S, Rosenne E, Sehayek E, Michaelson DM. Derangement in stress response of apolipoprotein E-deficient mice. Neurosci Lett. 1996;206:212&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710189</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Cheshire A, Howell LA, Ryan DH, Harris RB. Neuroautoantibody immunoreactivity in relation to aging and stress in apolipoprotein E-deficient mice. Brain Res Bull. 1999;49:173&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10435780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Elkins PD, Howell LA, Ryan DH, Harris RB. Apolipoprotein-E deficiency results in an altered stress responsiveness in addition to an impaired spatial memory in young mice. Brain Res. 1998;788:151&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9554991</ArticleId></ArticleIdList></Reference><Reference><Citation>de Kloet ER, Grootendorst J, Karssen AM, Oitzl MS. Gene x environment interaction and cognitive performance: animal studies on the role of corticosterone. Neurobiol Learn Mem. 2002;78:570&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559836</ArticleId></ArticleIdList></Reference><Reference><Citation>Grootendorst J, de Kloet ER, Dalm S, Oitzl MS. Reversal of cognitive deficit of apolipoprotein E knockout mice after repeated exposure to a common environmental experience. Neuroscience. 2001;108:237&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">11734357</ArticleId></ArticleIdList></Reference><Reference><Citation>Grootendorst J, Kempes M, Lucassen P, Dalm S, de Kloet E, Oitzl M. Differential effect of corticosterone on spatial learning abilities in apolipoprotein E knockout and C57BL/6J mice. Brain Research. 2002;953:281&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher-Thompson D, O&#x2019;Hara R, Simmons A, Kraemer HC, Murphy GM., Jr. Apolipoprotein E epsilon4 allele affects the relationship between stress and depression in caregivers of patients with Alzheimer&#x2019;s disease. J Geriatr Psychiatry Neurol. 2001;14:115&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11563433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Ann N Y Acad Sci. 2006;1071:137&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16891568</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G, Harris T. Social Origins of Depression: A Study of Psychiatric Disorders in Women. Tavistock; London: 1978.</Citation></Reference><Reference><Citation>Foa E, Cashman L, Jaycox L, et al. The validation of a self-report measure of posttraumatic stress disorder: The Posttraumatic Diagnostic Scale. Psychological Assessment. 1997;9:445&#x2013;451.</Citation></Reference><Reference><Citation>Mattis S. DRS: Dementia Rating Scale professional manual. Psychological Assessment Resources; New York: 1988.</Citation></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of Mild Cognitive Impairment and Progression to Dementia and Death. Dement Geriatr Cogn Disord. 2006;22:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">16940725</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G, Harris T. Life Events and Illness. Guilford Press; New York: 1989.</Citation></Reference><Reference><Citation>Dohrenwend BS, Krasnoff L, Askenasy AR, Dohrenwend BP. Exemplification of a method for scaling life events: the Peri Life Events Scale. J Health Soc Behav. 1978;19:205&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">681735</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant I, Brown GW, Harris T, McDonald WI, Patterson T, Trimble MR. Severely threatening events and marked life difficulties preceding onset or exacerbation of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52:8&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1032648</ArticleId><ArticleId IdType="pubmed">2709039</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielberger C. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Inc; Palo Alto, CA: 1983.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale - Revised. The Psychological Corporation; New York: 1987.</Citation></Reference><Reference><Citation>Delis D, Kramer J, Kaplan E, Ober B. The California Verbal Learning Test. The Psychological Corporation; New York: 1987.</Citation></Reference><Reference><Citation>Wenham P, Price W, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1674030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT, Powers PK. Detection of SstI restriction site polymorphism in human APOC3 by the polymerase chain reaction. Nucleic Acids Res. 1991;19:196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC333567</ArticleId><ArticleId IdType="pubmed">1672743</ArticleId></ArticleIdList></Reference><Reference><Citation>Touitou Y, Sulon J, Bogdan A, Touitou C, Reinberg A, Beck H, et al. Adrenal circadian system in young and elderly human subjects: a comparative study. J Endocrinol. 1982;93:201&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">7086322</ArticleId></ArticleIdList></Reference><Reference><Citation>SPSS . In: SPSS Graduate Pack 11.0 for Mac&#xae;. OS X, editor. SPSS, Inc; Chicago, IL: 2003.</Citation></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17:101&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17549256</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>117</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology.</ArticleTitle><Pagination><StartPage>1595</StartPage><EndPage>1604</EndPage><MedlinePgn>1595-604</MedlinePgn></Pagination><Abstract><AbstractText>Neuroinflammation is a conspicuous feature of Alzheimer disease (AD) pathology and is thought to contribute to the ultimate neurodegeneration that ensues. IL-1 beta has emerged as a prime candidate underlying this response. Here we describe a transgenic mouse model of sustained IL-1 beta overexpression that was capable of driving robust neuroinflammation lasting months after transgene activation. This response was characterized by astrocytic and microglial activation in addition to induction of proinflammatory cytokines. Surprisingly, when triggered in the hippocampus of the APPswe/PS1dE9 mouse model of AD, 4 weeks of IL-1 beta overexpression led to a reduction in amyloid pathology. Congophilic plaque area fraction and frequency as well as insoluble amyloid beta 40 (A beta 40) and A beta 42 decreased significantly. These results demonstrate a possible adaptive role for IL-1 beta-driven neuroinflammation in AD and may help explain recent failures of antiinflammatory therapeutics for this disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaftel</LastName><ForeName>Solomon S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Anatomy, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyrkanides</LastName><ForeName>Stephanos</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Olschowka</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Jen-nie H</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Renee E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>O'Banion</LastName><ForeName>M Kerry</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS048522</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 NS033553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM07356</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS033553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007356</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048522</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Invest. 2007 Jun;117(6):1483-5. doi: 10.1172/JCI32356.</RefSource><PMID Version="1">17549252</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17549256</ArticleId><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="doi">10.1172/JCI31450</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Basu A., Krady J.K., Levison S.W. Interleukin-1: a master regulator of neuroinflammation. J. Neurosci. Res. 2004;78:151&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378607</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan S.M., Tyrrell P.J., Rothwell N.J. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 2005;5:629&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">16034365</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley H.C., et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatr. 2005;76:1366&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739363</ArticleId><ArticleId IdType="pubmed">16170078</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin W.S., et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1989;86:7611&#x2013;7615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Everbroeck B., et al. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol. Aging. 2002;23:59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755020</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness M.C., et al. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. . J. Neuroimmunol. 1997;75:174&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak R.E., Griffin W.S. The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. J. Neurovirol. 1997;3:241&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291232</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 1987;79:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas S., et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001;1:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31338</ArticleId><ArticleId IdType="pubmed">11299042</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks A.I., Muhkerjee B., Panahian N., Cory-Slechta D., Federoff H.J. Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase. Nat. Biotechnol. 1997;15:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9035107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingren A.G., et al. Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell. Immunol. 1996;169:226&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">8620550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyrkanides S., Miller J.H., Bowers W.J., Federoff H.J. Transcriptional and posttranslational regulation of Cre recombinase by RU486 as the basis for an enhanced inducible expression system. Mol. Ther. 2003;8:790&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">14599812</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaccum M.B., et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J. Immunol. 1997;159:3364&#x2013;3371.</Citation><ArticleIdList><ArticleId IdType="pubmed">9317135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M., et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006;24:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin W.S., Liu L., Li Y., Mrak R.E., Barger S.W. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflammation. 2006;3:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435743</ArticleId><ArticleId IdType="pubmed">16542445</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A.R., Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer&#x2019;s disease. Mol. Psychiatry. 2006;11:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16491130</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J., Lue L.F. Microglial chemo&#xad;taxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer&#x2019;s disease. Neurochem. Int. 2001;39:333&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J., Strohmeyer R., Kovelowski C.J., Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 2002;40:260&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J., Luber-Narod J., Styren S.D., Civin W.H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer&#x2019;s disease. Neurobiol. Aging. 1988;9:339&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">3263583</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., McGeer E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697488</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A.H., O&#x2019;Banion M.K. Neuroinflammation and anti-inflammatory therapy for Alzheimer&#x2019;s disease. Adv. Drug Deliv. Rev. 2002;54:1627&#x2013;1656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453679</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin W.S. Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. 2006;83:470S&#x2013;474S.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470015</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer&#x2019;s disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 1995;54:276&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876895</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll J.A., et al. Association of interleukin-1 gene polymorphisms with Alzheimer&#x2019;s disease. Ann. Neurol. 2000;47:365&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833599</ArticleId><ArticleId IdType="pubmed">10716257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.T., et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5&#x3b9;-untranslated region sequences. J. Biol. Chem. 1999;274:6421&#x2013;6431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037734</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzing W.C., et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging. 1999;20:581&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G.P., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer&#x2019;s disease. J. Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Herber D.L., et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp. Neurol. 2004;190:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473997</ArticleId></ArticleIdList></Reference><Reference><Citation>DiCarlo G., Wilcock D., Henderson D., Gordon M., Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging. 2001;22:1007&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755009</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin W.S., et al. Glial-neuronal interactions in Alzheimer&#x2019;s disease: the potential role of a &#x2018;cytokine cycle&#x2019; in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgaber D., et al. Interleukin 1 regulates synthesis of amyloid &#x3b2;-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1989;86:7606&#x2013;7610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298115</ArticleId><ArticleId IdType="pubmed">2508093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T., et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001;7:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook T.J., Jiang L., Maier M., Lemere C.A. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia. 2006;53:776&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534778</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea M.R., Cole G.M., Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging. 2004;25:675&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere C.A., Maier M., Jiang L., Peng Y., Seabrook T.J. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 2006;9:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentlein R., Ludwig R., Martensen I. Proteolytic degradation of Alzheimer&#x2019;s disease amyloid beta-peptide by a metalloproteinase from microglia cells. J. Neurochem. 1998;70:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453567</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm T.M., et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 2005;18:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkdahl O., Akerblad P., Gjorloff-Wingren A., Leanderson T., Dohlsten M. Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product. Immunology. 1999;96:128&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2326720</ArticleId><ArticleId IdType="pubmed">10233687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y.C., et al. Intraarticular induction of interleukin-1beta expression in the adult mouse, with resultant temporomandibular joint pathologic changes, dysfunction, and pain. Arthritis Rheum. 2006;54:1184&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">16572453</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder A.K., et al. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 1998;153:767&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852999</ArticleId><ArticleId IdType="pubmed">9736027</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Banion M.K., Miller J.C., Chang J.W., Kaplan M.D., Coleman P.D. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclo&#xad;oxygenase-2) in primary murine astrocyte cultures. J. Neurochem. 1996;66:2532&#x2013;2540..</Citation><ArticleIdList><ArticleId IdType="pubmed">8632179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17551018</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>25</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity.</ArticleTitle><Pagination><StartPage>10673</StartPage><EndPage>10678</EndPage><MedlinePgn>10673-8</MedlinePgn></Pagination><Abstract><AbstractText>Aggregation of the amyloid-beta (Abeta) peptide in the extracellular space of the brain is critical in the pathogenesis of Alzheimer's disease. Abeta is produced by neurons and released into the brain interstitial fluid (ISF), a process regulated by synaptic activity. To determine whether behavioral stressors can regulate ISF Abeta levels, we assessed the effects of chronic and acute stress paradigms in amyloid precursor protein transgenic mice. Isolation stress over 3 months increased Abeta levels by 84%. Similarly, acute restraint stress increased Abeta levels over hours. Exogenous corticotropin-releasing factor (CRF) but not corticosterone mimicked the effects of acute restraint stress. Inhibition of endogenous CRF receptors or neuronal activity blocked the effects of acute stress on Abeta. Thus, behavioral stressors can rapidly increase ISF Abeta through neuronal activity in a CRF-dependent manner, and the results suggest a mechanism by which behavioral stress may affect Alzheimer's disease pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jae-Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Hongxin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Csernansky</LastName><ForeName>John G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA 07261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9015-71-8</RegistryNumber><NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003346" MajorTopicYN="N">Corticotropin-Releasing Hormone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17551018</ArticleId><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="doi">10.1073/pnas.0700148104</ArticleId><ArticleId IdType="pii">0700148104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Nat Cell Biol. 2004;6:1054&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT., Jr Biochemistry. 1999;38:8972&#x2013;8980.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. J Neurochem. 2006;99:689&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17076654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Bennett DA, Li Y, Bienias JL, Mendes de Leon CF, Evans DA. Neurology. 2005;64:380&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Neurology. 2003;61:1479&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">14663028</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC. Am J Psychiatry. 2006;163:2164&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780275</ArticleId><ArticleId IdType="pubmed">17151169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG. Neuroscience. 2004;127:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15283960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Youkin S, Yang F, Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RB, Zhou J, Shi M, Redmann S, Mynatt RL, Ryan DH. Physiol Behav. 2001;73:599&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">11495665</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts AG. Front Neuroendocrinol. 2005;26:109&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289311</ArticleId></ArticleIdList></Reference><Reference><Citation>Baram TZ, Hatalski CG. Trends Neurosci. 1998;21:471&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372323</ArticleId><ArticleId IdType="pubmed">9829688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Brunson KL, Muller MB, Cariaga W, Baram TZ. J Comp Neurol. 2000;420:305&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119344</ArticleId><ArticleId IdType="pubmed">10754504</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunson KL, Schultz L, Baram TZ. Brain Res Dev Brain Res. 1998;111:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129849</ArticleId><ArticleId IdType="pubmed">9804917</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldenhoff JB, Gruol DL, Rivier J, Vale W, Siggins GR. Science. 1983;221:875&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">6603658</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank T, Nijholt I, Eckart K, Spiess J. J Neurosci. 2002;22:3788&#x2013;3794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758360</ArticleId><ArticleId IdType="pubmed">11978854</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, et al. Neurology. 2000;55:1158&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. J Am Med Assoc. 1994;271:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale W, Spiess J, Rivier C, Rivier J. Science. 1981;213:1394&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">6267699</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CP, Pearse RV, 2nd, O'Connell S, Rosenfeld MG. Neuron. 1993;11:1187&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">8274282</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, Vale W. Proc Natl Acad Sci USA. 1994;91:8777&#x2013;8781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44689</ArticleId><ArticleId IdType="pubmed">8090722</ArticleId></ArticleIdList></Reference><Reference><Citation>Koob GF, Heinrichs SC, Pich EM, Menzaghi F, Baldwin H, Miczek K, Britton KT. Ciba Found Symp. 1993;172:277&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">8491090</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE. J Comp Neurol. 2000;428:191&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11064361</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Brunson KL, Adelmann G, Bender RA, Frotscher M, Baram TZ. Neuroscience. 2004;126:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923444</ArticleId><ArticleId IdType="pubmed">15183503</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen FM, Bilezikjian LM, Perrin MH, Rivier J, Vale W. Brain Res. 1986;381:49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">3019476</ArticleId></ArticleIdList></Reference><Reference><Citation>Haug T, Storm JF. J Neurophysiol. 2000;83:2071&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">10758117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z, Song M, Xiong J, Bai Y, Pei G. Nat Med. 2006;12:1390&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">17115048</ArticleId></ArticleIdList></Reference><Reference><Citation>De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW. Nature. 1986;319:593&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">3003585</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. J Neurosci. 2006;26:9047&#x2013;9056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675335</ArticleId><ArticleId IdType="pubmed">16943563</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. J Clin Invest. 1995;96:1698&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC185805</ArticleId><ArticleId IdType="pubmed">7560060</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Mintun MA. Annu Rev Neurosci. 2006;29:449&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">16776593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Cell. 2005;120:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV. J Neurosci. 2005;25:5217&#x2013;5224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440804</ArticleId><ArticleId IdType="pubmed">15917461</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlard PA, Perreau VM, Pop V, Cotman CW. J Neurosci. 2005;25:4217&#x2013;4221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725122</ArticleId><ArticleId IdType="pubmed">15858047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolomucci A, Palanza P, Sacerdote P, Ceresini G, Chirieleison A, Panerai AE, Parmigiani S. Psychoneuroendocrinology. 2003;28:540&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Fenoglio KA, Dube CM, Grigoriadis DE, Baram TZ. Mol Psychiatry. 2006;11:992&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927976</ArticleId><ArticleId IdType="pubmed">16801951</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. J Biol Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17553421</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>720</EndPage><MedlinePgn>713-20</MedlinePgn></Pagination><Abstract><AbstractText>The apolipoprotein E (APOE) epsilon4 allele is the best established genetic risk factor for late-onset Alzheimer's disease (LOAD). We conducted genome-wide surveys of 502,627 single-nucleotide polymorphisms (SNPs) to characterize and confirm other LOAD susceptibility genes. In epsilon4 carriers from neuropathologically verified discovery, neuropathologically verified replication, and clinically characterized replication cohorts of 1411 cases and controls, LOAD was associated with six SNPs from the GRB-associated binding protein 2 (GAB2) gene and a common haplotype encompassing the entire GAB2 gene. SNP rs2373115 (p = 9 x 10(-11)) was associated with an odds ratio of 4.06 (confidence interval 2.81-14.69), which interacts with APOE epsilon4 to further modify risk. GAB2 was overexpressed in pathologically vulnerable neurons; the Gab2 protein was detected in neurons, tangle-bearing neurons, and dystrophic neuritis; and interference with GAB2 gene expression increased tau phosphorylation. Our findings suggest that GAB2 modifies LOAD risk in APOE epsilon4 carriers and influences Alzheimer's neuropathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, 85004, USA. eric.reiman@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dunckley</LastName><ForeName>Travis</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zismann</LastName><ForeName>Victoria L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Joshipura</LastName><ForeName>Keta D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>John V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Hu-Lince</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Coon</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Winnie S</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Herbert</LastName><ForeName>RiLee H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Kristen C</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Alice S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Doris</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bryden</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Marlowe</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kaleem</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mastroeni</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Grover</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heward</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Ravid</LastName><ForeName>Rivka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Melquist</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ron C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Papassotiropoulos</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH60451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG25711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG029576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH060451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG17824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24NS051872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01HL084744</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS051872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG024079</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG017824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG23193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG024079</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS39764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG01542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490895">GAB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17553421</ArticleId><ArticleId IdType="mid">NIHMS40851</ArticleId><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.05.022</ArticleId><ArticleId IdType="pii">S0896-6273(07)00379-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmadian A, Gharizadeh B, Gustafsson AC, Sterky F, Nyren P, Uhlen M, Lundeberg J. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem. 2000;280:103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805527</ArticleId></ArticleIdList></Reference><Reference><Citation>Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004;23:2586&#x2013;2596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449766</ArticleId><ArticleId IdType="pubmed">15192701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer&#x2019;s disease. Neuroscience. 2000;95:721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer&#x2019;s-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner R, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Hu-Lince D, Zismann VL, Beach T, Leung D, Bryden L, et al. A high density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer&#x2019;s disease. J Clin Psychiatry. 2007;68:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schemchel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer&#x2019;s disease in a community population of older persons: higher than previously reported. JAMA. 1989;262:2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A metaanalysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu H, Saito K, Klaman LD, Shen J, Fleming T, Wang Y, Pratt JC, Lin G, Lim B, Kinet JP, Neel BG. Essential role for Gab2 in the allergic response. Nature. 2001;412:186&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11449275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua J, Craig DW, Brun M, Webster J, Zismann V, Tembe W, Joshipura K, Huentelman MJ, Dougherty ER, Stephan DA. SNiPer-HD: Improved genotype calling accuracy by an expectation-maximization algorithm for high-density SNP arrays. Bioinformatics. 2007;23:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17062589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, O&#x2019;Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, Hansen KW, Gleason CE, Carlsson CM, Ries ML, et al. Activation of brain regions vulnerable to Alzheimer&#x2019;s disease: The effect of mild cognitive impairment. Neurobiol Aging. 2006;27:1604&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH. Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem. 2005;208:31537&#x2013;31547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014629</ArticleId></ArticleIdList></Reference><Reference><Citation>Koncz G, Bodor C, Kovesdi D, Gati R, Sarmay G. BCR mediated signal transduction in immature and mature B cells. Immunol Lett. 2002;82:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">12008033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruglyak L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet. 1999;22:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai E, Riley J, Purvis I, Roses A. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics. 1998;54:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">9806827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:160&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Liu C, Sun W, Yuan S, Yu T. A system for enhancing genome-wide coexpression dynamic study. Proc Natl Acad Sci USA. 2004a;101:15561&#x2013;15566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524832</ArticleId><ArticleId IdType="pubmed">15492223</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Strohmeyer R, Liang Z, Lue LF, Rogers J. CCAAT/Enhancer binding protein &#x3b4; (C/EBP-&#x3b4;) expression and elevation in Alzheimer&#x2019;s disease. Neurobiol Aging. 2004b;25:991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212823</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, Caselli RJ, Kukull WA, McKeel D, Morris JC, et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics. 2007;28:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2259385</ArticleId><ArticleId IdType="pubmed">17077275</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics and proteomics of Alzheimer&#x2019;s disease. J Clin Psychiatry. 2006;67:652&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2259384</ArticleId><ArticleId IdType="pubmed">16669732</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt JC, Igras VE, Maeda H, Baksh S, Gelfand EW, Burakoff SJ, Neel BG, Gu H. Cutting edge: gab2 mediates an inhibitory phosphatidylinositol 3&#x2032;-kinase pathway in T cell antigen receptor signaling. J Immunol. 2001;165:4158&#x2013;4163.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035047</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461096</ArticleId><ArticleId IdType="pubmed">10835412</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence for Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Correlations between apolipoprotein E &#x3b5;4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA. 2005;102:8299&#x2013;8302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149416</ArticleId><ArticleId IdType="pubmed">15932949</ArticleId></ArticleIdList></Reference><Reference><Citation>The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zompi S, Gu H, Colucci F. The absence of Grb2-associated binder 2 (Gab2) does not disrupt NK cell development and functions. J Leukoc Biol. 2004;76:896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">15240750</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>